




CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

# Proposed Grant Awards

August 21, 2024





CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

---

---

**MEMORANDUM**

---

---

**TO:** OVERSIGHT COMMITTEE MEMBERS  
**FROM:** MICHELLE LE BEAU, PH.D., CHIEF SCIENTIFIC OFFICER  
**SUBJECT:** ACADEMIC RESEARCH FY2024 CYCLE 2 AND RECRUITMENT  
AWARD RECOMMENDATIONS FY2024, CYCLE 24.12  
**DATE:** AUGUST 21, 2024

---

---

The Scientific Review Council (SRC) and Program Integration Committee (PIC) recommendations for FY2024 Cycle 2 and Recruitment Cycles 24.12 include 36 **awards** from five grant mechanisms totaling **\$60,577,922** as displayed in Table 1.

**Table 1.**

Grant Mechanism	SRC Recommendations	
	Awards	Funding
Clinical Investigator Award	6	\$6,624,889
Core Facility Support Awards	9	\$20,595,792
High-Impact/High-Risk Awards	12	\$2,998,030
Multi-Investigator Research Awards	5	\$22,359,211
Recruitment of First-Time, Tenure-Track Faculty Members	4	\$8,000,000
<b>Total</b>	<b>36</b>	<b>\$60,577,922</b>

**Program Priorities Addressed:**

The applications proposed to the Program Integration Committee for funding address the following Academic Research Program Priorities: recruitment of outstanding cancer researchers to Texas, investment in core facilities, innovative investigator-initiated research projects, cancer disparities, childhood and adolescent cancers, hepatocellular carcinoma, drug discovery, and computational oncology. Priorities addressed by the proposed slate of awards are displayed in Table 2 and Attachment 1.

**Table 2.**

Program Priorities Addressed by Grant Recommendations		
# Awards*	Program Priorities	Funding*
4	Recruitment of outstanding cancer researchers to Texas	\$8,000,000
9	Investment in Core Facilities	\$20,595,792
28	A broad range of innovative, investigator-initiated research projects	\$42,976,671
3	Implementation research	\$5,554,952
13	Expanding access to Innovative Clinical Trials	\$32,983,860
11	Childhood and Adolescent Cancers	\$26,287,893
3	Hepatocellular cancer	\$8,498,763
2	Drug Discovery	\$6,362,563
6	Computational oncology and analytic methods	\$7,829,893
*Some grant awards address more than one program priority and are double counted.		

## ***1. CLINICAL INVESTIGATOR AWARD (RFA R-24.2 CIA) SLATE***

### **Scientific Review Council Recommendations:**

Out of 6 Clinical Investigator Award (CIA) grant applications submitted, the SRC recommended six, totaling \$6,624,889.

### **Purpose of Clinical Investigator Award:**

Supports mid-career clinician scientists with specialty training relevant to delivery of cancer care to devote more time to augment their capabilities in clinical cancer research, and to provide mentoring to early-stage investigators in the conduct of clinical research. The CIA will provide protected time from clinical responsibilities to provide physicians with the opportunity to expand clinical research skills, to develop investigator-initiated clinical trials, to develop external relations with industry and pharmaceutical company partners, and to expand partnerships with laboratory-based collaborators to design and conduct correlative studies needed to interpret the outcome of an interventional trial. The CIA initiative will increase the pool of clinical investigators at Texas academic institutions who are conducting patient-oriented studies, who will be able to compete successfully for peer-reviewed grants, and who will mentor the next generation of clinical investigators

### **Clinical Investigator Award Funding Levels:**

Award: Up to \$1.5M (total costs); Maximum duration: 5 years.

**Recommended CIA Institutions (3):**

Baylor College of Medicine, (2 awards), The University Texas M.D. Anderson Cancer Center (2 awards) and The University of Texas Southwestern Medical Center (2 awards).

Note that the awards are listed in order of the evaluation score.

**RP240478**

**PI:** Meenakshi Hegde, M.D.

**Title:** Advancing immunotherapy for high-risk cancers in children and adolescents

**Applicant Organization:** Baylor College of Medicine

**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]:1.4

**Recommended Total Budget Award and Duration:** \$1,030,892

**CPRIT Priorities Addressed:** Expanding access to innovative clinical trials, particularly to regions of the state currently with limited access; Childhood and Adolescent Cancers; A broad range of innovative, investigator-initiated research projects

**Description:**

Dr Meenakshi Hegde is a pediatric oncologist with significant basic research training in the design, development, and optimization of CAR-T cells and early-phase immunotherapy trials. Her research focuses on understanding mechanisms of immune escape with an emphasis on high-risk pediatric cancers and the development of effective immunotherapy approaches for these high-risk childhood cancers, with the focus on sarcomas, brain tumors, and therapy resistant B-cell leukemia. She has led numerous investigator-initiated trials (IITs) for pediatric brain tumors and led studies through development and regulatory approval. Additionally, a significant portion of her professional effort has been focused on training new physician-scientists in the field. She has a strong track record of mentorship, and her previous mentees have been successful in terms of conducting clinical studies, obtaining independent funding, and publishing novel therapeutic approaches for pediatric cancers.

**RP240473**

**PI:** Bilal Omer, M.D.

**Title:** Signal-Augmented Cancer Cell Therapies: Integrating Advanced Correlatory Studies and Mentorship

**Applicant Organization:** Baylor College of Medicine

**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]:1.6

**Recommended Total Budget Award and Duration:** \$1,046,414

**CPRIT Priorities Addressed:** Expanding access to innovative clinical trials, particularly to regions of the state currently with limited access; Childhood and Adolescent Cancers, Computational oncology and analytic methods; A broad range of innovative, investigator-initiated research projects

**Description:**

With dual training in Pediatrics and Adult/Internal Medicine, Dr. Omer has significantly contributed to the field of cancer treatment, particularly through his innovative work in T-cell therapy clinical trials. His research is centered around the treatment of relapsed cancers and

includes three cutting-edge trials that focus on using immune cells enhanced with special signaling genes to target cancer more effectively. These trials aim to treat different types of cancers, including blood cancers and pediatric brain tumors. A key aspect of his work is the integration of advanced bioinformatics – essentially using complex computer analysis to understand cancer better – and exploring how these enhanced immune cells interact with and modify the cancer environment. In addition to his research, Dr. Omer is a dedicated mentor, guiding junior faculty in their clinical research careers. He has been instrumental in developing the careers of young investigators, particularly in pediatric cancer research.

**RP240557**

**PI:** Jennifer McQuade, M.D.

**Title:** Dietary intervention to modulate the microbiome and immune response

**Applicant Organization:** The University of Texas M. D. Anderson Cancer Center

**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]:1.8

**Recommended Total Budget Award and Duration:** \$1,074,727

**CPRIT Priorities Addressed:** Expanding access to innovative clinical trials, particularly to regions of the state currently with limited access; Computational oncology and analytic methods; A broad range of innovative, investigator-initiated research projects

**Description:**

Dr. McQuade is a medical oncologist specializing in metastatic melanoma whose work has contributed paradigm-shifting concepts regarding the impact of host-derived factors (diet, microbiome, etc.) on immunotherapy efficacy. The primary focus of her work is on the development of approaches to enhance efficacy of immune therapies for melanoma. She made the intriguing observation that obesity was associated with increased efficacy of immune therapies for melanoma and has focused on laboratory studies designed to understand the mechanisms for this clinical association and clinical trials designed to enhance tumor immunity through dietary interventions. Dr. McQuade is the Director of the Melanoma Medical Oncology Rotation for the MD Anderson Hematology/Oncology Fellowship Program and thus interacts with and trains all fellows.

**RP240442**

**PI:** Kevine Courtney, M.D., PhD

**Title:** Identifying and exploiting novel metabolic vulnerabilities in the treatment of kidney cancer

**Applicant Organization:** The University of Texas Southwestern Medical Center

**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]:2.1

**Recommended Total Budget Award and Duration:** \$913,682

**CPRIT Priorities Addressed:** Expanding access to innovative clinical trials, particularly to regions of the state currently with limited access; A broad range of innovative, investigator-initiated research projects

**Description:**

Kevin Courtney, M.D., Ph.D., is an Associate Professor of Internal Medicine in the Division of Hematology and Oncology, at the University of Texas Southwestern Medical Center (UTSW). He has a very active clinical practice, leads several clinical research efforts at UTSW, developed and ran an investigator-initiated trial (ITT) in prostate cancer, and has participated in the development and running of a series of additional trials. He co-leads one of the projects in the UTSW renal Sponsored Program of Research Excellence (SPORE). Dr. Courtney has established a strong track record of research excellence through publications and grant funding. He is very active in designing clinical trials and mentoring new investigators. With this award Dr. Courtney will work on the following specific aims: (1) contributing to the design and development of new clinical trials for patients with genitourinary cancers and making those trials available to patients at UT Southwestern; (2) studying how kidney cancer tumors use the amino acid glutamine as fuel in an effort to better understand how this can be exploited to develop potential new treatments for kidney cancer; and (3) mentoring early career clinical investigators, including clinical fellows and junior faculty physicians within his group, to train the next generation of clinical investigators dedicated to improving the treatments available to patients with genitourinary cancers.

**RP240441****PI:** Jianjun Zhang, M.D., PhD**Title:** Precision Lung Cancer Interception by Targeting High-Risk Lung Nodules**Applicant Organization:** The University of Texas M. D. Anderson Cancer Center**Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]:**2.2**Recommended Total Budget Award and Duration:** \$1,098,945**CPRIT Priorities Addressed:** Expanding access to innovative clinical trials; A broad range of innovative, investigator-initiated research projects; Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions and population research addressing cancer disparities**Description:**

Dr. Zhang is a clinical and translational investigator with expertise in lung cancer immunotherapy. He is one of the rare trialists with expertise in lung cancer prevention/interception. Dr. Zhang is the Lung Cancer Moon Shot Genomic Marker-Guided Therapy Initiative Program Chair, the Lung Cancer Interception Program Director, and the Lung Cancer Genomics Program Director at MD Anderson. Dr. Zhang has published numerous impactful papers that contribute to a better understanding of early lung cancer evolution, which has helped in the development of novel strategies in lung cancer interception and prevention. These findings have led to the development of 2 clinical trials, Can-Prevent-Lung and the IMPRINT-Lung, which constitute the central component of his research project. Dr Zhang has a strong track record of mentoring fellows, including supervision of 11 postdoctoral fellows, 5 graduate students, and 3 clinical fellows. Four of these trainees were promoted to assistant professor level and several won various awards, including the ASCO Merit Award and the American Association for Cancer Research Scholar-in-Training Award. The investigator has also mentored/co-mentored many junior faculty members, leading to high-impact publications and successful peer-reviewed funding (ASCO Career Development Award, NIH/NCI R01, NIH/NCI

R03, and a CPRIT IIRA). Finally, his mentorship skill was recognized by the MD Anderson Distinguished Mentor Award in 2023.

**RP240518**

**PI:** Neil Desai, M.D.

**Title:** Adapting radiotherapy clinical trials to treatment response and artificial intelligence innovations

**Applicant Organization:** The University of Texas Southwestern Medical Center

**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.4

**Recommended Total Budget Award and Duration:** \$1,460,229

**CPRIT Priorities Addressed:** Expanding access to innovative clinical trials, particularly to regions of the state currently with limited access; A broad range of innovative, investigator-initiated research projects; Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions and population research addressing cancer disparities; Computational oncology and analytic methods

**Description:**

Dr. Neil Desai is an Associate Professor of Radiation Oncology, at the University of Texas Southwestern Medical Center, Harold C. Simmons Comprehensive Cancer Center. He currently serves as the national PI of two potentially practice-changing randomized control multicenter trials in prostate cancer. Dr Desai’s efforts are striving to better personalize cancer treatments, as well as to inspire young doctors toward careers in clinical research He is working with multiple scientists and unique technologies to apply adaptive radiotherapy to prostate and bladder cancers to determine when there has been adequate treatment in order to reduce side effects. More recently, he has focused on a substantial investment and expertise in integrating adaptive radiotherapy and use AI to automatically check if patients qualify for ongoing studies and to ensure the quality of radiotherapy given on these studies. Through these efforts, he believes we can better personalize cancer treatment and inspire talented young doctors towards careers in clinical research. He notes that he aspires to train new clinical researchers to reduce barriers to their studies, such as cost and time, through the use of AI.

**2. CORE FACILITY SUPPORT AWARDS  
(RFA R-24.2 CFSA) SLATE**

**Scientific Review Council Recommendations:**

Out of 22 Core Facility Support (CFSA) grant applications submitted, the SRC recommended nine, totaling \$20,595,792.

**Purpose of Core Facility Support Awards:**

Solicits applications from institutions to establish or enhance core facilities (laboratory, clinical, population-based, or computer-based) that will directly support cancer research programs to advance knowledge of the causes, prevention, and/or treatment of cancer or improve quality of life for patients with, and survivors of, cancer.

**Core Facility Support Award Funding Levels:**

Award: Up to \$3M (total costs) for a new application and up to \$2M for renewals; Maximum duration: 5 years.

**Recommended CFSA Institutions (6):**

Baylor College of Medicine (2 awards), The University of Texas Austin, The University of Texas Health Science Center at Houston, The University of Texas M. D. Anderson Cancer Center (2 awards), Texas Southern University, and The University of Texas Southwestern Medical Center (2 awards).

Note that the awards are listed in order of the evaluation score.

**RP240545**

**PI:** Natalia Lapteva, Ph.D.

**Title:** Renewal of CPRIT GMP Core

**Applicant Organization:** Baylor College of Medicine

**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.0

**Recommended Total Budget Award and Duration:** \$2,000,000

**CPRIT Priorities Addressed:** Investment in core facilities; A broad range of innovative, investigator-initiated research projects; Childhood and adolescent cancers; Hepatocellular cancer; Expanding access to innovative clinical trials, particularly to regions of the state currently with limited access

**Description:**

This is a renewal award to continue support of the Good Manufacturing Practice (GMP) facility at Baylor College of Medicine (BCM), which has expertise in the preparation of gene transfer vectors and gene-modified cell therapy products at cost, thus providing academic investigators and pediatric patients a unique access to the advanced cell therapies. The core specializes in serving pediatric patients under the Texas Children's Hospital (TCH) umbrella, manufacturing both gene transfer vectors and gene-modified cell therapy products. Since 2018, they have served as the CPRIT Core GMP facility for the Children's Access to Regenerative Medicine in Texas (CARMIT) program. In that time, more than 130 children have received cutting-edge therapeutic products, including genetically modified T cells, virus-specific T cells, and tumor antigen-specific T cells. Among the goals of the renewal award are to broaden the access of pediatric cancer patients in Texas to new cell therapy products manufactured using the advanced technologies in their facility. They hope to complete studies initiated in the first cycle of CARMIT and continue providing novel autologous cell therapy products to Texas pediatric patients. In the last five years, they manufactured 17 virus-specific T cell banks and administered them to 13 pediatric patients at TCH. In this renewal, they would like to make these allogeneic banks available to children in other Texas hospitals.



**RP240610****PI:** Zhongming Zhao, Ph.D.**Title:** UTHealth Cancer Genomics Core (UTHealth CGC)**Applicant Organization:** The University of Texas Health Science Center at Houston**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.4**Recommended Total Budget Award and Duration:** \$2,000,000**CPRIT Priorities Addressed:** Investment in core facilities.**Description:**

Since 2018, the UTHealth Cancer Genomics Core has provided various services to over 164 Principal Investigators across 18 academic institutes for their sequencing and genomics projects. This renewal application has four specific aims. 1) Substantially expand sequencing services by providing the state-of-the-art sequencing platforms including long-read sequencing, single-cell omics, and spatial transcriptomics. 2) Enhance customized project design and advanced bioinformatics analysis to help a large group of investigators whose lab size is small to medium. 3) Coordinate with UTHealth OCGM office to expand cancer genomics services to thousands of clinical samples through partnerships with clinical departments and UTHealth affiliated hospitals. 4) Expand cancer genomics services with a subsidized price to TREC-eligible and other regional institutes within Texas.

**RP240494****PI:** Ralph DeBerardinis, MD, Ph.D.**Title:** Children's Research Institute Metabolomics Core: Advanced Methodologies in Cancer Metabolism**Applicant Organization:** The University of Texas Southwestern Medical Center**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.7**Recommended Total Budget Award and Duration:** \$2,601,616**CPRIT Priorities Addressed:** Investment in core facilities; Childhood and Adolescent Cancers**Description:**

Recognizing a need for centralized services in specialized assays, the Children's Research Institute (CRI) at the University of Texas Southwestern Medical Center (UTSW) established the CRI Metabolomics Core Facility, the first such core at UTSW, in 2012. Led by Dr. Ralph DeBerardinis, the Core has leveraged institutional support to serve investigators from UTSW, Texas, and beyond. Technical advancements developed in the Core include methods to assess the metabolome in rare cell populations and to perform isotope tracing in tumors in vivo, in mice and patients with cancer. The Core's aims for the current project period are (1) to develop new software to speed up and customize data analysis which will, among other things, provide Core personnel and users informatic shortcuts to identify metabolites from pathways of interest; and (2) to overhaul the Core's website to host these and other new informatics tools, as well as databases of metabolic features that will help users explore and interpret their data. These advances will give users the ability to search tens of thousands of data sets acquired by Core to connect experiments with shared metabolic features.

**RP240497****PI:** Nicholas Navin, Ph.D.**Title:** Advanced Spatial Genomics Core Facility**Applicant Organization:** The University of Texas M. D. Anderson Cancer Center**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.7**Recommended Total Budget Award and Duration:** \$2,999,993**CPRIT Priorities Addressed:** Investment in core facilities**Description:**

The aim of this new Core is to establish an Advanced Spatial Genomics (ASG) core facility at the University of Texas MD Anderson Cancer Center, which will be directed by Dr. Nicholas Navin. The ASG core will serve as a resource hub for cancer researchers across the Texas Medical Center (TMC) area and greater state of Texas. This facility will provide comprehensive services and expertise for tissue processing, slide imaging, spatial genomics technologies and spatial data analysis methods and will be organized into three main components: preparing tissue sections (OCT frozen, FFPE) using microtomes/cryomicrotomes and imaging the stained H&E tissue sections for QC analysis and to select specific regions for spatial profiling, running unbiased transcriptomic platforms (ST Visium, Curio) or targeted in situ platforms (Xenium, Merscope) on the frozen or FFPE tissue sections and pre-processing data and reporting QC metrics and reports, and supporting data analysis to identify cell types, cell states or cancer subclones in the tissue sections. Collectively, these components will provide comprehensive end-to-end support and expertise in spatial genomic methods to the user group.

**RP240432****PI:** Christine Beeton, Ph.D.**Title:** Advanced Multiparameter Cytometry and Cell Sorting Core**Applicant Organization:** Baylor College of Medicine**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.8**Recommended Total Budget Award and Duration:** \$1,999,882**CPRIT Priorities Addressed:** Investment in core facilities**Description:**

This is a renewal for the Advanced Multiparameter Cytometry and Cell Sorting Core facility, which assists cancer researchers who have identified or are in the process of identifying discrete cell populations and need to separate these cells based on large antibody panels and on expression levels, as well as subcellular localization of markers of interest. The core used previous CPRIT funds to expand their analysis capabilities through the creation of a high parameter analysis unit accessible to all cancer researchers within Baylor College of Medicine and the greater Houston area. Through this renewal, they aim to bridge the gap between high parameter analysis and high parameter sorting through the installation of the first spectral and imaging cell sorter, the support of current staff members, and the recruitment of a bioinformatician specialized in high parameter cytometry. This renewal will build upon the high parameter unit built with the prior funding and will provide cancer researchers the ability to not only analyze more than 30 markers on single cells, but also to sort cells based on expression levels and subcellular localization of these markers. This will provide them with the opportunity to study enriched populations of discrete cell types for function, genomics, and proteomics, and

to better define the roles of these cell subsets in tumor formation, resistance to treatment, and interactions with other cells of the tumor microenvironment.

**RP240430**

**PI:** Dong Liang, Ph.D.

**Title:** GCC Center for Comprehensive PK/PD & Formulation

**Applicant Organization:** Texas Southern University

**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.9

**Recommended Total Budget Award and Duration:** \$2,000,000

**CPRIT Priorities Addressed:** Investment in core facilities; A broad range of innovative, investigator-initiated research projects.

**Description:**

This is a renewal award to continue support for the GCC Center for Comprehensive pharmacokinetic/pharmacodynamic (PK/PD) & Formulation (CCPF) to expand preclinical drug development services to 1) include peptides and peptide mimetics such as peptoids; 2) enhance model-informed drug development tools such as physiologically-based pharmacokinetic (PBPK), to advance new technology in vitro drug metabolism and membrane permeability models; and 3) to include cost-effective non-GLP toxicokinetic services in rodents. In its first five years, CCPF has provided services for 211 novel small molecule drug candidate projects for investigators from 15 different academic institutions and/or companies in Texas. Through this expansion, they hope to be able to support an even larger range of innovative cancer therapeutics projects in Texas and enable a greater number of talented cancer researchers to advance a greater range of drug candidates toward IND filing, clinical trials, and ultimate commercialization.

**RP240508**

**PI:** Robert Volk, Ph.D.

**Title:** The Texas Decision Science Core Facility: A CPRIT Population Science Core

**Applicant Organization:** The University of Texas M. D. Anderson Cancer Center

**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.1

**Recommended Total Budget Award and Duration:** \$2,995,778

**CPRIT Priorities Addressed:** Investment in core facilities; A broad range of innovative, investigator-initiated research projects; Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions and population research addressing cancer disparities

**Description:**

The Texas Decision Science Core is a statewide resource for cancer research that combines the expertise and experience of the Decision Support Lab at MD Anderson Cancer Center with the network of Texas institutions participating in the UT Health Houston Center for Clinical Translation Science (CCTS). This new Core represents a significant expansion to meet the needs of cancer researchers at other Texas institutions, as it will extend its services through the Clinical Translation Science Hub at UTHealth Houston to reach rural patients from East Texas and Hispanics in the lower Rio Grande Valley and Far West Texas. The Core will support investigator-initiated research projects focused on improving the quality of decision-making in

cancer care and aims to prioritize decision-making projects about cancer prevention, early detection, treatment, and palliation services highlighted in the Texas Cancer Plan. The Core plans to expand services to researchers from Texas Regional Excellence in Cancer (TREC) eligible institutions affiliated with the UTHealth Houston CCTS. The overall goal of the Core is to improve the quality of patients' and clinicians' decisions about cancer care by serving as a state-wide resource for cancer researchers interested in decision science interventions about the prevention, early detection, and treatment of cancer.

**RP240559****PI:** Jennifer Brodbelt, Ph.D.**Title:** High Performance Mass Spectrometry Imaging Core Facility**Applicant Organization:** The University of Texas at Austin**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.1**Recommended Total Budget Award and Duration:** \$1,998,763**CPRIT Priorities Addressed:** Investment in core facilities; A broad range of innovative, investigator-initiated research projects; Computational oncology and analytic methods; Hepatocellular cancer**Description:**

This is a renewal award to continue support for expansion of the Mass Spectrometry Imaging Core facility at UT-Austin. The core was initially founded to aid cancer research based on integrating mass spectrometry imaging, ultraviolet photodissociation, and biostatistical tools to harvest chemical profiles from tissues and other biological samples. They have established connections to many cancer researchers from numerous medical institutions, particularly clinical/translational groups with an interest in understanding cancer etiology and predicting long-term outcomes based on variations in molecular profiles. Over the past two years, collaborations and services have been provided to 60 groups. These collaborations have spanned investigators at 21 institutions, including UT-Austin, Baylor College of Medicine, MD Anderson Cancer Center, Rice, UT Medical Branch at Galveston, UT Southwestern, The University of Houston, Houston Methodist, and TREC institutions Texas A&M and UT Rio Grande Valley. Future performance goals include increasing the number of users and types of samples imaged in the facility with a mission towards self-sustainability, expanding the types and depth of molecular coverage with new sample preparation strategies, and extending data analysis for multiplex applications.

**RP240521****PI:** Yang Xie, MD, Ph.D.**Title:** Pediatric Cancer Data Core**Applicant Organization:** The University of Texas Southwestern Medical Center**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.3**Recommended Total Budget Award and Duration:** \$1,999,760**CPRIT Priorities Addressed:** Investment in core facilities; Computational oncology and analytic methods; Childhood and adolescent cancers; Expanding access to innovative clinical trials, particularly to regions of the state currently with limited access

**Description:**

This is a renewal award to continue support for the Pediatric Cancer Data Core (PCDC) which was established in 2018. During the initial CPRIT funding period, PCDC achieved several significant milestones including successfully acquiring, standardizing, and integrating real-world pediatric cancer care data from various institutions. This effort has led to a comprehensive data resource, currently comprising data from more than 16,000 patients, 1,000 genomic profiling cases, and 21,000 pathology images. In addition, a suite of “Cancer Explorer” web portals was developed and released. These portals provide online data exploration, cohort formation, analysis, and visualization functions based on the PCDC databases, greatly enhancing researchers’ accessibility to pediatric cancer data. The PCDC was pivotal in fostering 98 grant applications and more than 100 peer-reviewed publications. The overarching objective of the project renewal is to provide a robust research platform and services that facilitate data sharing, management, harmonization, and analysis for the pediatric cancer research community.

### ***3. HIGH-IMPACT/HIGH RISK AWARDS (RFA R-24.2 HIHR) SLATE***

**Scientific Review Council Recommendations:**

Out of 101 High Impact/High Risk research award grant applications submitted, the SRC recommended 12, totaling \$2,998,030.

**Purpose of High Impact/High Risk Research Awards:**

Provides short-term funding to explore the feasibility of high-risk projects that, if successful, would contribute major new insights into the etiology, diagnosis, treatment, or prevention of cancers.

**High Impact/High Risk Research Award Funding Levels:**

Up to \$250,000 (total costs); Maximum duration: 2 years.

**Recommended HIHR Institutions (7):** Rice University, Texas Biomedical Research Institute, The University of Texas at Austin (3 awards), The University of Texas at Dallas (4 awards), The University Texas M.D. Anderson Cancer Center, The University of Texas at San Antonio, and The University of Texas Southwestern Medical Center

**Table 1: \*High Impact/High Risk Research Awards Recommended for Funding. Note that awards are listed in order of the evaluation score.**

ID	Score	Application Title	PI	PI Organization	Budget
RP240590	2.0	Bidentate ERK Traps: Revolutionizing Combination Cancer Therapy Strategies	Dalby, Kevin	The University of Texas at Austin	\$249,996
RP240539	2.0	Spectroscopy for quantitative real-time imaging of radical formation in ultra-high dose rate radiation therapy	Gustavsson, Anna-Karin	Rice University	\$250,000
RP240446	2.1	Regulation of Transcription Factor Function by Local Chromatin Context	Soshnev, Alexey	The University of Texas at San Antonio	\$249,561
RP240579	2.3	Renal Clearable Nano Delivery Systems for Maximizing Anti-tumor Immunity in Breast Cancer Brain Metastasis Treatment	Zheng, Jie	The University of Texas at Dallas	\$250,000
RP240462	2.5	Development of an Endoscopic Nuclear Imaging Capsule for Radio-Guided Cancer Surgery	Zannoni, Elena Maria	The University of Texas at Austin	\$250,000
RP240501	2.6	Delivering Immunotherapy more effectively to glioblastoma with a “magnetic switch”	Qin, Zhenpeng	The University of Texas at Dallas	\$250,000
RP240542	2.6	Digital Twin Augmented Reality for Prostate Laparoscopic Surgery	Fei, Baowei	The University of Texas at Dallas	\$250,000

RP240454	2.7	Reversing Tumor Immune Exclusion with Sphingosine-1-Phosphate Depleting Therapeutics	Stone, Everett	The University of Texas at Austin	\$249,998
RP240498	2.7	Improving the management of gastric peritoneal carcinomatosis with Photo-Betabody Immunotherapy	Obaid, Girgis	The University of Texas at Dallas	\$248,991
RP240493	2.8	Engineering in vivo chimeric antigen receptor (CAR) macrophages for diffuse midline glioma	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$250,000
RP240516	2.9	Mapping multivalent chromatin interactions to define the 3D genome of Clear cell renal cell carcinoma	Mani, Ram	The University of Texas Southwestern Medical Center	\$250,000
RP240605	3.1	Stimulate Mucosal-associated Invariant T cells to Kill Cancer Cells	Huang, Shouxiong	Texas Biomedical Research Institute	\$249,484

#### **4. MULTI-INVESTIGATOR RESEARCH AWARDS (RFA R-24.2 MIRA) SLATE**

**Scientific Review Council Recommendations:**

Out of 18 Multi-Investigator Research Awards grant applications submitted, the SRC recommended 5, totaling \$22,359,211.

**Purpose of Multi-Investigator Research Awards:** Supports highly integrated programs of collaborative and cross-disciplinary research among multiple Texas investigators and Institutions.

**Multi-Investigator Research Awards Funding Levels:** \$4,500,000 in total costs for a maximum period of 4 years.

**Recommended MIRA Institutions (4):** Baylor College of Medicine (2), The University Texas M.D. Anderson Cancer Center (2 awards), and The University of Texas Southwestern Medical Center

Note that the awards are listed in order of the evaluation score.

**RP240440**

**PI:** Richard Gorlick, M.D.

**Title:** Novel Therapies for Osteosarcoma

**Applicant Organization:** The University of Texas M. D. Anderson Cancer Center

**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]:1.8

**Recommended Total Budget Award and Duration:** \$4,498,684

**CPRIT Priorities Addressed:** A broad range of innovative, investigator-initiated research projects; Childhood and adolescent cancers; Expanding access to innovative clinical trials, particularly to regions of the state currently with limited access; Drug development

**Description:**

The overall goal of the Pediatric Osteosarcoma Research Program (POS RP) is to reduce morbidity and mortality from pediatric osteosarcoma (OS). This project consists of 3 projects and 3 cores with a goal to develop novel therapeutics for OS, which has not benefited from therapeutic advances over the last 30 years. The majority of OS patients are children, adolescents, and young adults, and over the past five years, the number of patients diagnosed with OS in the state of Texas has significantly increased. Although more patients are being diagnosed with OS, there have been no new therapies developed in more than three decades. This lack of newly available therapies is compounded by the fact that approximately 30 to 40% of OS patients will recur and/or relapse and that currently used chemotherapies are highly toxic. Moreover, combinations of two to four chemotherapies have not resulted in significant changes in OS patient survival. Thus, the POS RP will focus on identifying and validating OS cell-surface therapeutic targets and developing OS-specific targeted therapies in preclinical tumor models for clinical translation as well as for a clinical trial for the future treatment of OS patients.

**RP240438**

**PI:** Cliona Rooney, PhD

**Title:** Overcoming major barriers to the delivery of successful T-cell immunotherapies

**Applicant Organization:** Baylor College of Medicine

**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]:2.2

**Recommended Total Budget Award and Duration:** \$4,500,000

**CPRIT Priorities Addressed:** A broad range of innovative, investigator-initiated research projects; Hepatocellular cancer; Expanding access to innovative clinical trials, particularly to regions of the state currently with limited access.



**Description:**

The overarching goals of this MIRA are to produce safe and effective CAR-T cell (CAR-T) therapies that will be readily available at reduced cost for all patients, including those with hard-to-treat cancers. There are 3 subgoals encompassed by one or more projects to (1) provide all signals required for expansion and functional persistence of CAR-Ts in the TME; (2) overcome inhibitory signals of the TME; and (3) decrease the overall cost of CAR-T therapies to make them more accessible.

**RP240439****PI:** Sattva Neelapu, M.D.**Title:** Innovative cell therapy approaches for hematological and solid malignancies**Applicant Organization:** The University of Texas M. D. Anderson Cancer Center**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]:3.1**Recommended Total Budget Award and Duration:** \$4,500,000**CPRIT Priorities Addressed:** A broad range of innovative, investigator-initiated research projects, Expanding access to innovative clinical trials, particularly to regions of the state currently with limited access**Description:**

The overall goal of this MIRA is to develop innovative chimeric antigen receptor (CAR) T cell therapy approaches to solid tumors and hematological malignancies beyond B-cell malignancies and multiple myeloma. Although CAR-T cell therapy has been highly effective in patients with B-cell malignancies and multiple myeloma, translating this success to other tumors has been challenging due to several reasons including: 1) lack of defined and targetable tumor antigens; 2) on-target off-tumor toxicities induced by CAR-T cells; 3) the immunosuppressive tumor microenvironment; and 4) barriers to CAR-T cell trafficking and tumor infiltration. The three projects proposed in this proposal will address these major challenges using innovative approaches. Specifically, we will develop novel CAR-T products for T/NK-cell malignancies and ovarian, breast, and uterine cancers in a collaborative and cross-disciplinary approach. To achieve this goal, we have formed a ‘Consortium for Immune Cell Engineering’ from two Texas institutions, MD Anderson Cancer Center (MDACC) and the University of Houston and bring together three Principal Investigators (PIs) and a multidisciplinary team of co-investigators with complementary expertise who will integrate basic and clinical disciplines for aggressive translation of laboratory discoveries into the clinic.

**RP240489****PI:** Sean Morrison, PhD**Title:** Neural Regulation of Childhood Cancers**Applicant Organization:** The University of Texas Southwestern Medical Center**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)] 3.2**Recommended Total Budget Award and Duration:** \$4,362,563**CPRIT Priorities Addressed:** A broad range of innovative, investigator-initiated research projects; Childhood and adolescent cancers; Expanding access to innovative clinical trials, particularly to regions of the state currently with limited access; Drug discovery.

**Description:**

This MIRA research project is designed to address two fundamental questions related to the neural regulation of cancers arising in childhood, a period in life when the nervous system displays remarkable plasticity. First, what are the molecular mechanisms through which cancer cells promote neuronal activity? Second, how does reciprocal neuron-cancer signaling regulate cancers, including in bones and bone marrow?

This research will include complementary studies in acute leukemia, osteosarcoma, and glioma, integrating findings to better understand the neural regulation of pediatric cancers. Through this effort, they aim to open new areas of inquiry related to our understanding of neuron-cancer crosstalk and use these insights to develop new therapies for pediatric cancers.

**RP240474****PI:** Leonid Metelitsa, M.D., PhD**Title:** Cellular Immunotherapies for Pediatric Solid Tumors**Applicant Organization:** Baylor College of Medicine**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]:3.6**Recommended Total Budget Award and Duration:** \$4,497,964**CPRIT Priorities Addressed:** A broad range of innovative, investigator-initiated research projects; Childhood and adolescent cancers; Expanding access to innovative clinical trials, particularly to regions of the state currently with limited access.**Description:**

The focus of this research is the development and clinical testing of innovative cell therapies for children with solid tumors, for cancers that are currently difficult to cure. The investigators aim to develop new treatments as well as to understand more about how these treatments work, how we can improve them, and what side effects they might have. This research could pave the way for future advances in cancer therapy, ultimately benefiting both children and adults.

The goal of this proposal is to develop safe and effective immunotherapies for GD2-positive pediatric solid tumors using innovative cell-based products that combine cutting-edge advances in immunology and synthetic biology to effectively target tumor cells and tumor-supportive elements in the tumor microenvironment (TME).

GD2 is a marker that is expressed at high levels in some of the most difficult to treat childhood cancers including neuroblastoma, osteosarcoma, and certain brain tumors such as diffuse midline glioma. Several treatments designed to target GD2 have been proven safe and shown promising clinical responses. However, the success rates of these treatments are still quite low, especially when compared to responses seen in patients with blood cancers. This is due to several reasons including that the therapy may not reach the site of the tumor, the tumor microenvironment prevents the therapy from working effectively, or the cancer changes to evade treatment.

## **5. RECRUITMENT OF FIRST-TIME TENURE-TRACK FACULTY MEMBERS (RFA R-24.1 – Cycle 24.12) Slate**

### **Peer Review Recommendations**

The applications were evaluated and scored by the Scientific Review Council to determine the candidates' potential to make a significant contribution to the cancer research program of the nominating institution. Review criteria focused on the overall impression of the candidate and his/her potential for continued superb performance as a cancer researcher, scientific merit of the proposed research program, his/her long-term contribution to and impact on the field of cancer research, and strength of the institutional commitment to the candidate.

### **Purpose of First-Time Tenure-Track Faculty Recruitment**

The aim is to recruit and support very promising emerging investigators, pursuing their first faculty appointment in Texas, who can make outstanding contributions to the field of cancer research.

### **Funding levels for First-Time Tenure-Track Faculty Members Recruitment**

Up to \$2 million over a period of up to 5 years.

### **Recommended Projects:**

Eight Recruitment of First-Time Tenure-Track Faculty Members grant applications were submitted and four were recommended by the Scientific Review Council for an award.

Below is a listing of the candidates with their associated expertise:

#### **RR240070**

**Candidate:** Louai Labanieh PhD

**Funding Mechanism:** Recruitment of First-Time, Tenure Track Faculty Member

**Title:** Expanding the Accessibility and Efficacy of CAR-T Cells Through In Vivo Engineering

**Applicant Organization:** Baylor College of Medicine

**Original Organization of Nominee:** Stanford University

**Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]:**1.0

**Recommended Total Budget Award and Duration:** \$2,000,000.

**CPRIT Priorities Addressed:** Recruitment of outstanding cancer researchers to Texas, Childhood and Adolescent cancers

### **Description:**

Louai Labanieh PhD is being recruited to Baylor College of Medicine for his first tenure-track Assistant Professor position and has been nominated for a CPRIT Scholar Award in Cancer Research. He will be jointly recruited to the Center for Cell and Gene Therapy, the Dan L. Duncan Comprehensive Cancer Center, and the Department of Molecular and Cell Biology. Dr. Labanieh is an exceptionally well-qualified candidate with a strong background in synthetic biology, immunology, and immune engineering.

Patient-derived T cells that have been genetically engineered in the laboratory to express chimeric antigen receptors (CAR-T) have shown remarkable clinical success against hematologic cancers, leading to 6 commercial CAR-T drugs across 14 FDA approvals. However, the complicated manufacturing and logistical challenges associated with current CAR-T manufacturing methods limit who stands to benefit from this class of therapeutics. In vivo engineering has the potential to overcome these limitations and expand the access of these potent immunotherapies but requires technical innovations for clinical deployment.

During his training at Stanford University with Dr. Crystal Mackall, a translational immunotherapy expert and Dr. Jennifer Cochran, a pioneer in the field of protein engineering and biochemistry, Dr. Labanieh developed the SNIP system - a drug-regulated CAR platform that enhances the safety and efficacy of CAR-T cells - which is now moving to clinical testing and has been licensed as a best-in-class platform. He now proposes to develop platform technologies for in vivo engineering that could overcome current barriers and enable cell therapies to be generated in situ via a gene delivery vector, e.g., lentivirus or mRNA, that can be directly infused into the patient, resulting in broader applicability of “off-the-shelf” CAR-T therapy.

In Aim 1, he will seek to overcome the limited infection efficiencies seen in vivo and develop methods to expand T cell numbers to therapeutic levels, by developing, testing, and characterizing a synthetic cytokine receptor system which allows for regulated expansion of T cells in vivo using a small molecule drug (note: cytokines are modulators of cell signaling in immune cells). In Aim 2, he will tackle another limitation, namely improving the specificity of infection of immune cells, i.e., targeting the desired population of T cells, to improve safety and clinical translatability. Specifically, he will develop novel lentivirus-based gene delivery vectors which sense host mRNAs and only activate within target cell types of interest. This innovative approach using regulated control over CAR-T cell behavior provides opportunities to enhance their safety and efficacy as cancer therapies and has the potential to have widespread impact on cellular immunotherapy for neoplastic diseases.

**RR240076**

**Candidate:** Hojong Yoon, PhD

**Funding Mechanism:** Recruitment of First-Time, Tenure Track Faculty Member

**Title:** Discovery of Molecular Glue Degradable Targeting the Undruggable Cancer Proteome

**Applicant Organization:** The University of Texas M. D. Anderson Cancer Center

**Original Organization of Nominee:** Broad Institute of MIT and Harvard University

**Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]:**1.0

**Recommended Total Budget Award and Duration:** \$2,000,000.

**CPRIT Priorities Addressed:** Recruitment of outstanding cancer researchers to Texas; Drug Discovery

**Description:**

The University of Texas MD Anderson Cancer Center has nominated Hojong Yoon, PhD for a CPRIT First-Time, Tenure-Track Faculty Award, and appointment as an Assistant Professor in the Department of Experimental Therapeutics. Dr. Yoon is an outstanding research scientist who

has already made substantial contributions as a chemical biologist with unique expertise in small molecule drug discovery and targeted protein degradation. His work will focus on developing small molecules to target undruggable proteins, through a combination of techniques in medicinal chemistry, biochemistry, structural biology and genetic screens. Dr. Yoon is already accomplished in securing outside funding, including an NCI F99/K00 award supporting his transition from pre- to post-doctoral research, and an NCI Pathway to Independence Early Career K99/R00 award in 2024.

Recent advances in cancer biology have led to the identification of a number of cancer-driving genes and proteins for targeted cancer therapy. Traditional drugs act by fitting into specific pockets on proteins, but many cancer-related proteins lack these structural features. “Molecular glue degraders” have emerged as a promising solution for targeting these difficult proteins. These compounds work by binding two proteins together: the target protein to be eliminated, and another protein that marks it for destruction (an E3 ligase, the body’s natural protein-disposal system). Although these two proteins do not naturally interact, their surfaces are highly complementary, and molecular glues provide the additional binding energy needed to stabilize this interaction.

There have been several successes in bringing molecular glues to the clinic as new therapies; however, most discoveries of molecular glue degraders thus far have been serendipitous, and there is no systematic approach to finding such molecules. To address these problems, Dr. Yoon developed a highly innovative chemical proteomic platform that can identify novel molecular glue compounds. As proof-of-principle of this approach, he identified a novel molecular glue degrader - M12 - which recruits DDX18 to an E3 ligase complex for targeted degradation. DDX18 is an undruggable transcriptional activator that promotes pancreatic ductal adenocarcinoma (PDAC). In his independent laboratory, Dr. Yoon aims to develop this DDX18 molecular glue degrader through preclinical validation, and to translate it into clinical applications for PDAC treatment. Ultimately, this research will provide a foundation for novel therapeutic strategies and has the potential to significantly advance the treatment of PDAC.

**RR240082****Candidate:** Yanjun Sun, PhD**Funding Mechanism:** Recruitment of First-Time, Tenure Track Faculty Member**Title:** Identification of Neural Mechanisms Contributing to Chemotherapy-Associated Cognitive Impairments**Applicant Organization:** The University of Texas Health Science Center at Houston**Original Organization of Nominee:** Stanford University**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]:1.2**Recommended Total Budget Award and Duration:** \$2,000,000.**CPRIT Priorities Addressed:** Recruitment of outstanding cancer researchers to Texas**Description:**

Yanjun Sun, PhD, has been nominated by the University of Texas Health Science Center at Houston for a CPRIT First-time, Tenure-track Faculty Scholar Award, and appointment as an Assistant Professor in the Department of Neurobiology and Anatomy. As a well-trained

neurobiologist, Dr. Sun has focused on investigating the neural circuit mechanisms of learning and memory, specifically studying the functional cell types (e.g., place neurons) underlying learning and memory, as well as cognitive impairments. Dr. Sun is a recipient of a K01 grant from the National Institute on Drug Abuse to investigate neural mechanisms underlying how a specific context forms associative memory with drugs of abuse. Recently, he received the prestigious Simons Collaboration on the Global Brain Transition to Independence Award. In his proposed research, Dr. Sun will investigate the neural mechanisms contributing to chemotherapy-induced cognitive impairments to discover strategies to alleviate this condition.

For many cancer patients, chemotherapy remains the best treatment option. However, about 75% of patients undergoing chemotherapy develop cognitive impairments, with around 50% experiencing long-lasting effects post-chemotherapy. These impairments, collectively termed chemotherapy-induced cognitive impairment (CICI) or ‘chemobrain’, include memory deficits, concentration difficulties, and impaired executive function, significantly impacting survivors' quality-of-life. At present, the neural circuit mechanisms driving chemotherapy-induced learning and memory deficits remain unclear, resulting in the lack of effective treatments for these side effects. Dr. Sun’s research aims to fill this gap by elucidating the chemotherapy-induced neuroanatomical and neurophysiological changes in the hippocampus, and probing whether we can prevent or reverse CICI using a novel antibody-based treatment.

In Aim 1, he will use viral tracers to map changes in the connections between neurons in the hippocampus after chemotherapy, to determine a clear understanding of the changes in brain circuit wiring. Next in Aim 2, he will use advanced neural imaging techniques to simultaneously monitor the activity of hundreds of hippocampal neurons and determine how chemotherapy changes their normal activity patterns. Identifying these abnormal activities will help reveal the underlying mechanisms that lead to disrupted brain function. Finally in Aim 3, he will test a new potential therapeutic for CICI by reducing brain inflammation using a novel antibody that can directly penetrate the brain. This research may lead to an improved understanding of how chemotherapy changes the brain and could lead to new treatments that reduce cognitive side effects, improving the quality-of-life for cancer survivors.

**RR240079**

**Candidate:** Marianna Trakala, PhD

**Funding Mechanism:** Recruitment of First-Time, Tenure Track Faculty Member

**Title:** Immune surveillance and elimination of aneuploid cells in vivo

**Applicant Organization:** The University of Texas M. D. Anderson Cancer Center

**Original Organization of Nominee:** Massachusetts Institute of Technology

**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]:1.7

**Recommended Total Budget Award and Duration:** \$2,000,000.

**CPRIT Priorities Addressed:** Recruitment of outstanding cancer researchers to Texas

**Description:**


The University of Texas MD Anderson Cancer Center is recruiting Marianna Trakala, PhD, to the Department of Genetics as an Assistant Professor, and has nominated her for a CPRIT First-time, Tenure-track Faculty Award. Dr. Trakala’s research has focused on understanding the

molecular mechanisms underlying cell division, and the consequences that errors in this process have on cellular physiology and the development of aneuploidy. Aneuploidy – an abnormal number of chromosomes - is a hallmark of human cancer, and commonly results from chromosomal instability. During her post-doctoral fellowship at MIT, Dr. Trakala generated a novel mouse model, which induces chromosome missegregation and aneuploidy in vivo. She discovered that the mice had low levels of aneuploidy in various tissues such as the intestinal tract, which led to the hypothesis that aneuploid cells were being recognized and eliminated by the immune system. She later showed that CD8 T-cells and natural killer cells in the small intestine can eliminate aneuploid cells in vivo.

Dr. Trakala is now deeply invested in understanding the immune response, identifying the immune cell types that participate in the immune response against aneuploidy, and determining how aneuploidy triggers this immune response and why it fails in some circumstances leading to the retention of aneuploid cells and, eventually, transformation. To this end, she will focus on colorectal cancer, and will use genetic, single-cell, and proteomic, genomic, and transcriptomic models to (1) Identify the main immune cell types that participate in the immune response against aneuploid cells in vivo, as well as the underlying molecular mechanisms; (2) Explore how aneuploidy can affect the repertoire of immunopeptides and the implications that this has on the adaptive immune response; and (3) Study how overall immune surveillance is affected in the presence of driver oncogenes, and how oncogenic transformation can impact the elimination of aneuploid cells by the immune system. The long-term goal is to develop new treatments that combine immune-based therapies with other targeted approaches.

**Attachment #1**

*Academic Research Program Priorities Addressed by Recommended Awards									
(*Some grant awards address more than one program priority and are double counted.)									
Scale	Recruitment of outstanding cancer researchers to Texas	Drug Discovery	A broad range of innovative, investigator-initiated research projects.	Childhood and Adolescent Cancers	Implementation Research	Computational oncology and analytic methods	Hepatocellular Cancer	Clinical Trials	Investment in Core Facilities





**Attachment #2**  
RFA Descriptions



- **Clinical Investigator Award (RFA R-24-2. CIA):**  
Supports mid-career clinician scientists with specialty training relevant to delivery of cancer care to devote more time to augment their capabilities in clinical cancer research, and to provide mentoring to early-stage investigators in the conduct of clinical research.  
*Award: Up to \$1,500,000 for a period of up to five years.*
- **Core Facility Support Awards (RFA R-24-2. CFSA):**  
Supports applications that facilitate the development or improvement of core facilities that will provide valuable services to support and enhance scientifically meritorious cancer research projects.  
*Award: Up to \$3 million over a period of five years.*
- **High-Impact/High-Risk Research Awards (RFA R-24-2. HIHRA):**  
Supports applications that explore the feasibility of high-risk projects that, if successful, would contribute major new insights into the etiology, diagnosis, treatment, or prevention of cancers.  
*Award: Up to \$250,000 for a period of up to 24 months.*
- **Multi-Investigator Research Awards (RFA R-24-2. MIRA):**  
Supports highly integrated programs of collaborative and cross-disciplinary research among multiple Texas investigators and Institutions  
*Award: Up to \$4,500,000 over a period of four years.*
- **Recruitment of First-Time, Tenure-Track Faculty Members (RFA R-24-1. RFT):**  
Supports very promising emerging investigators, pursuing their first faculty appointment in Texas, who have the ability to make outstanding contributions to the field of cancer research.  
*Award: Up to \$2 million over a period of up to five years.*

# UC San Diego

## SCHOOL OF MEDICINE

July 29, 2024

Dr. David A. Cummings, M.D.  
Oversight Committee Presiding Officer  
Cancer Prevention and Research Institute of Texas  
Via email to [dcummingsmd@yahoo.com](mailto:dcummingsmd@yahoo.com)

Ms. Kristen Doyle  
Chief Executive Officer  
Cancer Prevention and Research Institute of Texas  
Via email to [kdoyle@cprit.texas.gov](mailto:kdoyle@cprit.texas.gov)

Dear Dr. Cummings and Ms. Doyle,

The Scientific Review Council (SRC) is pleased to submit this list of 36 research grant recommendations for the Clinical Investigator Award, Core Facility Support Awards, High-Impact/High Risk Awards, Multi-Investigator Research Awards and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on July 11, 2024 to review First-Time Tenure-Track Faculty Members recruitment applications submitted for Cycle FY24.12 and to consider the applications recommended by the peer review panels following their meetings held April 16, 2024 to April 25, 2024. On July 29, 2024 the SRC met to discuss application RP240474, which was peer reviewed on April 25, 2024 but not recommended. The application received a favorable score but just missed the cut off line made by the peer review panel. The SRC chose to consider and recommend RP240474 because of how it addresses program priorities of childhood and adolescent cancers. With available funds the SRC recommended RP240474 to the Program Integration Committee (PIC), bringing the total number of recommended academic research awards to 36.

Recommended funding amounts and the overall evaluation score are stated for each grant application in the following table. The total amount for the applications recommended to the PIC is \$60,577,922.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • [rkolodner@health.ucsd.edu](mailto:rkolodner@health.ucsd.edu)

Richard D. Kolodner, Ph.D.  
Chair, CPRIT Scientific Review Council

Rank	ID	RFA	Score	Application Title	PI	PI Org.	Rec. Budget
1	RP240545	CFSA	1.0	Renewal of CPRIT GMP Core	Lapteva, Natalia	Baylor College of Medicine	\$2,000,000
2	RR240070	RFTFM	1.0	Expanding the Accessibility and Efficacy of CAR-T Cells Through In Vivo Engineering	Labanieh, Louai	Baylor College of Medicine	\$2,000,000
3	RR240076	RFTFM	1.0	Discovery of Molecular Glue Degraders Targeting the Undruggable Cancer Proteome	Yoon, Hojong	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
4	RR240082	RFTFM	1.2	Identification of Neural Mechanisms Contributing to Chemotherapy-Associated Cognitive Impairments	Sun, Yanjun	The University of Texas Health Science Center at Houston	\$2,000,000
5	RP240610	CFSA	1.4	UTHealth Cancer Genomics Core (UTHealth CGC)	Zhao, Zhongming	The University of Texas Health Science Center at Houston	\$2,000,000
6	RP240478	CIA	1.4	Advancing immunotherapy for high-risk cancers in children and adolescents	Hegde, Meenakshi	Baylor College of Medicine	\$1,030,892
7	RP240473	CIA	1.6	Signal-Augmented Cancer Cell Therapies: Integrating Advanced	Omer, Bilal	Baylor College of Medicine	\$1,046,414

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

**UC San Diego**  
SCHOOL OF MEDICINE

				Correlatory Studies and Mentorship			
8	RP240494	CFSA	1.7	Children's Research Institute Metabolomics Core: Advanced Methodologies in Cancer Metabolism	DeBerardinis, Ralph	The University of Texas Southwestern Medical Center	\$2,601,616
9	RP240497	CFSA	1.7	Advanced Spatial Genomics Core Facility	Navin, Nicholas	The University of Texas M. D. Anderson Cancer Center	\$2,999,993
10	RR240079	RFTFM	1.7	Immune surveillance and elimination of aneuploid cells in vivo	Trakala, Marianna	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
11	RP240432	CFSA	1.8	Advanced Multiparameter Cytometry and Cell Sorting Core	Beeton, Christine	Baylor College of Medicine	\$1,999,882
12	RP240440	MIRA2	1.8	Novel Therapies for Osteosarcoma	Gorlick, Richard	The University of Texas M. D. Anderson Cancer Center	\$4,498,684
13	RP240557	CIA	1.8	Dietary intervention to modulate the microbiome and immune response	McQuade, Jennifer	The University of Texas M. D. Anderson Cancer Center	\$1,074,727
14	RP240430	CFSA	1.9	GCC Center for Comprehensive PK/PD & Formulation	Liang, Dong	Texas Southern University	\$2,000,000
15	RP240590	HIHRA	2.0	Bidentate ERK Traps: Revolutionizing Combination Cancer Therapy Strategies	Dalby, Kevin	The University of Texas at Austin	\$249,996
16	RP240539	HIHRA	2.0	Spectroscopy for quantitative real-time imaging of radical formation	Gustavsson, Anna-Karin	Rice University	\$250,000

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

				in ultra-high dose rate radiation therapy			
17	RP240508	CFSA	2.1	The Texas Decision Science Core Facility: A CPRIT Population Science Core	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	\$2,995,778
18	RP240446	HIHRA	2.1	Regulation of Transcription Factor Function by Local Chromatin Context	Soshnev, Alexey	The University of Texas at San Antonio	\$249,561
19	RP240442	CIA	2.1	Identifying and exploiting novel metabolic vulnerabilities in the treatment of kidney cancer	Courtney, Kevin	The University of Texas Southwestern Medical Center	\$913,682
20	RP240559	CFSA	2.1	High Performance Mass Spectrometry Imaging Core Facility	Brodbelt, Jennifer	The University of Texas at Austin	\$1,998,763
21	RP240441	CIA	2.2	Precision Lung Cancer Interception by Targeting High-Risk Lung Nodules	Zhang, Jianjun	The University of Texas M. D. Anderson Cancer Center	\$1,098,945
22	RP240438	MIRA2	2.2	Overcoming major barriers to the delivery of successful T-cell immunotherapies	Rooney, Cliona	Baylor College of Medicine	\$4,500,000
23	RP240579	HIHRA	2.3	Renal Clearable Nano Delivery Systems for Maximizing Anti-tumor Immunity in Breast Cancer Brain Metastasis Treatment	Zheng, Jie	The University of Texas at Dallas	\$250,000
24	RP240521	CFSA	2.3	Pediatric Cancer Data Core	Xie, Yang	The University of Texas Southwestern Medical Center	\$1,999,760

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

**UC San Diego**  
SCHOOL OF MEDICINE

25	RP240518	CIA	2.4	Adapting radiotherapy clinical trials to treatment response and artificial intelligence innovations	Desai, Neil	The University of Texas Southwestern Medical Center	\$1,460,229
26	RP240462	HIHRRRA	2.5	Development of an Endoscopic Nuclear Imaging Capsule for Radio-Guided Cancer Surgery	Zannoni, Elena Maria	The University of Texas at Austin	\$250,000
27	RP240501	HIHRRRA	2.6	Delivering Immunotherapy more effectively to glioblastoma with a “magnetic switch”	Qin, Zhenpeng	The University of Texas at Dallas	\$250,000
28	RP240542	HIHRRRA	2.6	Digital Twin Augmented Reality for Prostate Laparoscopic Surgery	Fei, Baowei	The University of Texas at Dallas	\$250,000
29	RP240454	HIHRRRA	2.7	Reversing Tumor Immune Exclusion with Sphingosine-1-Phosphate Depleting Therapeutics	Stone, Everett	The University of Texas at Austin	\$249,998
30	RP240498	HIHRRRA	2.7	Improving the management of gastric peritoneal carcinomatosis with Photo-Betabody Immunotherapy	Obaid, Girgis	The University of Texas at Dallas	\$248,991
31	RP240493	HIHRRRA	2.8	Engineering in vivo chimeric antigen receptor (CAR) macrophages for diffuse midline glioma	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$250,000
32	RP240516	HIHRRRA	2.9	Mapping multivalent chromatin	Mani, Ram	The University of Texas	\$250,000

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

**UC San Diego**  
SCHOOL OF MEDICINE

				interactions to define the 3D genome of Clear cell renal cell carcinoma		Southwestern Medical Center	
33	RP240605	HIHRA	3.1	Stimulate Mucosal-associated Invariant T cells to Kill Cancer Cells	Huang, Shouxiong	Texas Biomedical Research Institute	\$249,484
34	RP240439	MIRA2	3.1	Innovative cell therapy approaches for hematological and solid malignancies	Neelapu, Sattva	The University of Texas M. D. Anderson Cancer Center	\$4,500,000
35	RP240489	MIRA2	3.2	Neural Regulation of Childhood Cancers	Morrison, Sean	The University of Texas Southwestern Medical Center	\$4,362,563
36	RP240474	MIRA2	3.6	Cellular Immunotherapies for Pediatric Solid Tumors	Metelitsa, Leonid	Baylor College of Medicine	\$4,497,964

Clinical Investigator Award (CIA)  
Core Facility Support Awards (CFSA)  
High-Impact/High Risk Awards (HIHR)  
Multi-Investigator Research Awards (MIRA2)  
Recruitment of First-Time, Tenure Track Faculty Members (RFTTFM)

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu



CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

August 9, 2024

Dear Oversight Committee Members:

I am pleased to present the Program Integration Committee's (PIC) unanimous recommendation for funding 36 grant applications totaling \$60,577,922. I have attached the PIC's recommendations for the 36 academic research grant awards.

CPRIT Chief Scientific Officer Dr. Michelle Le Beau has prepared an overview of the recommended academic research slates to assist your evaluation of the recommended awards. We intend for the overview to provide a comprehensive summary with enough detail to understand the substance of the proposal and the reasons endorsing grant funding. In addition to the full overview, all the information considered by the Scientific Review Council is available by clicking on the appropriate link in the portal. This information includes the application, peer reviewer critiques, and the CEO affidavit for each proposal.

The statutory process governing the approval of these grant recommendations requires two-thirds of the members present and voting to approve each recommendation. Vince Burgess, CPRIT's Chief Compliance Officer, will certify that the review process for the recommended grants followed CPRIT's award process prior to any Oversight Committee action.

The award recommendations are not final until the Oversight Committee approves the awards at the meeting on August 21, 2024. Consistent with the non-disclosure agreement that all Oversight Committee members have signed, please keep the recommendations confidential and do not disclose information to anyone until CPRIT announces the award list publicly at the Oversight Committee meeting. I request that Oversight Committee members not print, email, or save to your computer's hard drive any material on the portal. I appreciate your assistance in taking all necessary precautions to protect this information.

These projects recommended for awards are a major step in our efforts to mitigate the effects of cancer in Texas. If you have any questions or would like more information on the review process or any of the proposed projects, CPRIT's staff, including myself and Dr. Le Beau, are always available. Please feel free to contact us directly should you have any questions.

Thank you for being part of this endeavor.

Sincerely,  
Kristen P. Doyle  
Chief Executive Officer



**ACADEMIC RESEARCH GRANT AWARD RECOMMENDATIONS**

The PIC unanimously recommends approval of 36 academic research grant proposals totaling \$60,577,922. Applicants submitted the recommended grant proposals in response to the following grant mechanisms: *Clinical Investigator Award; Core Facility Support Awards; High-Impact/High-Risk Research Awards; Multi-Investigator Research Awards; and Recruitment of First-Time, Tenure-Track Faculty Members*. The Scientific Review Council (SRC) provided a prioritized list of 36 grant award recommendations to the presiding officers of the PIC and Oversight Committee on July 29, 2024.

The PIC must give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these academic research proposals met the following CPRIT funding priorities:

Statutory Funding Priority	CIA	CFSA	HIHRRRA	MIRA2	RFTFM
<i>CIA: Clinical Investigator Award            CFSA: Core Facility Support Awards            HIHRRRA: High-Impact/High Risk Research Awards            MIRA2: Multi-Investigator Research Awards            RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>					
Could lead to immediate or long-term medical and scientific breakthroughs in the area of cancer prevention or cures for cancer;	✓	✓	✓	✓	✓
Strengthen and enhance fundamental science in cancer research;	✓	✓	✓	✓	✓
Ensure a comprehensive coordinated approach to cancer research;	✓	✓		✓	✓
Are interdisciplinary or interinstitutional;	✓	✓		✓	✓
Address federal or other major research sponsors' priorities in emerging scientific or technology Fields in the area of cancer prevention or cures for cancer;	✓	✓	✓	✓	✓
Are matched with funds available by a private or nonprofit entity and institution or institutions of higher education;	✓	✓	✓	✓	✓
Are collaborative between any combination of private and nonprofit entities, public or private agencies or institutions in this state, and public or private institutions outside this state		✓		✓	
Have a demonstrable economic development benefit to this state	✓	✓	✓	✓	✓
Enhance research superiority at institutions of higher education in this state by creating new research superiority, attracting existing research superiority from institutions not located in this state and other research entities, or enhancing existing research	✓	✓	✓	✓	✓

Statutory Funding Priority	CIA	CFSA	HIHRRRA	MIRA2	RFTFM
<i>CIA: Clinical Investigator Award</i> <i>CFSA: Core Facility Support Awards</i> <i>HIHRRRA: High-Impact/High Risk Research Awards</i> <i>MIRA2: Multi-Investigator Research Awards</i> <i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>					
superiority by attracting from outside this state additional researchers and resources					
Expedite innovation and product development, attract, create, or expand private sector entities that will drive a substantial increase in high-quality jobs, and increase higher education applied science or technology research capabilities	✓	✓		✓	✓
Address the goals of the Texas Cancer Plan	✓	✓	✓	✓	✓

<b>Academic Research Award Recommendations</b> <b>Research Cycle 24.2 and Recruitment Cycle 24.12</b>							
<i>CIA: Clinical Investigator Award</i> <i>CFSA: Core Facility Support Awards</i> <i>HIHRRRA: High-Impact/High Risk Research Awards</i> <i>MIRA2: Multi-Investigator Research Awards</i> <i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>							
Rank	App. ID	Mech.	Application Title	PI	PI organization	Budget	Final score
1	RP240545	CFSA	Renewal of CPRIT GMP Core	Lapteva, Natalia	Baylor College of Medicine	\$2,000,000	1.0
2	RR240070	RFTFM	Expanding the Accessibility and Efficacy of CAR-T Cells Through In Vivo Engineering	Labanieh, Louai	Baylor College of Medicine	\$2,000,000	1.0
3	RR240076	RFTFM	Discovery of Molecular Glue Degradors Targeting the Undruggable Cancer Proteome	Yoon, Hojong	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.0
4	RR240082	RFTFM	Identification of Neural Mechanisms Contributing to Chemotherapy-Associated Cognitive Impairments	Sun, Yanjun	The University of Texas Health Science Center at Houston	\$2,000,000	1.2

<b>Academic Research Award Recommendations</b> <b>Research Cycle 24.2 and Recruitment Cycle 24.12</b> <i>CIA: Clinical Investigator Award</i> <i>CFSA: Core Facility Support Awards</i> <i>HIHRR: High-Impact/High Risk Research Awards</i> <i>MIRA2: Multi-Investigator Research Awards</i> <i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>							
Rank	App. ID	Mech.	Application Title	PI	PI organization	Budget	Final score
5	RP240610	CFSA	UTHealth Cancer Genomics Core (UTHealth CGC)	Zhao, Zhongming	The University of Texas Health Science Center at Houston	\$2,000,000	1.4
6	RP240478	CIA	Advancing immunotherapy for high-risk cancers in children and adolescents	Hegde, Meenakshi	Baylor College of Medicine	\$1,030,892	1.4
7	RP240473	CIA	Signal-Augmented Cancer Cell Therapies: Integrating Advanced Correlatory Studies and Mentorship	Omer, Bilal	Baylor College of Medicine	\$1,046,414	1.6
8	RP240494	CFSA	Children's Research Institute Metabolomics Core: Advanced Methodologies in Cancer Metabolism	DeBerardinis, Ralph	The University of Texas Southwestern Medical Center	\$2,601,616	1.7
9	RP240497	CFSA	Advanced Spatial Genomics Core Facility	Navin, Nicholas	The University of Texas M. D. Anderson Cancer Center	\$2,999,993	1.7
10	RR240079	RFTFM	Immune surveillance and elimination of aneuploid cells in vivo	Trakala, Marianna	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.7
11	RP240432	CFSA	Advanced Multiparameter Cytometry and Cell Sorting Core	Beeton, Christine	Baylor College of Medicine	\$1,999,882	1.8
12	RP240440	MIRA2	Novel Therapies for Osteosarcoma	Gorlick, Richard	The University of Texas M. D. Anderson Cancer Center	\$4,498,684	1.8

<b>Academic Research Award Recommendations</b> <b>Research Cycle 24.2 and Recruitment Cycle 24.12</b> <i>CIA: Clinical Investigator Award</i> <i>CFSA: Core Facility Support Awards</i> <i>HIHRRRA: High-Impact/High Risk Research Awards</i> <i>MIRA2: Multi-Investigator Research Awards</i> <i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>							
Rank	App. ID	Mech.	Application Title	PI	PI organization	Budget	Final score
13	RP240557	CIA	Dietary intervention to modulate the microbiome and immune response	McQuade, Jennifer	The University of Texas M. D. Anderson Cancer Center	\$1,074,727	1.8
14	RP240430	CFSA	GCC Center for Comprehensive PK/PD & Formulation	Liang, Dong	Texas Southern University	\$2,000,000	1.9
15	RP240590	HIHRRRA	Bidentate ERK Traps: Revolutionizing Combination Cancer Therapy Strategies	Dalby, Kevin	The University of Texas at Austin	\$249,996	2.0
16	RP240539	HIHRRRA	Spectroscopy for quantitative real- time imaging of radical formation in ultra-high dose rate radiation therapy	Gustavsson, Anna- Karin	Rice University	\$250,000	2.0
17	RP240508	CFSA	The Texas Decision Science Core Facility: A CPRIT Population Science Core	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	\$2,995,778	2.1
18	RP240446	HIHRRRA	Regulation of Transcription Factor Function by Local Chromatin Context	Soshnev, Alexey	The University of Texas at San Antonio	\$249,561	2.1
19	RP240442	CIA	Identifying and exploiting novel metabolic vulnerabilities in the treatment of kidney cancer	Courtney, Kevin	The University of Texas Southwestern Medical Center	\$913,682	2.1
20	RP240559	CFSA	High Performance Mass Spectrometry Imaging Core Facility	Brodbelt, Jennifer	The University of Texas at Austin	\$1,998,763	2.1
21	RP240441	CIA	Precision Lung Cancer Interception by Targeting High- Risk Lung Nodules	Zhang, Jianjun	The University of Texas M. D.	\$1,098,945	2.2

<b>Academic Research Award Recommendations</b> <b>Research Cycle 24.2 and Recruitment Cycle 24.12</b> <i>CIA: Clinical Investigator Award</i> <i>CFSA: Core Facility Support Awards</i> <i>HIHRRRA: High-Impact/High Risk Research Awards</i> <i>MIRA2: Multi-Investigator Research Awards</i> <i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>							
Rank	App. ID	Mech.	Application Title	PI	PI organization	Budget	Final score
					Anderson Cancer Center		
22	RP240438	MIRA2	Overcoming major barriers to the delivery of successful T-cell immunotherapies	Rooney, Cliona	Baylor College of Medicine	\$4,500,000	2.2
23	RP240579	HIHRRRA	Renal Clearable Nano Delivery Systems for Maximizing Anti- tumor Immunity in Breast Cancer Brain Metastasis Treatment	Zheng, Jie	The University of Texas at Dallas	\$250,000	2.3
24	RP240521	CFSA	Pediatric Cancer Data Core	Xie, Yang	The University of Texas Southwestern Medical Center	\$1,999,760	2.3
25	RP240518	CIA	Adapting radiotherapy clinical trials to treatment response and artificial intelligence innovations	Desai, Neil	The University of Texas Southwestern Medical Center	\$1,460,229	2.4
26	RP240462	HIHRRRA	Development of an Endoscopic Nuclear Imaging Capsule for Radio- Guided Cancer Surgery	Zannoni, Elena Maria	The University of Texas at Austin	\$250,000	2.5
27	RP240501	HIHRRRA	Delivering Immunotherapy more effectively to glioblastoma with a “magnetic switch”	Qin, Zhenpeng	The University of Texas at Dallas	\$250,000	2.6
28	RP240542	HIHRRRA	Digital Twin Augmented Reality for Prostate Laparoscopic Surgery	Fei, Baowei	The University of Texas at Dallas	\$250,000	2.6
29	RP240454	HIHRRRA	Reversing Tumor Immune Exclusion with	Stone, Everett	The University of Texas at Austin	\$249,998	2.7

<b>Academic Research Award Recommendations</b> <b>Research Cycle 24.2 and Recruitment Cycle 24.12</b> <i>CIA: Clinical Investigator Award</i> <i>CFSA: Core Facility Support Awards</i> <i>HIHRRRA: High-Impact/High Risk Research Awards</i> <i>MIRA2: Multi-Investigator Research Awards</i> <i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>							
Rank	App. ID	Mech.	Application Title	PI	PI organization	Budget	Final score
			Sphingosine- 1-Phosphate Depleting Therapeutics				
30	RP240498	HIHRRRA	Improving the management of gastric peritoneal carcinomatosis with Photo- Betabody Immunotherapy	Obaid, Girgis	The University of Texas at Dallas	\$248,991	2.7
31	RP240493	HIHRRRA	Engineering in vivo chimeric antigen receptor (CAR) macrophages for diffuse midline glioma	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$250,000	2.8
32	RP240516	HIHRRRA	Mapping multivalent chromatin interactions to define the 3D genome of Clear cell renal cell carcinoma	Mani, Ram	The University of Texas Southwestern Medical Center	\$250,000	2.9
33	RP240605	HIHRRRA	Stimulate Mucosal-associated Invariant T cells to Kill Cancer Cells	Huang, Shouxiong	Texas Biomedical Research Institute	\$249,484	3.1
34	RP240439	MIRA2	Innovative cell therapy approaches for hematological and solid malignancies	Neelapu, Sattva	The University of Texas M. D. Anderson Cancer Center	\$4,500,000	3.1
35	RP240489	MIRA2	Neural Regulation of Childhood Cancers	Morrison, Sean	The University of Texas Southwestern Medical Center	\$4,362,563	3.2
36	RP240474	MIRA2	Cellular Immunotherapies for Pediatric Solid Tumors	Metelitsa, Leonid	Baylor College of Medicine	\$4,497,964	3.6



CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

---

---

**MEMORANDUM**

---

---

**TO:** OVERSIGHT COMMITTEE MEMBERS  
**FROM:** VINCE BURGESS, CHIEF COMPLIANCE OFFICER  
**SUBJECT:** COMPLIANCE CERTIFICATION – AUGUST 2024 AWARDS  
**DATE:** AUGUST 8, 2024

---

---

**Summary and Recommendation:**

As CPRIT’s Chief Compliance Officer, I am responsible for reporting to the Oversight Committee regarding the agency’s compliance with applicable statutory and administrative rule requirements during the grant review process. I have reviewed the compliance pedigrees for the grant applications submitted to CPRIT for the:

- Recruitment of First-Time, Tenure-Track Faculty Members
- Clinical Investigator Awards
- Core Facility Support Awards
- High-Impact/High-Risk Research Awards
- Multi-Investigator Research Awards

I have conferred with staff at CPRIT and General Dynamics Information Technology (GDIT), CPRIT’s contracted third-party grants administrator, regarding the academic research awards and studied the supporting grant review documentation, including third-party observer reports for the peer review meetings. I am satisfied that the application review process that resulted in the above mechanisms recommended by the Program Integration Committee (PIC) followed applicable laws and agency administrative rules. I certify the academic research award recommendations for the Oversight Committee’s consideration.

**Background:**

CPRIT’s Chief Compliance Officer must report to the Oversight Committee regarding compliance with the statute and the agency’s administrative rules. Among the Chief Compliance Officer’s responsibilities is the obligation “to ensure that all grant proposals comply with this chapter and rules adopted under this chapter before the proposals are submitted to the oversight committee for approval.” Texas Health & Safety Code § 102.051(c) and (d).

CPRIT uses a compliance pedigree process to formally document compliance for the grant award process. The compliance pedigree tracks the grant application as it moves through the review process and documents compliance with applicable laws and administrative rules. A compliance pedigree is created for each application; the information related to the procedural steps listed on the pedigree is entered and attested to by GDIT employees and CPRIT employees. CPRIT relies on GDIT to accurately record a majority of the information on the pedigree from the pre-receipt stage to final Review Council recommendation. To the greatest extent possible, information reported in the compliance pedigree is imported directly from data contained in CPRIT's Application Receipt System (CARS), the grant application database managed by GDIT. This is done to minimize the opportunity for error caused by manual data entry.

### **No Prohibited Donations:**

Although CPRIT is statutorily authorized to accept gifts and grants pursuant to Texas Health & Safety Code § 102.054, the statute prohibits CPRIT from awarding a grant to an applicant who has made a gift or grant to CPRIT, or a nonprofit organization established to provide support to CPRIT. I note that Texas Health & Safety Code § 102.251(a)(3) specifically addresses “donors from any nonprofit organization established to provide support to the institute compiled from information made available under § 102.262(c).” To the best of my knowledge, there are no nonprofit organizations that have been established to provide support to CPRIT on or after June 14, 2013, the effective date of this statutory change. The only nonprofit organization established to provide support to the Institute was the CPRIT Foundation; however, the CPRIT Foundation ceased operations and changed its name and its purpose prior to June 14, 2013. The institute has received no donations from the CPRIT Foundation made on or after June 14, 2013.

*I have reviewed the list of donors to CPRIT maintained by CPRIT (and listed on CPRIT's website) and compared the donors to the list of applicants. No donors to CPRIT have submitted applications for grant awards during the award cycles that are the subject of this report.*

### **Pre-Receipt Compliance:**

The activities listed on a compliance pedigree in the pre-receipt stage cover the period beginning with CPRIT's approval and issuance of the Request for Applications (RFA) through the submission of grant applications. The RFA specifies a deadline and mandates that only those applications submitted electronically through CPRIT's Application Receipt System (CARS) are eligible for consideration. CARS blocks an application from being submitted once the deadline passes. Occasionally, an applicant may have technical difficulties that prevent the applicant from completing the application submission. When this occurs, the applicant may appeal to CPRIT (through the CPRIT Helpdesk that is managed by GDIT) to allow for a submission after the deadline. The program officer considers any requests for extension and may approve an



extension for good cause. When a late filing request is approved, the applicant is notified, and CARS is reopened for a brief period – usually two to three hours – the next business day.

Academic Research:

*For recruitment cycle 24.12, nine applications were received in response to the Recruitment of First-Time, Tenure Track Faculty Members RFA.*

*In response to the academic, non-recruitment RFAs for cycle 24.2, CPRIT received 147 applications.*

*All applications were submitted through CARS. One applicant requested an extension to submit an application after the deadline. The program officer determined that there was good cause for the request and the deadline was extended.*

**Receipt, Referral, and Assignment Compliance:**

Once applications have been submitted through CARS, GDIT staff reviews the applications for compliance with RFA directions. If an applicant does not comply with the directions, GDIT notifies the program officer, and the program officer makes the final decision whether to administratively withdraw the application. Recruitment grant applications are assigned to the Scientific Review Council members for peer review. All other academic research, product development research, and prevention applications are assigned by the peer review panel chair to their respective peer review panels. Prior to distribution of the applications, reviewers are given summary information about the applicant, including the Project Director and collaborators. Reviewers must sign a conflict of interest agreement and confirm that they do not have a conflict of interest with the application before they are provided with the full application.

*The pedigrees attest that a conflict of interest statement was signed by each primary reviewer for each Grant Application.*

Academic Research:

*One academic research, recruitment application was administratively withdrawn for cycle 24.12. Ten academic research, non-recruitment applications were withdrawn during cycle 24.2: nine applications were administratively withdrawn prior to peer review, and one application was withdrawn by the applicant after peer review but prior to the Scientific Review Council (SRC) meeting.*

**Peer Review:**

Primary reviewers (typically three) must submit written critiques for each of their assigned applications prior to the peer review meeting. Sign out sheets are used to document when a reviewer

with a conflict of interest associated with a particular application leaves the room (or disengages from the conference call) during the discussion and scoring of the application.

Following the peer review meeting, each participating peer reviewer must sign a post-review peer review statement certifying that the reviewer knew of and understood CPRIT's conflict of interest policy and followed the policy for this review process. After the peer review meetings, a final score report from the review committee is delivered to the Review Council for additional review.

Academic Research:

*For the recruitment awards, the applications are reviewed by the SRC, which assigns two members of the SRC to be primary reviewers. I reviewed the supporting documentation, such as the sign-out sheets, third-party observer reports, and post-review peer reviewer statements. Sign out sheets are used to document when a reviewer with a conflict of interest associated with a particular application leaves the room (or disengages from the conference call) during the discussion and scoring of the application. One conflict of interest was declared by an SRC member for recruitment cycle 24.12.*

*I reviewed and confirmed that the post review conflict of interest statements were signed by the seven SRC members that attended the 24.12 Recruitment Review Panel meeting on July 11, 2024.*

*Academic research applications (non-recruitment) are reviewed by peer review panels and recommended to the SRC. As documented by GDIT, reviewers with conflicts of interest did not participate in review of those applications. I reviewed supporting documentation, such as conflict of interest statements (COIs), third-party observer reports, and sign out sheets. All declared COIs left the room or disengaged from the conference call and did not participate in the discussion of relevant applications.*

*I also reviewed and confirmed that the post review conflict of interest statements were signed by peer review members for each review panel as well as the six SRC members that attended the Scientific Review Council meeting on July 11, 2024, and the six SRC members that attended the SRC meeting on July 29, 2024.*

**Programmatic Review:**

Programmatic review is conducted by the Scientific Review Council, Prevention Review Council, and Product Development Review Council for their respective awards. Each review council creates a final list of grant applications it will recommend to the PIC for grant award slates.

*To the extent that any Review Council member identified a conflict of interest, I reviewed documentation confirming that the review council member did not participate in the discussion or vote on the application(s).*

*I also reviewed the third-party observer reports for each Review Council meeting. The third-party observer reports document that the Review Council discussion was limited to the merits of the applications and established evaluation criteria and that conflicted reviewers, if applicable, exited the room or the conference call when the application was discussed.*

*For the academic research awards, I reviewed and confirmed that the Review Council recommendations corresponded to RFAs that had been released. I also confirmed that the pedigrees reflect the date of the Review Council meeting and that the applications were recommended by the Review Council.*

#### Academic Research:

*I note that within the Multi-Investigator Research Award and High-Impact/High-Risk Research Award mechanisms some grant applications are not recommended for funding with scores that are the same as or more favorable than some applications that were recommended within each mechanism. An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be discussed or recommended for funding by a peer review panel.*

*Within the Core Facility Support Award grant mechanism, one, not recommended application has a score that is more favorable than some recommended applications. The application was withdrawn after peer review but prior to the SRC meeting so the members did not consider it.*

*The SRC met twice to consider and recommend 32 academic non-recruitment applications from cycle 24.2 to the PIC. After its first meeting on July 11, 2024, the SRC met on July 29, 2024, to recommend an additional application after it became clear to the SRC that grant funds were available to fund the additional application. The SRC also recommended four academic recruitment applications at their meeting on July 11, 2024, for cycle 24.12. The SRC recommended a total of 36 applications to the Program Integration Committee (PIC) for consideration.*

#### **Program Integration Committee (PIC) Review:**

Texas Health & Safety Code § 102.051(d) requires the Chief Compliance Officer to attend and observe the PIC meetings to ensure compliance with CPRIT's statute and administrative rules. CPRIT's statute requires that, at the time the PIC's final Grant Award recommendations are formally submitted to the Oversight Committee, the Chief Executive Officer shall prepare a written affidavit for each Grant Application recommended by the PIC containing relevant information related to the Grant Application recommendations.

*I attended the August 7, 2024, PIC meeting as an observer and confirm that the PIC review process complied with CPRIT's statute and administrative rules. Three PIC members were present for the meeting.*

*The PIC considered 36 applications and voted to recommend all 36 applications to move forward to the Oversight Committee.*

*A review of the CEO affidavits confirms that such affidavits were executed and provided for each grant application recommendation.*



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

# **CEO Affidavit Supporting Information**

**Academic Research  
FY 2024—Cycle 2  
*Core Facility Support Awards***

# **Request for Applications**

---



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**REQUEST FOR APPLICATIONS**

**RFA R-24.2-CFSA**

**Core Facility Support Awards**

**Please also refer to the Instructions for Applicants document,  
which will be posted on September 14, 2023**

Applications for this award mechanism are subject to institutional limits.  
Applicants are advised to consult with their institution's  
Office of Research and Sponsored Programs (or equivalent).

**Application Receipt Opening Date:** October 17, 2023

**Application Receipt Closing Date:** January 18, 2024

**FY2024**

Fiscal Year Award Period

September 1, 2023-August 31, 2024

## TABLE OF CONTENTS

<b>1. BRIEF DESCRIPTION OF RFA</b> .....	<b>4</b>
<b>2. ABOUT CPRIT</b> .....	<b>5</b>
2.1. ACADEMIC RESEARCH PROGRAM PRIORITIES.....	5
<b>3. RATIONALE</b> .....	<b>6</b>
<b>4. RESEARCH OBJECTIVES</b> .....	<b>6</b>
<b>5. FUNDING INFORMATION</b> .....	<b>7</b>
<b>6. ELIGIBILITY</b> .....	<b>8</b>
<b>7. RESUBMISSION POLICY</b> .....	<b>10</b>
<b>8. RENEWAL POLICY -NEW</b> .....	<b>10</b>
<b>9. RESPONDING TO THIS RFA</b> .....	<b>11</b>
9.1. APPLICATION SUBMISSION GUIDELINES.....	11
9.1.1. <i>Submission Deadline Extension</i> .....	11
9.2. APPLICATION COMPONENTS.....	12
9.2.1. <i>Abstract and Significance (5,000 characters)</i> .....	12
9.2.2. <i>Layperson’s Summary (2,000 characters)</i> .....	12
9.2.3. <i>Specific Aims and Sub Aims</i> .....	13
9.2.4. <i>Timeline (1 page)</i> .....	13
9.2.5. <i>Institutional Support (2 pages)</i> .....	13
9.2.6. <i>Resubmission Summary (1 page)</i> .....	13
9.2.7. <i>Renewal Summary (2 pages not including facility impact forms)</i> .....	14
9.2.8. <i>Core Facility Plan (5 pages)</i> .....	15
9.2.9. <i>Documentation That the Proposed Core Facility Does Not Duplicate Existing Services (2 pages)</i> 16	
9.2.10. <i>Vertebrate Animals and/or Human Subjects (2 pages)</i> .....	17
9.2.11. <i>Publications/References</i> .....	17
9.2.12. <i>Budget and Justification</i> .....	17
9.2.13. <i>User Group (8 pages)</i> .....	18
9.2.14. <i>Biographical Sketches (5 pages each)</i> .....	18
9.2.15. <i>Current and Pending Support</i> .....	19
9.2.16. <i>Institutional/Collaborator Support and/or Other Certification (4 pages)</i> .....	19
9.2.17. <i>Previous Summary Statement</i> .....	19
9.3. FORMATTING INSTRUCTIONS.....	19
<b>10. APPLICATION REVIEW</b> .....	<b>20</b>
10.1. REVIEW PROCESS OVERVIEW.....	20
10.2. CONFIDENTIALITY OF REVIEW .....	21
10.3. REVIEW CRITERIA .....	22
10.3.1. <i>Primary Criteria</i> .....	22
10.3.2. <i>Secondary Criteria</i> .....	23
<b>11. KEY DATES</b> .....	<b>24</b>
<b>12. AWARD ADMINISTRATION</b> .....	<b>24</b>
<b>13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS</b> .....	<b>25</b>
<b>14. CONTACT INFORMATION</b> .....	<b>26</b>
14.1. HELPDESK.....	26
14.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS .....	26



## **RFA VERSION HISTORY**

09/14/23 RFA release

1/16/24 Revised to extend the submission deadline to 4 PM central time on January 18, 2024

## 1. BRIEF DESCRIPTION OF RFA

CPRIT limits the number of applications that a single institution may submit under this RFA. For purposes of this RFA, an institution is defined as that component of a university system that has a geographically distinct campus. Academic institutions and health science centers that are components of the same university system and share contiguous or near-contiguous campuses are eligible to submit a single application.

- Due to limited funding allocated to the Academic Research Program, an institution may submit only 1 application (1 new, 1 renewal, or 1 resubmission) under the CFSA RFA during this funding cycle. **An exception will be made for institutions submitting applications for core facilities that support research directed toward childhood and adolescent cancer or population science; in this case, institutions may submit 1 childhood and adolescent cancer application or 1 population science and 1 additional application in another aspect of cancer research (new, renewal, or resubmission).**
- CPRIT's maximum total funding under this RFA is \$3,000,000 for a period of 5 years.
- CPRIT only allows 1 opportunity to submit an active award renewal application in response to this RFA.
- For a Renewal CFSA, an applicant may request a maximum of \$2,000,000 in total costs for a period of 5 years.
- The CFSA must be led by one PI, multi-PIs are not allowed.

## **2. ABOUT CPRIT**

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of or cures for cancer.
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas.
- Develop and implement the Texas Cancer Plan.

### **2.1. Academic Research Program Priorities**

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

To accomplish CPRIT's long-term vision, the Oversight Committee has identified these 2024 priorities:

- Investing in the cancer research capacity of Texas institutions through recruitment of cancer scholars, investment in core facilities, and investment in individual investigator awards in all regions of the state;
- Building the Texas cancer life science ecosystem across Texas by bridging discovery and translational research into early-stage company products with high impact on cancer patient care and creating economic development for the State of Texas; and
- Increasing the capacity for Texas to have a significant impact on cancer prevention and early detection, ultimately decreasing cancer incidence and mortality.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure in all regions of the state
- Reducing cancer disparities

The program priorities for academic research adopted by the Oversight Committee include funding projects that address the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions and population research addressing cancer disparities
- Computational oncology and analytic methods
- Childhood cancer and adolescent cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials, particularly to regions of the state currently with limited access

### **3. RATIONALE**

Core Facility Support Awards seek to facilitate the development or improvement of core facilities that will provide valuable services to support and enhance scientifically meritorious cancer research projects. A user group of Texas-based investigators must be identified, each of whom should have supported cancer research projects that will make use of the requested facility. This requirement is not intended to exclude early-career-stage investigators who have not yet secured peer-reviewed grant support. Successful applicants should be working in a research environment capable of supporting potentially high-impact cancer studies.

**CPRIT is particularly interested in supporting core facilities that provide services to cancer investigators from multiple Texas institutions, in particular TREC-eligible institutions (see IFA for list of institutions) and that address CPRIT Program Priorities.**

### **4. RESEARCH OBJECTIVES**

CPRIT will foster cancer research in Texas by providing financial support for a wide variety of projects relevant to cancer research. This RFA solicits applications from institutions to establish or enhance core facilities (laboratory, clinical, population-based, or computer-based) that will

directly support cancer research programs to advance knowledge of the causes, prevention, and/or treatment of cancer or improve quality of life for patients with, and survivors of, cancer.

CPRIT expects outcomes of supported activities to directly and indirectly benefit subsequent cancer research efforts, cancer public health policy, or the continuum of cancer care—from prevention to survivorship. To fulfill this vision, applications may address any topic or issue related to cancer biology, causation, prevention, detection or screening, treatment, cure, quality of life, or survivorship. This award provides cancer researchers access to appropriate research infrastructure, instrumentation, and technical expertise necessary to achieve their research objectives.

Funds may be requested to develop a new facility or to enhance the capabilities of an existing facility that will directly support and impact cancer research programs at the institution and in the region. **CPRIT will look with special favor on applications that propose a facility that will serve cancer researchers at multiple Texas research institutions, in particular, TREC-eligible institutions (see IFA for list of institutions).**

## **5. FUNDING INFORMATION**

The maximum duration for this award mechanism is 5 years. Applicants may request up to a maximum of \$3,000,000 in total costs.

Allowable expenses include the cost of instruments (must be expended in the first 2 years), installation and/or necessary renovation expenses in the first year (installation/renovation expenses not to exceed 10% of the total first-year request), and maintenance/service contracts. Note that maintenance/service agreements must not extend past the award period, if seeking reimbursement from CPRIT.

Installation/renovation expenses can be requested in the first year only. **Equipment must be purchased within the first 2 years. Note this will be monitored by CPRIT.** Applicants may request salary support and fringe benefits for the facility director, data analysts, and technical staff. Travel to scientific/technical meetings or collaborating institutions is also an allowable expense for these individuals. Note all international travel must receive prior approval by CPRIT. *All of these costs and expenses must be prorated for direct use in cancer research efforts if the core facility also serves non-cancer-related researchers.* Also allowable are funds to

support the use of the facility by qualified cancer research investigators for relevant projects (research supplies and services, clinical research costs, etc). Institutions must describe and justify the process to be used to disburse funds to support use of the facility by cancer investigators. Finally, some fraction of available funds may be used by the facility director for development of new or improved approaches to technical challenges.

State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the total award amount.

## 6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution or organization that conducts research is eligible to apply for funding under this award mechanism.
- A public or private company is not eligible for funding under this award mechanism; these entities must use the appropriate award mechanism(s) under CPRIT's Product Development Research Program.
- The Principal Investigator (PI) must be the director of the facility and must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, and must reside in Texas during the time the research that is the subject of the grant is conducted. The PI should also hold a faculty position, preferably at the level of associate or full professor or the equivalent.
- The PI must commit a minimum 10% level of effort throughout the entire award period.
- This award and core facility must be directed by the PI. Multi-PIs are not permitted.
- Collaborations are permitted and encouraged, and collaborators may or may not reside in Texas. However, collaborators who do not reside in Texas are not eligible to receive CPRIT funds. Collaborators should have specific and well-defined roles. Subcontracting and collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds. In no event shall equipment purchased under this award leave the State of Texas.
- **An institution may submit only 1 application (1 new, 1 renewal, or 1 resubmission) under this RFA during this funding cycle. An exception will be made for institutions submitting applications for core facilities that support research totally directed**

**toward childhood and adolescent cancer or population science; in this case, institutions may submit 1 childhood and adolescent cancer application or 1 population science application and 1 additional application in another aspect of cancer research (new, renewal, or resubmission).**

- For purposes of this RFA, an institution is defined as that component of a university system that has a geographically distinct campus.
- Academic institutions and health science centers that are components of the same university system and share a contiguous or near-contiguous campus are eligible to submit a single application.
- An institution may only resubmit an application that was previously not funded once (see [section 6](#)).
- Support for only 1 facility may be requested per application. Applications that propose to provide services to researchers at multiple institutions are permitted and encouraged.
- The coherence of the facility and the ability of the PI to oversee all of the facility's operations will be critical components of the review process. If support is requested for an existing facility, applicants must provide details on how CPRIT support will enhance its capabilities and improve access for cancer investigators rather than simply replace ongoing institutional support.
- An individual may serve as a PI or Multi-PI on no more than 3 active Academic Research grants. Recruitment grants and research training awards do not count toward the 3-grant maximum; however, CPRIT considers project leaders on a MIRA award equivalent to a PI. For the purpose of calculating the number of active grants, CPRIT will consider the number of active grants at the time of the award contract effective date (for this cycle expected to be 8/31/2024).
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.

- An applicant is not eligible to receive a CPRIT grant award if the applicant PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the PI, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, whether or not those individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds because of scientific misconduct or fraud or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 11](#) and [section 12](#). All statutory provisions and relevant administrative rules can be found at [www.cprit.texas.gov](http://www.cprit.texas.gov).

## **7. RESUBMISSION POLICY**

An application previously submitted to CPRIT but not funded may be resubmitted **once** and must follow all resubmission guidelines. More than 1 resubmission per application is not permitted.

## **8. RENEWAL POLICY -NEW**

CPRIT only allows one opportunity to submit an active award renewal application in response to this RFA. Funding for renewal applications is capped at \$2,000,000 as the Core Facility has matured over the initial 5 years and is expected to be partially funded by substantial charge backs and institutional commitment.

Renewal applications must demonstrate a compelling justification for continued CPRIT support of the facility that is based upon the scientific impact of current and continued CPRIT support, as well as a strong plan delineating how the services provided will be developed further to advance cancer research. Quality and cost efficiency of the services alone are not sufficient justifications



for continued CPRIT support. Renewal applications will be expected to demonstrate an exceptional record of impact on cancer research as measured by:

- Utilization (number of PIs utilizing facility; number of institutions served);
- Publications that cite CPRIT support;
- New peer-reviewed grant awards supported;
- Clinical trials supported;
- Patents supported.

The applicant should time the submission of the renewal application so that the new contract execution date for the grant award comes after the contract expiration date of the initial CPRIT award; any overlap in funding should be avoided. In the event that a renewal application is funded prior to the expiration date of the current CPRIT award, an early termination of the current award is required.

## **9. RESPONDING TO THIS RFA**

### **9.1. Application Submission Guidelines**

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and submit an application. Furthermore, the Authorized Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS.

Applications will be accepted beginning on October 17, 2023 at 7 AM central time and must be submitted by 4 PM central time on January 18, 2024. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

#### **9.1.1. Submission Deadline Extension**

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grants applications will be denied. All requests for extension of the submission deadline must be

submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

## **9.2. Application Components**

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the *IFA* document for details. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 5](#) will be administratively rejected without review.

### **9.2.1. Abstract and Significance (5,000 characters)**

Clearly explain the proposed program, including a summary of the facility to be developed, an outline of the overall goals of the research projects that will be supported, and an overview of institutional infrastructure and commitment. The specific aims of the application must be obvious from the abstract. Clearly address how the proposed project, if successful, will have a major impact on cancer.

**If the application is a renewal of an existing CPRIT-funded resource, the abstract must state the impact of the resource and document why continued CPRIT support is justified and how the resource will be developed further to advance cancer research.**

**Note:** It is the responsibility of the applicant to capture CPRIT's attention primarily with the Abstract and Significance statement alone. Therefore, applicants are advised to prepare this section wisely. Applicants should not waste this valuable space by stating obvious facts (eg, that cancer is a significant problem, that better diagnostic and therapeutic approaches are needed urgently, or that the type of cancer of interest to the PI is important, vexing, or deadly).

### **9.2.2. Layperson's Summary (2,000 characters)**

Provide a layperson's summary of the proposed work. Describe, in simple, nontechnical terms, the overall goals of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early diagnosis, prevention, or treatment. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding.

Do not include any proprietary information in the layperson's summary. The layperson's summary will also be used by advocate reviewers ([section 9.1](#)) in evaluating the significance and impact of the proposed work.

### **9.2.3. Specific Aims and Sub Aims**

List specific aims and sub aims for each year of the project. These aims and sub aims will also be used during the submission and evaluation of progress reports and assessment of the project's success if the award is made.

### **9.2.4. Timeline (1 page)**

Provide an outline of anticipated major milestones to be tracked. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful applications. If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

### **9.2.5. Institutional Support (2 pages)**

Each application must be accompanied by a strong letter of institutional support from the president or provost or equivalent indicating and detailing the commitment to the program and certifying that this is the sole application submitted by this institution in response to this RFA. Furthermore, the letter should indicate any support of the facility for activities not related to cancer research. The letter should address the institutional oversight ensuring that the facility will be operated in a superior fashion and discuss how this will be ascertained. If the application is a renewal of an existing CPRIT-funded resource, a compelling justification for continued CPRIT support of the resource must be provided.

### **9.2.6. Resubmission Summary (1 page)**

An application previously submitted to CPRIT but not funded may be resubmitted **once** after careful consideration of the reasons for lack of prior success. Applicants preparing a resubmission must describe the approach to the resubmission. If a summary statement was prepared for the original application review, applicants are advised to address all noted concerns.

### 9.2.7. Renewal Summary (2 pages not including facility impact forms)

Note that CPRIT only allows one opportunity to submit an active award renewal application in response to this RFA. Funding for renewal applications is capped at \$2,000,000 as the Core Facility has matured over the initial 5 years and it is expected that the Core will be partially funded by substantial charge backs and institutional commitment.

Applicants preparing a renewal of a CPRIT-funded core facility must describe and demonstrate that exceptional progress has been made on the current funded award and demonstrate a compelling justification for continued CPRIT support of the facility that is based upon the scientific impact of continued CPRIT support and the innovation and impact of the proposed evolution of the facility. Quality and cost efficiency of the services alone are not sufficient justifications for continued CPRIT support.

Using facility impact forms provided, list the number of PIs utilizing the facility and the institutions served (Table 1), the peer-reviewed grants resulting from facility support (Table 2), publications (published and in press) citing utilization of the facility (Table 3), clinical trials utilizing the facility (Table 4), and patents filed or granted that have resulted from work supported by the facility (Table 5) for the prior grant funding period.

The following 5 tables displayed below are required. **Note that the utilization parameters and table formats should follow the instructions for completing the CPRIT annual progress report.** Refer to the Table templates in the document located in [Current Funding Opportunities](#) for Academic Research in CARS.

**Table 1: Utilization of the facility by PIs.** (Provide the total number of PIs that have utilized the facility by PI's institution).

**Table 2: Additional/Follow-On Funding.** (Provide information in Table 2 about the funding source, type of funder, grant ID, title of grant, total amount received (direct plus indirect costs over the entire performance period), total project period of investment/award, a description of the subject of the funding, PI of the grant, and PI's organization).

Funding Source	Type of Funder	Award ID	Title of Grant	Total Amount Received  (Direct and Indirect Costs for All Years)	Total Project Period of Investment/Award	Investment/Award Description	PI	PI Organization
----------------	----------------	----------	----------------	--	--	------------------------------	----	-----------------

**Table 3: Publications citing the facility.** Enter information about each publication in the table. Information includes PubMed ID, author, title, journal, and publication date.

**Table 4: Clinical trials supported by the facility.** Enter trial name, clinicaltrials.gov identifier, clinical research categories (interventional and observational), primary purpose, primary anatomic cancer site, phase, clinical trial focus, clinical trial site, and number of patients enrolled.

**Table 5: Filed/granted patents resulting from research supported by the facility.** Enter patent number, inventors, patent title, description, date of publication or issue, and date the patent application was filed and/or granted.

### 9.2.8. Core Facility Plan (5 pages)

**Background:** Present the rationale and need for the facility, emphasizing the pressing problems in cancer research that will be addressed. Address the research community served and if researchers at other institutions will have access. Address how the proposed facility does not duplicate services provided by existing facilities. Address how the proposed facility addresses CPRIT priorities.

**Instrument Details:** Provide details of the equipment/instruments, if any, that will be acquired.

**Technical Expertise:** Describe the qualifications of the facility director and other key personnel that make them suitable to oversee the establishment and operations of the facility.

**Administrative Plan:**

1. Clearly describe the plan under which the operation, sharing, time allocation, and maintenance of the facility will be administered.

2. Discuss in detail the plan for cost recovery and charge backs for core services. If a cost recovery plan is not included in the administrative plan, provide strong justification for its absence.
3. Discuss whether cancer researchers from other Texas academic institutions or industry scientists have access to the facility and the terms for such access.
4. Discuss if funds will be allocated to support the use of the facility by qualified cancer research investigators, and describe the process to be used to disburse funds to support use of the facility by these cancer investigators. If some fraction of available funds is to be used by the facility director for development of new or improved approaches to technical challenges, discuss the process to identify and evaluate such development projects.
5. Discuss plans including the creation of a website link for disseminating information on the resource services, fees, and operations, particularly to external institutions and investigators.

**Training Plan:** Describe the plan to train users to use the facility, to educate users on applications and advances in the technology, and to evaluate the results obtained. If applicable, describe the plan to contribute to the preparation of research grant proposals.

**Evaluation Plan:** Describe an evaluation plan for the facility.

**Sustainability:** Describe in detail the plans for continuation of the core facility service at the conclusion of the CPRIT award, such as documentation of institutional support and additional award mechanisms and/or user fees.

### **9.2.9. Documentation That the Proposed Core Facility Does Not Duplicate Existing Services (2 pages)**

In this section, provide a comprehensive list of existing cores or facilities in Texas that offer researchers access to technology and services similar to that proposed in this application. Explain why the proposed core is not duplicative of these and is required to support the research of the users of the new core proposed in this application.

### 9.2.10. Vertebrate Animals and/or Human Subjects (2 pages)

If vertebrate animals will be used, provide an outline of the appropriate protocols that will be followed. If human subjects or human biological samples will be used, provide a plan for recruitment of subjects or acquisition of samples that will meet the time constraints of this award mechanism.

### 9.2.11. Publications/References

Provide a concise and relevant list of publications/references cited for the application.

### 9.2.12. Budget and Justification

Provide a compelling and clear justification of the budget, demonstrating need for the entire proposed period of support, including salaries and benefits, supplies, equipment, patient care costs, animal care costs, and other expenses. Applicants are advised not to interpret the maximum allowable request under this award as a suggestion that they should expand their anticipated budget to this level. However, if there is a highly specific and defensible need to request more than the maximum amount in any year(s) of the proposed budget, include a special and clearly labeled section in the budget justification that explains the request. Poorly justified requests of this type will likely have a negative impact on the overall evaluation of the application.

In preparing the requested budget, applicants should be aware of the following:

- Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit **must be specifically approved by CPRIT**. An applicant does not need to seek this approval prior to submitting the application.
- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at [www.cpriti.texas.gov](http://www.cpriti.texas.gov). So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be administratively withdrawn.

- The annual salary (also referred to as direct salary or institutional base salary) that an individual may be reimbursed from a CPRIT award is limited to a maximum of \$200,000. In other words, an individual may request salary proportional to the percent of effort up to a maximum of \$200,000. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization. The PI must commit a minimum 10% level of effort throughout the entire award period.
- The PI is expected to attend CPRIT's Conference. CPRIT funds may be used to send up to 2 people to the conference.

### **9.2.13. User Group (8 pages)**

Provide concise descriptions of the research projects of major users of the facility. Provide a tabular summary of all users of the requested facility. List the names of all researchers, their academic appointment and affiliation, include user grant-funded award data (project title(s)/number(s), award grant ID, award duration), a brief description of the project(s), and approximate percentage use of the facility for direct use in cancer research efforts. Discuss whether cancer researchers from other Texas academic institutions or industry scientists have access to the facility and the terms for such access. CPRIT will look with special favor on the development of core facilities that serve multi-institutions, including TREC-eligible institutions.

### **9.2.14. Biographical Sketches (5 pages each)**

The PI should provide a biographical sketch that describes his/her education and training, professional experience, awards and honors, and publications relevant to cancer research.

A biographical sketch must be provided for the PI (as required by the online application receipt system). Up to 5 additional biographical sketches for key personnel from the user group may be provided. Each biographical sketch must not exceed 5 pages.



### 9.2.15. Current and Pending Support

State the funding source and duration of all current and pending support for all personnel who have included a biographical sketch with the application. For each award, provide the title, a 2-line summary of the goal of the project, and, if relevant, a statement of overlap with the current application. All current and pending support of the PI must be provided. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

### 9.2.16. Institutional/Collaborator Support and/or Other Certification (4 pages)

Applicants are required to provide letters of institutional support, collaborator support, and/or other certification documentation relevant to the proposed project. A maximum of 4 pages may be provided.

### 9.2.17. Previous Summary Statement

If the application is being resubmitted, the summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission. The applicant is not responsible for providing this document.

**Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or that do not meet the eligibility requirements listed above will be administratively withdrawn.**

## 9.3. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English
- **Document Format:** PDF only
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations must be submitted as part of the appropriate submitted document. Applicants should

include text to explain illustrations that may be difficult to interpret when printed in black and white.

- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.
- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters are also acceptable as long as the journal information is stated. Include URLs of publications referenced in the application.  
Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45–67.
- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants should not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see following point).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be filled out, printed, signed, scanned, and then uploaded in PDF format.

## 10. APPLICATION REVIEW

### 10.1. Review Process Overview

All eligible applications will be evaluated using a 2-stage peer review process: (1) Peer review and (2) prioritization of grant applications by the CPRIT Scientific Review Council (SRC). In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts, as well as advocate reviewers, using the criteria listed below. In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT SRC based on comparisons with applications from all of the peer review panels and programmatic priorities. Applications approved by the SRC will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider

factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

## **10.2. Confidentiality of Review**

Each stage of application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, SRC members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and SRC members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website.

**By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed conflict of interest as set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, chapters 701 to 703](#)**

Communication, regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, a Scientific Review Panel member, or an SRC member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism

are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period prior to the opening of CARS. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

### **10.3. Review Criteria**

Peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Review committees will evaluate and score each primary criterion and subsequently assign a global score that reflects an overall assessment of the application. **The overall assessment will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

#### **10.3.1. Primary Criteria**

Primary criteria will evaluate the scientific merit and potential impact of the proposed work contained in the application. Concerns with any of these criteria potentially indicate a major flaw in the request for the instrument/equipment. Primary criteria include the following:

**Justification of Need/Value:** Is the uniqueness of the facility addressed? Is the need for the facility justified? Is it necessary and appropriate for the research projects? Will the state-of-the-art facility directly support and impact cancer research programs at the institution and in the region? How will the availability of the facility offer incipient research projects by investigators at various career stages the opportunity to develop? Will the facility make the user group more competitive for external funding? Will the facility provide cancer researchers from other Texas academic institutions or industry scientists access to the facility? Does the facility address CPRIT priorities?

If this is a renewal application, is there evidence that the facility has had an exceptional impact on the cancer research and that the renewal will provide further innovation and impact.

**Quality and Significance of research projects supported:** Does the facility support a significant number of different, independently funded users? Are the projects at the forefront of cancer research? Are the projects of significance in reducing cancer incidence, morbidity, or mortality?

**Technical Expertise:** Is there sufficient technical expertise for optimal use of the facility? How well qualified is the user group to take optimal advantage of the facility and evaluate the research results for the proposed projects? How will the facility be maintained? Is there a satisfactory training plan for new users?

**Administration:** Is there assurance that the facility will be managed and operated in a superior fashion? To whom does the facility director report? Is that person committed to appropriate oversight (a letter of commitment should be submitted)? Is there an adequate plan for the management of the facility, including an appropriate system for charging for services and subsidy of user fees for specific cancer-related projects and individuals (especially early-career-stage investigators)? How will facility time be allocated among the projects? Have biosafety issues been addressed? Are there criteria and is there a mechanism for prioritization of user requests? Are there appropriate advisory committees?

**Institutional Commitment:** Is there clear institutional commitment for support and sustainability of the facility for cancer research? Has the host institution provided an appropriate site for the facility? For renewal applications, is there evidence of a significant institutional commitment and/or financial plan for sustainability of the facility beyond the period of this award.

### 10.3.2. Secondary Criteria

Secondary criteria contribute to the global score assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed project.

Secondary criteria include the following:

**Research Environment:** Does the team have the needed expertise and resources to accomplish all aspects of the project? Are the levels of effort of the key personnel appropriate? Is there evidence of institutional support for the project?

**Vertebrate Animals and/or Human Subjects:** If vertebrate animals and/or human biological samples are included in the proposed research, is the vertebrate animals and/or human subjects plan adequate and sufficiently detailed? Note that certification of approval by the institutional IACUC and/or IRB, as appropriate, will be required before funding can occur.

**Budget:** Is the budget appropriate for the proposed work?

**Duration:** Is the stated duration appropriate for the proposed work?

## 11. KEY DATES

### RFA

RFA release September 14, 2023

### Application

Online application opens October 17, 2023, 7 AM central time

Application due January 18, 2024, 4 PM central time

Application review February 2024 to August 2024

### Award

Award notification August 2024

Anticipated start date August 31, 2024

## 12. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [Texas Administrative Code, Title 25, chapters 701 to 703](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at [www.cprit.texas.gov](http://www.cprit.texas.gov). Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [Texas Administrative Code, Title 25, chapters 701 to 703](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, chapters 701 to 703](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals documented in the grant award contract and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate.

CPRIT will review annual progress reports and continuation of funding is contingent upon the timely receipt of these reports and documentation of sufficient progress toward completing project goals. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of award contract. Forms and instructions will be made available at [www.cprit.texas.gov](http://www.cprit.texas.gov).

### **13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS**

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. The demonstration of available matching funds must be made at the time the award contract is executed, and annually thereafter, not when the application is submitted. Grant applicants are advised to consult CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, chapters 701 to 703](#), for specific requirements regarding demonstration of available funding.

## **14. CONTACT INFORMATION**

### **14.1. Helpdesk**

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding scientific aspects of applications.

**Hours of operation:** Monday through Friday, 8 AM to 6 PM central time

**Tel:** 866-941-7146

**Email:** [Help@CPRITGrants.org](mailto:Help@CPRITGrants.org)

### **14.2. Scientific and Programmatic Questions**

Questions regarding the CPRIT program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Director for Academic Research.

**Tel:** 512-305-8491

**Email:** [research@cprit.texas.gov](mailto:research@cprit.texas.gov)

**Website:** [www.cprit.texas.gov](http://www.cprit.texas.gov)



# **Third Party Observer Reports**

---

**Cancer Prevention and Research Institute of Texas (CPRIT)****24.2 Academic Research - Basic Cancer Research-1****(24.2 ACR BCR-1)****Observation Report**

Report No. 2024-04-16 24.2\_ACR\_BCR-1  
Program Name: Academic Research  
Panel Name: 24.2 Academic Research - Basic Cancer Research-1 (24.2\_ACR\_BCR-1)  
Panel Date: April 16, 2024  
Report Date: April 23, 2024

***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

***INTRODUCTION***

The subject of this report is the 24.2 Academic Research - Basic Cancer Research-1 (24.2\_ACR\_BCR-1) meeting. The meeting was chaired by Eric Fearon and conducted via videoconference on April 16, 2024.

***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Thirteen (13) applications were discussed and thirteen (13) applications were not discussed
- Panelists: One (1) panel chair, fourteen (14) expert reviewers, two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

**Cancer Prevention and Research Institute of Texas (CPRIT)****24.2 Academic Research Basic Cancer Research – 2****(24.2 ACR BCR-2)****Observation Report**

Report No. 2024-04-17 24.2\_ACR\_BCR-2  
Program Name: Academic Research  
Panel Name: 24.2 Academic Research Basic Cancer Research – 2 (24.2\_ACR\_BCR-2)  
Panel Date: April 17, 2024  
Report Date: April 23, 2024

***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

***INTRODUCTION***

The subject of this report is the 24.2 Academic Research Basic Cancer Research – 2 (24.2\_ACR\_BCR-2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on April 17, 2024.

***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Fifteen (15) applications were discussed and Thirty (30) were not discussed.
- Panelists: One (1) panel chair, eighteen (18) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were thirteen (13) Conflicts of Interest (COIs) identified prior to and/or during the meeting. No (0) applications with COIs were discussed.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

**Cancer Prevention and Research Institute of Texas (CPRIT)****24.2 Academic Research Cancer Biology (CB)****(24.2 ACR CB)****Observation Report**

Report No. 2024-04-24 24.2\_ACR\_CB  
Program Name: Academic Research  
Panel Name: 24.2 Academic Research Cancer Biology (CB) (24.2 \_ACR\_CB)  
Panel Date: April 24, 2024  
Report Date: April 29, 2024

***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

***INTRODUCTION***

The subject of this report is the 24.2 Academic Research Cancer Biology (CB) (24.2\_ACR\_CB) meeting. The meeting was chaired by Peter Jones and conducted via videoconference on April 24, 2024.

***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.



## **SUMMARY OF OBSERVATION RESULTS**

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and thirty-six (36) applications were not discussed
- Panelists: One (1) panel chair, nineteen (19) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were eight (8) Conflicts of Interest (COIs) identified prior to and/or during the meeting. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the closing text.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

**Cancer Prevention and Research Institute of Texas (CPRIT)****24.2 Academic Research - Imaging Technology and****Informatics (24.2 ACR ITI)****Observation Report**

Report No. 2024-04-23 24.2\_ACR\_ITI  
Program Name: Academic Research  
Panel Name: 24.2 Academic Research - Imaging Technology and Informatics  
(24.2\_ACR\_ITI)  
Panel Date: April 23, 2024  
Report Date: April 29, 2024

***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

***INTRODUCTION***

The subject of this report is the 24.2 Academic Research - Imaging Technology and Informatics (24.2\_ACR\_ITI) meeting. The meeting was chaired by Henry VanBrocklin and conducted via videoconference on April 23, 2024.

***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twelve (12) applications were discussed and fourteen (14) were not discussed
- Panelists: One (1) panel chair, twelve (12) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

**Cancer Prevention and Research Institute of Texas (CPRIT)**  
**24.2 Academic Research Clinical and Translational Cancer**  
**Research-1 (24.2 ACR CTCR-1)**  
**Observation Report**

Report No. 2024-04-18 24.2\_ACR\_CTCR-1  
Program Name: Academic Research  
Panel Name: 24.2 Academic Research Clinical and Translational Cancer  
Research-1 (24.2\_ACR\_CTCR-1)  
Panel Date: April 18, 2024  
Report Date: April 23, 2024

### ***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

### ***INTRODUCTION***

The subject of this report is the 24.2 Academic Research Clinical and Translational Cancer Research-1 (24.2\_ACR\_CTCR-1) meeting. The meeting was chaired by Margaret Tempero and conducted via videoconference on April 18, 2024.

### ***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Eighteen (18) applications were discussed and twenty-four (24) were not discussed
- Panelists: One (1) panel chair, sixteen (16) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were six (6) Conflicts of Interest (COIs) identified prior to and/or during the meeting. No (0) applications with COIs were discussed.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', with a stylized, flowing script.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney



**Cancer Prevention and Research Institute of Texas (CPRIT)**  
**24.2 Academic Research Clinical and Translational Cancer**  
**Research-2 (24.2 ACR C/TCR-2)**  
**Observation Report**

Report No. 2024-04-25 24.2\_ACR\_C/TCR-2  
Program Name: Academic Research  
Panel Name: 24.2 Academic Research Clinical and Translational Cancer  
Research-2 (24.2\_ACR\_C/TCR-2)  
Panel Date: April 25, 2024  
Report Date: April 29, 2024

### ***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

### ***INTRODUCTION***

The subject of this report is the 24.2 Academic Research Clinical and Translational Cancer Research-2 (24.2\_ACR\_C/TCR-2) meeting. The meeting was chaired by Richard O'Reilly and conducted via videoconference on April 25, 2024.

### ***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twenty-eight (28) applications were discussed and eleven (11) were not discussed
- Panelists: One (1) panel chair, fourteen (14) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were fourteen (14) Conflicts of Interest (COIs) identified prior to and/or during the meeting. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written in a cursive style.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

**Cancer Prevention and Research Institute of Texas (CPRIT)**  
**FY24.2 Scientific Review Council (24.2 SRC)**  
**Observation Report**

Report No.            2024-07-11 24.2 SRC  
Program Name:        Academic Research  
Panel Name:           FY24.2 Scientific Review Council (24.2 SRC)  
Panel Date:           July 11, 2024  
Report Date:          July 17, 2024

### ***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

### ***INTRODUCTION***

The subject of this report is the FY24.2 Scientific Review Council (24.2 SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on July 11, 2024.

### ***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

One (1) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Thirty one (31) applications were discussed and one (1) application was withdrawn
- Panelists: One (1) discussion lead, and five (5) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Three (3)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

# **Conflicts of Interest Disclosure**

---

# Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 24.2

Awards Announced at the August 21, 2024, Oversight Committee Meeting

The following table lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research cycle 24.2 include *Core Facility Support Awards*; *Clinical Investigator Award*; *High-Impact/High-Risk Research Awards*; and *Multi-Investigator Research Awards*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
<b>Applications considered by the PIC and Oversight Committee:</b>			
RP240440	Richard Gorlick	The University of Texas M. D. Anderson Cancer Center	Patrick Grohar
RP240439	Sattva Neelapu	The University of Texas M. D. Anderson Cancer Center	Joshua Campbell
RP240454	Everett Stone	The University of Texas at Austin	Weiping Zou
RP240474	Leonid Metelitsa	Baylor College of Medicine	W. Martin Kast
<b>Applications not considered by the PIC or Oversight Committee:</b>			
RP240428	Neelam Mukherjee	The University of Texas Health Science Center at San Antonio	Jose Conejo-Garcia
RP240564	Kevin Pinney	Baylor University	Jose Conejo-Garcia
<b>RP240591</b>	Ming You	The Methodist Hospital Research Institute	Steven Belinsky



<b>Application ID</b>	<b>Principal Investigator</b>	<b>Organization</b>	<b>Conflict Noted by Reviewer</b>
RP240448	Kevin Dalby	The University of Texas at Austin	Joseph Mancias
RP240459	Abhishek Jain	Texas A&M Engineering Experiment Station	Benjamin Greenbaum

# De-Identified Overall Evaluation Scores

---

# Core Facility Support Awards

## Academic Research Cycle 24.2

Application ID	Final Overall Evaluation Score
RP240545*	1.0
RP240610*	1.4
RP240494*	1.7
RP240497*	1.7
RP240432*	1.8
RP240430*	1.9
Da <sup>i</sup>	2.0
RP240508*	2.1
RP240559*	2.1
RP240521*	2.3
Db	3.0
Dc	3.0
Dd	3.3
De	3.4
Df	3.7
Dg	3.7
Dh	4.0
Di	4.3
Dj	4.7
Dk	4.8
DI	5.7

---

<sup>i</sup> This application was withdrawn after peer review but prior to the review council meeting.

\* Recommended for funding.

# **Final Overall Evaluation Scores and Rank Order Scores**

---

# UC San Diego

## SCHOOL OF MEDICINE

July 29, 2024

Dr. David A. Cummings, M.D.  
Oversight Committee Presiding Officer  
Cancer Prevention and Research Institute of Texas  
Via email to [dcummingsmd@yahoo.com](mailto:dcummingsmd@yahoo.com)

Ms. Kristen Doyle  
Chief Executive Officer  
Cancer Prevention and Research Institute of Texas  
Via email to [kdoyle@cprit.texas.gov](mailto:kdoyle@cprit.texas.gov)

Dear Dr. Cummings and Ms. Doyle,

The Scientific Review Council (SRC) is pleased to submit this list of 36 research grant recommendations for the Clinical Investigator Award, Core Facility Support Awards, High-Impact/High Risk Awards, Multi-Investigator Research Awards and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on July 11, 2024 to review First-Time Tenure-Track Faculty Members recruitment applications submitted for Cycle FY24.12 and to consider the applications recommended by the peer review panels following their meetings held April 16, 2024 to April 25, 2024. On July 29, 2024 the SRC met to discuss application RP240474, which was peer reviewed on April 25, 2024 but not recommended. The application received a favorable score but just missed the cut off line made by the peer review panel. The SRC chose to consider and recommend RP240474 because of how it addresses program priorities of childhood and adolescent cancers. With available funds the SRC recommended RP240474 to the Program Integration Committee (PIC), bringing the total number of recommended academic research awards to 36.

Recommended funding amounts and the overall evaluation score are stated for each grant application in the following table. The total amount for the applications recommended to the PIC is \$60,577,922.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • [rkolodner@health.ucsd.edu](mailto:rkolodner@health.ucsd.edu)

Richard D. Kolodner, Ph.D.  
Chair, CPRIT Scientific Review Council

Rank	ID	RFA	Score	Application Title	PI	PI Org.	Rec. Budget
1	RP240545	CFSA	1.0	Renewal of CPRIT GMP Core	Lapteva, Natalia	Baylor College of Medicine	\$2,000,000
2	RR240070	RFTFM	1.0	Expanding the Accessibility and Efficacy of CAR-T Cells Through In Vivo Engineering	Labanieh, Louai	Baylor College of Medicine	\$2,000,000
3	RR240076	RFTFM	1.0	Discovery of Molecular Glue Degraders Targeting the Undruggable Cancer Proteome	Yoon, Hojong	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
4	RR240082	RFTFM	1.2	Identification of Neural Mechanisms Contributing to Chemotherapy-Associated Cognitive Impairments	Sun, Yanjun	The University of Texas Health Science Center at Houston	\$2,000,000
5	RP240610	CFSA	1.4	UTHealth Cancer Genomics Core (UTHealth CGC)	Zhao, Zhongming	The University of Texas Health Science Center at Houston	\$2,000,000
6	RP240478	CIA	1.4	Advancing immunotherapy for high-risk cancers in children and adolescents	Hegde, Meenakshi	Baylor College of Medicine	\$1,030,892
7	RP240473	CIA	1.6	Signal-Augmented Cancer Cell Therapies: Integrating Advanced	Omer, Bilal	Baylor College of Medicine	\$1,046,414

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

**UC San Diego**  
SCHOOL OF MEDICINE

				Correlatory Studies and Mentorship			
8	RP240494	CFSA	1.7	Children's Research Institute Metabolomics Core: Advanced Methodologies in Cancer Metabolism	DeBerardinis, Ralph	The University of Texas Southwestern Medical Center	\$2,601,616
9	RP240497	CFSA	1.7	Advanced Spatial Genomics Core Facility	Navin, Nicholas	The University of Texas M. D. Anderson Cancer Center	\$2,999,993
10	RR240079	RFTFM	1.7	Immune surveillance and elimination of aneuploid cells in vivo	Trakala, Marianna	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
11	RP240432	CFSA	1.8	Advanced Multiparameter Cytometry and Cell Sorting Core	Beeton, Christine	Baylor College of Medicine	\$1,999,882
12	RP240440	MIRA2	1.8	Novel Therapies for Osteosarcoma	Gorlick, Richard	The University of Texas M. D. Anderson Cancer Center	\$4,498,684
13	RP240557	CIA	1.8	Dietary intervention to modulate the microbiome and immune response	McQuade, Jennifer	The University of Texas M. D. Anderson Cancer Center	\$1,074,727
14	RP240430	CFSA	1.9	GCC Center for Comprehensive PK/PD & Formulation	Liang, Dong	Texas Southern University	\$2,000,000
15	RP240590	HIHRA	2.0	Bidentate ERK Traps: Revolutionizing Combination Cancer Therapy Strategies	Dalby, Kevin	The University of Texas at Austin	\$249,996
16	RP240539	HIHRA	2.0	Spectroscopy for quantitative real-time imaging of radical formation	Gustavsson, Anna-Karin	Rice University	\$250,000

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

				in ultra-high dose rate radiation therapy			
17	RP240508	CFSA	2.1	The Texas Decision Science Core Facility: A CPRIT Population Science Core	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	\$2,995,778
18	RP240446	HIHRA	2.1	Regulation of Transcription Factor Function by Local Chromatin Context	Soshnev, Alexey	The University of Texas at San Antonio	\$249,561
19	RP240442	CIA	2.1	Identifying and exploiting novel metabolic vulnerabilities in the treatment of kidney cancer	Courtney, Kevin	The University of Texas Southwestern Medical Center	\$913,682
20	RP240559	CFSA	2.1	High Performance Mass Spectrometry Imaging Core Facility	Brodbelt, Jennifer	The University of Texas at Austin	\$1,998,763
21	RP240441	CIA	2.2	Precision Lung Cancer Interception by Targeting High-Risk Lung Nodules	Zhang, Jianjun	The University of Texas M. D. Anderson Cancer Center	\$1,098,945
22	RP240438	MIRA2	2.2	Overcoming major barriers to the delivery of successful T-cell immunotherapies	Rooney, Cliona	Baylor College of Medicine	\$4,500,000
23	RP240579	HIHRA	2.3	Renal Clearable Nano Delivery Systems for Maximizing Anti-tumor Immunity in Breast Cancer Brain Metastasis Treatment	Zheng, Jie	The University of Texas at Dallas	\$250,000
24	RP240521	CFSA	2.3	Pediatric Cancer Data Core	Xie, Yang	The University of Texas Southwestern Medical Center	\$1,999,760

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu



**UC San Diego**  
SCHOOL OF MEDICINE

25	RP240518	CIA	2.4	Adapting radiotherapy clinical trials to treatment response and artificial intelligence innovations	Desai, Neil	The University of Texas Southwestern Medical Center	\$1,460,229
26	RP240462	HIHRA	2.5	Development of an Endoscopic Nuclear Imaging Capsule for Radio-Guided Cancer Surgery	Zannoni, Elena Maria	The University of Texas at Austin	\$250,000
27	RP240501	HIHRA	2.6	Delivering Immunotherapy more effectively to glioblastoma with a “magnetic switch”	Qin, Zhenpeng	The University of Texas at Dallas	\$250,000
28	RP240542	HIHRA	2.6	Digital Twin Augmented Reality for Prostate Laparoscopic Surgery	Fei, Baowei	The University of Texas at Dallas	\$250,000
29	RP240454	HIHRA	2.7	Reversing Tumor Immune Exclusion with Sphingosine-1-Phosphate Depleting Therapeutics	Stone, Everett	The University of Texas at Austin	\$249,998
30	RP240498	HIHRA	2.7	Improving the management of gastric peritoneal carcinomatosis with Photo-Betabody Immunotherapy	Obaid, Girgis	The University of Texas at Dallas	\$248,991
31	RP240493	HIHRA	2.8	Engineering in vivo chimeric antigen receptor (CAR) macrophages for diffuse midline glioma	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$250,000
32	RP240516	HIHRA	2.9	Mapping multivalent chromatin	Mani, Ram	The University of Texas	\$250,000

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

**UC San Diego**  
SCHOOL OF MEDICINE

				interactions to define the 3D genome of Clear cell renal cell carcinoma		Southwestern Medical Center	
33	RP240605	HIHRA	3.1	Stimulate Mucosal-associated Invariant T cells to Kill Cancer Cells	Huang, Shouxiong	Texas Biomedical Research Institute	\$249,484
34	RP240439	MIRA2	3.1	Innovative cell therapy approaches for hematological and solid malignancies	Neelapu, Sattva	The University of Texas M. D. Anderson Cancer Center	\$4,500,000
35	RP240489	MIRA2	3.2	Neural Regulation of Childhood Cancers	Morrison, Sean	The University of Texas Southwestern Medical Center	\$4,362,563
36	RP240474	MIRA2	3.6	Cellular Immunotherapies for Pediatric Solid Tumors	Metelitsa, Leonid	Baylor College of Medicine	\$4,497,964

Clinical Investigator Award (CIA)  
Core Facility Support Awards (CFSA)  
High-Impact/High Risk Awards (HIHR)  
Multi-Investigator Research Awards (MIRA2)  
Recruitment of First-Time, Tenure Track Faculty Members (RFTTFM)

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

# **CEO Affidavit Supporting Information**

**Academic Research  
FY 2024—Cycle 2  
*Clinical Investigator Award***

# Request for Applications

---



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**REQUEST FOR APPLICATIONS**  
**RFA R-24.2-CIA**

**Clinical Investigator Award**

**Please also refer to the Instructions for Applicants document,  
which will be posted on September 14, 2023**

Applications for this award mechanism are subject to institutional limits.  
Applicants are advised to consult with their institution's Office of Research and  
Sponsored Programs (or equivalent).

**Application Receipt Opening Date:** October 17, 2023

**Application Receipt Closing Date:** January 18, 2024

**FY 2024**

Fiscal Year Award Period

September 1, 2023-August 31, 2024

## TABLE OF CONTENTS

<b>1. BRIEF DESCRIPTION OF RFA.....</b>	<b>4</b>
<b>2. ABOUT CPRIT .....</b>	<b>4</b>
2.1. ACADEMIC RESEARCH PROGRAM PRIORITIES.....	5
<b>3. RATIONALE .....</b>	<b>6</b>
<b>4. OBJECTIVES .....</b>	<b>7</b>
<b>5. INSTITUTIONAL COMMITMENT .....</b>	<b>9</b>
<b>6. FUNDING INFORMATION .....</b>	<b>10</b>
<b>7. ELIGIBILITY.....</b>	<b>10</b>
<b>8. RESUBMISSION POLICY .....</b>	<b>13</b>
<b>9. RESPONDING TO THIS RFA .....</b>	<b>13</b>
9.1. APPLICATION SUBMISSION GUIDELINES .....	13
9.1.1. <i>Submission Deadline Extension</i> .....	14
9.2. APPLICATION COMPONENTS.....	14
9.2.1. <i>Summary of Nomination (2,000 characters)</i> .....	14
9.2.2. <i>Layperson’s Summary (2,000 characters)</i> .....	14
9.2.3. <i>Institutional Commitment (3 pages)</i> .....	14
9.2.4. <i>Specific Aims and Subaims (1,200 Characters per Aim and per Subaims)</i> .....	15
9.2.5. <i>PI Information and Career Development Plan (12 pages)</i> .....	15
9.2.6. <i>PI’s Plan to Provide Mentoring (4-page description)</i> .....	18
9.2.7. <i>PI Biographical Sketch (5 pages)</i> .....	18
9.2.8. <i>Biographical Sketches of Collaborators (5 pages each)</i> .....	18
9.2.9. <i>Timeline (1 page)</i> .....	19
9.2.10. <i>Current and Pending Support</i> .....	19
9.2.10 <i>Institutional/Collaborator Support and/or Other Certification (2 pages)</i> .....	19
9.2.11. <i>Research Environment (1 page)</i> .....	19
9.2.12. <i>Previous Summary Statement</i> .....	19
9.3. FORMATTING INSTRUCTIONS.....	20
<b>10. APPLICATION REVIEW.....</b>	<b>21</b>
10.1. REVIEW PROCESS.....	21
10.2. CONFIDENTIALITY OF REVIEW .....	21
10.3. REVIEW CRITERIA.....	22
<b>11. KEY DATES .....</b>	<b>23</b>
<b>12. AWARD ADMINISTRATION.....</b>	<b>23</b>
<b>13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS.....</b>	<b>24</b>
<b>14. CONTACT INFORMATION.....</b>	<b>25</b>
14.1. HELPDESK.....	25
14.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS.....	25

## RFA VERSION HISTORY

- 09/14/23 RFA release
- 10/17/23 Modified section 9.2 – Application Components; Added Layperson’s Summary (Section 9.2.2) as a required application component.
- 10/17/23 Modified section 7- Eligibility – Added language indicating that “A minimum level of 4 person months (33%) full-time professional effort is required for the PI”.
- 10/17/23 Modified section 7- Eligibility – Modified the following sentence “The PI must hold active independent peer-reviewed research support for patient-oriented research, **or hold other funding for clinical research, e.g., support for investigator-initiated clinical trials.**”
- 01/16/24 Revised to extend the submission deadline to 4 PM central time on January 18, 2024

## **1. BRIEF DESCRIPTION OF RFA**

- The Clinical Investigator Award (CIA) provides protected time (33%-50% effort) for midcareer clinician-scientists with specialty training relevant to the delivery of cancer care, including therapeutic intervention, early detection, and prevention to devote more time to augment their capabilities in clinical cancer research, particularly investigator-initiated clinical trials, and to provide mentoring to junior investigators in the conduct of clinical research.
- Applicants must hold active independent peer-reviewed research support for patient-oriented research, or hold other funding for clinical research, e.g., support for investigator-initiated clinical trials.
- Applicants must have a track record of supervising and mentoring patient-oriented researchers.
- PIs must be within 5 years of their first appointment at the associate professor level or equivalent at an accredited academic institution, research institution, government agency, or private foundation. The PI must have an MD or DO degree and reside in Texas at the time an award contract is made and for the duration of the appointment.
- Applicants may request a maximum of \$300,000 per year for up to 5 years.
- Multi-Principal Investigators (PIs) (MIs) are not allowed under this RFA.
- Note that the Cancer Prevention and Research Institute of Texas (CPRIT) does not allow the use of the term Co-PI.
- Minimum effort for the PI throughout the project period is required.

## **2. ABOUT CPRIT**

The State of Texas has established CPRIT, which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of or cures for cancer.



- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas.
- Develop and implement the Texas Cancer Plan.

## 2.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency regarding how the Oversight Committee directs the orientation of the agency’s funding portfolio.

To accomplish CPRIT’s long-term vision, the Oversight Committee has these 2024 priorities:

- Investing in the cancer research capacity of Texas institutions through recruitment of cancer scholars, investment in core facilities, and investment in individual investigator awards in all regions of the state;
- Building the Texas cancer life science ecosystem across Texas by bridging discovery and translational research into early-stage company products with high impact on cancer patient care and creating economic development for the State of Texas; and
- Increasing the capacity for Texas to have a significant impact on cancer prevention and early detection, ultimately decreasing cancer incidence and mortality.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure in all regions of the state
- Reducing cancer disparities

The program priorities for academic research adopted by the Oversight Committee include funding projects that address or utilize the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
-

- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions and population research addressing cancer disparities.
- Computational oncology and analytic methods
- Childhood and adolescent cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials, particularly to regions of the state currently with limited access.

### 3. RATIONALE

The overall goal of the CPRIT CIA is to contribute to ensuring that a diverse pool of highly trained and accomplished physician-scientists is available to address Texas' and the nation's needs in clinical oncology research. The number of highly talented individuals entering a career in clinical investigation is decreasing at a time when the excitement and challenge associated with clinical cancer research has never been greater. The reasons for the decline in cancer clinical investigators are many and include the increased demands on clinical faculty to generate clinical revenue and, as a consequence, limited opportunities for clinical faculty to pursue research, as well as the increasingly complex nature of clinical research requiring specialized training not offered by clinical training programs. Consequently, clinical faculty often do not have the opportunity or experience required to initiate and maintain a career as a clinical investigator.

There is concern that this pattern of oncology-trained clinicians electing not to pursue careers in patient-oriented research and clinical investigation will seriously impair the ability to translate what has been discovered in the preclinical setting into advances that can benefit patients. Accordingly, there is an urgent need to develop a pipeline of cancer clinicians equipped with the skills and experience necessary to pursue careers in patient-oriented research and capable of leading innovative discovery campaigns through the conduct of clinical trials, and **to provide these clinical investigators with the protected time from clinical responsibilities that is required to develop and conduct investigator-initiated clinical trials.**

## 4. OBJECTIVES

The CIA is designed to enable midcareer clinician-scientists with specialty training relevant to delivery of cancer care, including therapeutic intervention, early detection, and prevention to do the following:

- Devote more time to augment their capabilities in clinical cancer research; and
- Provide mentoring to junior clinical investigators in the conduct of clinical research, contributing to stabilizing the careers of these individuals so that they can continue to conduct clinical research and, ultimately, provide mentorship to others.

PIs are expected to demonstrate a track record in research and the commitment to develop patient-driven hypotheses that can be tested in the clinic with the results, either positive or negative, refining standards of care and informing subsequent clinical research questions.

The CIA is intended to provide protected time to midcareer clinical investigators who exhibit the following:

- **Are at the associate professor level or equivalent;**
- Have completed specialty training relevant to cancer care, detection, or prevention and are certified by their institution to provide patient care in an oncology-related practice;
- Have an established record of independent peer-reviewed funding in clinical research, a record of supervising and mentoring early-stage researchers, and record of publications;
- Have current active independent peer-reviewed research support for patient-oriented research, or hold other funding for clinical research, e.g., support for investigator-initiated clinical trials;
- Will plan research that involves the conduct of clinical trials involving a therapeutic intervention, early detection, prevention, symptom control, or behavioral interventions; and
- Will maintain existing, or obtain additional, independent peer-reviewed funding as PD/PI or MI and assume leadership roles in collaborative clinical research programs.

Note that a CIA recipient who continues to have an independent peer-reviewed clinical research program and to provide mentorship to early-stage investigators can continue to hold this award and contribute to the overall goals of the program if promoted to full professor during the tenure

of the award. Progress in achieving these objectives will be monitored via annual progress reports (see [section 12](#)).

The CPRIT CIA will do the following:

- Provide physicians with the opportunity to expand clinical research skills, eg, gaining experience in advanced methods and experimental approaches and developing external relations with industry and pharmaceutical company partners and clinical research leaders at federal agencies.
- Provide an opportunity to establish or expand partnerships with laboratory-based collaborators to design and conduct correlative studies needed to interpret the outcome of an interventional trial.
- Provide the protected time from clinical responsibilities required to develop and conduct investigator-initiated and industry-sponsored clinical trials.
- Increase the pool of clinical investigators at Texas academic institutions who are conducting patient-oriented studies, who will be able to compete successfully for peer-reviewed grants and become institutional leaders in clinical research and who will mentor the next generation of clinical investigators. CIA recipients will also capitalize on basic discoveries and translate them through the conduct of innovative clinical trials involving cancer patients or individuals at risk for cancer.

To accomplish these objectives, the CPRIT CIA will provide awards of up to \$300,000 for up to 5 years to physicians who are within the first 5 years of a faculty appointment as an associate professor to acquire additional skills and experience in clinical research, to develop preliminary data that can be used to prepare applications for future clinical research projects to further both the investigator's career and the CPRIT mission, and to provide mentorship for an early-stage investigator in clinical research. This award may be used for the following:

- To provide salary support to the PI for levels of effort between 4 and 6 months full-time professional effort annually (33%-50%).
- Up to \$75,000 annually may be requested to support didactic study including enrollment in a degree-granting graduate training program course to enhance theoretical and practical skills in design, implementation, and interpretation of data from clinical

investigations or to expand their ongoing clinical trials by including translational studies, such as biomarker studies, correlative studies, or extended data analyses.

Relevance to cancer and to CPRIT's priority areas are important evaluation criteria for CPRIT funding. CPRIT encourages the participation of all groups underrepresented in biomedical research.

## 5. INSTITUTIONAL COMMITMENT

CPRIT CIAs are intended to provide midcareer clinical faculty with dedicated time for clinical research and to devote more time to augment their capabilities in clinical cancer research and to provide mentoring to new clinical investigators in the conduct of clinical research. The sponsoring institution must provide a letter of commitment to the PI's career goals as a productive, independent investigator and that this commitment to the PI is not contingent upon receiving this award. Additionally, the institution should describe how the PI is an integral part of the institution's research and academic programs. CPRIT recognizes that clinical investigators will need to commit time to direct patient care and that the time commitment required will vary depending on the nature of the individual's clinical practice and level of prior experience; however, the **institution must commit to providing the protected time (4- to 6- person months or 33% to 50% full-time professional effort) required, as well as describe the duties from which the applicant will be relieved and the institutional commitment to, and methods for, enhancing the PI's ability to be a productive independent investigator.**

A critical component of the CIA is the identification of a mentee(s) and the design of a mentoring program that is tailored to the goals and prior experience of the institutional pool of mentees. The CIA PI should be a clinical investigator with a strong track record for conducting patient-oriented research. The mentor will be expected to provide an annual progress report that documents progress made toward the goal of enhancing their capabilities as a clinical investigator.

## 6. FUNDING INFORMATION

This award is for **up to 5 years** providing applicants the opportunity to tailor the content and the duration of the award period based upon their individual program. This award is not renewable, although individuals may apply for other future CPRIT funding as appropriate.

Grant funds of up to \$1,500,000 (total costs) may be requested. Funding may be used by the clinical investigator for salary and fringe support (salary up to the CPRIT maximum of \$200,000/FTE) for protected time and didactic study including enrollment in a degree-granting graduate program.

Applicants are encouraged to design a scholarly clinical research experience that fits their background and program plan. Funds can be used to provide up to \$75,000 per year for activities that support translational studies. For example, funds may be requested to support (a) research expenses such as supplies, core facility services or outsourced services, eg, for biomarker or correlative assays; (b) travel to research meetings or training; or (c) statistical or analytical services including personnel or computer time. Requests for salary support for mentees are not appropriate for this award. Funds from this award mechanism may not be used to construct or renovate laboratory space.

The award request may include indirect costs of up to 5% of the total award amount (5.263% of the direct costs). PIs and mentee(s) are expected to attend CPRIT's conference. CPRIT funds may be used to reimburse registration, travel, and lodging expenses for the PI and up to 1 mentee to attend the biennial CPRIT conference.

Given the above parameters, CPRIT anticipates that a typical application budget will not exceed \$250,000.

**Continuation of funding of this award is contingent upon receipt of an annual progress report that documents achievement of the approved project milestones (see [section 9.2.8](#)).**

## 7. ELIGIBILITY

- The applicant must be a Texas-based entity. Any accredited academic institution, research institution, or government agency that provides cancer care and training and conducts clinical cancer research is eligible to apply for funding under this award

mechanism. A public or private company is not eligible for funding under this award mechanism.

- **An institution may submit only 2 applications under this RFA during this funding cycle.**
- PIs must be nominated by the president, provost, vice president for research, or appropriate dean of a Texas-based public or private institution of higher education, including academic health institutions. The application must be submitted on behalf of a specific PI.
- At the time of the application, the PI must be within 5 years of their first appointment at the associate professor level or equivalent at an accredited academic institution, research institution, government agency, or private foundation. Assistant professors whose appointment as associate professor will be active by the time of initiation of this award are eligible to apply. The PI must have an MD or DO degree and reside in Texas at the time an award contract is made and for the duration of the appointment.
- The PI must have oncology subspecialty training or equivalent and be certified by their institution to provide patient care in an oncology-related practice. Individuals with specialty training in other areas who are conducting clinical trials relevant to cancer, eg, prevention trials, are also eligible. Note: pathologists and radiologists are eligible for this award.
- The PI must hold active independent peer-reviewed research support for patient-oriented research, or hold other funding for clinical research, e.g., support for investigator-initiated clinical trials.
- A minimum level of 4 person months (33%) full-time professional effort is required for the PI.
- Multi-PIs are not allowed for this award.
- Individuals who have received a recruitment CPRIT Rising Star Scholar Award or a CPRIT Early Clinical Investigator Award are not eligible for the CIA.
- Individuals who hold an active NCI Clinical Investigator Team Leadership Award are not eligible to hold this award concurrently but may hold successive awards. Individuals holding an NIH R01 or equivalent award, such as a DOD Congressionally Directed Medical Research Programs Peer Reviewed Cancer Research Program Award or a

CPRIT Individual Investigator Research Award (IIRA), eg, the IIRA Clinical Translation grant, are eligible to apply for the CIA.

- PIs must have identified appropriate junior investigators who are located at the applicant's institution for mentoring and describe this pool (see [section 9.2.5](#)).
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the nominator, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant nominator, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the nominator, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, whether or not the individuals will receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.

CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 12](#) and [section 13](#). All statutory provisions and relevant administrative rules can be found at [www.cprit.texas.gov](http://www.cprit.texas.gov).



## 8. RESUBMISSION POLICY

An application previously submitted to CPRIT in response to this RFA but not funded may be resubmitted once following the reissuance of this RFA, based on the eligibility criteria of the initial application, and must follow all resubmission guidelines.

## 9. RESPONDING TO THIS RFA

### 9.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application is submitted. PIs must be nominated by the institution's president, provost, vice president for research, or appropriate dean. The individual submitting the application (Nominator) must create a user account in the system to start and apply. Furthermore, the Application/Authorized Signing Official, who is the person authorized to sign and submit the application for the organization, and the Grants Contract/Office of Sponsored Projects Official, who is the individual who will manage the grant contract if an award is made, also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on October 17, 2023, and must be submitted by 4 PM central time on January 18, 2024. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

### 9.1.1. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grants applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

## 9.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. For details, please refer to the *Instructions for Applicants* document that will be available on or about the time that this RFA is posted. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 7](#) will be administratively withdrawn without review.

### 9.2.1. Summary of Nomination (2,000 characters)

Provide a brief summary of the nomination. Include the PI's name and the department and/or entity within the nominator's organization where the PI is appointed.

### 9.2.2. Layperson's Summary (2,000 characters)

Provide a layperson's summary of the proposed work. **This section must be completed by the PI.** Describe, in simple, nontechnical terms, the overall aims of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early detection, prevention, treatment, or survivorship. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. Do not include any proprietary information in the layperson's summary.

### 9.2.3. Institutional Commitment (3 pages)

- The institutional commitment should be clearly documented in the application in the form of a letter signed by the applicant institution's president, provost, or appropriate dean and

the chair of the PI's department. The following information should be included in the letter:

- Describe the PIs selection process and the organization's commitment to the PI's further development as a clinical investigator and mentor.
- State the total award amount and duration requested.
- Document that at the time the CIA contract begins the PI will be appointed at the associate professor level (or equivalent) and will be eligible to provide patient care in a cancer-related discipline at the applicant institution.
- Document the institution's commitment to the PI's career goals as a productive, independent investigator, and that this commitment to the PI is not contingent upon receiving this award. If the individual(s) providing the institutional commitment letter is not the leader of the health care system or individual with authority to approve protected time from clinical service, provide an additional letter of commitment from the appropriate individual confirming the commitment to providing the protected time requested in the application.
- Document the institution's commitment to providing the protected time (4- to 6-person months or 33% to 50% full-time professional effort) required. Breach of this requirement will constitute grounds for discontinuation of the award.
- Provide additional information in support of a PI's research plan to demonstrate how the institutional commitment through development of strategic collaborations and leveraging the institution's unique strengths will foster the PI's career trajectory.

#### **9.2.4. Specific Aims and Subaims (1,200 Characters per Aim and per Subaims)**

List specific aims and subaims for each year of the project. These aims and subaims will also be used during the submission and evaluation of progress reports and assessment of project success if the award is made. **This section and the following section (9.2.4) must be prepared by the PI.**

#### **9.2.5. PI Information and Career Development Plan (12 pages)**

##### **PI Background**

- Describe the PI's short- and long-term career objectives in patient-oriented research and in mentoring new clinician investigators.
- Provide a summary of the research career of the PI, documenting the clinical and research accomplishments and ability of the PI to conduct patient-oriented research and commitment to a career in clinical research.
- Describe the PI's clinical and other professional responsibilities/activities in the grantee institution beyond the commitment to clinical research and elsewhere, and describe their relationship to the proposed activities on this award.
- Describe the PI's ability to provide mentoring to new clinician investigators. Provide the number of years of mentoring experience, mentoring role, the number of clinicians mentored, the specialties of individual mentees and the stages in their professional career. Describe the types of research conducted by the individuals mentored and the proportion of mentored individuals currently in academic medicine and/or directly participating in patient-oriented research.
- Provide an explanation of how relief from patient care or administrative responsibilities through protected time provided by this award will contribute to the development or expansion of the PI's clinical research program and increased level of commitment to mentoring early-stage clinical investigators. It is important to convey to the reviewers the rationale for needing protected time to continue a vibrant research program and that this award will permit the PI to spend more time on research and mentoring and less time on administrative and clinical responsibilities for the institution.

### **Career Goals and Objectives**

- Describe the PI's career goals and objectives under this award, including prior experience and current research support. A timeline for accomplishing these goals may be included.

### **Career Development Plan and Training Activities**

- Describe the professional responsibilities/activities including other research projects beyond the minimum effort commitment to the career award. Explain how these responsibilities/activities will help ensure career progression.
- Describe any didactic and research experience(s) designed to develop the necessary knowledge and research skills in scientific areas relevant to the PI's career goals and how

these skills and experiences will significantly enhance his/her ability to advance his/her research program.

- Demonstrate that the PI has received training or will participate in training covering the legal and ethical issues associated with research on human subjects, as well as other issues relevant to clinical research, eg, FDA regulatory process.

## **Research Plan**

- Describe a sound research plan that is consistent with the PI's level of research development and objectives and his/her career development plan. The research description should demonstrate not only the quality of the PI's research but also the novelty, significance and impact, creativity, and approach, as well as the ability of the PI to carry out the proposed research. Describe how this award will be used to help augment the PI's research skills and/or to develop new directions in clinical research.
- Briefly describe currently funded research (hypotheses and specific aims, background, significance and rationale, preliminary studies, results, and research design) to permit the peer reviewers to evaluate the extent, novelty, and quality of the PI's research activities and opportunities for mentoring.
- This award provides an opportunity for the PI to expand their ongoing clinical trials. Examples include biomarker studies, correlative studies, or extended data analyses. In this event, the description of the studies should include a statement of the hypothesis and specific aims, background, preliminary studies, significance and rationale, and research design and methods. It is not expected that this section will be as detailed as an investigator-initiated research grant; however, sufficient detail should be provided to permit an evaluation of the scientific merit of the research and to showcase the opportunities for mentoring. If correlative assays are proposed, the studies may be outsourced or performed using the services of a core facility. Alternatively, a qualified investigator who is able and willing to participate in the design and conduct of the correlative studies needed may be identified and included as a collaborator. In the *Research Environment* section ([section 9.2.11](#)), documentation must be provided that appropriate and adequate resources, both in terms of support and facilities, are available

to the PI to conduct the research, an important component of rationale and justification of the need for protected time.

#### **9.2.6. PI's Plan to Provide Mentoring (4-page description)**

- Describe the availability of early-stage investigators for mentoring; their previous training and specialization; plans for recruitment, selection, and supervision; the types of educational and research experiences that will be provided; and the role and activities of the CIA PI in mentoring, including proposed level of effort dedicated to mentoring for the PI.
- If there is an existing clinical research curriculum, for example, through the CTSA or Cancer Center's Clinical Trials Office, describe how the mentoring plan will be integrated with the curriculum. PIs must also describe a plan for supporting the research of their mentees during the period of the career award.
- The PI must provide mentoring for at least 1 junior clinical researcher during this award period. Applications that fail to document the availability of multiple mentees or a high likelihood of mentoring multiple clinical researchers are less likely to be viewed favorably by reviewers.

The CIA mentor must agree to provide annual evaluations of the mentee's progress in the annual progress report.

#### **9.2.7. PI Biographical Sketch (5 pages)**

A biosketch that includes current and past funding for the CIA PI must be provided. Biosketches should also include education and training, professional experience, awards and honors, and publications relevant to cancer research. Each biographical sketch must not exceed 5 pages. The NIH biosketch format is appropriate.

#### **9.2.8. Biographical Sketches of Collaborators (5 pages each)**

Applicants may provide up to 4 additional biographical sketches for co-mentors, collaborators, or key personnel. Each biographical sketch must not exceed 5 pages. The NIH biosketch format is appropriate.

### **9.2.9. Timeline (1 page)**

Provide an outline of anticipated major award outcomes to be tracked. Timelines will be reviewed during the evaluation of annual progress reports. If the application is approved for funding, this section will be included in the award contract and will be used to monitor progress. Failure to demonstrate robust progress may result in early termination of the grant award. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

### **9.2.10. Current and Pending Support**

State the funding source, duration, and title of all current and pending financial support including any research awards held by the PI. If the PI has no current or pending funding, a document stating this must be submitted. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

### **9.2.10 Institutional/Collaborator Support and/or Other Certification (2 pages)**

Applicants may provide letters of institutional support, e.g., documentation of services to be provided by a core facility, confirmation of collaborator support, and/or other certification documentation relevant to the proposed project. A maximum of 2 pages may be provided.

### **9.2.11. Research Environment (1 page)**

Clearly and concisely describe the research environment available to support the PI's research program as well as access to clinical facilities and patients, core facilities, didactic programs, and collaborative opportunities.

### **9.2.12. Previous Summary Statement**

If the application is being resubmitted, the summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission. The applicant is not responsible for providing this document.

**Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or do not meet the eligibility requirements listed above will be administratively withdrawn without review.**

### 9.3. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English
- **Document Format:** PDF only
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations must be submitted as part of the appropriate submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.
- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.
- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters are also acceptable as long as the journal information is stated. Include URLs of publications referenced in the application.  
Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45-67.
- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants should not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see following point).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be filled out, printed, signed, scanned, and then uploaded in PDF format.



## 10. APPLICATION REVIEW

### 10.1. Review Process

All applications will undergo a 2-stage peer review process: (1) Full peer review and (2) prioritization of grant applications by the CPRIT Scientific Review Council. In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts as well as advocate reviewers using the criteria listed in [section 10.3](#). Applicants will be notified of peer review panel assignments prior to the peer review meeting dates. Peer review panel membership can be found on the CPRIT website. In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT Scientific Review Council based on comparisons with applications from all the peer review panels and programmatic priorities. Applications approved by Scientific Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, chapters 701 to 703](#).

### 10.2. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b). Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Review Council members are non-Texas residents.

**By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed conflict of interest as**

set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, chapters 701 to 703](#).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: An Oversight Committee member, a PIC member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention and Communications Officer, the Chief Product Development Officer, and the Commissioner of the Department of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant applicant from further consideration for a grant award.

### **10.3. Review Criteria**

Applications will be assessed based on evaluation of the quality of the PI, his or her track-record, and his or her potential for further contributions as a clinical investigator. **Also of critical importance is the strength of the institutional commitment to the PI's career development.**

Review criteria will focus on the overall impression of the PI and the proposed career development plan, the institution's commitment to the PI's career development as a clinical investigator, and his or her long-term potential to have an impact on the field of cancer research. Questions to be considered by the reviewers are as follows:

**Quality of the PI:** Has the PI demonstrated academic excellence? Has the PI received excellent training as a clinician in a cancer discipline? Does the PI show exceptional potential for making an impact on cancer research in the future, and mentoring early-stage clinical investigators.

**Institutional commitment, career development, and mentorship plan:** Will the PI have enough time and support to develop further as a clinical investigator? Is the career development plan well developed and tailored to enable the PI to achieve their career goals? Is the mentorship plan well developed and tailored to guide the mentee to achieve their career goals?

**Relevance of PI's career and clinical trials plan:** Is the proposed area of focus likely to have a significant impact on reducing the burden of cancer in the near term?

**Research Environment:** Does the institution have the necessary facilities, expertise, and resources including access to patients to support the PI's development? Is there evidence of strong institutional support? Will the PI's administrative/clinical responsibilities be sufficiently limited so that he or she can focus on growing his or her research? Is the pool of early-stage investigators appropriate to ensure the applicant's engagement in productive mentoring? If biomarker or correlative studies are proposed, is a qualified laboratory, or collaborator who is able and willing to participate in the design and conduct of the studies identified.

## **11. KEY DATES**

### **RFA**

RFA release                      September 14, 2023

### **Application**

Online application opens      October 17, 2023, 7 AM central time

Application due                 January 18, 2024, 4 PM central time

Application review              February 2024 to August 2024

### **Award**

Award notification              August 2024

Anticipated start date         August 31, 2024

## **12. AWARD ADMINISTRATION**

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Awards made under this RFA are not transferable to another institution. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in

accordance with CPRIT's electronic signature policy as set forth in [Texas Administrative Code, Title 25, chapters 701 to 703](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at [www.cprit.texas.gov](http://www.cprit.texas.gov).

Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [Texas Administrative Code, Title 25, chapters 701 to 703](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, chapters 701 to 703](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals outlined in [section 9.2.4](#) and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. **CPRIT's Academic Research Program staff reviews the progress reports, and continuation of funding is contingent upon demonstration of progress and achievement of the goals set forth in [section 9.2.3](#).** Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at [www.cprit.texas.gov](http://www.cprit.texas.gov).

### **13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS**

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. The demonstration of available matching funds must be made at the time the award contract is executed and annually thereafter, not when the application is submitted. Grant applicants are advised to consult CPRIT's Administrative Rules,

[Texas Administrative Code, Title 25, chapters 701 to 703](#), for specific requirements regarding the demonstration of available funding.

## **14. CONTACT INFORMATION**

### **14.1. Helpdesk**

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff members are not in a position to answer questions regarding scientific aspects of applications.

**Hours of operation:** Monday through Friday, 8 AM to 6 PM central time

**Tel:** 866-941-7146

**Email:** [Help@CPRITGrants.org](mailto:Help@CPRITGrants.org)

### **14.2. Scientific and Programmatic Questions**

Questions regarding the CPRIT Program, including questions regarding this or other funding opportunities, should be directed to the CPRIT Director for Academic Research.

**Tel:** 512-305-8491

**Email:** [research@cprit.texas.gov](mailto:research@cprit.texas.gov)

**Website:** [www.cprit.texas.gov](http://www.cprit.texas.gov)

# **Third Party Observer Reports**

---

**Cancer Prevention and Research Institute of Texas (CPRIT)****24.2 Academic Research - Basic Cancer Research-1****(24.2 ACR BCR-1)****Observation Report**

Report No. 2024-04-16 24.2\_ACR\_BCR-1  
Program Name: Academic Research  
Panel Name: 24.2 Academic Research - Basic Cancer Research-1 (24.2\_ACR\_BCR-1)  
Panel Date: April 16, 2024  
Report Date: April 23, 2024

***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

***INTRODUCTION***

The subject of this report is the 24.2 Academic Research - Basic Cancer Research-1 (24.2\_ACR\_BCR-1) meeting. The meeting was chaired by Eric Fearon and conducted via videoconference on April 16, 2024.

***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Thirteen (13) applications were discussed and thirteen (13) applications were not discussed
- Panelists: One (1) panel chair, fourteen (14) expert reviewers, two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.



With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a series of connected loops and a long horizontal tail.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

**Cancer Prevention and Research Institute of Texas (CPRIT)****24.2 Academic Research Basic Cancer Research – 2****(24.2 ACR BCR-2)****Observation Report**

Report No. 2024-04-17 24.2\_ACR\_BCR-2  
Program Name: Academic Research  
Panel Name: 24.2 Academic Research Basic Cancer Research – 2 (24.2\_ACR\_BCR-2)  
Panel Date: April 17, 2024  
Report Date: April 23, 2024

***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

***INTRODUCTION***

The subject of this report is the 24.2 Academic Research Basic Cancer Research – 2 (24.2\_ACR\_BCR-2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on April 17, 2024.

***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Fifteen (15) applications were discussed and Thirty (30) were not discussed.
- Panelists: One (1) panel chair, eighteen (18) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were thirteen (13) Conflicts of Interest (COIs) identified prior to and/or during the meeting. No (0) applications with COIs were discussed.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

**Cancer Prevention and Research Institute of Texas (CPRIT)****24.2 Academic Research Cancer Biology (CB)****(24.2 ACR CB)****Observation Report**

Report No. 2024-04-24 24.2\_ACR\_CB  
Program Name: Academic Research  
Panel Name: 24.2 Academic Research Cancer Biology (CB) (24.2 \_ACR\_CB)  
Panel Date: April 24, 2024  
Report Date: April 29, 2024

***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

***INTRODUCTION***

The subject of this report is the 24.2 Academic Research Cancer Biology (CB) (24.2\_ACR\_CB) meeting. The meeting was chaired by Peter Jones and conducted via videoconference on April 24, 2024.

***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and thirty-six (36) applications were not discussed
- Panelists: One (1) panel chair, nineteen (19) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were eight (8) Conflicts of Interest (COIs) identified prior to and/or during the meeting. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized 'M' followed by a horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

**Cancer Prevention and Research Institute of Texas (CPRIT)****24.2 Academic Research - Imaging Technology and****Informatics (24.2 ACR ITI)****Observation Report**

Report No. 2024-04-23 24.2\_ACR\_ITI  
Program Name: Academic Research  
Panel Name: 24.2 Academic Research - Imaging Technology and Informatics  
(24.2\_ACR\_ITI)  
Panel Date: April 23, 2024  
Report Date: April 29, 2024

***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

***INTRODUCTION***

The subject of this report is the 24.2 Academic Research - Imaging Technology and Informatics (24.2\_ACR\_ITI) meeting. The meeting was chaired by Henry VanBrocklin and conducted via videoconference on April 23, 2024.

***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.



## **SUMMARY OF OBSERVATION RESULTS**

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twelve (12) applications were discussed and fourteen (14) were not discussed
- Panelists: One (1) panel chair, twelve (12) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

**Cancer Prevention and Research Institute of Texas (CPRIT)**  
**24.2 Academic Research Clinical and Translational Cancer**  
**Research-1 (24.2 ACR CTCR-1)**  
**Observation Report**

Report No. 2024-04-18 24.2\_ACR\_CTCR-1  
Program Name: Academic Research  
Panel Name: 24.2 Academic Research Clinical and Translational Cancer  
Research-1 (24.2\_ACR\_CTCR-1)  
Panel Date: April 18, 2024  
Report Date: April 23, 2024

### ***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

### ***INTRODUCTION***

The subject of this report is the 24.2 Academic Research Clinical and Translational Cancer Research-1 (24.2\_ACR\_CTCR-1) meeting. The meeting was chaired by Margaret Tempero and conducted via videoconference on April 18, 2024.

### ***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Eighteen (18) applications were discussed and twenty-four (24) were not discussed
- Panelists: One (1) panel chair, sixteen (16) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were six (6) Conflicts of Interest (COIs) identified prior to and/or during the meeting. No (0) applications with COIs were discussed.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

**Cancer Prevention and Research Institute of Texas (CPRIT)**  
**24.2 Academic Research Clinical and Translational Cancer**  
**Research-2 (24.2 ACR C/TCR-2)**  
**Observation Report**

Report No. 2024-04-25 24.2\_ACR\_C/TCR-2  
Program Name: Academic Research  
Panel Name: 24.2 Academic Research Clinical and Translational Cancer  
Research-2 (24.2\_ACR\_C/TCR-2)  
Panel Date: April 25, 2024  
Report Date: April 29, 2024

### ***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

### ***INTRODUCTION***

The subject of this report is the 24.2 Academic Research Clinical and Translational Cancer Research-2 (24.2\_ACR\_C/TCR-2) meeting. The meeting was chaired by Richard O'Reilly and conducted via videoconference on April 25, 2024.

### ***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twenty-eight (28) applications were discussed and eleven (11) were not discussed
- Panelists: One (1) panel chair, fourteen (14) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were fourteen (14) Conflicts of Interest (COIs) identified prior to and/or during the meeting. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written in a cursive style.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney



**Cancer Prevention and Research Institute of Texas (CPRIT)**  
**FY24.2 Scientific Review Council (24.2 SRC)**  
**Observation Report**

Report No.            2024-07-11 24.2 SRC  
Program Name:       Academic Research  
Panel Name:          FY24.2 Scientific Review Council (24.2 SRC)  
Panel Date:           July 11, 2024  
Report Date:          July 17, 2024

### ***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

### ***INTRODUCTION***

The subject of this report is the FY24.2 Scientific Review Council (24.2 SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on July 11, 2024.

### ***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

One (1) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Thirty one (31) applications were discussed and one (1) application was withdrawn
- Panelists: One (1) discussion lead, and five (5) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Three (3)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line extending to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

# **Conflicts of Interest Disclosure**

---

# Conflicts of Interest Disclosure

## CPRIT Academic Research Cycle 24.2

### Awards Announced at the August 21, 2024, Oversight Committee Meeting

The following table lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research cycle 24.2 include *Core Facility Support Awards*; *Clinical Investigator Award*; *High-Impact/High-Risk Research Awards*; and *Multi-Investigator Research Awards*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
<b>Applications considered by the PIC and Oversight Committee:</b>			
RP240440	Richard Gorlick	The University of Texas M. D. Anderson Cancer Center	Patrick Grohar
RP240439	Sattva Neelapu	The University of Texas M. D. Anderson Cancer Center	Joshua Campbell
RP240454	Everett Stone	The University of Texas at Austin	Weiping Zou
RP240474	Leonid Metelitsa	Baylor College of Medicine	W. Martin Kast
<b>Applications not considered by the PIC or Oversight Committee:</b>			
RP240428	Neelam Mukherjee	The University of Texas Health Science Center at San Antonio	Jose Conejo-Garcia
RP240564	Kevin Pinney	Baylor University	Jose Conejo-Garcia
<b>RP240591</b>	Ming You	The Methodist Hospital Research Institute	Steven Belinsky

<b>Application ID</b>	<b>Principal Investigator</b>	<b>Organization</b>	<b>Conflict Noted by Reviewer</b>
RP240448	Kevin Dalby	The University of Texas at Austin	Joseph Mancias
RP240459	Abhishek Jain	Texas A&M Engineering Experiment Station	Benjamin Greenbaum

# De-Identified Overall Evaluation Scores

---

# Clinical Investigator Award

## Academic Research Cycle 24.2

Application ID	Final Overall Evaluation Score
RP240478*	1.4
RP240473*	1.6
RP240557*	1.8
RP240442*	2.1
RP240441*	2.2
RP240518*	2.4

\* Recommended for funding.



# **Final Overall Evaluation Scores and Rank Order Scores**

---

# UC San Diego

## SCHOOL OF MEDICINE

July 29, 2024

Dr. David A. Cummings, M.D.  
Oversight Committee Presiding Officer  
Cancer Prevention and Research Institute of Texas  
Via email to [dcummingsmd@yahoo.com](mailto:dcummingsmd@yahoo.com)

Ms. Kristen Doyle  
Chief Executive Officer  
Cancer Prevention and Research Institute of Texas  
Via email to [kdoyle@cprit.texas.gov](mailto:kdoyle@cprit.texas.gov)

Dear Dr. Cummings and Ms. Doyle,

The Scientific Review Council (SRC) is pleased to submit this list of 36 research grant recommendations for the Clinical Investigator Award, Core Facility Support Awards, High-Impact/High Risk Awards, Multi-Investigator Research Awards and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on July 11, 2024 to review First-Time Tenure-Track Faculty Members recruitment applications submitted for Cycle FY24.12 and to consider the applications recommended by the peer review panels following their meetings held April 16, 2024 to April 25, 2024. On July 29, 2024 the SRC met to discuss application RP240474, which was peer reviewed on April 25, 2024 but not recommended. The application received a favorable score but just missed the cut off line made by the peer review panel. The SRC chose to consider and recommend RP240474 because of how it addresses program priorities of childhood and adolescent cancers. With available funds the SRC recommended RP240474 to the Program Integration Committee (PIC), bringing the total number of recommended academic research awards to 36.

Recommended funding amounts and the overall evaluation score are stated for each grant application in the following table. The total amount for the applications recommended to the PIC is \$60,577,922.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • [rkolodner@health.ucsd.edu](mailto:rkolodner@health.ucsd.edu)

Richard D. Kolodner, Ph.D.  
Chair, CPRIT Scientific Review Council

Rank	ID	RFA	Score	Application Title	PI	PI Org.	Rec. Budget
1	RP240545	CFSA	1.0	Renewal of CPRIT GMP Core	Lapteva, Natalia	Baylor College of Medicine	\$2,000,000
2	RR240070	RFTFM	1.0	Expanding the Accessibility and Efficacy of CAR-T Cells Through In Vivo Engineering	Labanieh, Louai	Baylor College of Medicine	\$2,000,000
3	RR240076	RFTFM	1.0	Discovery of Molecular Glue Degraders Targeting the Undruggable Cancer Proteome	Yoon, Hojong	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
4	RR240082	RFTFM	1.2	Identification of Neural Mechanisms Contributing to Chemotherapy-Associated Cognitive Impairments	Sun, Yanjun	The University of Texas Health Science Center at Houston	\$2,000,000
5	RP240610	CFSA	1.4	UTHealth Cancer Genomics Core (UTHealth CGC)	Zhao, Zhongming	The University of Texas Health Science Center at Houston	\$2,000,000
6	RP240478	CIA	1.4	Advancing immunotherapy for high-risk cancers in children and adolescents	Hegde, Meenakshi	Baylor College of Medicine	\$1,030,892
7	RP240473	CIA	1.6	Signal-Augmented Cancer Cell Therapies: Integrating Advanced	Omer, Bilal	Baylor College of Medicine	\$1,046,414

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

**UC San Diego**  
SCHOOL OF MEDICINE

				Correlatory Studies and Mentorship			
8	RP240494	CFSA	1.7	Children's Research Institute Metabolomics Core: Advanced Methodologies in Cancer Metabolism	DeBerardinis, Ralph	The University of Texas Southwestern Medical Center	\$2,601,616
9	RP240497	CFSA	1.7	Advanced Spatial Genomics Core Facility	Navin, Nicholas	The University of Texas M. D. Anderson Cancer Center	\$2,999,993
10	RR240079	RFTFM	1.7	Immune surveillance and elimination of aneuploid cells in vivo	Trakala, Marianna	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
11	RP240432	CFSA	1.8	Advanced Multiparameter Cytometry and Cell Sorting Core	Beeton, Christine	Baylor College of Medicine	\$1,999,882
12	RP240440	MIRA2	1.8	Novel Therapies for Osteosarcoma	Gorlick, Richard	The University of Texas M. D. Anderson Cancer Center	\$4,498,684
13	RP240557	CIA	1.8	Dietary intervention to modulate the microbiome and immune response	McQuade, Jennifer	The University of Texas M. D. Anderson Cancer Center	\$1,074,727
14	RP240430	CFSA	1.9	GCC Center for Comprehensive PK/PD & Formulation	Liang, Dong	Texas Southern University	\$2,000,000
15	RP240590	HIHRA	2.0	Bidentate ERK Traps: Revolutionizing Combination Cancer Therapy Strategies	Dalby, Kevin	The University of Texas at Austin	\$249,996
16	RP240539	HIHRA	2.0	Spectroscopy for quantitative real-time imaging of radical formation	Gustavsson, Anna-Karin	Rice University	\$250,000

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

				in ultra-high dose rate radiation therapy			
17	RP240508	CFSA	2.1	The Texas Decision Science Core Facility: A CPRIT Population Science Core	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	\$2,995,778
18	RP240446	HIHRA	2.1	Regulation of Transcription Factor Function by Local Chromatin Context	Soshnev, Alexey	The University of Texas at San Antonio	\$249,561
19	RP240442	CIA	2.1	Identifying and exploiting novel metabolic vulnerabilities in the treatment of kidney cancer	Courtney, Kevin	The University of Texas Southwestern Medical Center	\$913,682
20	RP240559	CFSA	2.1	High Performance Mass Spectrometry Imaging Core Facility	Brodbelt, Jennifer	The University of Texas at Austin	\$1,998,763
21	RP240441	CIA	2.2	Precision Lung Cancer Interception by Targeting High-Risk Lung Nodules	Zhang, Jianjun	The University of Texas M. D. Anderson Cancer Center	\$1,098,945
22	RP240438	MIRA2	2.2	Overcoming major barriers to the delivery of successful T-cell immunotherapies	Rooney, Cliona	Baylor College of Medicine	\$4,500,000
23	RP240579	HIHRA	2.3	Renal Clearable Nano Delivery Systems for Maximizing Anti-tumor Immunity in Breast Cancer Brain Metastasis Treatment	Zheng, Jie	The University of Texas at Dallas	\$250,000
24	RP240521	CFSA	2.3	Pediatric Cancer Data Core	Xie, Yang	The University of Texas Southwestern Medical Center	\$1,999,760

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

**UC San Diego**  
SCHOOL OF MEDICINE

25	RP240518	CIA	2.4	Adapting radiotherapy clinical trials to treatment response and artificial intelligence innovations	Desai, Neil	The University of Texas Southwestern Medical Center	\$1,460,229
26	RP240462	HIHRA	2.5	Development of an Endoscopic Nuclear Imaging Capsule for Radio-Guided Cancer Surgery	Zannoni, Elena Maria	The University of Texas at Austin	\$250,000
27	RP240501	HIHRA	2.6	Delivering Immunotherapy more effectively to glioblastoma with a “magnetic switch”	Qin, Zhenpeng	The University of Texas at Dallas	\$250,000
28	RP240542	HIHRA	2.6	Digital Twin Augmented Reality for Prostate Laparoscopic Surgery	Fei, Baowei	The University of Texas at Dallas	\$250,000
29	RP240454	HIHRA	2.7	Reversing Tumor Immune Exclusion with Sphingosine-1-Phosphate Depleting Therapeutics	Stone, Everett	The University of Texas at Austin	\$249,998
30	RP240498	HIHRA	2.7	Improving the management of gastric peritoneal carcinomatosis with Photo-Betabody Immunotherapy	Obaid, Girgis	The University of Texas at Dallas	\$248,991
31	RP240493	HIHRA	2.8	Engineering in vivo chimeric antigen receptor (CAR) macrophages for diffuse midline glioma	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$250,000
32	RP240516	HIHRA	2.9	Mapping multivalent chromatin	Mani, Ram	The University of Texas	\$250,000

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

**UC San Diego**  
SCHOOL OF MEDICINE

				interactions to define the 3D genome of Clear cell renal cell carcinoma		Southwestern Medical Center	
33	RP240605	HIHRA	3.1	Stimulate Mucosal-associated Invariant T cells to Kill Cancer Cells	Huang, Shouxiong	Texas Biomedical Research Institute	\$249,484
34	RP240439	MIRA2	3.1	Innovative cell therapy approaches for hematological and solid malignancies	Neelapu, Sattva	The University of Texas M. D. Anderson Cancer Center	\$4,500,000
35	RP240489	MIRA2	3.2	Neural Regulation of Childhood Cancers	Morrison, Sean	The University of Texas Southwestern Medical Center	\$4,362,563
36	RP240474	MIRA2	3.6	Cellular Immunotherapies for Pediatric Solid Tumors	Metelitsa, Leonid	Baylor College of Medicine	\$4,497,964

Clinical Investigator Award (CIA)  
Core Facility Support Awards (CFSA)  
High-Impact/High Risk Awards (HIHR)  
Multi-Investigator Research Awards (MIRA2)  
Recruitment of First-Time, Tenure Track Faculty Members (RFTTFM)

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

# **CEO Affidavit Supporting Information**

**Academic Research  
FY 2024—Cycle 2  
*High-Impact/High-Risk Research Awards***



# Request for Applications

---



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**REQUEST FOR APPLICATIONS**  
**RFA R-24.2-HIHR**

**High-Impact/High-Risk Research Awards**

**Please also refer to the Instructions for Applicants document,  
which will be posted September 14, 2023**

Applications for this award mechanism are subject to institutional limits.  
Applicants are advised to consult with their institution's  
Office of Research and Sponsored Programs (or equivalent).

**Application Receipt Opening Date:** October 17, 2023

**Application Receipt Closing Date:** January 18, 2024

**FY 2024**

Fiscal Year Award Period

September 1, 2023-August 31, 2024

# TABLE OF CONTENTS

<b>1. ABOUT CPRIT</b> .....	<b>4</b>
1.1. ACADEMIC RESEARCH PROGRAM PRIORITIES .....	4
<b>2. RATIONALE</b> .....	<b>5</b>
<b>3. RESEARCH OBJECTIVES</b> .....	<b>6</b>
<b>4. FUNDING INFORMATION</b> .....	<b>6</b>
<b>5. ELIGIBILITY</b> .....	<b>6</b>
<b>6. RESUBMISSION POLICY</b> .....	<b>8</b>
<b>7. RESPONDING TO THIS RFA</b> .....	<b>8</b>
7.1. APPLICATION SUBMISSION GUIDELINES .....	8
7.1.1. <i>Submission Deadline Extension</i> .....	9
7.2. APPLICATION COMPONENTS .....	9
7.2.1. <i>Abstract and Significance (5,000 characters)</i> .....	9
7.2.2. <i>Layperson’s Summary (2,000 characters)</i> .....	10
7.2.3. <i>Specific Aims and Sub Aims</i> .....	10
7.2.4. <i>Timeline (1 page)</i> .....	10
7.2.5. <i>Specific Aims (1 Page)</i> .....	10
7.2.6. <i>Resubmission Summary (1 page)</i> .....	10
7.2.7. <i>Research Plan (4 pages)</i> .....	11
7.2.8. <i>Vertebrate Animals and/or Human Subjects (2 pages)</i> .....	11
7.2.9. <i>Publications/References</i> .....	11
7.2.10. <i>Budget and Justification</i> .....	11
7.2.11. <i>Biographical Sketches (5 pages each)</i> .....	12
7.2.12. <i>Current and Pending Support</i> .....	12
7.2.13. <i>Institutional/Collaborator Support and/or Other Certification (2 pages)</i> .....	13
7.2.14. <i>Previous Summary Statement</i> .....	13
7.2.15. <i>Institutional Limits</i> .....	13
7.3. FORMATTING INSTRUCTIONS .....	13
<b>8. APPLICATION REVIEW</b> .....	<b>15</b>
8.1. REVIEW PROCESS OVERVIEW .....	15
8.2. CONFIDENTIALITY OF REVIEW .....	15
8.3. REVIEW CRITERIA.....	16
8.3.1. <i>Primary Criteria</i> .....	16
8.3.2. <i>Secondary Criteria</i> .....	17
<b>9. KEY DATES</b> .....	<b>18</b>
<b>10. AWARD ADMINISTRATION</b> .....	<b>18</b>
<b>11. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS</b> .....	<b>19</b>
<b>12. CONTACT INFORMATION</b> .....	<b>20</b>
12.1. HELPDESK.....	20
12.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS .....	20

## **RFA VERSION HISTORY**

9/14/23 RFA release

1/16/24 Revised to extend the submission deadline to 4 PM central time on January 18, 2024

## **1. ABOUT CPRIT**

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of, or cures for, cancer.
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas.
- Develop and implement the Texas Cancer Plan.

### **1.1. Academic Research Program Priorities**

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

To accomplish CPRIT's long-term vision, the Oversight Committee has identified these 2024 priorities:

- Investing in the cancer research capacity of Texas institutions through recruitment of cancer scholars, investment in core facilities, and investment in individual investigator awards in all regions of the state;
- Building the Texas cancer life science ecosystem across Texas by bridging discovery and translational research into early-stage company products with high impact on cancer patient care and creating economic development for the State of Texas; and
- Increasing the capacity for Texas to have a significant impact on cancer prevention and early detection, ultimately decreasing cancer incidence and mortality.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure in all regions of the state

- Reducing cancer disparities

The program priorities for academic research adopted by the Oversight Committee include funding projects that address the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions and population research addressing cancer disparities.
- Computational oncology and analytic methods
- Childhood and adolescent cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials, particularly to regions of the state currently with limited access

## 2. RATIONALE

CPRIT High-Impact/High-Risk (HIHR) Research Awards seek to provide short-term funding to explore the feasibility of high-risk projects that, if successful, would contribute major new insights into the etiology, diagnosis, treatment, or prevention of cancers. Because HIHR Research Awards are designed to support new ideas, preliminary data are not required. Using this mechanism, CPRIT intends to support innovative, developmental projects that focus on exceptionally promising topics that are not yet sufficiently mature to compete successfully for more conventional funding. The HIHR Research Awards are expected to provide the foundation for individual or multiple investigator peer-reviewed awards upon completion. Applicants must explain why more conventional sources of support are not available for the proposed research and how short-term funding will lead to strong applications for additional support.

Applications that might be described as “mini-R01s” will not be competitive. **The goal of this award mechanism is to fund uncommonly great ideas that merit the opportunity to acquire preliminary data. There should be reasons for the idea to be plausible, but CPRIT acknowledges that most of the selected projects will ultimately fail to meet their primary**

**goals. The rare proposals that succeed will be of sufficient importance to justify this program.** Applications may address any research topic related to cancer biology, causation, prevention, detection, screening, treatment, or survivorship.

### **3. RESEARCH OBJECTIVES**

Areas of interest include laboratory research, translational studies, and population-based and/or clinical investigations. In that cancers arise from a large number of derangements of basic molecular and cellular functions, which, in turn, cause many alterations in basic biological processes, almost any aspect of biology may be relevant to cancer research, more or less directly. The *degree of relevance* to cancer research will be an important criterion for evaluation of projects for funding by CPRIT ([section 8.3.1](#)). For example, are alterations in the process in question *primarily* responsible for oncogenesis or secondary manifestations of malignant transformation? Will understanding the process or interfering with it offer selective and useful insight into prevention, diagnosis, or treatment of cancer? *Successful applicants for funding from CPRIT will have addressed these questions satisfactorily.*

### **4. FUNDING INFORMATION**

Applicants may request a total of \$250,000 for a period of up to 24 months (2 years), inclusive of both direct and indirect costs. Because of the nature of this funding mechanism, renewal applications will not be accepted. Follow-on applications will not be funded until the initial HIHR Award grant period has passed. Award funds may be used to pay for salary and benefits, research supplies, equipment, and clinical costs. *Requests for funds for travel to scientific meetings other than the CPRIT biennial conference are not appropriate for this funding mechanism, nor are requests for funds to support construction and/or renovation.* State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the total award amount.

### **5. ELIGIBILITY**

- The applicant must be a Texas-based entity. Any not-for-profit institution or organization that conducts research is eligible to apply for funding under this award mechanism. A public or private company is also eligible for funding under this award mechanism.

- The Principal Investigator (PI) must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent and reside in Texas for the period of the time that the research that is the subject of the grant application is conducted.
- A PI may submit only 1 new or resubmission application under this RFA during this funding cycle. The PI must commit a minimum 5% level of effort throughout the entire award period.
- Multi-PIs are not permitted.
- One Coinvestigator may be included. An individual may serve as a Coinvestigator in more than 1 application but should ensure that he or she could dedicate adequate time and effort should more than 1 application be funded. The Coinvestigator must reside in Texas for the period of the time that the research that is the subject of the grant application is conducted.
- Collaborations are permitted and encouraged, and collaborators may or may not reside in Texas. However, collaborators who do not reside in Texas are not eligible to receive CPRIT funds. Collaborators should have specific and well-defined roles. Subcontracting and collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.
- An individual may serve as a PI on no more than 3 active Academic Research grants. Recruitment Grants and Research Training Awards do not count toward the 3-grant maximum; however, CPRIT considers project leaders on a MIRA award equivalent to a PI. For the purpose of calculating the number of active grants, CPRIT will consider the number of active grants at the time of the award contract effective date (for this cycle expected to be 8/31/2024).
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.



- An applicant is not eligible to receive a CPRIT grant award if the applicant PI, any senior member, or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the PI, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, whether or not those individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 10](#) and [section 11](#). All statutory provisions and relevant administrative rules can be found at [www.cprit.texas.gov](http://www.cprit.texas.gov).

## 6. RESUBMISSION POLICY

An application previously submitted to CPRIT but not funded may be resubmitted once and must follow all resubmission guidelines. More than 1 resubmission is not permitted.

## 7. RESPONDING TO THIS RFA

### 7.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and submit an application. Furthermore, the Authorized Signing Official (a person authorized to sign and submit the application for the organization), and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant

contract if an award is made) also must create a user account in CARS. Please refer to the *Instructions for Applicants (IFA)* document for the instructions on adding Key Personnel to an application.

Applications will be accepted beginning at 7 AM central time on October 17, 2023 and must be submitted by 4 PM central time on January 18, 2024. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

### **7.1.1. Submission Deadline Extension**

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grants applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

## **7.2. Application Components**

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the *Instructions for Applicants* document for details that will be available when the application receipt system opens. Submissions that are missing 1 or more components or that do not meet the eligibility requirements listed in [section 5](#) will be administratively withdrawn without review.

### **7.2.1. Abstract and Significance (5,000 characters)**

Clearly explain the question or problem to be addressed and the approach to its answer or solution. The overall goal(s) and specific aims of the application, as well as the experimental approaches must be obvious from the abstract. Clearly address how the proposed project, if successful, will have a major impact on the field of cancer research or on the care of patients with cancer. Summarize how the proposed research creates new paradigms or challenges existing ones.

### **7.2.2. Layperson’s Summary (2,000 characters)**

Provide a layperson’s summary of the proposed work. Describe, in simple, nontechnical terms, the overall goals of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer prevention research, early diagnosis, or treatment. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. Do not include any proprietary information in the layperson’s summary. The layperson’s summary will also be used by advocate reviewers ([section 8.1](#)) in evaluating the significance and impact of the proposed work.

### **7.2.3. Specific Aims and Sub Aims**

List specific aims and sub aims for each year of the project. These aims will also be used during the submission and evaluation of progress reports and assessment of project success if the award is made.

### **7.2.4. Timeline (1 page)**

Provide an outline of anticipated major milestones to be tracked. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful applications. If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

### **7.2.5. Specific Aims (1 Page)**

Please provide a 1-page summary of the aims of the proposal. The Specific Aims page should identify the problem or gap in our current knowledge. It should present a hypothesis and briefly describe the aims and approaches. Address the proposal’s innovation, novel approaches, and significance and impact on the field and cancer research. Please also refer to the template located in [Current Funding Opportunities](#) for Academic Research in CARS.

### **7.2.6. Resubmission Summary (1 page)**

An application previously submitted to CPRIT but not funded may be resubmitted **once** after careful consideration of the reasons for lack of prior success. Applicants preparing a

resubmission must describe the approach to the resubmission. If a summary statement was prepared for the original application review, applicants are advised to address all noted concerns.

### **7.2.7. Research Plan (4 pages)**

**Background:** Present the rationale behind the proposed project, emphasizing the pressing problem in cancer research that will be addressed. Describe the relevance to cancer disparities and impact on the burden of cancer in Texas, if any. Preliminary data are not required, but strong reasoning and literature support will obviously enhance the application.

**Hypothesis and Specific Aims:** Concisely state the hypothesis and/or specific aims to be tested or addressed by the research described in the application.

**Research Strategy:** Describe the experimental design, including methods, anticipated results, potential problems or pitfalls, and alternative approaches. Preliminary data that support the proposed hypothesis are encouraged but not required. Briefly comment on future directions and plans to secure future funding.

### **7.2.8. Vertebrate Animals and/or Human Subjects (2 pages)**

If vertebrate animals will be used, provide an outline of the appropriate protocols that will be followed. If human subjects or human biological samples will be used, provide a plan for recruitment of subjects or acquisition of samples that will meet the time constraints of this award mechanism.

### **7.2.9. Publications/References**

Provide a concise and relevant list of publications/references cited for the application.

### **7.2.10. Budget and Justification**

Provide a compelling justification of the budget for the entire proposed period of support, including salaries and benefits, supplies, equipment, patient care costs, animal care costs, and other expenses. Applications requesting more than \$250,000 (total costs) over a maximum period of 24 months (2 years) will be administratively withdrawn.

In preparing the requested budget, applicants should be aware of the following:

- Major equipment purchases are discouraged for this funding mechanism. Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit

must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application.

- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at [www.cprit.texas.gov](http://www.cprit.texas.gov). So-called grants management and facilities fees (e.g., sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be rejected administratively and returned without review.
- The annual salary (also referred to as direct salary or institutional base salary) that an individual may be reimbursed from a CPRIT award is limited to a maximum of \$200,000. In other words, an individual may request salary proportional to the percent of effort up to a maximum of \$200,000. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.
- The PI must commit a minimum 5% level of effort throughout the entire award period.

### **7.2.11. Biographical Sketches (5 pages each)**

Applicants should provide a biographical sketch that describes their education and training, professional experience, awards and honors, and publications relevant to cancer research.

A biographical sketch must be provided for the PI and, if applicable, the Coinvestigator (as required by the online application receipt system). Up to 2 additional biographical sketches for key personnel may be provided. Each biographical sketch must not exceed 5 pages.

### **7.2.12. Current and Pending Support**

State the funding source and duration of all current and pending support for all personnel who have included a biographical sketch with the application. For each award, provide the title, a 2-line summary of the goal of the project and, if relevant, a statement of overlap with the current

application. At a minimum, current and pending support of the PI and, if applicable, any additional investigator must be provided. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

#### **7.2.13. Institutional/Collaborator Support and/or Other Certification (2 pages)**

Applicants may provide letters of institutional support, collaborator support, and/or other certification documentation relevant to the proposed project. A maximum of 2 pages may be provided.

#### **7.2.14. Previous Summary Statement**

If the application is being resubmitted, the summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission. The applicant is not responsible for providing this document.

#### **7.2.15. Institutional Limits**

In order to ensure timely and high-quality review of the most innovative and cutting-edge research with the greatest potential for advancement of cancer research, CPRIT is imposing a limit of 5 applications from an academic research institution and 1 each from public or private companies on the number of HIHR Research Award applications that may be submitted by an institution during this review cycle.

The limit on the number of applications may seem restrictive, but experience indicates that truly innovative ideas that are appropriate for this award mechanism are uncommon. CPRIT expects institutions to initiate an internal review process and only authorize submission of the appropriate number of applications that have been rigorously judged to be responsive to this RFA.

**Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or do not meet the eligibility requirements listed above will be administratively withdrawn without review.**

### **7.3. Formatting Instructions**

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English

- **Document Format:** PDF only
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations must be submitted as part of the appropriate submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.
- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.
- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters are also acceptable as long as the journal information is stated. Include URLs of publications referenced in the application.
 

Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45-67.
- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants should not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see following point).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be filled out, printed, signed, scanned, and then uploaded in PDF format.

## **8. APPLICATION REVIEW**

### **8.1. Review Process Overview**

All eligible applications will be evaluated using a 2-stage peer review process: (1) Peer review and (2) prioritization of grant applications by the CPRIT Scientific Review Council (SRC). In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts, as well as advocate reviewers, using the criteria listed below. In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT SRC based on comparisons with applications from all of the peer review panels and programmatic priorities. Applications approved by the SRC will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding.

The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

### **8.2. Confidentiality of Review**

Each stage of application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, SRC members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and SRC members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website.



**By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed conflict of interest as set forth in CPRIT’s Administrative Rules, Texas [Administrative Code, Title 25, chapters 701 to 703](#).**

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant’s behalf) and the following individuals: an Oversight Committee member, a PIC member, a Scientific Review Panel member, or a SRC member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Officer, and the Commissioner of State Health Services.

The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period prior to the opening of CARS. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant applicant from further consideration for a grant award.

### **8.3. Review Criteria**

Peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Review committees will evaluate and score each primary criterion and subsequently assign a global score that reflects an overall assessment of the application. **The overall assessment will not be an average of the scores of individual criteria; rather, it will reflect the reviewers’ overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

#### **8.3.1. Primary Criteria**

Primary criteria will evaluate the scientific merit and potential impact of the proposed work contained in the application. Concerns with any of these criteria potentially indicate a major flaw in the significance and/or design of the proposed study. Primary criteria include the following:

**Significance and Impact:** Is the application clearly responsive to the RFA and specifically to the HIHR Research Award mechanism? What is the innovative potential of the project? Does the

applicant propose new paradigms or challenge existing ones? Does the project develop state-of-the-art technologies, methods, tools, or resources for cancer research or address important underexplored or unexplored areas? If the research project is successful, will it lead to truly substantial advances in the field rather than add modest increments of insight? Responsive applications will be highly speculative or exploratory; they need not be based on preliminary data but must have the potential for high scientific payoff because of exceptionally promising ideas.

**Research Plan:** Is the proposed work presented as a self-contained research project? Does the proposed research have a clearly defined hypothesis or goal that is supported by a sound scientific rationale? Are the methods appropriate, and are potential experimental obstacles and unexpected results discussed?

**Applicant Investigator:** Does the applicant investigator demonstrate the required creativity, expertise, experience, and accomplishments to make a significant contribution to the research? Applicants' credentials will be evaluated in a career-stage-specific fashion. Have early-career-stage investigators received excellent training, and do their accomplishments to date offer great promise for a successful career? Has the applicant devoted a sufficient amount of his or her time (percent effort) to this project?

**Relevance:** Does the proposed research have a high degree of relevance to cancer? This will be an important criterion for evaluation of projects for CPRIT support.

### **8.3.2. Secondary Criteria**

Secondary criteria contribute to the global score assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed research. Secondary criteria include the following:

**Research Environment:** Does the research team have the needed expertise, facilities, and resources to accomplish all aspects of the proposed research? Are the levels of effort of the key personnel appropriate? Is there evidence of institutional support of the research team and the project?

**Vertebrate Animals and/or Human Subjects:** If vertebrate animals and/or human biological samples are included in the proposed research, is the vertebrate animals and/or human subjects

plan adequate and sufficiently detailed? Note that certification of approval by the institutional IACUC and/or IRB, as appropriate, will be required before funding can occur.

**Budget and Duration:** Are the budget and the duration appropriate for the proposed work?

## 9. KEY DATES

### RFA

RFA release September 14, 2023

### Application

Online application opens October 17, 2023, 7 AM central time

Application due January 18, 2024, 4 PM central time

Application review February 2024 to August 2024

### Award

Award notification August 2024

Anticipated start date August 31, 2024

## 10. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in Texas [Administrative Code, Title 25, chapters 701 to 703](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at [www.cprit.texas.gov](http://www.cprit.texas.gov). Applicants are advised to review CPRIT's Administrative Rules related to

contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in Texas [Administrative Code, Title 25, chapters 701 to 703](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, Texas [Administrative Code, Title 25, chapters 701 to 703](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate.

Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of award contract. Forms and instructions will be made available at [www.cprit.texas.gov](http://www.cprit.texas.gov).

## **11. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS**

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. The demonstration of available matching funds must be made at the time the award contract is executed and annually thereafter, not when the application is submitted. Grant applicants are advised to consult CPRIT's Administrative Rules, Texas [Administrative Code, Title 25, chapters 701 to 703](#) for specific requirements regarding the demonstration of available funding.

## **12. CONTACT INFORMATION**

### **12.1. Helpdesk**

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding scientific aspects of applications.

**Hours of operation:** Monday through Friday, 8 AM to 6 PM central time

**Tel:** 866-941-7146

**Email:** [Help@CPRITGrants.org](mailto:Help@CPRITGrants.org)

### **12.2. Scientific and Programmatic Questions**

Questions regarding the CPRIT program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Director for Academic Research.

**Tel:** 512-305-8491

**Email:** [research@cprit.texas.gov](mailto:research@cprit.texas.gov)

**Website:** [www.cprit.texas.gov](http://www.cprit.texas.gov)

# **Third Party Observer Reports**

---

**Cancer Prevention and Research Institute of Texas (CPRIT)****24.2 Academic Research - Basic Cancer Research-1****(24.2 ACR BCR-1)****Observation Report**

Report No. 2024-04-16 24.2\_ACR\_BCR-1  
Program Name: Academic Research  
Panel Name: 24.2 Academic Research - Basic Cancer Research-1 (24.2\_ACR\_BCR-1)  
Panel Date: April 16, 2024  
Report Date: April 23, 2024

***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

***INTRODUCTION***

The subject of this report is the 24.2 Academic Research - Basic Cancer Research-1 (24.2\_ACR\_BCR-1) meeting. The meeting was chaired by Eric Fearon and conducted via videoconference on April 16, 2024.

***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Thirteen (13) applications were discussed and thirteen (13) applications were not discussed
- Panelists: One (1) panel chair, fourteen (14) expert reviewers, two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.



With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a series of connected loops and a horizontal line extending to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

**Cancer Prevention and Research Institute of Texas (CPRIT)****24.2 Academic Research Basic Cancer Research – 2****(24.2 ACR BCR-2)****Observation Report**

Report No. 2024-04-17 24.2\_ACR\_BCR-2  
Program Name: Academic Research  
Panel Name: 24.2 Academic Research Basic Cancer Research – 2 (24.2\_ACR\_BCR-2)  
Panel Date: April 17, 2024  
Report Date: April 23, 2024

***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

***INTRODUCTION***

The subject of this report is the 24.2 Academic Research Basic Cancer Research – 2 (24.2\_ACR\_BCR-2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on April 17, 2024.

***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Fifteen (15) applications were discussed and Thirty (30) were not discussed.
- Panelists: One (1) panel chair, eighteen (18) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were thirteen (13) Conflicts of Interest (COIs) identified prior to and/or during the meeting. No (0) applications with COIs were discussed.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

**Cancer Prevention and Research Institute of Texas (CPRIT)****24.2 Academic Research Cancer Biology (CB)****(24.2 ACR CB)****Observation Report**

Report No. 2024-04-24 24.2\_ACR\_CB  
Program Name: Academic Research  
Panel Name: 24.2 Academic Research Cancer Biology (CB) (24.2 \_ACR\_CB)  
Panel Date: April 24, 2024  
Report Date: April 29, 2024

***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

***INTRODUCTION***

The subject of this report is the 24.2 Academic Research Cancer Biology (CB) (24.2\_ACR\_CB) meeting. The meeting was chaired by Peter Jones and conducted via videoconference on April 24, 2024.

***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and thirty-six (36) applications were not discussed
- Panelists: One (1) panel chair, nineteen (19) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were eight (8) Conflicts of Interest (COIs) identified prior to and/or during the meeting. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized 'M' followed by a horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

**Cancer Prevention and Research Institute of Texas (CPRIT)****24.2 Academic Research - Imaging Technology and****Informatics (24.2 ACR ITI)****Observation Report**

Report No. 2024-04-23 24.2\_ACR\_ITI  
Program Name: Academic Research  
Panel Name: 24.2 Academic Research - Imaging Technology and Informatics  
(24.2\_ACR\_ITI)  
Panel Date: April 23, 2024  
Report Date: April 29, 2024

***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

***INTRODUCTION***

The subject of this report is the 24.2 Academic Research - Imaging Technology and Informatics (24.2\_ACR\_ITI) meeting. The meeting was chaired by Henry VanBrocklin and conducted via videoconference on April 23, 2024.

***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.



## **SUMMARY OF OBSERVATION RESULTS**

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twelve (12) applications were discussed and fourteen (14) were not discussed
- Panelists: One (1) panel chair, twelve (12) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

**Cancer Prevention and Research Institute of Texas (CPRIT)**  
**24.2 Academic Research Clinical and Translational Cancer**  
**Research-1 (24.2 ACR CTCR-1)**  
**Observation Report**

Report No. 2024-04-18 24.2\_ACR\_CTCR-1  
Program Name: Academic Research  
Panel Name: 24.2 Academic Research Clinical and Translational Cancer  
Research-1 (24.2\_ACR\_CTCR-1)  
Panel Date: April 18, 2024  
Report Date: April 23, 2024

### ***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

### ***INTRODUCTION***

The subject of this report is the 24.2 Academic Research Clinical and Translational Cancer Research-1 (24.2\_ACR\_CTCR-1) meeting. The meeting was chaired by Margaret Tempero and conducted via videoconference on April 18, 2024.

### ***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Eighteen (18) applications were discussed and twenty-four (24) were not discussed
- Panelists: One (1) panel chair, sixteen (16) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were six (6) Conflicts of Interest (COIs) identified prior to and/or during the meeting. No (0) applications with COIs were discussed.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', with a stylized, flowing script.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

**Cancer Prevention and Research Institute of Texas (CPRIT)**  
**24.2 Academic Research Clinical and Translational Cancer**  
**Research-2 (24.2 ACR C/TCR-2)**  
**Observation Report**

Report No. 2024-04-25 24.2\_ACR\_C/TCR-2  
Program Name: Academic Research  
Panel Name: 24.2 Academic Research Clinical and Translational Cancer  
Research-2 (24.2\_ACR\_C/TCR-2)  
Panel Date: April 25, 2024  
Report Date: April 29, 2024

### ***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

### ***INTRODUCTION***

The subject of this report is the 24.2 Academic Research Clinical and Translational Cancer Research-2 (24.2\_ACR\_C/TCR-2) meeting. The meeting was chaired by Richard O'Reilly and conducted via videoconference on April 25, 2024.

### ***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twenty-eight (28) applications were discussed and eleven (11) were not discussed
- Panelists: One (1) panel chair, fourteen (14) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were fourteen (14) Conflicts of Interest (COIs) identified prior to and/or during the meeting. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written in a cursive style.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney



**Cancer Prevention and Research Institute of Texas (CPRIT)**  
**FY24.2 Scientific Review Council (24.2 SRC)**  
**Observation Report**

Report No.            2024-07-11 24.2 SRC  
Program Name:        Academic Research  
Panel Name:          FY24.2 Scientific Review Council (24.2 SRC)  
Panel Date:           July 11, 2024  
Report Date:          July 17, 2024

### ***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

### ***INTRODUCTION***

The subject of this report is the FY24.2 Scientific Review Council (24.2 SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on July 11, 2024.

### ***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

One (1) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Thirty one (31) applications were discussed and one (1) application was withdrawn
- Panelists: One (1) discussion lead, and five (5) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Three (3)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

# **Conflicts of Interest Disclosure**

---

# Conflicts of Interest Disclosure

## CPRIT Academic Research Cycle 24.2

### Awards Announced at the August 21, 2024, Oversight Committee Meeting

The following table lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research cycle 24.2 include *Core Facility Support Awards*; *Clinical Investigator Award*; *High-Impact/High-Risk Research Awards*; and *Multi-Investigator Research Awards*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
<b>Applications considered by the PIC and Oversight Committee:</b>			
RP240440	Richard Gorlick	The University of Texas M. D. Anderson Cancer Center	Patrick Grohar
RP240439	Sattva Neelapu	The University of Texas M. D. Anderson Cancer Center	Joshua Campbell
RP240454	Everett Stone	The University of Texas at Austin	Weiping Zou
RP240474	Leonid Metelitsa	Baylor College of Medicine	W. Martin Kast
<b>Applications not considered by the PIC or Oversight Committee:</b>			
RP240428	Neelam Mukherjee	The University of Texas Health Science Center at San Antonio	Jose Conejo-Garcia
RP240564	Kevin Pinney	Baylor University	Jose Conejo-Garcia
<b>RP240591</b>	Ming You	The Methodist Hospital Research Institute	Steven Belinsky

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP240448	Kevin Dalby	The University of Texas at Austin	Joseph Mancias
RP240459	Abhishek Jain	Texas A&M Engineering Experiment Station	Benjamin Greenbaum

# De-Identified Overall Evaluation Scores

---

# High-Impact/High-Risk Research Awards

## Academic Research Cycle 24.2

One application not recommended for funding has a score that is the same as an application that was recommended. An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding.

This comprehensive list of de-identified application scores created for the purpose of this CEO affidavit packet combines the information for all Academic Research review panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not. Within each panel, no application with a less favorable score was recommended ahead of an application with a more favorable score.

Application ID	Final Overall Evaluation Score
RP240590*	2.0
RP240539*	2.0
RP240446*	2.1
RP240579*	2.3
RP240462*	2.5
RP240501*	2.6
RP240542*	2.6
RP240454*	2.7
RP240498*	2.7
RP240493*	2.8
RP240516*	2.9
RP240605*	3.1
A	3.1
B	3.2
C	3.3
D	3.4

\* Recommended for funding.



Application ID	Final Overall Evaluation Score
E	3.5
F	3.6
G	3.6
H	3.7
I	3.7
J	3.7
K	3.7
L	3.8
M	4.0
N	4.0
O	4.0
P	4.0
Q	4.0
R	4.0
S	4.0
T	4.0
U	4.0
V	4.0
W	4.0
X	4.0
Y	4.3
Z	4.3
Aa	4.3
Ab	4.3
Ac	4.3
Ad	4.3
Ae	4.3
Af	4.3
Ag	4.3
Ah	4.3
Ai	4.3
Aj	4.3

\* Recommended for funding.

Application ID	Final Overall Evaluation Score
Ak	4.5
Al	4.6
Am	4.7
An	4.7
Ao	4.7
Ap	4.7
Aq	4.7
Ar	4.7
As	4.7
At	4.7
Au	4.7
Av	4.7
Aw	4.7
Ax	4.9
Ay	5.0
Az	5.0
Ba	5.0
Bb	5.0
Bc	5.0
Bd	5.0
Be	5.0
Bf	5.3
Bg	5.3
Bh	5.3
Bi	5.3
Bj	5.3
Bk	5.3
Bl	5.3
Bm	5.7
Bn	5.7
Bo	5.7
Bp	5.7

\* Recommended for funding.

Application ID	Final Overall Evaluation Score
Bq	5.7
Br	5.7
Bs	5.8
Bt	5.9
Bu	6.0
Bv	6.0
Bw	6.3
Bx	6.3
By	6.3
Bz	6.3
Ca	6.3
Cb	6.8
Cc	8.0

\* Recommended for funding.

# **Final Overall Evaluation Scores and Rank Order Scores**

---

# UC San Diego

## SCHOOL OF MEDICINE

July 29, 2024

Dr. David A. Cummings, M.D.  
Oversight Committee Presiding Officer  
Cancer Prevention and Research Institute of Texas  
Via email to [dcummingsmd@yahoo.com](mailto:dcummingsmd@yahoo.com)

Ms. Kristen Doyle  
Chief Executive Officer  
Cancer Prevention and Research Institute of Texas  
Via email to [kdoyle@cprit.texas.gov](mailto:kdoyle@cprit.texas.gov)

Dear Dr. Cummings and Ms. Doyle,

The Scientific Review Council (SRC) is pleased to submit this list of 36 research grant recommendations for the Clinical Investigator Award, Core Facility Support Awards, High-Impact/High Risk Awards, Multi-Investigator Research Awards and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on July 11, 2024 to review First-Time Tenure-Track Faculty Members recruitment applications submitted for Cycle FY24.12 and to consider the applications recommended by the peer review panels following their meetings held April 16, 2024 to April 25, 2024. On July 29, 2024 the SRC met to discuss application RP240474, which was peer reviewed on April 25, 2024 but not recommended. The application received a favorable score but just missed the cut off line made by the peer review panel. The SRC chose to consider and recommend RP240474 because of how it addresses program priorities of childhood and adolescent cancers. With available funds the SRC recommended RP240474 to the Program Integration Committee (PIC), bringing the total number of recommended academic research awards to 36.

Recommended funding amounts and the overall evaluation score are stated for each grant application in the following table. The total amount for the applications recommended to the PIC is \$60,577,922.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • [rkolodner@health.ucsd.edu](mailto:rkolodner@health.ucsd.edu)

Richard D. Kolodner, Ph.D.  
Chair, CPRIT Scientific Review Council

Rank	ID	RFA	Score	Application Title	PI	PI Org.	Rec. Budget
1	RP240545	CFSA	1.0	Renewal of CPRIT GMP Core	Lapteva, Natalia	Baylor College of Medicine	\$2,000,000
2	RR240070	RFTFM	1.0	Expanding the Accessibility and Efficacy of CAR-T Cells Through In Vivo Engineering	Labanieh, Louai	Baylor College of Medicine	\$2,000,000
3	RR240076	RFTFM	1.0	Discovery of Molecular Glue Degraders Targeting the Undruggable Cancer Proteome	Yoon, Hojong	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
4	RR240082	RFTFM	1.2	Identification of Neural Mechanisms Contributing to Chemotherapy-Associated Cognitive Impairments	Sun, Yanjun	The University of Texas Health Science Center at Houston	\$2,000,000
5	RP240610	CFSA	1.4	UTHealth Cancer Genomics Core (UTHealth CGC)	Zhao, Zhongming	The University of Texas Health Science Center at Houston	\$2,000,000
6	RP240478	CIA	1.4	Advancing immunotherapy for high-risk cancers in children and adolescents	Hegde, Meenakshi	Baylor College of Medicine	\$1,030,892
7	RP240473	CIA	1.6	Signal-Augmented Cancer Cell Therapies: Integrating Advanced	Omer, Bilal	Baylor College of Medicine	\$1,046,414

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

**UC San Diego**  
SCHOOL OF MEDICINE

				Correlatory Studies and Mentorship			
8	RP240494	CFSA	1.7	Children's Research Institute Metabolomics Core: Advanced Methodologies in Cancer Metabolism	DeBerardinis, Ralph	The University of Texas Southwestern Medical Center	\$2,601,616
9	RP240497	CFSA	1.7	Advanced Spatial Genomics Core Facility	Navin, Nicholas	The University of Texas M. D. Anderson Cancer Center	\$2,999,993
10	RR240079	RFTFM	1.7	Immune surveillance and elimination of aneuploid cells in vivo	Trakala, Marianna	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
11	RP240432	CFSA	1.8	Advanced Multiparameter Cytometry and Cell Sorting Core	Beeton, Christine	Baylor College of Medicine	\$1,999,882
12	RP240440	MIRA2	1.8	Novel Therapies for Osteosarcoma	Gorlick, Richard	The University of Texas M. D. Anderson Cancer Center	\$4,498,684
13	RP240557	CIA	1.8	Dietary intervention to modulate the microbiome and immune response	McQuade, Jennifer	The University of Texas M. D. Anderson Cancer Center	\$1,074,727
14	RP240430	CFSA	1.9	GCC Center for Comprehensive PK/PD & Formulation	Liang, Dong	Texas Southern University	\$2,000,000
15	RP240590	HIHRA	2.0	Bidentate ERK Traps: Revolutionizing Combination Cancer Therapy Strategies	Dalby, Kevin	The University of Texas at Austin	\$249,996
16	RP240539	HIHRA	2.0	Spectroscopy for quantitative real-time imaging of radical formation	Gustavsson, Anna-Karin	Rice University	\$250,000

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

				in ultra-high dose rate radiation therapy			
17	RP240508	CFSA	2.1	The Texas Decision Science Core Facility: A CPRIT Population Science Core	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	\$2,995,778
18	RP240446	HIHRA	2.1	Regulation of Transcription Factor Function by Local Chromatin Context	Soshnev, Alexey	The University of Texas at San Antonio	\$249,561
19	RP240442	CIA	2.1	Identifying and exploiting novel metabolic vulnerabilities in the treatment of kidney cancer	Courtney, Kevin	The University of Texas Southwestern Medical Center	\$913,682
20	RP240559	CFSA	2.1	High Performance Mass Spectrometry Imaging Core Facility	Brodbelt, Jennifer	The University of Texas at Austin	\$1,998,763
21	RP240441	CIA	2.2	Precision Lung Cancer Interception by Targeting High-Risk Lung Nodules	Zhang, Jianjun	The University of Texas M. D. Anderson Cancer Center	\$1,098,945
22	RP240438	MIRA2	2.2	Overcoming major barriers to the delivery of successful T-cell immunotherapies	Rooney, Cliona	Baylor College of Medicine	\$4,500,000
23	RP240579	HIHRA	2.3	Renal Clearable Nano Delivery Systems for Maximizing Anti-tumor Immunity in Breast Cancer Brain Metastasis Treatment	Zheng, Jie	The University of Texas at Dallas	\$250,000
24	RP240521	CFSA	2.3	Pediatric Cancer Data Core	Xie, Yang	The University of Texas Southwestern Medical Center	\$1,999,760

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu



**UC San Diego**  
SCHOOL OF MEDICINE

25	RP240518	CIA	2.4	Adapting radiotherapy clinical trials to treatment response and artificial intelligence innovations	Desai, Neil	The University of Texas Southwestern Medical Center	\$1,460,229
26	RP240462	HIHRRRA	2.5	Development of an Endoscopic Nuclear Imaging Capsule for Radio-Guided Cancer Surgery	Zannoni, Elena Maria	The University of Texas at Austin	\$250,000
27	RP240501	HIHRRRA	2.6	Delivering Immunotherapy more effectively to glioblastoma with a “magnetic switch”	Qin, Zhenpeng	The University of Texas at Dallas	\$250,000
28	RP240542	HIHRRRA	2.6	Digital Twin Augmented Reality for Prostate Laparoscopic Surgery	Fei, Baowei	The University of Texas at Dallas	\$250,000
29	RP240454	HIHRRRA	2.7	Reversing Tumor Immune Exclusion with Sphingosine-1-Phosphate Depleting Therapeutics	Stone, Everett	The University of Texas at Austin	\$249,998
30	RP240498	HIHRRRA	2.7	Improving the management of gastric peritoneal carcinomatosis with Photo-Betabody Immunotherapy	Obaid, Girgis	The University of Texas at Dallas	\$248,991
31	RP240493	HIHRRRA	2.8	Engineering in vivo chimeric antigen receptor (CAR) macrophages for diffuse midline glioma	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$250,000
32	RP240516	HIHRRRA	2.9	Mapping multivalent chromatin	Mani, Ram	The University of Texas	\$250,000

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

# UC San Diego

SCHOOL OF MEDICINE

				interactions to define the 3D genome of Clear cell renal cell carcinoma		Southwestern Medical Center	
33	RP240605	HIHRA	3.1	Stimulate Mucosal-associated Invariant T cells to Kill Cancer Cells	Huang, Shouxiong	Texas Biomedical Research Institute	\$249,484
34	RP240439	MIRA2	3.1	Innovative cell therapy approaches for hematological and solid malignancies	Neelapu, Sattva	The University of Texas M. D. Anderson Cancer Center	\$4,500,000
35	RP240489	MIRA2	3.2	Neural Regulation of Childhood Cancers	Morrison, Sean	The University of Texas Southwestern Medical Center	\$4,362,563
36	RP240474	MIRA2	3.6	Cellular Immunotherapies for Pediatric Solid Tumors	Metelitsa, Leonid	Baylor College of Medicine	\$4,497,964

Clinical Investigator Award (CIA)  
 Core Facility Support Awards (CFSA)  
 High-Impact/High Risk Awards (HIHR)  
 Multi-Investigator Research Awards (MIRA2)  
 Recruitment of First-Time, Tenure Track Faculty Members (RFTTFM)

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

# **CEO Affidavit Supporting Information**

**Academic Research  
FY 2024—Cycle 2  
*Multi-Investigator Research Awards***

# Request for Applications

---



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**REQUEST FOR APPLICATIONS**  
**RFA R-24.2-MIRA**

**Multi-Investigator Research Awards**

**Please also refer to the Instructions for Applicants document,  
which will be posted on September 14, 2023**

**Application Receipt Opening Date:** October 17, 2023

**Application Receipt Closing Date:** January 16, 2024

**FY2024**

Fiscal Year Award Period  
September 1, 2023-August 31, 2024

## TABLE OF CONTENTS

<b>1. BRIEF DESCRIPTION OF RFA.....</b>	<b>5</b>
<b>2. ABOUT CPRIT.....</b>	<b>6</b>
2.1. ACADEMIC RESEARCH PROGRAM PRIORITIES .....	6
<b>3. RATIONALE.....</b>	<b>7</b>
<b>4. RESEARCH OBJECTIVES .....</b>	<b>8</b>
<b>5. FUNDING INFORMATION .....</b>	<b>9</b>
<b>6. ELIGIBILITY .....</b>	<b>10</b>
<b>7. RESUBMISSION POLICY .....</b>	<b>11</b>
<b>8. RENEWAL POLICY .....</b>	<b>12</b>
<b>9. CHARACTERISTICS OF MULTI-INVESTIGATOR RESEARCH AWARDS .....</b>	<b>12</b>
9.1. SYNERGY .....	12
9.2. LEADERSHIP .....	12
9.2.1. Contact Principal Investigator (PI) .....	12
9.2.2. Multi-Principal Investigator (MI) .....	13
9.3. RESEARCH PROJECTS .....	13
9.4. CORE RESOURCES .....	13
9.5. SELECTION OF RESEARCH PROJECTS AND CORE RESOURCES .....	14
9.6. COMMITMENT OF TIME AND EFFORT .....	15
9.7. PARTICIPATION ON MORE THAN 1 APPLICATION.....	15
<b>10. RESPONDING TO THIS RFA .....</b>	<b>16</b>
10.1. APPLICATION SUBMISSION GUIDELINES.....	16
10.1.1. Submission Deadline Extension .....	16
10.2. APPLICATION COMPONENTS .....	16
10.2.1. Abstract and Significance (15,000 characters) .....	17
10.2.2. Layperson’s Summary (10,000 characters).....	17
10.2.3. Specific Aims and Sub Aims (Maximum of 3 Aims and 3 Subaims per Aim for Each Project and Core).....	17
10.2.4. Timeline (Maximum of 1 page per Project and Core).....	18
10.2.5. Overview of Overall Program (10 pages).....	18
10.2.6. Research Project Abstract (Maximum of 5,000 Characters per Project).....	18
10.2.7. Research Project Plan (Up to 25 pages for Each Project).....	19
10.2.8. Core Resource Abstract (Maximum of 5,000 characters per Core Resource) .....	20
10.2.9. Core Resource Plan (Up to 25 pages for Each Core Resource).....	20
10.2.10. Administrative Core Plan (7 pages).....	21
10.2.11. Synergy Illustration (3 pages).....	22
10.2.12. Sustainability Plan (2 pages) .....	22
10.2.13. Publications/References .....	22
10.2.14. Budget and Justification .....	22
10.2.15. Biographical Sketches for Key Personnel (5 pages Each) .....	23
10.2.16. Current and Pending Support .....	23
10.2.17. Institutional/Collaborator Support and/or Other Certification (15 pages) .....	24
<b>11. APPLICATION REVIEW.....</b>	<b>24</b>
11.1. FULL PEER REVIEW .....	24
11.2. CONFIDENTIALITY OF REVIEW .....	24

11.3. REVIEW CRITERIA .....	25
11.3.1. Primary Criteria .....	26
11.3.2. Secondary Criteria.....	27
<b>12. KEY DATES.....</b>	<b>28</b>
<b>13. AWARD ADMINISTRATION.....</b>	<b>28</b>
<b>14. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS.....</b>	<b>29</b>
<b>15. CONTACT INFORMATION .....</b>	<b>30</b>
15.1. HELPDESK .....	30
15.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS .....	30

## RFA VERSION HISTORY

- 9/14/23 RFA release
- 10/17/23 Edited language throughout the document to clarify that the Lead PI should be the Contact PI for the application.

Section 1-Brief Description of RFA: Added the following language: “*Multi-Principal Investigators (MI) (Required) Each research project and core resource within the overall research program must be directed by a single individual designated as an MI on the application for the overall research program. Each MI will be responsible for the research activities of his or her research project(s) and/or core resource(s) within the framework and goals of the overall research program. Projects and cores located outside of the PI’s institution must be supported through a subcontract with the applicant institution.*”



## 1. BRIEF DESCRIPTION OF RFA

- Multi-Investigator Research Awards (MIRAs) support highly integrated programs of collaborative and cross-disciplinary research among multiple Texas investigators. MIRAs are expected to integrate basic and/or clinical disciplines leading to the aggressive translation of scientific discoveries into tools and applications that have the potential to make a significant impact on cancer prevention, detection, treatment, and/or survivorship.
- Applicants are encouraged to submit proposals that address the Cancer Prevention Research Institute of Texas' (CPRIT's) Academic Research Program Priorities (section 2.1).
- Applicants may request a maximum of \$4,500,000 total over a maximum period of 4 years (\$1,125,000 annually).
- Funds may be requested for research projects and administrative and technical cores.
- The MIRA RFA requires a Principal Investigator who serves as the contact PI and Multi-Principal Investigators who lead each research project and core resources within the overall research program.
- Contact Principal Investigator (Required): The Contact PI is responsible for the submission of the application, all reporting requirements, and all budgeting decisions.
- Multi-Principal Investigators (MI) (Required) Each research project and core resource within the overall research program must be directed by a single individual designated as an MI on the application for the overall research program. Each MI will be responsible for the research activities of his or her research project(s) and/or core resource(s) within the framework and goals of the overall research program. Projects and cores located outside of the PI's institution must be supported through a subcontract with the applicant institution.
- An individual serving as the Contact Principal Investigator or Multi-Principal Investigators may submit only 1 application under this RFA and will not be eligible to participate as a Contact PI or an MI on another MIRA application (including subcontracts) in response to this RFA except for special circumstances as discussed under section 9.7.
- Note that CPRIT does not allow the use of the term Co-PI.
- Resubmissions of MIRA proposals previously reviewed under this RFA are not available under this RFA.
- Renewals are not available under this RFA.

- Minimum effort for the PI and MIs is required throughout the project period.

## **2. ABOUT CPRIT**

The State of Texas has established CPRIT, which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of or cures for cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

### **2.1. Academic Research Program Priorities**

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

To accomplish CPRIT's long-term vision, the Oversight Committee has these 2024 priorities:

- Investing in the cancer research capacity of Texas institutions through recruitment of cancer scholars, investment in core facilities, and investment in individual investigator awards in all regions of the state;
- Building the Texas cancer life science ecosystem across Texas by bridging discovery and translational research into early-stage company products with high impact on cancer patient care and creating economic development for the State of Texas; and
- Increasing the capacity for Texas to have a significant impact on cancer prevention and early detection, ultimately decreasing cancer incidence and mortality.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure in all regions of the state
- Reducing cancer disparities

The program priorities for academic research adopted by the Oversight Committee include funding projects that address or utilize the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions and population research addressing cancer disparities.
- Computational oncology and analytic methods
- Childhood and adolescent cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials, particularly to regions of the state currently with limited access.

### 3. RATIONALE

This MIRA mechanism is intended to support highly integrated programs of collaborative and cross-disciplinary research among multiple Texas investigators. Applications responding to this RFA that address one of the program priorities for academic research adopted by CPRIT's Oversight Committee are particularly encouraged.

MIRAs are expected to promote a cooperative environment that fosters intensive interaction among members in all aspects of the research program. This approach is expected to transform the research process through the integration of basic and/or clinical disciplines leading to the aggressive translation of scientific discoveries into tools and applications that have the potential to make a significant impact on cancer incidence, detection, treatment, and/or survivorship.

While all investigators need not be trained specifically in cancer research, this award is intended to initiate sustainable, collaborative programs of cancer research that cannot be addressed effectively by an individual researcher or a group of researchers within the same discipline. **It is aimed at interactive research programs that, by their complexity and interdisciplinary nature, require a cross-disciplinary team approach to achieve significant progress and sustainability, thereby creating a culture for teaching and research that transcends traditional disciplinary**

**boundaries.** Clinical research or a clinical trial (phase 1, 1/2, or 2) may be included as part of the proposed program.

Investigators are expected to work together to develop the research plan, determine the management structure, and prepare the application. It should be clear that all investigators have a substantial level of intellectual input into the proposed program, and there should be evidence that the participants have a track record of collaboration. Collectively, the members of the teams should represent the appropriate diversity of expertise necessary for addressing the research question.

Effort is expected to be appropriately balanced among the investigators and their respective teams.

**CPRIT encourages the inclusion of early-stage investigators and recognizes the value of the inclusion of new technologies often contributed by these investigators, as well as the mentorship opportunities inherent in collaborative or multiproject research awards.**

Applicants must present a clear plan for how they would manage and facilitate meaningful collaboration among the separate research teams to enable successful completion of the proposed research. Participating institutions must be willing to resolve potential intellectual and material property issues/conflicts and subcontracting issues and remove institutional barriers to achieving high levels of cooperation.

This funding mechanism offers an attractive opportunity for investigators to test new ideas, explore new areas, and/or implement new approaches. These types of applicant responses are desired and encouraged. However, successful applications must demonstrate that the proposed research builds on a strong track record of existing interactions among the proposed projects, or if new research partnerships are being proposed, the application must provide compelling evidence that the new partnerships will catalyze significant synergies and impact.

#### **4. RESEARCH OBJECTIVES**

This RFA solicits applications for integrated programs of collaborative and cross-disciplinary research among multiple investigators that will contribute meaningfully to advancing knowledge of the causes, prevention, and/or treatment of cancer. CPRIT encourages applicants who seek to develop or apply state-of-the-art technologies, tools, and/or resources for cancer research, including those with projects having potential commercialization opportunities.

CPRIT expects outcomes of supported activities to benefit subsequent cancer research efforts directly and indirectly, cancer public health policy, or the continuum of cancer care—from

prevention to treatment and survivorship. While applications may address any research topic or issue related to cancer biology, causation, prevention, detection or screening, treatment, or quality of life, CPRIT encourages applications that address 1 or more of the priority areas that have been identified by the CPRIT Oversight Committee.

Because MIRAs, by definition, support collaborative research projects, this award mechanism will accommodate applications that encompass a wide variety of activities and administrative structures. Creative, collaborative projects that address critical questions should leverage cancer research taking place in Texas into a leadership position from both national and international perspectives. Successful applications will demonstrate a clear plan for sustainability of the research after the completion of the award period.

## **5. FUNDING INFORMATION**

CPRIT anticipates having sufficient funds to support a limited number of only the most meritorious applications in response to this RFA.

Applicants may request a maximum of \$4,500,000 in total costs for a maximum period of 4 years. Exceptions to the maximum amount may be requested if extremely well justified. Funds may be used for salary and fringe benefits, research supplies, equipment, clinical costs, pilot projects, and travel to scientific/technical meetings or collaborating institutions. Funds may be used for core resources that provide support services necessary to achieve the goals of the MIRA projects. Requests for funds to support construction and/or renovation will not be approved under this funding mechanism. State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the total award amount.

In an attempt to reduce the administrative difficulties in submitting programmatic and financial reports, MIRAs will be submitted as a single application. The PI will lead the project through the Administrative Core, which will be housed at the applicant institution. Individual projects and cores must be handled through subcontracts if participating institutions are located outside of the applicant institution. The applicant institution will develop the overall program budget with the assistance of individual participating institutions. Therefore, the institution that leads the Administrative Core will be responsible for coordinating subcontracts, submission of progress reports, and all related annual and financial reports. There will not be a requirement for other participating institutions to submit these reports to CPRIT.

## 6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution or organization that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism; these entities must use the appropriate award mechanism(s) under CPRIT's Product Development Research Program.
- The PI and MIs must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent. Individuals serving as a PI or MI must reside in Texas during the time the research that is the subject of the grant is conducted. (MIRA PI and MI roles are defined in sections 9.2.1 and 9.2.2.)
- An individual serving as a PI may submit only 1 application under this RFA and will not be eligible to participate as a PI or an MI on another MIRA application (including subcontracts) in response to this RFA except for special circumstances as discussed under section 9.7.
- An individual may participate as a MI on only 1 application under this RFA except for special circumstances as discussed under section 9.7.
- A major criterion for successful applications will be the evidence that the assembled team has established collaborations or complementary expertise that will be accelerated by participation in the MIRA. While CPRIT encourages the creation of teams composed of researchers from across Texas who have stellar reputations in their given areas of expertise, successful applications must demonstrate either a strong track record of collaboration or how newly proposed collaborations will contribute to the project as a whole.
- Collaborators may or may not reside in Texas. However, collaborators who do not reside in Texas are not eligible to receive CPRIT funds. Collaborators should have specific and well-defined roles. Subcontracting and collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds. In no event shall equipment purchased under this award leave the State of Texas.
- **An institution may submit only 1 new application under this RFA during this funding cycle. An exception will be made for institutions submitting MIRAs that support research totally directed toward childhood and adolescent cancer; in this case,**

**institutions may submit 1 childhood and adolescent cancer application and 1 additional application in another aspect of cancer research.**

- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant PI, any senior member, or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the PI, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, whether or not those individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds because of scientific misconduct or fraud or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 13](#) and [section 14](#). All statutory provisions and relevant administrative rules can be found at [www.cprit.texas.gov](http://www.cprit.texas.gov).

## **7. RESUBMISSION POLICY**

Resubmissions of MIRA proposals previously reviewed under this RFA are not available under this RFA. PIs of previously reviewed, but unfunded, MIRAs are eligible to submit a MIRA award on a different topic.

## **8. RENEWAL POLICY**

Renewals are not available under this RFA. A project that was previously funded under the MIRA and would be a continuation of MIRA program activities is not eligible to be submitted under this RFA.

## **9. CHARACTERISTICS OF MULTI-INVESTIGATOR RESEARCH AWARDS**

### **9.1. Synergy**

Successful multi-investigator research programs are characterized by an exceptionally synergistic theme. Applications in response to this RFA must bring together a strong group of research projects and necessary core resources that contribute to a common goal in cancer research as a single, coherent entity. The overall program must provide greater value than the sum of its individual components.

Synergy between projects and cores to support the overall objective of the proposed program and the multidisciplinary focus of each project and core are essential aspects of the award mechanism and are major considerations of the review process. Applications are expected to demonstrate an existing track record of interactions among the proposed individual research programs and to discuss how the MIRA will accelerate existing synergies.

It is envisioned that most or all of the proposed research programs already interact with each other and that the MIRA will accelerate these interactions to bring Texas-based cancer discoveries to the market for the benefit of patients with cancer everywhere.

### **9.2. Leadership**

#### **9.2.1. Contact Principal Investigator (PI)**

The overall research program will be directed and overseen by a Contact Principal Investigator (PI). The Contact PI is responsible for developing and managing an integrated and collaborative research environment that permits uninterrupted progress of the research projects regardless of distinct geographic locations of collaborators within the state. The Contact PI must direct the required Administrative Core (see [section 9.4](#) and [section 10.2](#)). The Contact PI is responsible for the submission of the application, all reporting requirements, and all budgeting decisions. The PI may also direct a research project and/or core resource.



### **9.2.2. Multi-Principal Investigator (MI)**

Each research project and core resource within the overall research program must be directed by a single individual designated as an MI on the application for the overall research program.

Each MI will be responsible for the research activities of his or her research project(s) and/or core resource(s) within the framework and goals of the overall research program. Projects and cores located outside of the PI's institution must be supported through a subcontract with the applicant institution.

### **9.3. Research Projects**

Research projects (also referred to as *projects* in this RFA) will challenge existing paradigms; develop or employ novel concepts, approaches, methodologies, tools, or technologies for the proposed cancer research area; or address important underexplored or unexplored areas. CPRIT seeks to support original and innovative projects. The thrust of the MIRA mechanism is to support research projects that lead to truly substantial advances in the field rather than add modest increments of insight. Projects that modestly extend current lines of research will not be considered for this award.

Each project must be poised individually to make significant contributions to the field of cancer research as well as be complementary to the overall research program. Application of a single approach to multiple forms of cancer does not justify a request for multiple research projects.

The guidelines for research projects are as follows:

- Minimum: 3 projects
- Maximum: 5 projects
- Each research project must be directed by the PI or by a participating MI. The PI and each MI can direct only 1 project within the MIRA application.

### **9.4. Core Resources**

Supporting core resources (also referred to as *cores* in this RFA) constitute integral components of multi-investigator research programs by providing the expertise and/or infrastructure essential to the completion of the individual research projects. Examples of core resources include, but are not limited to, administrative core, tissue/specimen core, sequencing/bioinformatics core, histopathology core, imaging core, and clinical trials core. All applications submitted in response

to this RFA must include an administrative core that comprehensively coordinates all activities proposed within the objectives of the projects and cores and is directed by the PI.

The guidelines for core resources are as follows:

- Minimum: Administrative Core
- Maximum: 3 technical cores
- A maximum of 4 cores is permitted (ie, the Administrative Core and 3 technical cores).
- Each core must be directed by the PI or by a participating MI. Each MI can direct 1 project and/or 1 technical core. The PI can direct 1 project and/or technical core in addition to the Administrative Core. The Administrative Core must be directed by the PI.
- Cores should include clear descriptions of the projects they are designed to support and the services to be provided.
- Core resources may propose new facilities not currently available in Texas or extend existing facilities. Cores that duplicate services already available at the institution will be considered nonresponsive. If support is requested for an existing facility, applicants must provide details on how CPRIT support will enhance its capabilities and improve access for MIRA investigators rather than simply replace ongoing institutional support.
- **The program investigators are encouraged to consider the suitability of utilizing Core resources at other institutions within Texas, particularly those supported by CPRIT awards, to avoid establishing new services at new or existing core facilities that may not serve a larger group of investigators. Funds to purchase services at external core facilities within the State of Texas are considered allowable costs within the budget of research projects for this RFA.**
- CPRIT strongly supports the development or adaptation of new technologies and resources that are made available to non-MIRA investigators at the host institution as well as at other institutions in Texas.
- Projects and cores are subject to different review criteria (see [section 11.3](#)). Research projects must **not** be submitted as cores in an attempt to circumvent the limitation on the number of research projects that may be submitted as part of a single MIRA application.

## 9.5. Selection of Research Projects and Core Resources

The PI is expected not only to coordinate and develop the overall research program but also to *limit the number of projects and cores* to only those that are considered highly meritorious and

significant within the context of the entire application. The collaborative impact, merit, and feasibility of all the projects—not the cores—will determine whether an application for a MIRA receives support. Investigators are strongly discouraged from including weaker projects in an effort to obtain a higher level of funding. Rather, inclusion of fewer, highly focused projects is strongly recommended.

## **9.6. Commitment of Time and Effort**

Investigators are expected to commit *significant percent effort* to research projects and cores throughout the award funding period. A minimum time commitment of 20% effort is required for the PI. Research project and core resource MIs should commit at least 10% effort for each project and/or core that he or she directs.

**Note:** CPRIT requires that the percent effort of the PI and MIs remain the same in every year of support requested unless there is a corresponding change in the budget and level of activity of the project/core directed by the PI or the MI(s) in question.

CPRIT recognizes that multi-investigator programs will vary significantly in size and scope; thus, a single guideline for commitment of time and effort is not appropriate for all applications. Applications should exhibit a reasonable correlation between time commitment and funds requested unless there are special circumstances, which must be explained. In addition, it should be clear from the other support information provided that the investigator will be able to achieve the required percent effort and what activities may have to be contracted or curtailed to achieve the required percent effort for the application submitted.

## **9.7. Participation on More than 1 Application**

CPRIT is concerned that many investigators appear frequently as part of several different research programs, which makes it difficult to discern the investigators' commitment to a given project. CPRIT believes that this leads to weaker, less competitive applications. Therefore, an investigator may participate as a PI or MI on only 1 MIRA application in a given funding cycle. However, CPRIT recognizes that specific individuals directing and/or participating in core resources (eg, biostatistics, bioinformatics, or pathology cores) may be involved in multiple research studies. Thus, exceptions to such investigators being listed on only 1 application as an MI may be made if compelling justification for such exceptions and assurance of commitment (usually in the form of percent effort) are provided. Reductions in percent level of effort will usually not be approved

after an application is funded unless there have been major changes in scope and, therefore, in budget.

## **10. RESPONDING TO THIS RFA**

### **10.1. Application Submission Guidelines**

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and submit an application. Furthermore, the Application/Authorized Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS. The MI does not have to create a user account in CARS; the MI will be added to the application by the PI. Please refer to the *Instructions for Applicants (IFA)* document for the instructions on adding MIs to an application. The IFA document will be available at the time of posting of this RFA or shortly thereafter. Applications will be accepted beginning at 7 AM central time on October 17, 2023, and must be submitted by 4 PM central time on January 16, 2024. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

#### **10.1.1. Submission Deadline Extension**

The submission deadline may be extended upon a showing of good cause. A request for a deadline extension based on the need to complete multiple CPRIT or other grants applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

### **10.2. Application Components**

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the IFA document for details. Submissions that are

missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively rejected without review.

### **10.2.1. Abstract and Significance (15,000 characters)**

Clearly explain the question or problem to be addressed by the proposed overall research program and the approach to its answer or solution. Address how the proposed research, if successful, will have a major impact on the field of cancer research or on the care of patients with cancer. Indicate whether this research will address cancers associated with disparities in incidence or mortality in Texas. Summarize how the proposed research creates new paradigms or challenges existing ones. State the synergistic value that the individual research projects and core resources present to the goals of the overall application. Summarize the proposed core resources. Clearly state the project(s) that the core resources will support and the synergistic value the core resources provide to the goals of the research project(s).

**Note:** It is the responsibility of the applicant to capture CPRIT's attention primarily with the Abstract and Significance statement alone. Therefore, applicants are advised to prepare this section wisely. Applicants should not waste this valuable space by stating obvious facts (eg, that cancer is a significant problem, that better diagnostic and therapeutic approaches are needed urgently, or that the type of cancer of interest to the PI is important, vexing, or deadly).

### **10.2.2. Layperson's Summary (10,000 characters)**

Provide a layperson's summary of the proposed program. Describe, in simple, nontechnical terms, the overall goals of the proposed program, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early diagnosis, prevention, or treatment. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. Do not include any proprietary information in the Layperson's Summary. The Layperson's Summary will also be used by advocate reviewers ([section 11.1](#)) in evaluating the significance and impact of the proposed work.

### **10.2.3. Specific Aims and Sub Aims (Maximum of 3 Aims and 3 Subaims per Aim for Each Project and Core)**

Provide a list of specific aims and subaims for each year of the project. These aims and subaims will also be used during the submission and evaluation of progress reports and assessment of

project success. Aims and subaims should be listed for the overall project as well as for each project and core separately. Projects and cores should be labeled numerically (AC for the Administrative Core, Project 1 to Project 5, and Core 1 to Core 3) and be clearly identified. Aims and subaims for cores should indicate the project(s) to be supported.

Aims and subaims for the overall project should be listed under Administrative Core and prepared by the PI.

#### **10.2.4. Timeline (Maximum of 1 page per Project and Core)**

Provide an outline of anticipated major milestones to be tracked. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful applications. Timelines should be listed for the overall program as well as for each project and core separately. Projects and cores should be labeled numerically (AC for the Administrative Core, Project 1 to Project 5, and Core 1 to Core 3) and be clearly identified. The timeline for the overall project should be listed under Administrative Core and prepared by the PI.

If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

#### **10.2.5. Overview of Overall Program (10 pages)**

**Background:** Present the rationale behind the proposed research program, emphasizing the pressing problem(s) in cancer research that will be addressed.

**Research Strategy:** Describe the overall goals of the research program and briefly summarize each component project and core resource. Describe the significance, innovation, and impact of the proposed research. Indicate whether this research will address cancers associated with increased incidence and/or mortality in Texas or with population disparities.

**Synergy:** Describe how individual component projects provide synergistic value to the research program.

#### **10.2.6. Research Project Abstract (Maximum of 5,000 Characters per Project)**

Clearly explain the question or problem to be addressed by the proposed project and the approach to its answer or solution. Provide the specific aims and brief description of experimental approaches. Indicate whether this research will address cancers associated with disparities.

Address how the proposed research, if successful, will have a major impact on the field of cancer research or on the care of patients with cancer. Summarize how the proposed research creates new paradigms or challenges existing ones. State the synergistic value that the project has to the overall research program and other projects and core resources in accomplishing the goals and objectives of the overall program.

### **10.2.7. Research Project Plan (Up to 25 pages for Each Project)**

**Specific Aims and Subaims:** List specific aims and subaims for each year of the project. These aims and subaims will also be used during the submission and evaluation of progress reports and assessment of project success.

**Specific Aims:** Please provide a 1-page summary of the aims and subaims of the proposal. The Specific Aims page should identify the problem or gap in our current knowledge. It should present a hypothesis and briefly describe the aims and approaches. Address the proposal's innovation, novel approaches, and significance and impact on cancer research. Please also refer to the template located in [Current Funding Opportunities](#) for Academic Research Programs in CARS.

**Background:** Present the rationale behind the proposed project, emphasizing the pressing problem in cancer research that will be addressed.

**Research Strategy:** Describe the experimental design, including methods, anticipated results, potential problems or pitfalls, and alternative approaches. The inclusion of preliminary data that support the proposed hypothesis is recommended.

**Synergy:** Describe how the project provides synergistic value to the entire research program. Describe interactions with other components of the MIRA and the potential for enriching the program.

**Biographical Sketches:** A biographical sketch must be provided for each individual leading a project. Applicants should provide a biographical sketch that describes their education and training, professional experience, awards and honors, and publications relevant to cancer research. Each biographical sketch must not exceed 5 pages. The NIH biosketch format is appropriate.

**Vertebrate Animals and/or Human Subjects:** If vertebrate animals will be used, provide an outline of the appropriate protocols that will be followed. If human subjects or human biological samples will be used, provide a plan for IRB approval or exemption and recruitment of subjects or acquisition of samples that will meet the time constraints of this award mechanism.

**Publications/References:** Provide a concise and relevant list of publications/references cited for the research project.

**Budget and Justification:** While there will be 1 budget for the entire program, an individual budget and budget justification must be included for each project. A 4-year budget table with a justification of budget expenses should be sufficient. This budget should not be as detailed as the overall program budget but rather a high-level budget that allows reviewers to evaluate project expenses.

#### **10.2.8. Core Resource Abstract (Maximum of 5,000 characters per Core Resource)**

Clearly explain the question or problem to be addressed by the proposed core resource and the approach to its answer or solution. Describe the services to be provided and which projects the core resource will support. Describe new technologies and approaches or resources to be developed to support the needs of the MIRA projects. Address how the core will have a major impact on the field of cancer research or on the care of patients with cancer. State the synergistic value that the core resource has to the overall research program and other projects and core resources in accomplishing the goals and objectives of the overall program.

#### **10.2.9. Core Resource Plan (Up to 25 pages for Each Core Resource)**

**Background:** Present the rationale and need for the facility, emphasizing the pressing problems in cancer research that will be addressed by the technologies/services provided. Address the projects served and if researchers at other institutions will have access to these services and technologies. Describe how the proposed facility does not duplicate services provided by existing facilities. Address how the proposed facility addresses CPRIT priorities.

**Support Strategy:** Describe the services to be provided, the projects utilizing the services, and new technologies or resources that may be developed or adapted to support the goals of the projects proposed in the MIRA. Describe training and education initiatives that will be provided by the core resource, if relevant. Describe how access to the core will be made available and how the core services will be sustained. Preliminary data demonstrating the capabilities of the core are encouraged but not required.

**Synergy:** Describe how the core resource provides synergistic value to the research program.

**Biographical Sketches:** A biographical sketch must be provided for each individual leading a core resource. Applicants should provide a biographical sketch that describes their education and



training, professional experience, awards and honors, and publications relevant to cancer research. Each biographical sketch must not exceed 5 pages. The NIH biosketch format is appropriate.

**Vertebrate Animals and/or Human Subjects:** If vertebrate animals will be used, provide an outline of the appropriate protocols that will be followed. If human subjects or human biological samples will be used, provide a plan for IRB approval or exemption and recruitment of subjects or acquisition of samples that will meet the time constraints of this award mechanism.

**Publications/References:** Provide a concise and relevant list of publications/references cited for the core resource.

**Budget and Justification:** While there will be 1 budget for the entire program, an individual budget and budget justification must be included for each core. A 4-year budget table with a justification of budget expenses should be sufficient. This budget should not be as detailed as the overall program budget but rather a high-level budget that allows reviewers to evaluate core expenses.

#### **10.2.10. Administrative Core Plan (7 pages)**

Describe the organizational and management structure that will be established to manage all aspects of the research program efficiently, effectively, and comprehensively. State how the leaders of individual projects and cores (ie, the PI and MIs) will communicate and discuss results, report progress, and resolve potential problems throughout the duration of the research program.

*Pilot Projects:* Up to \$100,000 may be requested annually to support pilot projects that address new hypotheses related to the focus of the MIRA or extend the scope of the existing projects.

If pilot project funds are requested, describe the goals of this initiative and the components of an application, including total allowable budget request. Describe the review criteria and the processes for selecting, funding, and managing the pilot projects.

*External Advisory Board (EAB):* Each MIRA must recruit external experts who will serve as scientific advisors to the program leadership. This EAB, consisting of 3 to 5 individuals, will advise the MIRA on ongoing research and strategic planning for future research directions. The EAB should convene at least annually (either in person or virtually) and provide a written report to leadership. EAB members may reside in Texas or outside of the state. Describe the composition of the EAB and the expertise provided relevant to the focus of the MIRA program. Honoraria and travel costs are considered allowable costs for this RFA.

### **10.2.11. Synergy Illustration (3 pages)**

Provide a detailed narrative and diagrammatic representation of interactions among the Administrative Core, all research projects, and all core resources of the proposed research program.

### **10.2.12. Sustainability Plan (2 pages)**

Provide a detailed narrative that discusses a sustainability plan for how the progress of the MIRA will be continued after the conclusion of the CPRIT award. For example, the MIRA may lead to follow-on funding as P01s, SPORes, or multi-investigator R01s; development of a new center or other institutional mechanisms that recognize and support a multi-investigator program; new faculty recruitment; identification of a new lead compound; the proof-of-principle leading to a clinical trial; or impact on public policy.

### **10.2.13. Publications/References**

Provide a concise and relevant list of publications/references cited for the application.

### **10.2.14. Budget and Justification**

Provide a compelling justification of the budget for the entire proposed period of support, including salaries and benefits, supplies, equipment, patient care costs, animal care costs, and other expenses. Applicants are advised not to interpret the maximum allowable request under this award as a suggestion that they should expand their anticipated budget to this level.

Reasonable budgets clearly work in favor of the applicant.

However, if there is a highly specific and defensible need to request more than the maximum amount in any year(s) of the proposed budget, include a special and clearly labeled section in the budget justification that explains the request. Poorly justified requests of this type will likely have a negative impact on the overall evaluation of the application.

In preparing the requested budget, applicants should be aware of the following:

- One budget will be submitted on behalf of the entire program and will include costs for individual projects and cores. While there will be 1 budget for the entire program, individual budget breakdowns must be included for each project and core resource as a part of the research or core resources plan. For programs that have outside institutions participating, a subcontract must be executed for that institution to receive CPRIT funds.

- Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application.
- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at [www.cprit.texas.gov](http://www.cprit.texas.gov). So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be rejected administratively and returned without review.

The annual salary (also referred to as direct salary or institutional base salary) that an individual may receive under a CPRIT award for FY 2024 is \$200,000; CPRIT FY 2024 is from September 1, 2023, through August 31, 2024. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.

#### **10.2.15. Biographical Sketches for Key Personnel (5 pages Each)**

Up to 10 additional biographical sketches for key personnel may be provided. Each individual biographical sketch must not exceed 5 pages. The NIH biosketch format is appropriate.

Biographical sketches for Project and Core MIs must be submitted as part of the research project or core resource plans. Biographical sketches must be provided for members of the EAB.

#### **10.2.16. Current and Pending Support**

Describe the funding source and duration of all current and pending support for all personnel who have included a biographical sketch with the application. Note that support information is not needed for members of the EAB. For each award, provide the title, a 2-line summary of the goal of the project, and, if relevant, a statement of overlap with the current application. At a minimum, current and pending support of the PI and MIs must be provided.

## **10.2.17. Institutional/Collaborator Support and/or Other Certification (15 pages)**

Applicants are encouraged to provide letters of institutional support, collaborator and EAB member support, and/or other certification documentation relevant to the proposed project. A maximum of 15 pages may be provided.

**Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or that do not meet the eligibility requirements listed above will be administratively rejected without review.**

## **11. APPLICATION REVIEW**

### **11.1. Full Peer Review**

Applications submitted in response to the MIRA RFA will undergo a full peer review using a 2-stage peer review process: (1) Full peer review and (2) prioritization of grant applications by the CPRIT Scientific Review Council. In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts as well as advocate reviewers using the criteria listed below. In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT Scientific Review Council based on comparisons with applications from all of the peer review panels and programmatic priorities. Applications approved by Scientific Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the CPRIT Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

Applicants will be notified of peer review panel assignment prior to the peer review meeting dates.

### **11.2. Confidentiality of Review**

Each stage of application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to

sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and Scientific Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website.

**By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules, [chapter 703, section 703.9](#).**

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: An Oversight Committee member, a PIC member, a Scientific Review Panel member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Officer, and the Commissioner of State Health Services.

The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period prior to the opening of CARS. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

### **11.3. Review Criteria**

Peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Review panels will evaluate and score each project and core individually according to the primary criteria and subsequently assign a global score that reflects an overall assessment of the application. **The overall assessment will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application.**

**Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

### **11.3.1. Primary Criteria**

Primary criteria will evaluate the scientific merit and potential impact of the proposed work in each project and core as well as the overall program as described in the application. Concerns with any of these criteria potentially indicate a major flaw in the significance and/or design of the proposed study. Primary criteria include the following:

**Significance and Impact of Overall Program:** What is the innovative potential of the program? Does the program propose new paradigms or challenge existing ones? Does the program develop state-of-the-art technologies, methods, tools, or resources for cancer research or address important underexplored or unexplored areas? If successful, will it lead to truly substantial advances in the field rather than add modest increments of insight? For MIRAs that involve translational research, is there the potential to impact the standard of care? Does the program address cancers with disparities and/or cancers that are particularly relevant to the cancer burden of Texas?

Investigators and biomedical personnel must want and need to know the results of CPRIT-funded research because such knowledge will change the ways in which they conduct their own research or approach and care for their patients. Programs that modestly extend current lines of research will not be considered for this award.

**Research Plan for Research Projects:** Is the proposed work presented as a self-contained research project? Does the proposed research have a clearly defined hypothesis or goal that is supported by sufficient preliminary data and/or scientific rationale? Are the methods appropriate, and are potential experimental obstacles and unexpected results discussed? Does the proposed project provide strong synergistic activities as part of a multidisciplinary collaboration? See [section 9.1](#).

**Project Leader for Research Projects:** Does the project leader demonstrate the required creativity, expertise, experience, and accomplishments to achieve the goals of the research project? Has the project leader devoted a sufficient amount of his or her time (percent effort) to this project?

**Synergy and Collaborative Teams:** Does the proposed project provide strong synergistic activities as part of a multidisciplinary collaboration; that is, is the value of this program

significantly greater than the sum of its parts? If core facilities are described, are they necessary and sufficient to support the project in achieving the overall goals proposed? Has the project assembled the best-qualified collaborative and multidisciplinary teams to achieve the proposed goals? Are the levels of effort of the key personnel appropriate as outlined in [section 9.6](#)?

**Relevance of Research Projects:** Does the proposed research have a high degree of relevance to reduce the burden of cancer? This will be an important criterion for evaluation of projects for CPRIT support.

**Sufficiency and Capability of Core Resources:** Is the proposed core resource necessary? Does it have the needed facilities and sufficient resources to support the proposed research project(s) in accomplishing the proposed goals? Does it provide strong synergistic activities as part of a multidisciplinary collaboration? Is there a mechanism for prioritizing the work of the core?

**Core Resources Leader:** Does the core leader demonstrate the required expertise and experience to direct the core resource in supporting the research project(s)? Has the core leader devoted a sufficient amount of his or her time (percent effort) to this resource?

**Administrative Core Plan:** Is the proposed organizational and management structure capable of comprehensively overseeing and coordinating all aspects and activities, including scientific oversight, of the proposed research program? If funds are requested for pilot projects, is there an appropriate plan described for soliciting and selecting scientifically sound and impactful projects?

**Administrative Core Leader:** Does the core leader demonstrate the required expertise and experience to direct the research program? Has the core leader devoted a sufficient amount of his or her time (percent effort) to this activity? Are there plans for coordination of the program and for facilitating interactions among the program components?

### 11.3.2. Secondary Criteria

Secondary criteria contribute to the global score assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed project. Secondary criteria include the following:

**Research Environment:** Does the team have the needed expertise, facilities, and resources to accomplish all aspects of the project? Are the levels of effort of the key personnel appropriate? Is there evidence of institutional support for the research team and the project?

**Vertebrate Animals and/or Human Subjects:** If vertebrate animals and/or human subjects are included in the proposed research, certification of approval by the institutional IACUC and/or IRB, as appropriate, will be required before funding can occur.

**Budget:** Is the budget appropriate for the proposed work?

**Duration:** Is the stated duration appropriate for the proposed work?

## 12. KEY DATES

### RFA

RFA release	September 14, 2023
-------------	--------------------

### Application

Online application opens	October 17, 2023, 7 AM central time
--------------------------	-------------------------------------

Application due	January 16, 2024, 4 PM central time
-----------------	-------------------------------------

Application review	February 2024 to August 2024
--------------------	------------------------------

Award notification	August 2024
--------------------	-------------

Anticipated start date	August 31, 2024
------------------------	-----------------

## 13. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports.

Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at [www.cprit.texas.gov](http://www.cprit.texas.gov). Applicants are advised to review CPRIT's Administrative Rules related to



contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of award contract. Forms and instructions will be made available at [www.cprit.texas.gov](http://www.cprit.texas.gov).

#### **14. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS**

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. The demonstration of available matching funds must be made at the time the award contract is executed, and annually thereafter, not when the application is submitted. Grant applicants are advised to consult CPRIT's Administrative Rules, [chapter 703, section 703.11](#), for specific requirements regarding demonstration of available funding.

## 15. CONTACT INFORMATION

### 15.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding scientific aspects of applications.

**Hours of operation:** Monday through Friday, 8 AM to 6 PM central time

**Tel:** 866-941-7146

**Email:** [Help@CPRITGrants.org](mailto:Help@CPRITGrants.org)

### 15.2. Scientific and Programmatic Questions

Questions regarding the CPRIT program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Director for Academic Research.

**Tel:** 512-305-8491

**Email:** [research@cprit.texas.gov](mailto:research@cprit.texas.gov)

**Website:** [www.cprit.texas.gov](http://www.cprit.texas.gov)

# **Third Party Observer Reports**

---

**Cancer Prevention and Research Institute of Texas (CPRIT)****24.2 Academic Research - Basic Cancer Research-1****(24.2 ACR BCR-1)****Observation Report**

Report No. 2024-04-16 24.2\_ACR\_BCR-1  
Program Name: Academic Research  
Panel Name: 24.2 Academic Research - Basic Cancer Research-1 (24.2\_ACR\_BCR-1)  
Panel Date: April 16, 2024  
Report Date: April 23, 2024

***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

***INTRODUCTION***

The subject of this report is the 24.2 Academic Research - Basic Cancer Research-1 (24.2\_ACR\_BCR-1) meeting. The meeting was chaired by Eric Fearon and conducted via videoconference on April 16, 2024.

***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Thirteen (13) applications were discussed and thirteen (13) applications were not discussed
- Panelists: One (1) panel chair, fourteen (14) expert reviewers, two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a series of connected loops and a horizontal line extending to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

**Cancer Prevention and Research Institute of Texas (CPRIT)****24.2 Academic Research Basic Cancer Research – 2****(24.2 ACR BCR-2)****Observation Report**

Report No. 2024-04-17 24.2\_ACR\_BCR-2  
Program Name: Academic Research  
Panel Name: 24.2 Academic Research Basic Cancer Research – 2 (24.2\_ACR\_BCR-2)  
Panel Date: April 17, 2024  
Report Date: April 23, 2024

***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

***INTRODUCTION***

The subject of this report is the 24.2 Academic Research Basic Cancer Research – 2 (24.2\_ACR\_BCR-2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on April 17, 2024.

***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Fifteen (15) applications were discussed and Thirty (30) were not discussed.
- Panelists: One (1) panel chair, eighteen (18) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were thirteen (13) Conflicts of Interest (COIs) identified prior to and/or during the meeting. No (0) applications with COIs were discussed.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.



With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a horizontal line extending to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

**Cancer Prevention and Research Institute of Texas (CPRIT)****24.2 Academic Research Cancer Biology (CB)****(24.2 ACR CB)****Observation Report**

Report No. 2024-04-24 24.2\_ACR\_CB  
Program Name: Academic Research  
Panel Name: 24.2 Academic Research Cancer Biology (CB) (24.2 \_ACR\_CB)  
Panel Date: April 24, 2024  
Report Date: April 29, 2024

***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

***INTRODUCTION***

The subject of this report is the 24.2 Academic Research Cancer Biology (CB) (24.2\_ACR\_CB) meeting. The meeting was chaired by Peter Jones and conducted via videoconference on April 24, 2024.

***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and thirty-six (36) applications were not discussed
- Panelists: One (1) panel chair, nineteen (19) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were eight (8) Conflicts of Interest (COIs) identified prior to and/or during the meeting. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the closing text.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

**Cancer Prevention and Research Institute of Texas (CPRIT)**  
**24.2 Academic Research - Imaging Technology and**  
**Informatics (24.2 ACR ITI)**  
**Observation Report**

Report No. 2024-04-23 24.2\_ACR\_ITI  
Program Name: Academic Research  
Panel Name: 24.2 Academic Research - Imaging Technology and Informatics  
(24.2\_ACR\_ITI)  
Panel Date: April 23, 2024  
Report Date: April 29, 2024

### ***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

### ***INTRODUCTION***

The subject of this report is the 24.2 Academic Research - Imaging Technology and Informatics (24.2\_ACR\_ITI) meeting. The meeting was chaired by Henry VanBrocklin and conducted via videoconference on April 23, 2024.

### ***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twelve (12) applications were discussed and fourteen (14) were not discussed
- Panelists: One (1) panel chair, twelve (12) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

**Cancer Prevention and Research Institute of Texas (CPRIT)**  
**24.2 Academic Research Clinical and Translational Cancer**  
**Research-1 (24.2 ACR CTCR-1)**  
**Observation Report**

Report No. 2024-04-18 24.2\_ACR\_CTCR-1  
Program Name: Academic Research  
Panel Name: 24.2 Academic Research Clinical and Translational Cancer  
Research-1 (24.2\_ACR\_CTCR-1)  
Panel Date: April 18, 2024  
Report Date: April 23, 2024

### ***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

### ***INTRODUCTION***

The subject of this report is the 24.2 Academic Research Clinical and Translational Cancer Research-1 (24.2\_ACR\_CTCR-1) meeting. The meeting was chaired by Margaret Tempero and conducted via videoconference on April 18, 2024.

### ***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.



## **SUMMARY OF OBSERVATION RESULTS**

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Eighteen (18) applications were discussed and twenty-four (24) were not discussed
- Panelists: One (1) panel chair, sixteen (16) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were six (6) Conflicts of Interest (COIs) identified prior to and/or during the meeting. No (0) applications with COIs were discussed.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written in a cursive style.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

**Cancer Prevention and Research Institute of Texas (CPRIT)**  
**24.2 Academic Research Clinical and Translational Cancer**  
**Research-2 (24.2 ACR C/TCR-2)**  
**Observation Report**

Report No. 2024-04-25 24.2\_ACR\_C/TCR-2  
Program Name: Academic Research  
Panel Name: 24.2 Academic Research Clinical and Translational Cancer  
Research-2 (24.2\_ACR\_C/TCR-2)  
Panel Date: April 25, 2024  
Report Date: April 29, 2024

### ***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

### ***INTRODUCTION***

The subject of this report is the 24.2 Academic Research Clinical and Translational Cancer Research-2 (24.2\_ACR\_C/TCR-2) meeting. The meeting was chaired by Richard O'Reilly and conducted via videoconference on April 25, 2024.

### ***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twenty-eight (28) applications were discussed and eleven (11) were not discussed
- Panelists: One (1) panel chair, fourteen (14) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were fourteen (14) Conflicts of Interest (COIs) identified prior to and/or during the meeting. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

**Cancer Prevention and Research Institute of Texas (CPRIT)**  
**FY24.2 Scientific Review Council (24.2 SRC)**  
**Observation Report**

Report No.           2024-07-11 24.2 SRC  
Program Name:       Academic Research  
Panel Name:          FY24.2 Scientific Review Council (24.2 SRC)  
Panel Date:           July 11, 2024  
Report Date:          July 17, 2024

### ***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

### ***INTRODUCTION***

The subject of this report is the FY24.2 Scientific Review Council (24.2 SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on July 11, 2024.

### ***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

One (1) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Thirty one (31) applications were discussed and one (1) application was withdrawn
- Panelists: One (1) discussion lead, and five (5) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Three (3)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line extending to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney



**Cancer Prevention and Research Institute of Texas (CPRIT)**  
**FY24.2 Scientific Review Council 2 (24.2 SRC 2)**  
**Observation Report**

Report No.           2024-07-29 24.2 SRC 2  
Program Name:       Academic Research  
Panel Name:          FY 24.2 Scientific Review Council 2 (24.2 SRC 2)  
Panel Date:          July 29, 2024  
Report Date:         August 2, 2024

### ***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

### ***INTRODUCTION***

The subject of this report is the FY 24.2 Scientific Review Council 2 (24.2 SRC 2) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on July 29, 2024.

### ***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

One (1) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: One (1) application was discussed
- Panelists: One (1) discussion lead, and five (5) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written in a cursive style.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

# **Conflicts of Interest Disclosure**

---

# Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 24.2

Awards Announced at the August 21, 2024, Oversight Committee Meeting

The following table lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research cycle 24.2 include *Core Facility Support Awards*; *Clinical Investigator Award*; *High-Impact/High-Risk Research Awards*; and *Multi-Investigator Research Awards*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
<b>Applications considered by the PIC and Oversight Committee:</b>			
RP240440	Richard Gorlick	The University of Texas M. D. Anderson Cancer Center	Patrick Grohar
RP240439	Sattva Neelapu	The University of Texas M. D. Anderson Cancer Center	Joshua Campbell
RP240454	Everett Stone	The University of Texas at Austin	Weiping Zou
RP240474	Leonid Metelitsa	Baylor College of Medicine	W. Martin Kast
<b>Applications not considered by the PIC or Oversight Committee:</b>			
RP240428	Neelam Mukherjee	The University of Texas Health Science Center at San Antonio	Jose Conejo-Garcia
RP240564	Kevin Pinney	Baylor University	Jose Conejo-Garcia
<b>RP240591</b>	Ming You	The Methodist Hospital Research Institute	Steven Belinsky

<b>Application ID</b>	<b>Principal Investigator</b>	<b>Organization</b>	<b>Conflict Noted by Reviewer</b>
RP240448	Kevin Dalby	The University of Texas at Austin	Joseph Mancias
RP240459	Abhishek Jain	Texas A&M Engineering Experiment Station	Benjamin Greenbaum

# De-Identified Overall Evaluation Scores

---

# Multi-Investigator Research Awards

## Academic Research Cycle 24.2

One application submitted in response to this RFA has a final overall evaluation score that is more favorable than three applications that were recommended for grant awards. An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be discussed or recommended for funding by a peer review panel.

CPRIT's administrative rules allow for the chairperson of each peer review panel to determine what applications are discussed during the peer review meeting if there is not enough time to discuss all applications that are assigned to the panel. The chairperson's decision is largely based on the initial overall evaluation score, which is the average of the scores from the primary reviewers of an application. If an application is not discussed at the peer review meeting, then the initial score becomes the final overall evaluation score. If an application is discussed by the full panel, then the primary reviewers may revise their initial scores based on the discussion at the panel. This means that the final overall evaluation score of a discussed application could be higher or lower than the initial evaluation score of that application. It is possible that this could result in a discussed application having a less favorable score than an application that was not discussed.

The four applications noted above were each assigned to a different peer review panel. The three recommended applications were discussed by each of their panels and the not-recommended application was not discussed. Since the application was not discussed, the initial overall evaluation score became the final overall evaluation score of the not-recommended application. The three applications that were discussed by the other panels had the chance for the primary reviewers to adjust their scores based on panel discussion. All of the panels conducted their review within CPRIT's administrative rules.

Application ID	Final Overall Evaluation Score
RP240440*	1.8
RP240438*	2.2
Fa	3.0
RP240439*	3.1
RP240489*	3.2
RP240474*	3.6
Fb	3.9
Fc	4.0
Fd	4.0
Fe	4.3
Ff	4.5
Fg	4.5
Fh	4.5
Fi	5.0

\* Recommended for funding.



Application ID	Final Overall Evaluation Score
Fj	5.0
Fk	5.5
Fl	5.5
Fm	5.5

\* Recommended for funding.

# **Final Overall Evaluation Scores and Rank Order Scores**

---

# UC San Diego

## SCHOOL OF MEDICINE

July 29, 2024

Dr. David A. Cummings, M.D.  
Oversight Committee Presiding Officer  
Cancer Prevention and Research Institute of Texas  
Via email to [dcummingsmd@yahoo.com](mailto:dcummingsmd@yahoo.com)

Ms. Kristen Doyle  
Chief Executive Officer  
Cancer Prevention and Research Institute of Texas  
Via email to [kdoyle@cprit.texas.gov](mailto:kdoyle@cprit.texas.gov)

Dear Dr. Cummings and Ms. Doyle,

The Scientific Review Council (SRC) is pleased to submit this list of 36 research grant recommendations for the Clinical Investigator Award, Core Facility Support Awards, High-Impact/High Risk Awards, Multi-Investigator Research Awards and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on July 11, 2024 to review First-Time Tenure-Track Faculty Members recruitment applications submitted for Cycle FY24.12 and to consider the applications recommended by the peer review panels following their meetings held April 16, 2024 to April 25, 2024. On July 29, 2024 the SRC met to discuss application RP240474, which was peer reviewed on April 25, 2024 but not recommended. The application received a favorable score but just missed the cut off line made by the peer review panel. The SRC chose to consider and recommend RP240474 because of how it addresses program priorities of childhood and adolescent cancers. With available funds the SRC recommended RP240474 to the Program Integration Committee (PIC), bringing the total number of recommended academic research awards to 36.

Recommended funding amounts and the overall evaluation score are stated for each grant application in the following table. The total amount for the applications recommended to the PIC is \$60,577,922.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • [rkolodner@health.ucsd.edu](mailto:rkolodner@health.ucsd.edu)

Richard D. Kolodner, Ph.D.  
Chair, CPRIT Scientific Review Council

Rank	ID	RFA	Score	Application Title	PI	PI Org.	Rec. Budget
1	RP240545	CFSA	1.0	Renewal of CPRIT GMP Core	Lapteva, Natalia	Baylor College of Medicine	\$2,000,000
2	RR240070	RFTFM	1.0	Expanding the Accessibility and Efficacy of CAR-T Cells Through In Vivo Engineering	Labanieh, Louai	Baylor College of Medicine	\$2,000,000
3	RR240076	RFTFM	1.0	Discovery of Molecular Glue Degraders Targeting the Undruggable Cancer Proteome	Yoon, Hojong	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
4	RR240082	RFTFM	1.2	Identification of Neural Mechanisms Contributing to Chemotherapy-Associated Cognitive Impairments	Sun, Yanjun	The University of Texas Health Science Center at Houston	\$2,000,000
5	RP240610	CFSA	1.4	UTHealth Cancer Genomics Core (UTHealth CGC)	Zhao, Zhongming	The University of Texas Health Science Center at Houston	\$2,000,000
6	RP240478	CIA	1.4	Advancing immunotherapy for high-risk cancers in children and adolescents	Hegde, Meenakshi	Baylor College of Medicine	\$1,030,892
7	RP240473	CIA	1.6	Signal-Augmented Cancer Cell Therapies: Integrating Advanced	Omer, Bilal	Baylor College of Medicine	\$1,046,414

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

**UC San Diego**  
SCHOOL OF MEDICINE

				Correlatory Studies and Mentorship			
8	RP240494	CFSA	1.7	Children's Research Institute Metabolomics Core: Advanced Methodologies in Cancer Metabolism	DeBerardinis, Ralph	The University of Texas Southwestern Medical Center	\$2,601,616
9	RP240497	CFSA	1.7	Advanced Spatial Genomics Core Facility	Navin, Nicholas	The University of Texas M. D. Anderson Cancer Center	\$2,999,993
10	RR240079	RFTFM	1.7	Immune surveillance and elimination of aneuploid cells in vivo	Trakala, Marianna	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
11	RP240432	CFSA	1.8	Advanced Multiparameter Cytometry and Cell Sorting Core	Beeton, Christine	Baylor College of Medicine	\$1,999,882
12	RP240440	MIRA2	1.8	Novel Therapies for Osteosarcoma	Gorlick, Richard	The University of Texas M. D. Anderson Cancer Center	\$4,498,684
13	RP240557	CIA	1.8	Dietary intervention to modulate the microbiome and immune response	McQuade, Jennifer	The University of Texas M. D. Anderson Cancer Center	\$1,074,727
14	RP240430	CFSA	1.9	GCC Center for Comprehensive PK/PD & Formulation	Liang, Dong	Texas Southern University	\$2,000,000
15	RP240590	HIHRA	2.0	Bidentate ERK Traps: Revolutionizing Combination Cancer Therapy Strategies	Dalby, Kevin	The University of Texas at Austin	\$249,996
16	RP240539	HIHRA	2.0	Spectroscopy for quantitative real-time imaging of radical formation	Gustavsson, Anna-Karin	Rice University	\$250,000

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

				in ultra-high dose rate radiation therapy			
17	RP240508	CFSA	2.1	The Texas Decision Science Core Facility: A CPRIT Population Science Core	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	\$2,995,778
18	RP240446	HIHRA	2.1	Regulation of Transcription Factor Function by Local Chromatin Context	Soshnev, Alexey	The University of Texas at San Antonio	\$249,561
19	RP240442	CIA	2.1	Identifying and exploiting novel metabolic vulnerabilities in the treatment of kidney cancer	Courtney, Kevin	The University of Texas Southwestern Medical Center	\$913,682
20	RP240559	CFSA	2.1	High Performance Mass Spectrometry Imaging Core Facility	Brodbelt, Jennifer	The University of Texas at Austin	\$1,998,763
21	RP240441	CIA	2.2	Precision Lung Cancer Interception by Targeting High-Risk Lung Nodules	Zhang, Jianjun	The University of Texas M. D. Anderson Cancer Center	\$1,098,945
22	RP240438	MIRA2	2.2	Overcoming major barriers to the delivery of successful T-cell immunotherapies	Rooney, Cliona	Baylor College of Medicine	\$4,500,000
23	RP240579	HIHRA	2.3	Renal Clearable Nano Delivery Systems for Maximizing Anti-tumor Immunity in Breast Cancer Brain Metastasis Treatment	Zheng, Jie	The University of Texas at Dallas	\$250,000
24	RP240521	CFSA	2.3	Pediatric Cancer Data Core	Xie, Yang	The University of Texas Southwestern Medical Center	\$1,999,760

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

**UC San Diego**  
SCHOOL OF MEDICINE

25	RP240518	CIA	2.4	Adapting radiotherapy clinical trials to treatment response and artificial intelligence innovations	Desai, Neil	The University of Texas Southwestern Medical Center	\$1,460,229
26	RP240462	HIHRA	2.5	Development of an Endoscopic Nuclear Imaging Capsule for Radio-Guided Cancer Surgery	Zannoni, Elena Maria	The University of Texas at Austin	\$250,000
27	RP240501	HIHRA	2.6	Delivering Immunotherapy more effectively to glioblastoma with a “magnetic switch”	Qin, Zhenpeng	The University of Texas at Dallas	\$250,000
28	RP240542	HIHRA	2.6	Digital Twin Augmented Reality for Prostate Laparoscopic Surgery	Fei, Baowei	The University of Texas at Dallas	\$250,000
29	RP240454	HIHRA	2.7	Reversing Tumor Immune Exclusion with Sphingosine-1-Phosphate Depleting Therapeutics	Stone, Everett	The University of Texas at Austin	\$249,998
30	RP240498	HIHRA	2.7	Improving the management of gastric peritoneal carcinomatosis with Photo-Betabody Immunotherapy	Obaid, Girgis	The University of Texas at Dallas	\$248,991
31	RP240493	HIHRA	2.8	Engineering in vivo chimeric antigen receptor (CAR) macrophages for diffuse midline glioma	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$250,000
32	RP240516	HIHRA	2.9	Mapping multivalent chromatin	Mani, Ram	The University of Texas	\$250,000

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

# UC San Diego

SCHOOL OF MEDICINE

				interactions to define the 3D genome of Clear cell renal cell carcinoma		Southwestern Medical Center	
33	RP240605	HIHRA	3.1	Stimulate Mucosal-associated Invariant T cells to Kill Cancer Cells	Huang, Shouxiong	Texas Biomedical Research Institute	\$249,484
34	RP240439	MIRA2	3.1	Innovative cell therapy approaches for hematological and solid malignancies	Neelapu, Sattva	The University of Texas M. D. Anderson Cancer Center	\$4,500,000
35	RP240489	MIRA2	3.2	Neural Regulation of Childhood Cancers	Morrison, Sean	The University of Texas Southwestern Medical Center	\$4,362,563
36	RP240474	MIRA2	3.6	Cellular Immunotherapies for Pediatric Solid Tumors	Metelitsa, Leonid	Baylor College of Medicine	\$4,497,964

Clinical Investigator Award (CIA)  
 Core Facility Support Awards (CFSA)  
 High-Impact/High Risk Awards (HIHR)  
 Multi-Investigator Research Awards (MIRA2)  
 Recruitment of First-Time, Tenure Track Faculty Members (RFTTFM)

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu





---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

# **CEO Affidavit Supporting Information**

**Academic Research Recruitment  
FY 2024—Cycle 12  
*Recruitment of First-Time, Tenure-Track  
Faculty Members***

# Request for Applications

---



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**REQUEST FOR APPLICATIONS**  
**RFA R-24.1-Cycle 12 RFT**

**Recruitment of First-Time, Tenure-Track  
Faculty Members**

**Please also refer to the Instructions for Applicants document,  
which will be posted on May 15, 2024.**

**NOTE: This RFA represents one cycle opening on May 15,  
2024, and closing on June 20, 2024, with limited funds available.**

**Application Receipt Dates:  
May 15, 2024-June 20, 2024**

**FY 2024**  
Fiscal Year Award Period  
September 1, 2023-August 31, 2024

## TABLE OF CONTENTS

<b>1. ABOUT CPRIT</b> .....	<b>4</b>
1.1. ACADEMIC RESEARCH PROGRAM PRIORITIES .....	4
<b>2. RATIONALE</b> .....	<b>5</b>
<b>3. RECRUITMENT OBJECTIVES</b> .....	<b>6</b>
<b>4. INSTITUTIONAL COMMITMENT</b> .....	<b>7</b>
<b>5. FUNDING INFORMATION</b> .....	<b>7</b>
<b>6. ELIGIBILITY</b> .....	<b>8</b>
<b>7. RESUBMISSION POLICY</b> .....	<b>10</b>
<b>8. RESPONDING TO THIS RFA</b> .....	<b>10</b>
8.1. APPLICATION SUBMISSION GUIDELINES .....	10
8.2. APPLICATION COMPONENTS .....	11
8.2.1. <i>Summary of Nomination (2,000 characters)</i> .....	11
8.2.2. <i>Layperson’s Summary (2,000 characters)</i> .....	11
8.2.3. <i>Summary of Specific Aims and Sub Aims (2,000 characters)</i> .....	11
8.2.4. <i>Specific Aims and Sub Aims</i> .....	12
8.2.5. <i>Institutional Commitment (3 pages)</i> .....	12
8.2.6. <i>Letter of Support from Department Chair (up to 2 pages)</i> .....	14
8.2.7. <i>Curriculum Vitae (CV)</i> .....	15
8.2.8. <i>Research (4 pages)</i> .....	15
8.2.9. <i>Publications/References (1 page)</i> .....	16
8.2.10. <i>Research Collaboration/Synergy Plan (2 pages)</i> .....	16
8.2.11. <i>Publications</i> .....	16
8.2.12. <i>Timeline (1 page)</i> .....	16
8.2.13. <i>Current and Pending Support</i> .....	16
8.2.14. <i>Letters of Recommendation</i> .....	17
8.2.15. <i>Research Environment (1 page)</i> .....	17
8.2.16. <i>Descriptive Biography (Up to 2 pages)</i> .....	17
<b>9. APPLICATION REVIEW</b> .....	<b>17</b>
9.1. REVIEW PROCESS.....	17
9.1.1. <i>Confidentiality of Review</i> .....	18
9.2. REVIEW CRITERIA.....	19
<b>10. KEY DATES</b> .....	<b>20</b>
<b>11. AWARD ADMINISTRATION</b> .....	<b>20</b>
<b>12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS</b> .....	<b>21</b>
<b>13. CONTACT INFORMATION</b> .....	<b>22</b>
13.1. HELPDESK.....	22
13.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS .....	22

**RFA VERSION HISTORY**

5/15/24 RFA Released

## **1. ABOUT CPRIT**

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of, or cures for, cancer
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas
- Develop and implement the Texas Cancer Plan

### **1.1. Academic Research Program Priorities**

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

To accomplish CPRIT's long-term vision, the Oversight Committee has identified these 2024 priorities:

- Investing in the cancer research capacity of Texas institutions through recruitment of cancer scholars, investment in core facilities, and investment in individual investigator awards in all regions of the state;
- Building the Texas cancer life science ecosystem across Texas by bridging discovery and translational research into early-stage company products with high impact on cancer patient care and creating economic development for the State of Texas; and
- Increasing the capacity for Texas to have a significant impact on cancer prevention and early detection, ultimately decreasing cancer incidence and mortality.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure in all regions of the state

- Reducing cancer disparities

The program priorities for academic research adopted by the Oversight Committee include funding projects that address the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions and population research addressing cancer disparities
- Computational oncology and analytic methods
- Childhood and adolescent cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials, particularly to regions of the state currently with limited access

## 2. RATIONALE

The aim of this award mechanism is to bolster cancer research in Texas by providing financial support to attract very promising investigators who are pursuing their first faculty appointment at the level of assistant professor (**first-time, tenure-track faculty members**). These individuals must have demonstrated academic excellence, innovation during predoctoral and/or postdoctoral research training, commitment to pursuing cancer research, and exceptional potential for achieving future impact in basic, translational, population-based, or clinical research. Awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research, thereby advancing cancer research and prevention efforts, and promoting economic development in the State of Texas.

The recruitment of outstanding scientists will greatly enhance programs of scientific excellence in cancer research and will position Texas as a leader in the fight against cancer. Applications may address any research topic related to cancer biology, causation, prevention, detection or screening, treatment, or survivorship. Principal Investigators (PIs) with research programs addressing CPRIT's priority areas for research are encouraged. These include implementation

research to accelerate the adoption and deployment of evidence-based prevention and screening interventions, computational oncology and analytic methods, research including population-based research addressing cancer disparities, childhood and adolescent cancers, hepatocellular cancer, and expansion of access to innovative clinical trials.

### **3. RECRUITMENT OBJECTIVES**

The goal of this award mechanism is to recruit exceptional faculty to universities and/or cancer research institutions in the State of Texas. All PIs are expected to have completed their doctoral and fellowship training and to have clearly demonstrated truly superior ability as evidenced by their accomplishments during training, proposed research plan, publication record, and letters of recommendation. This CPRIT-supported initiative is designed to enhance innovative programs of excellence by providing research support for promising, early-stage investigators **seeking their first tenure-track position.**

CPRIT will provide start-up funding for newly independent investigators, with the goal of augmenting and expanding the institution's efforts in cancer research. PIs will be expected to develop research projects within the sponsoring institution. Projects should be appropriate for a newly independent investigator and should foster the development of preliminary data that can be used to prepare applications for future independent research project grants to further both the investigator's research career and the CPRIT mission. The institution will be expected to work with each newly recruited research faculty member to design and execute a faculty career development plan consistent with his or her research emphasis. Relevance to cancer research and to CPRIT's priority areas are important evaluation criteria for CPRIT funding.

Applications nominating individuals who are well prepared to pursue careers in patient-oriented research and who have demonstrated exceptional potential to lead innovative discovery campaigns through conduct of clinical trials are appropriate for this mechanism and are encouraged.

Additionally, population research that addresses the burden of cancer in Texas is a priority for CPRIT. Applications nominating individuals who have demonstrated exceptional ability to lead innovative research programs involving any component across the continuum of cancer prevention and control research are appropriate for this mechanism and are highly encouraged.



Unless prohibited by policy, the institution is also expected to bestow on the newly recruited faculty member the prestigious title of “CPRIT Scholar in Cancer Research,” and the faculty member should be strongly encouraged to use this title on letterhead, business cards, publications, and other appropriate documents. The title is to be retained as long as the individual remains in Texas.

#### **4. INSTITUTIONAL COMMITMENT**

CPRIT recruitment awards are intended to provide institutions with a competitive edge in recruiting the world’s best talent in cancer research to Texas. The funds provided by CPRIT for the Recruitment of a First-Time, Tenure-Track Faculty Member (RFTTFM) Award must therefore be complemented by a strong institutional commitment to the PI’s career development that includes financial commitments that are in addition to the CPRIT award. The institutional commitment should be clearly documented in the application (see [section 8.2.5](#)) and include the amount and sources of salary support and all additional financial support that will be available to the PI’s research program through the course of the CPRIT award. The financial commitments made to the PI for his or her research program by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.

#### **5. FUNDING INFORMATION**

This award is up to 5 years and is not renewable, although individuals may apply for other future CPRIT funding as appropriate. Grant funds of up to \$2,000,000 (total costs) for the 5-year period may be requested. Applicants are encouraged to tailor the budget as appropriate to the exigencies of the project; grant funds totaling less than \$2,000,000 for the term of the award are acceptable if warranted by the scope of the research. Funding is to be used by the PI to support his or her research program. The award request may include indirect costs of up to 5% of the total award amount (5.263% of the direct costs). CPRIT will make every effort to be flexible in the timing for disbursement of funds; recipients will be asked at the beginning of each year for an estimate of their needs for the year. Funds may not be carried over beyond 5 years except under extraordinary circumstances with strong justification for a no-cost extension. In addition, funds for extraordinary equipment needs may be awarded in the first year of the grant if very well justified and a detailed justification is provided along with an institutional plan should the

additional funds not be approved. Scholars may request funds for travel for 2 project staff to attend CPRIT's conference.

**Funds from this CPRIT award may not be used for salary support of this PI or to construct or renovate laboratory space.**

## **6. ELIGIBILITY**

- The applicant must be a Texas-based entity. Any not-for-profit institution that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism.
- PIs must be nominated by the president, provost, vice president for research, or appropriate dean of a Texas-based public or private institution of higher education, including academic health institutions. The application must be submitted on behalf of a specific PI.
- A PI may be nominated by only 1 institution. If more than 1 institution is interested in a given PI, negotiations as to which institution will nominate him or her must be concluded before the nomination is made.
- No annual limit on the number of grant submissions by institutions has been set.
- A PI who has already accepted a position as a tenure-track assistant professor at the recruiting institution prior to the time that the Scientific Review Council reviews the PI for a recruitment award is not eligible for a recruitment award, as an investment by CPRIT is obviously not necessary. No award is final until approved by the Oversight Committee at a public meeting. However, in recognition of the timeline involved with recruiting highly sought-after PIs who are often considering multiple offers, CPRIT's Academic Research program staff will notify the nominating institution of the Scientific Review Council's review decision following the Scientific Review Council meeting. If a position is offered to the PI during the period following the Scientific Review Council's review decision but prior to the Oversight Committee's final approval, the institution does so at its own risk. There is no guarantee that the recruitment award will be approved by the Oversight Committee.
- The PI must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, **and reside in Texas for the duration of the appointment.** The PI must

devote at least 70% time to research activities. PIs whose major responsibilities are clinical care, teaching, or administration are not eligible.

- At the time of the application, the PI must ***not*** hold an appointment at the rank of assistant professor or above (or equivalent) at an accredited academic institution, research institution, industry, government agency, or private foundation. PIs holding non-tenure-track appointments at the rank of assistant professor are ***not*** eligible for this award. Examples of such appointments include research assistant professor, adjunct research assistant professor, assistant professor (non-tenure track).
- The PI may or may not reside in Texas at the time the application is submitted and may be nominated for a faculty position at the Texas institution where he or she is completing postdoctoral training or at another Texas institution.
- Applications nominating a PI for a faculty position at the Texas institution where he or she is completing postdoctoral training that do not clearly demonstrate a subsequent career pathway to independence for the PI will not be looked upon with favor.
- Successful PIs will be offered tenure-track academic positions at the rank of assistant professor.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the nominator, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant nominator, any senior member, or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the nominator, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, whether or not the individuals will receive salary or compensation under the grant award, are currently ineligible to receive federal grant

funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.

CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 11](#) and [section 12](#). All statutory provisions and relevant administrative rules can be found at [www.cprit.texas.gov](http://www.cprit.texas.gov).

## **7. RESUBMISSION POLICY**

Resubmissions will not be accepted for the RFTTFM Award mechanism. Any nomination for the RFTTFM Award that was previously submitted to CPRIT and reviewed but was not recommended for funding may not be resubmitted. If a nomination was administratively rejected prior to review, it can be resubmitted in the following cycles.

## **8. RESPONDING TO THIS RFA**

### **8.1. Application Submission Guidelines**

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application is submitted. PIs must be nominated by the institution's president, provost, vice president for research, or appropriate dean. The individual submitting the application (nominator) must create a user account in the system (which includes the nominator's credentials and email address) to start and submit an application. Furthermore, the Application Signing Official, who is the person authorized to sign and submit the application for the organization, and the Grants Contract/Office of Sponsored Projects Official, who is the individual who will manage the grant contract if an award is made, also must create a user account in CARS.

For an application to be considered for review for cycle 12, that application must be submitted on or before 11:59 PM central time on June 20, 2024. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

## **8.2. Application Components**

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. For details, please refer to the Instructions for Applicants (IFA) document that will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

### **8.2.1. Summary of Nomination (2,000 characters)**

Provide a brief summary of the nomination. Include the PI's name, organization from which the PI is being recruited, and also the department and/or entity within the nominator's organization where the PI will hold the faculty position.

### **8.2.2. Layperson's Summary (2,000 characters)**

Provide a layperson's summary of the proposed work. **This section must be completed by the PI.** Describe, in simple, nontechnical terms, the overall aims of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early detection, prevention, treatment, or survivorship. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. Do not include any proprietary information in the layperson's summary.

### **8.2.3. Summary of Specific Aims and Sub Aims (2,000 characters)**

Please provide a summary of the aims of the proposal. **This section must be completed by the PI.** The specific aims summary should identify the problem or gap in our current knowledge. It should present a hypothesis and briefly describe the aims and approaches and address the proposal's innovation, novel approaches, and significance and impact on the field and cancer research.

#### 8.2.4. Specific Aims and Sub Aims

List specific aims and sub aims to be achieved during this award. **This section must be completed by the PI.** These aims/sub aims will also be used during the submission and evaluation of progress reports and assessment of project success. Refer to the template specific aims and sub aims document located in [Current Funding Opportunities](#) for Academic Research in CARS.

#### 8.2.5. Institutional Commitment (3 pages)

CPRIT recruitment awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research to Texas. The funds provided by CPRIT for the RFTTFM Award must therefore be complemented by a strongly documented institutional commitment to the PI's career development that includes financial commitments that are in addition to the CPRIT award.

***The following guidelines should be followed when documenting the institutional commitment to the PI:***

- The institutional commitment should be clearly documented in the form of a letter signed by the applicant institution's president, provost, or appropriate dean and include the amount and sources of salary support and all additional financial support that will be available to the PI's research program through the course of the CPRIT award. The financial commitments made to the PI by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.
- The institutional commitment letter must include the following statement regarding the institution's financial commitment required to meet the 50% match.
  - This institutional financial commitment will not be offset by funds from a career transition award (K99/R00) or an investigator-initiated award received by the PI. If an award dictates that such funds must be used for salary, the corresponding amount of institutional funds committed to pay the PI's salary will be redirected to allow the PI to use them for program support.

- Institutional commitment as described above must be presented in a table (example below) that clearly identifies the salary amount, sources of salary, and any additional research support from institutional sources over the course of the CPRIT award. Sources of support for the PI's full salary, including summer salary, for the duration of the award must be documented. If the PI is expected to provide salary support from grants during the award period, the institutional commitment must identify the source for salary support in the event grant support is not available. Note that a federal indirect cost rate credit cannot be used to demonstrate an institutional commitment to the PI.
- Include a brief job description for the PI should recruitment be successful.
- Describe the institutional environment and any professional commitments to the PI including, but not limited to, dedicated personnel, access to students, space assignment, and access to shared equipment, and discuss all other agreements between the institution and the PI.
- Institutions may provide additional information in support of a PI's research plan to demonstrate how the institutional commitment through development of strategic collaborations will foster a PI's cancer research. This additional information is highly encouraged when proposing a PI with exceptional expertise and/or talent that can be directed to cancer research such as a computational biologist, chemist, etc, whose prior experience has not been directly focused on cancer research.
- Note that Texas law allows an institution of higher learning to use its federal indirect cost rate credit to comply with the requirement to demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award (see [section 12](#)). However, a federal indirect cost rate credit cannot be used to demonstrate an institutional commitment to the PI.

**Example of an acceptable Institutional Commitment table:**

**PI's Name, Institutional Commitments**

	Year 1	Year 2	Year 3	Year 4	Year 5
Salary/Benefits					
Research Support					
Administrative Support					
Moving Expenses					

Total =

Note: CPRIT acknowledges that the institutional commitments by category may change during the course of the award; however, the total financial commitment to the PI must remain equal to or greater than 50% of the CPRIT award.

**8.2.6. Letter of Support from Department Chair (up to 2 pages)**

Provide the letter of support from and signed by the chair of the department to which the PI is being recruited. The following information should be included in the letter:

**Recruitment Activities:** CPRIT is committed to increasing the life sciences infrastructure in Texas via the recruitment of exceptional cancer researchers, as well as expanding research resources. The letter should provide a description of the recruitment activities, strategies, and priorities that have led to the nomination of this PI. Provide the necessary context by describing the institution’s vision for the cancer programs, how the work of the nominee contributes to achieving these goals—including impact on diversity, equity, and inclusion, if applicable—and the expected impact of the recruitment on the institution (or department) and the burden of cancer in Texas (if applicable).

**Caliber of PI:** The letter should include a description of the caliber of the PI and justification of the nomination of the PI by the institution. CPRIT recognizes that there is variability in the metrics of impact applicable across the continuum of cancer research. For example, in some disciplines, research findings—although highly impactful on the field—are less likely to be published in the highest ranked journals, i.e., *Science*, *Cell*, or *Nature* series. Thus, it is incumbent upon the institution to describe the impact of a nominee’s work, including paradigm-



shifting, practice-changing, or influence on public policy, population health behavior, or cancer disparities.

**Description of PI Duties and Certification of 70% Time Commitment to Research:** While scholars may engage in direct patient care activities and/or have some administrative or teaching duties, at least 70% of the PI's time must be available for research. Breach of this requirement will constitute grounds for discontinuation of funding. The certification that 70% time will be spent on research must be included.

The letter of support from the department chair must also do the following:

1. Describe how the PI will be independent and autonomous in developing his or her research program at the institution.
2. Present a plan for mentoring that includes the design and execution of a faculty career development plan for the PI.

### **8.2.7. Curriculum Vitae (CV)**

Provide a complete CV and list of publications for the PI. Only articles that have been published or that have been accepted for publication ("in press") should be cited.

### **8.2.8. Research (4 pages)**

Summarize the key elements of the PI's research accomplishments and provide an overview of the proposed research by outlining the background and rationale, hypotheses and aims, strategies, specific aims, and projected impact of the focus of the research program. Highlight the innovative aspects of this effort and place it into context with regard to what pressing problem in cancer will be addressed. **This section of the application must be prepared by the PI.**

**References cited in this section should be included in the Publications/References section ([see 8.2.9](#)).**

PIs for CPRIT Scholar Awards must include the following signed statement at the end of this section. **Applications that do not contain this signed statement will be returned without review.**

"I understand that I do not need to have made a commitment to <nominating institution> before this application has been submitted. However, I also understand that only 1 Texas institution may

nominate me for a CPRIT Recruitment Award, and this is the nomination that I have endorsed. I understand that requests to change the recruiting institution during the recruitment process are not allowed after the application is submitted to CPRIT.”

### **8.2.9. Publications/References (1 page)**

Provide a concise and relevant list of publications/references cited in the Research section of the application. Any appropriate citation format is acceptable; official journal abbreviations should be used.

### **8.2.10. Research Collaboration/Synergy Plan (2 pages)**

Institutions may provide additional information in support of a PI’s research plan to demonstrate how the institutional commitment through development of strategic collaborations will foster a PI’s cancer research. This additional information is highly encouraged when proposing a PI with exceptional expertise and/or talent that can be directed to cancer research, such as a computational biologist, chemist, etc, whose prior experience has not been directly focused on cancer research. Biographical sketches of collaborators established in the research collaborative plan must be uploaded as part of the application. This will be in addition to the 2-page synergy plan (see IFA).

### **8.2.11. Publications**

Provide the 3 most significant publications that have resulted from the PI’s research efforts. Publications should be uploaded as PDFs of full-text articles. Only articles that have been published or that have been accepted for publication (“in press”) should be submitted.

### **8.2.12. Timeline (1 page)**

Provide a general outline of anticipated major award outcomes to be tracked. Timelines will be reviewed during the evaluation of annual progress reports. If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

### **8.2.13. Current and Pending Support**

State the funding source, duration, and title of all current and pending research support held by the PI. If the PI has no current or pending funding, a document stating this must be submitted.

Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

#### **8.2.14. Letters of Recommendation**

Provide 3 letters of recommendation from individuals who are in a position to detail the PI's academic and scientific research accomplishments, potential for high-impact research, and ability to make a significant contribution to the field of cancer research.

#### **8.2.15. Research Environment (1 page)**

Clearly and concisely describe the research environment available to support the PI's research program, including core facilities, training programs, and collaborative opportunities.

#### **8.2.16. Descriptive Biography (Up to 2 pages)**

Provide a brief descriptive biography of the PI, including his or her accomplishments, education and training, professional experience, awards and honors, publications relevant to cancer research, and a brief overview of the PI's specific aims, if selected, to receive the award. **This section of the application must be prepared by the PI.** If the application is approved for funding, this section will be made publicly available on CPRIT's website. PIs are advised not to include information that they consider confidential or proprietary when preparing this section.

**Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or do not meet the eligibility requirements listed above will be administratively withdrawn without review.**

## **9. APPLICATION REVIEW**

### **9.1. Review Process**

All eligible applications will be evaluated and scored by the CPRIT Scientific Review Council using the criteria listed in this RFA. Council members may seek additional ad hoc evaluations of PIs. Scientific Review Council members will review applications and provide an individual Overall Evaluation Score that conveys the members' recommendation related to the proposed recruitment. Applications recommended by the Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review, prioritization, and recommendation to the CPRIT

Oversight Committee for approval and funding. Approval is based on an application receiving a positive vote from at least two-thirds of the members of the Oversight Committee. The review process is described more fully in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

The decision of the Scientific Review Council not to recommend an application is final, and such applications may not be resubmitted for a recruitment award. Notification of review decisions is sent to the nominator.

### **9.1.1. Confidentiality of Review**

Each stage of application review is conducted confidentially, and all CPRIT Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Review Council members are non-Texas residents.

**By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed conflict of interest as set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#).**

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, or a Scientific Review Council member.

Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Officer, and the Commissioner of the Department of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant applicant from further consideration for a grant award.

## 9.2. Review Criteria

Applications will be assessed based on evaluation of the quality of the PI and his or her potential for continued superb performance as a cancer researcher. **Also, of critical importance is the strength of the institutional commitment to the PI. Recruitment efforts are not likely to be successful unless there is a strong commitment from both CPRIT and the host institution.** It is not necessary that a PI agrees to accept the recruitment offer at the time an application is submitted. However, applicant institutions should have an expectation that the recruitment will be successful if an award is granted by CPRIT. It is the expectation that the nominating institution provides CPRIT with a status of the award acceptance as soon as status is known.

Review criteria will focus on the overall impression of the PI, his or her proposed research program, and his or her long-term potential for contributions to, and impact on, the field of cancer research. Questions to be considered by the reviewers are as follows:

**Quality of the PI:** Has the PI demonstrated academic excellence? Has the PI received excellent predoctoral and postdoctoral training? Does the PI show exceptional potential for achieving future impact on basic, translational, clinical, or population-based cancer research in the future? Has the PI demonstrated a commitment to cancer research? Has the PI demonstrated independence or the potential for independence?

**Scientific Merit of Proposed Research:** Is the research plan comprehensive and well thought out? Does the proposed research program demonstrate innovation, creativity, and feasibility? Will it have a significant impact on the field of cancer research? Will the proposed research generate preliminary data that can be used for the preparation of applications for future independent research project grants?

**Relevance of PI's Research:** Is the proposed research likely to have a significant impact on reducing the burden of cancer in the near term or address unique aspects of the burden of cancer in Texas? Does the research contribute to basic, translational, clinical, or population-based cancer research?

**Letters of Recommendation:** Do the letters of recommendation detail the PI's academic and clinical research accomplishments, potential for high-impact research, and ability to make a significant contribution to the field of cancer research?

**Research Environment:** Does the institution have the necessary facilities, expertise, and resources to support the PI’s research? Is there evidence of strong institutional support? Will the PI be free of major administrative/clinical responsibilities so that he or she can focus on growing his or her research? Has the institution identified a mentor who will design and execute a faculty career development plan for the PI?

## 10. KEY DATES

### RFA

RFA Release: May 15, 2024

### Application

Online application opens	May 15, 2024
Application due	June 20, 2024, 11:59 PM central time
Application review	July 2024

## 11. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Awards made under this RFA are not transferable to another institution. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT’s electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT’s electronic signature policy as set forth in [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT’s Administrative Rules, which are available at [www.cprit.texas.gov](http://www.cprit.texas.gov).

Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the specific aims and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. CPRIT requires funding acknowledgement to include the award grant ID on all print and visual materials that are funded in whole or in part by CPRIT grants. Examples of print and visual materials include, but are not limited to, publications, brochures, pamphlets, project websites, videos, and media materials. Grantees must have written approval from CPRIT prior to the purchase of any equipment. If the equipment is clearly defined in the grantee's budget submitted with the initiating award requirements, then approval of the grant award constitutes "prior approval" for the purchase. Unless prohibited by policy, the institution is also expected to bestow on the newly recruited faculty member the prestigious title of "CPRIT Scholar in Cancer Research," and the faculty member should be strongly encouraged to use this title on letterhead, business cards, publications, and other appropriate documents. The title is to be retained as long as the individual remains in Texas.

**Continuation of funding is contingent upon the timely receipt of these reports.** Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at [www.cprit.texas.gov](http://www.cprit.texas.gov).

## **12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS**

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. The demonstration of available matching funds must

be made at the time the award contract is executed and annually thereafter, not when the application is submitted. Grant applicants are advised to consult CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#), for specific requirements regarding the demonstration of available funding.

## **13. CONTACT INFORMATION**

### **13.1. Helpdesk**

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff members are not in a position to answer questions regarding scientific aspects of applications.

**Hours of operation:** Monday through Friday, 8 AM to 6 PM central time

**Tel:** 866-941-7146

**Email:** [Help@CPRITGrants.org](mailto:Help@CPRITGrants.org)

### **13.2. Scientific and Programmatic Questions**

Questions regarding the CPRIT Program, including questions regarding this or other funding opportunities, should be directed to the CPRIT Director of Academic Research.

**Email:** [Research@cprit.texas.gov](mailto:Research@cprit.texas.gov)

**Website:** [www.cprit.texas.gov](http://www.cprit.texas.gov)



# **Third Party Observer Reports**

---

**Cancer Prevention and Research Institute of Texas (CPRIT)**  
**FY24-12 REC Recruitment Review Panel (REC 24.12)**  
**Observation Report**

Report No. 2024-07-11 REC\_24.12  
Program Name: Academic Research  
Panel Name: FY24-12 REC Recruitment Review Panel (REC\_24.12)  
Panel Date: July 11, 2024  
Report Date: July 17, 2024

### ***BACKGROUND***

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

### ***INTRODUCTION***

The subject of this report is the FY24-12 REC Recruitment Review Panel (REC\_24.12) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on July 11, 2024.

### ***PANEL OBSERVATION OBJECTIVES AND SCOPE***

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

## **SUMMARY OF OBSERVATION RESULTS**

One (1) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Eight (8) applications were discussed
- Panelists: One (1) discussion lead, and six (6) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Three (3)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

## **CONCLUSION**

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written in a cursive style.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA  
Senior Partner  
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer  
Cameron Eckel, Attorney

# **Conflicts of Interest Disclosure**

---

# Conflicts of Interest Disclosure

CPRIT Academic Research Recruitment Cycle 24.12

Awards Announced at the August 21, 2024, Oversight Committee Meeting

---

The following table lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Recruitment cycle 24.12 include *Recruitment of First-Time, Tenure-Track Faculty Members*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
<b>Applications considered by the PIC and Oversight Committee:</b>			
RR240076	Hojong Yoon	The University of Texas M.D. Anderson Cancer Center	Nathanael Gray
<b>Applications not considered by the PIC or Oversight Committee:</b>			
No reported COIs.			

# De-Identified Overall Evaluation Scores

---

# Recruitment of First-Time, Tenure-Track Faculty Members

## Academic Research Recruitment Cycle 24.12

Application ID	Final Overall Evaluation Score
RR240070*	1.0
RR240076*	1.0
RR240082*	1.2
RR240079*	1.7
Ea	3.3
Eb	3.5
Ec	4.0
Ed	4.5

\* Recommended for funding.



# **Final Overall Evaluation Scores and Rank Order Scores**

---

# UC San Diego

## SCHOOL OF MEDICINE

July 29, 2024

Dr. David A. Cummings, M.D.  
Oversight Committee Presiding Officer  
Cancer Prevention and Research Institute of Texas  
Via email to [dcummingsmd@yahoo.com](mailto:dcummingsmd@yahoo.com)

Ms. Kristen Doyle  
Chief Executive Officer  
Cancer Prevention and Research Institute of Texas  
Via email to [kdoyle@cprit.texas.gov](mailto:kdoyle@cprit.texas.gov)

Dear Dr. Cummings and Ms. Doyle,

The Scientific Review Council (SRC) is pleased to submit this list of 36 research grant recommendations for the Clinical Investigator Award, Core Facility Support Awards, High-Impact/High Risk Awards, Multi-Investigator Research Awards and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on July 11, 2024 to review First-Time Tenure-Track Faculty Members recruitment applications submitted for Cycle FY24.12 and to consider the applications recommended by the peer review panels following their meetings held April 16, 2024 to April 25, 2024. On July 29, 2024 the SRC met to discuss application RP240474, which was peer reviewed on April 25, 2024 but not recommended. The application received a favorable score but just missed the cut off line made by the peer review panel. The SRC chose to consider and recommend RP240474 because of how it addresses program priorities of childhood and adolescent cancers. With available funds the SRC recommended RP240474 to the Program Integration Committee (PIC), bringing the total number of recommended academic research awards to 36.

Recommended funding amounts and the overall evaluation score are stated for each grant application in the following table. The total amount for the applications recommended to the PIC is \$60,577,922.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • [rkolodner@health.ucsd.edu](mailto:rkolodner@health.ucsd.edu)

Richard D. Kolodner, Ph.D.  
Chair, CPRIT Scientific Review Council

Rank	ID	RFA	Score	Application Title	PI	PI Org.	Rec. Budget
1	RP240545	CFSA	1.0	Renewal of CPRIT GMP Core	Lapteva, Natalia	Baylor College of Medicine	\$2,000,000
2	RR240070	RFTFM	1.0	Expanding the Accessibility and Efficacy of CAR-T Cells Through In Vivo Engineering	Labanieh, Louai	Baylor College of Medicine	\$2,000,000
3	RR240076	RFTFM	1.0	Discovery of Molecular Glue Degraders Targeting the Undruggable Cancer Proteome	Yoon, Hojong	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
4	RR240082	RFTFM	1.2	Identification of Neural Mechanisms Contributing to Chemotherapy-Associated Cognitive Impairments	Sun, Yanjun	The University of Texas Health Science Center at Houston	\$2,000,000
5	RP240610	CFSA	1.4	UTHealth Cancer Genomics Core (UTHealth CGC)	Zhao, Zhongming	The University of Texas Health Science Center at Houston	\$2,000,000
6	RP240478	CIA	1.4	Advancing immunotherapy for high-risk cancers in children and adolescents	Hegde, Meenakshi	Baylor College of Medicine	\$1,030,892
7	RP240473	CIA	1.6	Signal-Augmented Cancer Cell Therapies: Integrating Advanced	Omer, Bilal	Baylor College of Medicine	\$1,046,414

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

**UC San Diego**  
SCHOOL OF MEDICINE

				Correlatory Studies and Mentorship			
8	RP240494	CFSA	1.7	Children's Research Institute Metabolomics Core: Advanced Methodologies in Cancer Metabolism	DeBerardinis, Ralph	The University of Texas Southwestern Medical Center	\$2,601,616
9	RP240497	CFSA	1.7	Advanced Spatial Genomics Core Facility	Navin, Nicholas	The University of Texas M. D. Anderson Cancer Center	\$2,999,993
10	RR240079	RFTFM	1.7	Immune surveillance and elimination of aneuploid cells in vivo	Trakala, Marianna	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
11	RP240432	CFSA	1.8	Advanced Multiparameter Cytometry and Cell Sorting Core	Beeton, Christine	Baylor College of Medicine	\$1,999,882
12	RP240440	MIRA2	1.8	Novel Therapies for Osteosarcoma	Gorlick, Richard	The University of Texas M. D. Anderson Cancer Center	\$4,498,684
13	RP240557	CIA	1.8	Dietary intervention to modulate the microbiome and immune response	McQuade, Jennifer	The University of Texas M. D. Anderson Cancer Center	\$1,074,727
14	RP240430	CFSA	1.9	GCC Center for Comprehensive PK/PD & Formulation	Liang, Dong	Texas Southern University	\$2,000,000
15	RP240590	HIHRA	2.0	Bidentate ERK Traps: Revolutionizing Combination Cancer Therapy Strategies	Dalby, Kevin	The University of Texas at Austin	\$249,996
16	RP240539	HIHRA	2.0	Spectroscopy for quantitative real-time imaging of radical formation	Gustavsson, Anna-Karin	Rice University	\$250,000

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

				in ultra-high dose rate radiation therapy			
17	RP240508	CFSA	2.1	The Texas Decision Science Core Facility: A CPRIT Population Science Core	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	\$2,995,778
18	RP240446	HIHRA	2.1	Regulation of Transcription Factor Function by Local Chromatin Context	Soshnev, Alexey	The University of Texas at San Antonio	\$249,561
19	RP240442	CIA	2.1	Identifying and exploiting novel metabolic vulnerabilities in the treatment of kidney cancer	Courtney, Kevin	The University of Texas Southwestern Medical Center	\$913,682
20	RP240559	CFSA	2.1	High Performance Mass Spectrometry Imaging Core Facility	Brodbelt, Jennifer	The University of Texas at Austin	\$1,998,763
21	RP240441	CIA	2.2	Precision Lung Cancer Interception by Targeting High-Risk Lung Nodules	Zhang, Jianjun	The University of Texas M. D. Anderson Cancer Center	\$1,098,945
22	RP240438	MIRA2	2.2	Overcoming major barriers to the delivery of successful T-cell immunotherapies	Rooney, Cliona	Baylor College of Medicine	\$4,500,000
23	RP240579	HIHRA	2.3	Renal Clearable Nano Delivery Systems for Maximizing Anti-tumor Immunity in Breast Cancer Brain Metastasis Treatment	Zheng, Jie	The University of Texas at Dallas	\$250,000
24	RP240521	CFSA	2.3	Pediatric Cancer Data Core	Xie, Yang	The University of Texas Southwestern Medical Center	\$1,999,760

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

**UC San Diego**  
SCHOOL OF MEDICINE

25	RP240518	CIA	2.4	Adapting radiotherapy clinical trials to treatment response and artificial intelligence innovations	Desai, Neil	The University of Texas Southwestern Medical Center	\$1,460,229
26	RP240462	HIHRA	2.5	Development of an Endoscopic Nuclear Imaging Capsule for Radio-Guided Cancer Surgery	Zannoni, Elena Maria	The University of Texas at Austin	\$250,000
27	RP240501	HIHRA	2.6	Delivering Immunotherapy more effectively to glioblastoma with a “magnetic switch”	Qin, Zhenpeng	The University of Texas at Dallas	\$250,000
28	RP240542	HIHRA	2.6	Digital Twin Augmented Reality for Prostate Laparoscopic Surgery	Fei, Baowei	The University of Texas at Dallas	\$250,000
29	RP240454	HIHRA	2.7	Reversing Tumor Immune Exclusion with Sphingosine-1-Phosphate Depleting Therapeutics	Stone, Everett	The University of Texas at Austin	\$249,998
30	RP240498	HIHRA	2.7	Improving the management of gastric peritoneal carcinomatosis with Photo-Betabody Immunotherapy	Obaid, Girgis	The University of Texas at Dallas	\$248,991
31	RP240493	HIHRA	2.8	Engineering in vivo chimeric antigen receptor (CAR) macrophages for diffuse midline glioma	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$250,000
32	RP240516	HIHRA	2.9	Mapping multivalent chromatin	Mani, Ram	The University of Texas	\$250,000

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

**UC San Diego**  
SCHOOL OF MEDICINE

				interactions to define the 3D genome of Clear cell renal cell carcinoma		Southwestern Medical Center	
33	RP240605	HIHRA	3.1	Stimulate Mucosal-associated Invariant T cells to Kill Cancer Cells	Huang, Shouxiong	Texas Biomedical Research Institute	\$249,484
34	RP240439	MIRA2	3.1	Innovative cell therapy approaches for hematological and solid malignancies	Neelapu, Sattva	The University of Texas M. D. Anderson Cancer Center	\$4,500,000
35	RP240489	MIRA2	3.2	Neural Regulation of Childhood Cancers	Morrison, Sean	The University of Texas Southwestern Medical Center	\$4,362,563
36	RP240474	MIRA2	3.6	Cellular Immunotherapies for Pediatric Solid Tumors	Metelitsa, Leonid	Baylor College of Medicine	\$4,497,964

Clinical Investigator Award (CIA)  
Core Facility Support Awards (CFSA)  
High-Impact/High Risk Awards (HIHR)  
Multi-Investigator Research Awards (MIRA2)  
Recruitment of First-Time, Tenure Track Faculty Members (RFTTFM)

**Department of Cellular and Molecular Medicine**

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660  
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240430**  
**Core Facility Support Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Core Facility Support Awards* Request for Applications (RFA). CPRIT received 22 applications in response to this RFA, including two withdrawn applications one of which was withdrawn after peer review but prior to the review council meeting. This application was assigned to the Clinical and Translational Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle




- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."

  
\_\_\_\_\_  
Kristen P. Doyle,  
CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
the 8<sup>th</sup> day of August, 2024,  
by KRISTEN P. DOYLE.

  
\_\_\_\_\_  
Sandra Reyes  
Notary Public, State of Texas



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/07/2024 01:28 PM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** Core Facilities Support Awards  
**APPLICATION ID:** RP240430  
**APPLICATION TITLE:** GCC Center for Comprehensive PK/PD & Formulation  
**APPLICANT NAME:** Liang, Dong  
**ORGANIZATION:** Texas Southern University  
**PANEL NAME:** 24.2 Clinical and Translational Cancer Research-1

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	<b>RFA Approved by CSO</b>	<b>09/13/2023</b>	07/09/2024	
	<b>RFA Approved by CSO (revised)</b>	<b>01/16/2024</b>	07/09/2024	
	<b>RFA published in Texas.gov eGrants</b>	<b>09/14/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) opened</b>	<b>10/17/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) closed</b>	<b>01/18/2024</b>	07/09/2024	
	<b>Date application submitted</b>	<b>01/15/2024</b>	07/10/2024	
	<b>Method of submission</b>	<b>CARS</b>	07/10/2024	
	<b>Within receipt period</b>	<b>YES</b>	07/10/2024	
	<b>Request for extension to submit application after CARS closed</b>	<b>N/A</b>	07/10/2024	
	<b>Request for extension for late application submission accepted</b>	<b>N/A</b>	07/10/2024	
	<b>Receipt, Referral, and Assignment</b>	<b>Administrative review notification</b>	<b>N/A</b>	07/10/2024
		<b>Donation(s) made to CPRIT / foundation</b>	<b>NO</b>	07/10/2024
<b>Assigned to primary reviewers</b>		<b>03/11/2024</b>	07/10/2024	
<b>Applicant notified of review panel assignment</b>		<b>02/28/2024</b>	07/09/2024	
<b>Primary Reviewer 1 COI signed</b>		<b>02/28/2024</b>	07/10/2024	
<b>Primary Reviewer 2 COI signed</b>		<b>02/27/2024</b>	07/10/2024	
<b>Primary Reviewer 3 COI signed</b>		<b>03/02/2024</b>	07/10/2024	
<b>Primary (Advocate) Reviewer 4 COI signed</b>		<b>02/27/2024</b>	07/10/2024	
<b>Preliminary Evaluation</b>	<b>Primary Reviewer 1 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>N/A</b>	07/10/2024	
	<b>Preliminary Evaluation score summary sent to Chair</b>	<b>N/A</b>	07/10/2024	
	<b>Recommended for full review</b>	<b>N/A</b>	07/10/2024	
	<b>Applicant notified of outcome</b>	<b>N/A</b>	07/10/2024	
<b>Peer Review Meeting</b>	<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/10/2024	
	<b>Primary Reviewer 1 COI signed</b>	<b>02/28/2024</b>	07/10/2024	
	<b>Primary Reviewer 2 COI signed</b>	<b>02/27/2024</b>	07/10/2024	
	<b>Primary Reviewer 3 COI signed</b>	<b>03/02/2024</b>	07/10/2024	
	<b>Primary (Advocate) Reviewer 4 COI signed</b>	<b>02/27/2024</b>	07/10/2024	
	<b>Primary Reviewer 1 critique submitted</b>	<b>04/04/2024</b>	07/10/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>03/29/2024</b>	07/10/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>04/06/2024</b>	07/10/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>03/12/2024</b>	07/10/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>NONE</b>	07/10/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/10/2024	
	<b>Discussed at Peer Review Meeting</b>	<b>YES</b>	07/10/2024	
	<b>Peer Review Meeting</b>	<b>04/18/2024</b>	07/10/2024	
	<b>Post review statements signed</b>	<b>04/18/2024</b>	07/09/2024	
	<b>Third Party Observer Report</b>	<b>04/23/2024</b>	07/09/2024	
	<b>Score report delivered to CSO</b>	<b>05/09/2024</b>	07/09/2024	
	<b>Recommended for SRC review</b>	<b>YES</b>	07/10/2024	
	<b>Final SRC Recommendation</b>	<b>COI indicated by SRC member</b>	<b>NONE</b>	07/12/2024
<b>COI recused from participation</b>		<b>N/A</b>	07/12/2024	
<b>SRC Meeting</b>		<b>07/11/2024</b>	07/16/2024	
<b>Third Party Observer Report</b>		<b>07/17/2024</b>	07/30/2024	
<b>Recommended for grant award</b>		<b>YES</b>	07/12/2024	
<b>SRC Chair Notification to PIC and OC</b>		<b>07/29/2024</b>	07/30/2024	
<b>PIC Review</b>	<b>COI indicated by PIC member</b>	<b>None</b>	08/07/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	08/07/2024	
	<b>PIC Review Meeting</b>	<b>08/07/2024</b>	08/07/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	08/07/2024	
<b>Oversight Committee Approval</b>	<b>CEO Notification to Oversight Committee</b>	<b>N/A</b>		
	<b>COI Indicated by Oversight Committee member</b>	<b>N/A</b>		
	<b>COI Recused from participation</b>	<b>N/A</b>		
	<b>Donation(s) made to CPRIT / foundation</b>	<b>N/A</b>		
	<b>Presented to CPRIT Oversight Committee</b>	<b>N/A</b>		
	<b>Award approved by Oversight Committee</b>	<b>N/A</b>		
	<b>Authority to advance funds requested</b>	<b>N/A</b>		
	<b>Advance authority approved by Oversight Committee</b>	<b>N/A</b>		



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240432**  
**Core Facility Support Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Core Facility Support Awards* Request for Applications (RFA). CPRIT received 22 applications in response to this RFA, including two withdrawn applications one of which was withdrawn after peer review but prior to the review council meeting. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true.

  
\_\_\_\_\_  
Kristen P. Doyle,  
CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
the 8<sup>th</sup> day of August, 2024,  
by KRISTEN P. DOYLE.

  
\_\_\_\_\_  
Sandra Reyes  
Notary Public, State of Texas



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/07/2024 01:28 PM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** Core Facilities Support Awards  
**APPLICATION ID:** RP240432  
**APPLICATION TITLE:** Advanced Multiparameter Cytometry and Cell Sorting Core  
**APPLICANT NAME:** Beeton, Christine  
**ORGANIZATION:** Baylor College of Medicine  
**PANEL NAME:** 24.2 Cancer Biology

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	<b>RFA Approved by CSO</b>	<b>09/13/2023</b>	07/09/2024	
	<b>RFA Approved by CSO (revised)</b>	<b>01/16/2024</b>	07/09/2024	
	<b>RFA published in Texas.gov eGrants</b>	<b>09/14/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) opened</b>	<b>10/17/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) closed</b>	<b>01/18/2024</b>	07/09/2024	
	<b>Date application submitted</b>	<b>01/16/2024</b>	07/09/2024	
	<b>Method of submission</b>	<b>CARS</b>	07/09/2024	
	<b>Within receipt period</b>	<b>YES</b>	07/09/2024	
	<b>Request for extension to submit application after CARS closed</b>	<b>N/A</b>	07/09/2024	
	<b>Request for extension for late application submission accepted</b>	<b>N/A</b>	07/09/2024	
	<b>Receipt, Referral, and Assignment</b>	<b>Administrative review notification</b>	<b>N/A</b>	07/09/2024
		<b>Donation(s) made to CPRIT / foundation</b>	<b>NO</b>	07/09/2024
		<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/09/2024
<b>Applicant notified of review panel assignment</b>		<b>02/28/2024</b>	07/09/2024	
<b>Primary Reviewer 1 COI signed</b>		<b>02/28/2024</b>	07/09/2024	
<b>Primary Reviewer 2 COI signed</b>		<b>03/07/2024</b>	07/09/2024	
<b>Primary Reviewer 3 COI signed</b>		<b>03/07/2024</b>	07/09/2024	
<b>Primary (Advocate) Reviewer 4 COI signed</b>		<b>03/06/2024</b>	07/09/2024	
<b>Preliminary Evaluation</b>	<b>Primary Reviewer 1 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>N/A</b>	07/09/2024	
	<b>Preliminary Evaluation score summary sent to Chair</b>	<b>N/A</b>	07/09/2024	
	<b>Recommended for full review</b>	<b>N/A</b>	07/09/2024	
	<b>Applicant notified of outcome</b>	<b>N/A</b>	07/09/2024	
<b>Peer Review Meeting</b>	<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/09/2024	
	<b>Primary Reviewer 1 COI signed</b>	<b>02/28/2024</b>	07/09/2024	
	<b>Primary Reviewer 2 COI signed</b>	<b>03/07/2024</b>	07/09/2024	
	<b>Primary Reviewer 3 COI signed</b>	<b>03/07/2024</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 COI signed</b>	<b>03/06/2024</b>	07/09/2024	
	<b>Primary Reviewer 1 critique submitted</b>	<b>04/10/2024</b>	07/09/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>04/11/2024</b>	07/09/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>04/16/2024</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>04/06/2024</b>	07/09/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>NONE</b>	07/09/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/09/2024	
	<b>Discussed at Peer Review Meeting</b>	<b>YES</b>	07/09/2024	
	<b>Peer Review Meeting</b>	<b>04/24/2024</b>	07/09/2024	
	<b>Post review statements signed</b>	<b>04/29/2024</b>	07/09/2024	
	<b>Third Party Observer Report</b>	<b>04/29/2024</b>	07/09/2024	
	<b>Score report delivered to CSO</b>	<b>05/09/2024</b>	07/09/2024	
	<b>Recommended for SRC review</b>	<b>YES</b>	07/09/2024	
<b>Final SRC Recommendation</b>	<b>COI indicated by SRC member</b>	<b>NONE</b>	07/12/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/12/2024	
	<b>SRC Meeting</b>	<b>07/11/2024</b>	07/16/2024	
	<b>Third Party Observer Report</b>	<b>07/17/2024</b>	07/30/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	07/12/2024	
	<b>SRC Chair Notification to PIC and OC</b>	<b>07/29/2024</b>	07/30/2024	
<b>PIC Review</b>	<b>COI indicated by PIC member</b>	<b>None</b>	08/07/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	08/07/2024	
	<b>PIC Review Meeting</b>	<b>08/07/2024</b>	08/07/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	08/07/2024	
<b>Oversight Committee Approval</b>	<b>CEO Notification to Oversight Committee</b>	<b>N/A</b>		
	<b>COI Indicated by Oversight Committee member</b>	<b>N/A</b>		
	<b>COI Recused from participation</b>	<b>N/A</b>		
	<b>Donation(s) made to CPRIT / foundation</b>	<b>N/A</b>		
	<b>Presented to CPRIT Oversight Committee</b>	<b>N/A</b>		
	<b>Award approved by Oversight Committee</b>	<b>N/A</b>		
	<b>Authority to advance funds requested</b>	<b>N/A</b>		
	<b>Advance authority approved by Oversight Committee</b>	<b>N/A</b>		



CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240494**  
**Core Facility Support Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Core Facility Support Awards* Request for Applications (RFA). CPRIT received 22 applications in response to this RFA, including two withdrawn applications one of which was withdrawn after peer review but prior to the review council meeting. This application was assigned to Basic Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.

This statement is true."




Kristen P. Doyle,  
CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
the 8<sup>th</sup> day of August, 2024,  
by KRISTEN P. DOYLE.



Sandra Reyes  
Notary Public, State of Texas



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/07/2024 01:28 PM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** Core Facilities Support Awards  
**APPLICATION ID:** RP240494  
**APPLICATION TITLE:** Children's Research Institute Metabolomics Core: Advanced Methodologies in Cancer Metabolism  
**APPLICANT NAME:** DeBerardinis, Ralph J  
**ORGANIZATION:** The University of Texas Southwestern Medical Center  
**PANEL NAME:** 24.2 Basic Cancer Research 2

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	<b>RFA Approved by CSO</b>	<b>09/13/2023</b>	07/09/2024	
	<b>RFA Approved by CSO (revised)</b>	<b>01/16/2024</b>	07/09/2024	
	<b>RFA published in Texas.gov eGrants</b>	<b>09/14/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) opened</b>	<b>10/17/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) closed</b>	<b>01/18/2024</b>	07/09/2024	
	<b>Date application submitted</b>	<b>01/15/2024</b>	07/09/2024	
	<b>Method of submission</b>	<b>CARS</b>	07/09/2024	
	<b>Within receipt period</b>	<b>YES</b>	07/09/2024	
	<b>Request for extension to submit application after CARS closed</b>	<b>N/A</b>	07/09/2024	
	<b>Request for extension for late application submission accepted</b>	<b>N/A</b>	07/09/2024	
	<b>Receipt, Referral, and Assignment</b>	<b>Administrative review notification</b>	<b>N/A</b>	07/09/2024
		<b>Donation(s) made to CPRIT / foundation</b>	<b>NO</b>	07/09/2024
		<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/09/2024
<b>Applicant notified of review panel assignment</b>		<b>02/28/2024</b>	07/09/2024	
<b>Primary Reviewer 1 COI signed</b>		<b>03/05/2024</b>	07/09/2024	
<b>Primary Reviewer 2 COI signed</b>		<b>02/27/2024</b>	07/09/2024	
<b>Primary Reviewer 3 COI signed</b>		<b>03/06/2024</b>	07/09/2024	
<b>Primary (Advocate) Reviewer 4 COI signed</b>		<b>03/04/2024</b>	07/09/2024	
<b>Preliminary Evaluation</b>	<b>Primary Reviewer 1 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>N/A</b>	07/09/2024	
	<b>Preliminary Evaluation score summary sent to Chair</b>	<b>N/A</b>	07/09/2024	
	<b>Recommended for full review</b>	<b>N/A</b>	07/09/2024	
	<b>Applicant notified of outcome</b>	<b>N/A</b>	07/09/2024	
<b>Peer Review Meeting</b>	<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/09/2024	
	<b>Primary Reviewer 1 COI signed</b>	<b>03/05/2024</b>	07/09/2024	
	<b>Primary Reviewer 2 COI signed</b>	<b>02/27/2024</b>	07/09/2024	
	<b>Primary Reviewer 3 COI signed</b>	<b>03/06/2024</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 COI signed</b>	<b>03/04/2024</b>	07/09/2024	
	<b>Primary Reviewer 1 critique submitted</b>	<b>03/31/2024</b>	07/09/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>04/03/2024</b>	07/09/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>03/29/2024</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>03/26/2024</b>	07/09/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>NONE</b>	07/09/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/09/2024	
	<b>Discussed at Peer Review Meeting</b>	<b>YES</b>	07/09/2024	
	<b>Peer Review Meeting</b>	<b>04/17/2024</b>	07/09/2024	
	<b>Post review statements signed</b>	<b>04/26/2024</b>	07/09/2024	
	<b>Third Party Observer Report</b>	<b>04/23/2024</b>	07/09/2024	
	<b>Score report delivered to CSO</b>	<b>05/09/2024</b>	07/09/2024	
	<b>Recommended for SRC review</b>	<b>YES</b>	07/09/2024	
	<b>Final SRC Recommendation</b>	<b>COI indicated by SRC member</b>	<b>NONE</b>	07/12/2024
<b>COI recused from participation</b>		<b>N/A</b>	07/12/2024	
<b>SRC Meeting</b>		<b>07/11/2024</b>	07/16/2024	
<b>Third Party Observer Report</b>		<b>07/17/2024</b>	07/30/2024	
<b>Recommended for grant award</b>		<b>YES</b>	07/12/2024	
<b>SRC Chair Notification to PIC and OC</b>		<b>07/29/2024</b>	07/30/2024	
<b>PIC Review</b>	<b>COI indicated by PIC member</b>	<b>None</b>	08/07/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	08/07/2024	
	<b>PIC Review Meeting</b>	<b>08/07/2024</b>	08/07/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	08/07/2024	
<b>Oversight Committee Approval</b>	<b>CEO Notification to Oversight Committee</b>	<b>N/A</b>		
	<b>COI Indicated by Oversight Committee member</b>	<b>N/A</b>		
	<b>COI Recused from participation</b>	<b>N/A</b>		
	<b>Donation(s) made to CPRIT / foundation</b>	<b>N/A</b>		
	<b>Presented to CPRIT Oversight Committee</b>	<b>N/A</b>		
	<b>Award approved by Oversight Committee</b>	<b>N/A</b>		
	<b>Authority to advance funds requested</b>	<b>N/A</b>		
	<b>Advance authority approved by Oversight Committee</b>	<b>N/A</b>		





---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240497**  
**Core Facility Support Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Core Facility Support Awards* Request for Applications (RFA). CPRIT received 22 applications in response to this RFA, including two withdrawn applications one of which was withdrawn after peer review but prior to the review council meeting. This application was assigned to Basic Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."

  
\_\_\_\_\_  
Kristen P. Doyle,  
CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
the 8<sup>th</sup> day of August, 2024,  
by KRISTEN P. DOYLE.

  
\_\_\_\_\_  
Sandra Reyes  
Notary Public, State of Texas



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/07/2024 01:28 PM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** Core Facilities Support Awards  
**APPLICATION ID:** RP240497  
**APPLICATION TITLE:** Advanced Spatial Genomics Core Facility  
**APPLICANT NAME:** Navin, Nicholas E  
**ORGANIZATION:** The University of Texas M. D. Anderson Cancer Center  
**PANEL NAME:** 24.2 Basic Cancer Research 2

Category	Compliance Requirement	Information	Attestation Date
<b>Pre-Receipt</b>	RFA Approved by CSO	09/13/2023	07/09/2024
	RFA Approved by CSO (revised)	01/16/2024	07/09/2024
	RFA published in Texas.gov eGrants	09/14/2023	07/09/2024
	CPRIT Application Receipt System (CARS) opened	10/17/2023	07/09/2024
	CPRIT Application Receipt System (CARS) closed	01/18/2024	07/09/2024
	Date application submitted	01/10/2024	07/09/2024
	Method of submission	CARS	07/09/2024
	Within receipt period	YES	07/09/2024
	Request for extension to submit application after CARS closed	N/A	07/09/2024
	Request for extension for late application submission accepted	N/A	07/09/2024
<b>Receipt, Referral, and Assignment</b>	Administrative review notification	02/15/2024	07/09/2024
	Administrative review notification	02/19/2024	07/09/2024
	Donation(s) made to CPRIT / foundation	NO	07/09/2024
	Assigned to primary reviewers	03/11/2024	07/09/2024
	Applicant notified of review panel assignment	02/28/2024	07/09/2024
	Primary Reviewer 1 COI signed	03/04/2024	07/09/2024
	Primary Reviewer 2 COI signed	03/05/2024	07/09/2024
	Primary Reviewer 3 COI signed	02/27/2024	07/09/2024
	Primary (Advocate) Reviewer 4 COI signed	03/01/2024	07/09/2024
<b>Preliminary Evaluation</b>	Primary Reviewer 1 critique submitted	N/A	07/09/2024
	Primary Reviewer 2 critique submitted	N/A	07/09/2024
	Primary Reviewer 3 critique submitted	N/A	07/09/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/09/2024
	COI indicated by non-primary reviewer	N/A	07/09/2024
	Preliminary Evaluation score summary sent to Chair	N/A	07/09/2024
	Recommended for full review	N/A	07/09/2024
	Applicant notified of outcome	N/A	07/09/2024
<b>Peer Review Meeting</b>	Assigned to primary reviewers	03/11/2024	07/09/2024
	Primary Reviewer 1 COI signed	03/04/2024	07/09/2024
	Primary Reviewer 2 COI signed	03/05/2024	07/09/2024
	Primary Reviewer 3 COI signed	02/27/2024	07/09/2024
	Primary (Advocate) Reviewer 4 COI signed	03/01/2024	07/09/2024
	Primary Reviewer 1 critique submitted	04/03/2024	07/09/2024
	Primary Reviewer 2 critique submitted	04/15/2024	07/09/2024
	Primary Reviewer 3 critique submitted	04/03/2024	07/09/2024
	Primary (Advocate) Reviewer 4 critique submitted	03/26/2024	07/09/2024
	COI indicated by non-primary reviewer	NONE	07/09/2024
	COI recused from participation	N/A	07/09/2024
	Discussed at Peer Review Meeting	YES	07/09/2024
	Peer Review Meeting	04/17/2024	07/09/2024
	Post review statements signed	04/26/2024	07/09/2024
	Third Party Observer Report	04/23/2024	07/09/2024
Score report delivered to CSO	05/09/2024	07/09/2024	
Recommended for SRC review	YES	07/09/2024	
<b>Final SRC Recommendation</b>	COI indicated by SRC member	NONE	07/12/2024
	COI recused from participation	N/A	07/12/2024
	SRC Meeting	07/11/2024	07/16/2024
	Third Party Observer Report	07/17/2024	07/30/2024
	Recommended for grant award	YES	07/12/2024
	SRC Chair Notification to PIC and OC	07/29/2024	07/30/2024
<b>PIC Review</b>	COI indicated by PIC member	None	08/07/2024
	COI recused from participation	N/A	08/07/2024
	PIC Review Meeting	08/07/2024	08/07/2024
	Recommended for grant award	YES	08/07/2024
<b>Oversight Committee Approval</b>	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
	Advance authority approved by Oversight Committee	N/A	



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240508**  
**Core Facility Support Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Core Facility Support Awards* Request for Applications (RFACPRIT received 22 applications in response to this RFA, including two withdrawn applications one of which was withdrawn after peer review but prior to the review council meeting. This application was assigned to Basic Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."

  
\_\_\_\_\_  
Kristen P. Doyle,  
CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
the 8<sup>th</sup> day of August, 2024,  
by KRISTEN P. DOYLE.

  
\_\_\_\_\_  
Sandra Reyes  
Notary Public, State of Texas



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/07/2024 01:28 PM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** Core Facilities Support Awards  
**APPLICATION ID:** RP240508  
**APPLICATION TITLE:** The Texas Decision Science Core Facility: A CPRIT Population Science Core  
**APPLICANT NAME:** Volk, Robert J  
**ORGANIZATION:** The University of Texas M. D. Anderson Cancer Center  
**PANEL NAME:** 24.2 Basic Cancer Research I

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	<b>RFA Approved by CSO</b>	<b>09/13/2023</b>	07/09/2024	
	<b>RFA Approved by CSO (revised)</b>	<b>01/16/2024</b>	07/09/2024	
	<b>RFA published in Texas.gov eGrants</b>	<b>09/14/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) opened</b>	<b>10/17/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) closed</b>	<b>01/18/2024</b>	07/09/2024	
	<b>Date application submitted</b>	<b>01/12/2024</b>	07/09/2024	
	<b>Method of submission</b>	<b>CARS</b>	07/09/2024	
	<b>Within receipt period</b>	<b>YES</b>	07/09/2024	
	<b>Request for extension to submit application after CARS closed</b>	<b>N/A</b>	07/09/2024	
	<b>Request for extension for late application submission accepted</b>	<b>N/A</b>	07/09/2024	
	<b>Receipt, Referral, and Assignment</b>	<b>Administrative review notification</b>	<b>02/15/2024</b>	07/09/2024
		<b>Donation(s) made to CPRIT / foundation</b>	<b>NO</b>	07/09/2024
		<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/09/2024
<b>Applicant notified of review panel assignment</b>		<b>02/28/2024</b>	07/09/2024	
<b>Primary Reviewer 1 COI signed</b>		<b>02/27/2024</b>	07/09/2024	
<b>Primary Reviewer 2 COI signed</b>		<b>03/14/2024</b>	07/09/2024	
<b>Primary Reviewer 3 COI signed</b>		<b>03/05/2024</b>	07/09/2024	
<b>Primary (Advocate) Reviewer 4 COI signed</b>		<b>02/27/2024</b>	07/09/2024	
<b>Preliminary Evaluation</b>	<b>Primary Reviewer 1 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>N/A</b>	07/09/2024	
	<b>Preliminary Evaluation score summary sent to Chair</b>	<b>N/A</b>	07/09/2024	
	<b>Recommended for full review</b>	<b>N/A</b>	07/09/2024	
	<b>Applicant notified of outcome</b>	<b>N/A</b>	07/09/2024	
<b>Peer Review Meeting</b>	<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/09/2024	
	<b>Primary Reviewer 1 COI signed</b>	<b>02/27/2024</b>	07/09/2024	
	<b>Primary Reviewer 2 COI signed</b>	<b>03/14/2024</b>	07/09/2024	
	<b>Primary Reviewer 3 COI signed</b>	<b>03/05/2024</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 COI signed</b>	<b>02/27/2024</b>	07/09/2024	
	<b>Primary Reviewer 1 critique submitted</b>	<b>03/18/2024</b>	07/09/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>04/08/2024</b>	07/09/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>04/04/2024</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>03/27/2024</b>	07/09/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>NONE</b>	07/09/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/09/2024	
	<b>Discussed at Peer Review Meeting</b>	<b>YES</b>	07/09/2024	
	<b>Peer Review Meeting</b>	<b>04/16/2024</b>	07/09/2024	
	<b>Post review statements signed</b>	<b>04/16/2024</b>	07/09/2024	
	<b>Third Party Observer Report</b>	<b>04/23/2024</b>	07/09/2024	
	<b>Score report delivered to CSO</b>	<b>05/09/2024</b>	07/09/2024	
	<b>Recommended for SRC review</b>	<b>YES</b>	07/09/2024	
<b>Final SRC Recommendation</b>	<b>COI indicated by SRC member</b>	<b>NONE</b>	07/12/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/12/2024	
	<b>SRC Meeting</b>	<b>07/11/2024</b>	07/16/2024	
	<b>Third Party Observer Report</b>	<b>07/17/2024</b>	07/30/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	07/12/2024	
	<b>SRC Chair Notification to PIC and OC</b>	<b>07/29/2024</b>	07/30/2024	
<b>PIC Review</b>	<b>COI indicated by PIC member</b>	<b>None</b>	08/07/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	08/07/2024	
	<b>PIC Review Meeting</b>	<b>08/07/2024</b>	08/07/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	08/07/2024	
<b>Oversight Committee Approval</b>	<b>CEO Notification to Oversight Committee</b>	<b>N/A</b>		
	<b>COI Indicated by Oversight Committee member</b>	<b>N/A</b>		
	<b>COI Recused from participation</b>	<b>N/A</b>		
	<b>Donation(s) made to CPRIT / foundation</b>	<b>N/A</b>		
	<b>Presented to CPRIT Oversight Committee</b>	<b>N/A</b>		
	<b>Award approved by Oversight Committee</b>	<b>N/A</b>		
	<b>Authority to advance funds requested</b>	<b>N/A</b>		
	<b>Advance authority approved by Oversight Committee</b>	<b>N/A</b>		



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240521**  
**Core Facility Support Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Core Facility Support Awards* Request for Applications (RFA). CPRIT received 22 applications in response to this RFA, including two withdrawn applications one of which was withdrawn after peer review but prior to the review council meeting. This application was assigned to the Imaging Technology and Informatics panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."



Kristen P. Doyle,  
CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
the 8<sup>th</sup> day of August, 2024,  
by KRISTEN P. DOYLE.

  
Sandra Reyes  
Notary Public, State of Texas



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/07/2024 01:28 PM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** Core Facilities Support Awards  
**APPLICATION ID:** RP240521  
**APPLICATION TITLE:** Pediatric Cancer Data Core  
**APPLICANT NAME:** Xie, Yang  
**ORGANIZATION:** The University of Texas Southwestern Medical Center  
**PANEL NAME:** 24.2 Imaging Technology and Informatics

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	<b>RFA Approved by CSO</b>	<b>09/13/2023</b>	07/09/2024	
	<b>RFA Approved by CSO (revised)</b>	<b>01/16/2024</b>	07/09/2024	
	<b>RFA published in Texas.gov eGrants</b>	<b>09/14/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) opened</b>	<b>10/17/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) closed</b>	<b>01/18/2024</b>	07/09/2024	
	<b>Date application submitted</b>	<b>01/16/2024</b>	07/11/2024	
	<b>Method of submission</b>	<b>CARS</b>	07/11/2024	
	<b>Within receipt period</b>	<b>YES</b>	07/11/2024	
	<b>Request for extension to submit application after CARS closed</b>	<b>N/A</b>	07/11/2024	
	<b>Request for extension for late application submission accepted</b>	<b>N/A</b>	07/11/2024	
	<b>Receipt, Referral, and Assignment</b>	<b>Administrative review notification</b>	<b>02/19/2024</b>	07/11/2024
		<b>Donation(s) made to CPRIT / foundation</b>	<b>NO</b>	07/11/2024
		<b>Assigned to primary reviewers</b>	<b>03/12/2024</b>	07/11/2024
<b>Applicant notified of review panel assignment</b>		<b>02/28/2024</b>	07/09/2024	
<b>Primary Reviewer 1 COI signed</b>		<b>03/04/2024</b>	07/11/2024	
<b>Primary Reviewer 2 COI signed</b>		<b>03/02/2024</b>	07/11/2024	
<b>Primary Reviewer 3 COI signed</b>		<b>03/04/2024</b>	07/11/2024	
<b>Primary (Advocate) Reviewer 4 COI signed</b>		<b>02/27/2024</b>	07/11/2024	
<b>Preliminary Evaluation</b>	<b>Primary Reviewer 1 critique submitted</b>	<b>N/A</b>	07/11/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>N/A</b>	07/11/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>N/A</b>	07/11/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>N/A</b>	07/11/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>N/A</b>	07/11/2024	
	<b>Preliminary Evaluation score summary sent to Chair</b>	<b>N/A</b>	07/11/2024	
	<b>Recommended for full review</b>	<b>N/A</b>	07/11/2024	
	<b>Applicant notified of outcome</b>	<b>N/A</b>	07/11/2024	
<b>Peer Review Meeting</b>	<b>Assigned to primary reviewers</b>	<b>03/12/2024</b>	07/11/2024	
	<b>Primary Reviewer 1 COI signed</b>	<b>03/04/2024</b>	07/11/2024	
	<b>Primary Reviewer 2 COI signed</b>	<b>03/02/2024</b>	07/11/2024	
	<b>Primary Reviewer 3 COI signed</b>	<b>03/04/2024</b>	07/11/2024	
	<b>Primary (Advocate) Reviewer 4 COI signed</b>	<b>02/27/2024</b>	07/11/2024	
	<b>Primary Reviewer 1 critique submitted</b>	<b>04/14/2024</b>	07/11/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>04/10/2024</b>	07/11/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>04/10/2024</b>	07/11/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>04/08/2024</b>	07/11/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>NONE</b>	07/11/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/11/2024	
	<b>Discussed at Peer Review Meeting</b>	<b>YES</b>	07/11/2024	
	<b>Peer Review Meeting</b>	<b>04/23/2024</b>	07/11/2024	
	<b>Post review statements signed</b>	<b>04/23/2024</b>	07/09/2024	
	<b>Third Party Observer Report</b>	<b>04/29/2024</b>	07/09/2024	
	<b>Score report delivered to CSO</b>	<b>05/09/2024</b>	07/09/2024	
	<b>Recommended for SRC review</b>	<b>YES</b>	07/11/2024	
<b>Final SRC Recommendation</b>	<b>COI indicated by SRC member</b>	<b>NONE</b>	07/11/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/11/2024	
	<b>SRC Meeting</b>	<b>07/11/2024</b>	07/16/2024	
	<b>Third Party Observer Report</b>	<b>07/17/2024</b>	07/30/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	07/11/2024	
	<b>SRC Chair Notification to PIC and OC</b>	<b>07/29/2024</b>	07/30/2024	
<b>PIC Review</b>	<b>COI indicated by PIC member</b>	<b>None</b>	08/07/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	08/07/2024	
	<b>PIC Review Meeting</b>	<b>08/07/2024</b>	08/07/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	08/07/2024	
<b>Oversight Committee Approval</b>	<b>CEO Notification to Oversight Committee</b>	<b>N/A</b>		
	<b>COI Indicated by Oversight Committee member</b>	<b>N/A</b>		
	<b>COI Recused from participation</b>	<b>N/A</b>		
	<b>Donation(s) made to CPRIT / foundation</b>	<b>N/A</b>		
	<b>Presented to CPRIT Oversight Committee</b>	<b>N/A</b>		
	<b>Award approved by Oversight Committee</b>	<b>N/A</b>		
	<b>Authority to advance funds requested</b>	<b>N/A</b>		
	<b>Advance authority approved by Oversight Committee</b>	<b>N/A</b>		



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240545**  
**Core Facility Support Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Core Facility Support Awards Request for Applications* (RFA). CPRIT received 22 applications in response to this RFA, including two withdrawn applications one of which was withdrawn after peer review but prior to the review council meeting. This application was assigned to the Clinical and Translational Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Kristen P. Doyle,  
CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
the 8<sup>th</sup> day of August, 2024,  
by KRISTEN P. DOYLE.



Sandra Reyes  
Notary Public, State of Texas



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/07/2024 01:28 PM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** Core Facilities Support Awards  
**APPLICATION ID:** RP240545  
**APPLICATION TITLE:** Renewal of CPRIT GMP Core  
**APPLICANT NAME:** Lapteva, Natalia  
**ORGANIZATION:** Baylor College of Medicine  
**PANEL NAME:** 24.2 Clinical and Translational Cancer Research-1

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	<b>RFA Approved by CSO</b>	<b>09/13/2023</b>	07/09/2024	
	<b>RFA Approved by CSO (revised)</b>	<b>01/16/2024</b>	07/09/2024	
	<b>RFA published in Texas.gov eGrants</b>	<b>09/14/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) opened</b>	<b>10/17/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) closed</b>	<b>01/18/2024</b>	07/09/2024	
	<b>Date application submitted</b>	<b>01/12/2024</b>	07/10/2024	
	<b>Method of submission</b>	<b>CARS</b>	07/10/2024	
	<b>Within receipt period</b>	<b>YES</b>	07/10/2024	
	<b>Request for extension to submit application after CARS closed</b>	<b>N/A</b>	07/10/2024	
	<b>Request for extension for late application submission accepted</b>	<b>N/A</b>	07/10/2024	
	<b>Receipt, Referral, and Assignment</b>	<b>Administrative review notification</b>	<b>N/A</b>	07/10/2024
		<b>Donation(s) made to CPRIT / foundation</b>	<b>NO</b>	07/10/2024
		<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/10/2024
<b>Applicant notified of review panel assignment</b>		<b>02/28/2024</b>	07/09/2024	
<b>Primary Reviewer 1 COI signed</b>		<b>03/04/2024</b>	07/10/2024	
<b>Primary Reviewer 2 COI signed</b>		<b>02/28/2024</b>	07/10/2024	
<b>Primary Reviewer 3 COI signed</b>		<b>02/29/2024</b>	07/10/2024	
<b>Primary (Advocate) Reviewer 4 COI signed</b>		<b>02/27/2024</b>	07/10/2024	
<b>Preliminary Evaluation</b>	<b>Primary Reviewer 1 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>N/A</b>	07/10/2024	
	<b>Preliminary Evaluation score summary sent to Chair</b>	<b>N/A</b>	07/10/2024	
	<b>Recommended for full review</b>	<b>N/A</b>	07/10/2024	
	<b>Applicant notified of outcome</b>	<b>N/A</b>	07/10/2024	
<b>Peer Review Meeting</b>	<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/10/2024	
	<b>Primary Reviewer 1 COI signed</b>	<b>03/04/2024</b>	07/10/2024	
	<b>Primary Reviewer 2 COI signed</b>	<b>02/28/2024</b>	07/10/2024	
	<b>Primary Reviewer 3 COI signed</b>	<b>02/29/2024</b>	07/10/2024	
	<b>Primary (Advocate) Reviewer 4 COI signed</b>	<b>02/27/2024</b>	07/10/2024	
	<b>Primary Reviewer 1 critique submitted</b>	<b>03/21/2024</b>	07/10/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>04/08/2024</b>	07/10/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>04/01/2024</b>	07/10/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>03/16/2024</b>	07/10/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>NONE</b>	07/10/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/10/2024	
	<b>Discussed at Peer Review Meeting</b>	<b>YES</b>	07/10/2024	
	<b>Peer Review Meeting</b>	<b>04/18/2024</b>	07/10/2024	
	<b>Post review statements signed</b>	<b>04/18/2024</b>	07/09/2024	
	<b>Third Party Observer Report</b>	<b>04/23/2024</b>	07/09/2024	
	<b>Score report delivered to CSO</b>	<b>05/09/2024</b>	07/09/2024	
	<b>Recommended for SRC review</b>	<b>YES</b>	07/10/2024	
<b>Final SRC Recommendation</b>	<b>COI indicated by SRC member</b>	<b>NONE</b>	07/12/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/12/2024	
	<b>SRC Meeting</b>	<b>07/11/2024</b>	07/16/2024	
	<b>Third Party Observer Report</b>	<b>07/17/2024</b>	07/30/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	07/12/2024	
	<b>SRC Chair Notification to PIC and OC</b>	<b>07/29/2024</b>	07/30/2024	
<b>PIC Review</b>	<b>COI indicated by PIC member</b>	<b>None</b>	08/07/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	08/07/2024	
	<b>PIC Review Meeting</b>	<b>08/07/2024</b>	08/07/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	08/07/2024	
<b>Oversight Committee Approval</b>	<b>CEO Notification to Oversight Committee</b>	<b>N/A</b>		
	<b>COI Indicated by Oversight Committee member</b>	<b>N/A</b>		
	<b>COI Recused from participation</b>	<b>N/A</b>		
	<b>Donation(s) made to CPRIT / foundation</b>	<b>N/A</b>		
	<b>Presented to CPRIT Oversight Committee</b>	<b>N/A</b>		
	<b>Award approved by Oversight Committee</b>	<b>N/A</b>		
	<b>Authority to advance funds requested</b>	<b>N/A</b>		
	<b>Advance authority approved by Oversight Committee</b>	<b>N/A</b>		



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240559**  
**Core Facility Support Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Core Facility Support Awards* Request for Applications (RFA). CPRIT received 22 applications in response to this RFA, including two withdrawn applications one of which was withdrawn after peer review but prior to the review council meeting. This application was assigned to the Imaging Technology and Informatics panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.

This statement is true."




Kristen P. Doyle,  
CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
the 8<sup>th</sup> day of August, 2024,  
by KRISTEN P. DOYLE.



Sandra Reyes  
Notary Public, State of Texas



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/07/2024 01:29 PM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** Core Facilities Support Awards  
**APPLICATION ID:** RP240559  
**APPLICATION TITLE:** High Performance Mass Spectrometry Imaging Core Facility  
**APPLICANT NAME:** Brodbelt, Jennifer S  
**ORGANIZATION:** The University of Texas at Austin  
**PANEL NAME:** 24.2 Imaging Technology and Informatics

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	<b>RFA Approved by CSO</b>	<b>09/13/2023</b>	07/09/2024	
	<b>RFA Approved by CSO (revised)</b>	<b>01/16/2024</b>	07/09/2024	
	<b>RFA published in Texas.gov eGrants</b>	<b>09/14/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) opened</b>	<b>10/17/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) closed</b>	<b>01/18/2024</b>	07/09/2024	
	<b>Date application submitted</b>	<b>01/12/2024</b>	07/12/2024	
	<b>Method of submission</b>	<b>CARS</b>	07/12/2024	
	<b>Within receipt period</b>	<b>YES</b>	07/12/2024	
	<b>Request for extension to submit application after CARS closed</b>	<b>N/A</b>	07/12/2024	
	<b>Request for extension for late application submission accepted</b>	<b>N/A</b>	07/12/2024	
	<b>Receipt, Referral, and Assignment</b>	<b>Administrative review notification</b>	<b>N/A</b>	07/12/2024
		<b>Donation(s) made to CPRIT / foundation</b>	<b>NO</b>	07/12/2024
<b>Assigned to primary reviewers</b>		<b>03/12/2024</b>	07/12/2024	
<b>Applicant notified of review panel assignment</b>		<b>02/28/2024</b>	07/09/2024	
<b>Primary Reviewer 1 COI signed</b>		<b>02/27/2024</b>	07/12/2024	
<b>Primary Reviewer 2 COI signed</b>		<b>02/27/2024</b>	07/12/2024	
<b>Primary Reviewer 3 COI signed</b>		<b>03/04/2024</b>	07/12/2024	
<b>Primary (Advocate) Reviewer 4 COI signed</b>		<b>02/27/2024</b>	07/12/2024	
<b>Preliminary Evaluation</b>	<b>Primary Reviewer 1 critique submitted</b>	<b>N/A</b>	07/12/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>N/A</b>	07/12/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>N/A</b>	07/12/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>N/A</b>	07/12/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>N/A</b>	07/12/2024	
	<b>Preliminary Evaluation score summary sent to Chair</b>	<b>N/A</b>	07/12/2024	
	<b>Recommended for full review</b>	<b>N/A</b>	07/12/2024	
	<b>Applicant notified of outcome</b>	<b>N/A</b>	07/12/2024	
<b>Peer Review Meeting</b>	<b>Assigned to primary reviewers</b>	<b>03/12/2024</b>	07/12/2024	
	<b>Primary Reviewer 1 COI signed</b>	<b>02/27/2024</b>	07/12/2024	
	<b>Primary Reviewer 2 COI signed</b>	<b>02/27/2024</b>	07/12/2024	
	<b>Primary Reviewer 3 COI signed</b>	<b>03/04/2024</b>	07/12/2024	
	<b>Primary (Advocate) Reviewer 4 COI signed</b>	<b>02/27/2024</b>	07/12/2024	
	<b>Primary Reviewer 1 critique submitted</b>	<b>04/08/2024</b>	07/12/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>04/10/2024</b>	07/12/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>04/14/2024</b>	07/12/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>04/08/2024</b>	07/12/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>NONE</b>	07/12/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/12/2024	
	<b>Discussed at Peer Review Meeting</b>	<b>YES</b>	07/12/2024	
	<b>Peer Review Meeting</b>	<b>04/23/2024</b>	07/12/2024	
	<b>Post review statements signed</b>	<b>04/23/2024</b>	07/09/2024	
	<b>Third Party Observer Report</b>	<b>04/29/2024</b>	07/09/2024	
	<b>Score report delivered to CSO</b>	<b>05/09/2024</b>	07/09/2024	
	<b>Recommended for SRC review</b>	<b>YES</b>	07/12/2024	
	<b>Final SRC Recommendation</b>	<b>COI indicated by SRC member</b>	<b>NONE</b>	07/12/2024
<b>COI recused from participation</b>		<b>N/A</b>	07/12/2024	
<b>SRC Meeting</b>		<b>07/11/2024</b>	07/16/2024	
<b>Third Party Observer Report</b>		<b>07/17/2024</b>	07/30/2024	
<b>Recommended for grant award</b>		<b>YES</b>	07/12/2024	
<b>SRC Chair Notification to PIC and OC</b>		<b>07/29/2024</b>	07/30/2024	
<b>PIC Review</b>	<b>COI indicated by PIC member</b>	<b>None</b>	08/07/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	08/07/2024	
	<b>PIC Review Meeting</b>	<b>08/07/2024</b>	08/07/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	08/07/2024	
<b>Oversight Committee Approval</b>	<b>CEO Notification to Oversight Committee</b>	<b>N/A</b>		
	<b>COI Indicated by Oversight Committee member</b>	<b>N/A</b>		
	<b>COI Recused from participation</b>	<b>N/A</b>		
	<b>Donation(s) made to CPRIT / foundation</b>	<b>N/A</b>		
	<b>Presented to CPRIT Oversight Committee</b>	<b>N/A</b>		
	<b>Award approved by Oversight Committee</b>	<b>N/A</b>		
	<b>Authority to advance funds requested</b>	<b>N/A</b>		
	<b>Advance authority approved by Oversight Committee</b>	<b>N/A</b>		



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240610**  
**Core Facility Support Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Core Facility Support Awards* Request for Applications (RFA). CPRIT received 22 applications in response to this RFA, including two withdrawn applications one of which was withdrawn after peer review but prior to the review council meeting. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle




- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."

  
\_\_\_\_\_  
Kristen P. Doyle,  
CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
the 8<sup>th</sup> day of August, 2024,  
by KRISTEN P. DOYLE.

  
\_\_\_\_\_  
Sandra Reyes  
Notary Public, State of Texas



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/07/2024 01:29 PM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** Core Facilities Support Awards  
**APPLICATION ID:** RP240610  
**APPLICATION TITLE:** UTHealth Cancer Genomics Core (UTHealth CGC)  
**APPLICANT NAME:** Zhao, Zhongming  
**ORGANIZATION:** The University of Texas Health Science Center at Houston  
**PANEL NAME:** 24.2 Cancer Biology

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	<b>RFA Approved by CSO</b>	<b>09/13/2023</b>	07/09/2024	
	<b>RFA Approved by CSO (revised)</b>	<b>01/16/2024</b>	07/09/2024	
	<b>RFA published in Texas.gov eGrants</b>	<b>09/14/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) opened</b>	<b>10/17/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) closed</b>	<b>01/18/2024</b>	07/09/2024	
	<b>Date application submitted</b>	<b>01/17/2024</b>	07/09/2024	
	<b>Method of submission</b>	<b>CARS</b>	07/09/2024	
	<b>Within receipt period</b>	<b>YES</b>	07/09/2024	
	<b>Request for extension to submit application after CARS closed</b>	<b>N/A</b>	07/09/2024	
	<b>Request for extension for late application submission accepted</b>	<b>N/A</b>	07/09/2024	
	<b>Receipt, Referral, and Assignment</b>	<b>Administrative review notification</b>	<b>N/A</b>	07/09/2024
		<b>Donation(s) made to CPRIT / foundation</b>	<b>NO</b>	07/09/2024
<b>Assigned to primary reviewers</b>		<b>03/11/2024</b>	07/09/2024	
<b>Applicant notified of review panel assignment</b>		<b>02/28/2024</b>	07/09/2024	
<b>Primary Reviewer 1 COI signed</b>		<b>02/27/2024</b>	07/09/2024	
<b>Primary Reviewer 2 COI signed</b>		<b>03/07/2024</b>	07/09/2024	
<b>Primary Reviewer 3 COI signed</b>		<b>02/27/2024</b>	07/09/2024	
<b>Primary (Advocate) Reviewer 4 COI signed</b>		<b>03/05/2024</b>	07/09/2024	
<b>Preliminary Evaluation</b>	<b>Primary Reviewer 1 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>N/A</b>	07/09/2024	
	<b>Preliminary Evaluation score summary sent to Chair</b>	<b>N/A</b>	07/09/2024	
	<b>Recommended for full review</b>	<b>N/A</b>	07/09/2024	
	<b>Applicant notified of outcome</b>	<b>N/A</b>	07/09/2024	
<b>Peer Review Meeting</b>	<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/09/2024	
	<b>Primary Reviewer 1 COI signed</b>	<b>02/27/2024</b>	07/09/2024	
	<b>Primary Reviewer 2 COI signed</b>	<b>03/07/2024</b>	07/09/2024	
	<b>Primary Reviewer 3 COI signed</b>	<b>02/27/2024</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 COI signed</b>	<b>03/05/2024</b>	07/09/2024	
	<b>Primary Reviewer 1 critique submitted</b>	<b>04/10/2024</b>	07/09/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>04/11/2024</b>	07/09/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>04/03/2024</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>04/11/2024</b>	07/09/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>NONE</b>	07/09/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/09/2024	
	<b>Discussed at Peer Review Meeting</b>	<b>YES</b>	07/09/2024	
	<b>Peer Review Meeting</b>	<b>04/24/2024</b>	07/09/2024	
	<b>Post review statements signed</b>	<b>04/29/2024</b>	07/09/2024	
	<b>Third Party Observer Report</b>	<b>04/29/2024</b>	07/09/2024	
	<b>Score report delivered to CSO</b>	<b>05/09/2024</b>	07/09/2024	
	<b>Recommended for SRC review</b>	<b>YES</b>	07/09/2024	
	<b>Final SRC Recommendation</b>	<b>COI indicated by SRC member</b>	<b>NONE</b>	07/12/2024
<b>COI recused from participation</b>		<b>N/A</b>	07/12/2024	
<b>SRC Meeting</b>		<b>07/11/2024</b>	07/16/2024	
<b>Third Party Observer Report</b>		<b>07/17/2024</b>	07/30/2024	
<b>Recommended for grant award</b>		<b>YES</b>	07/12/2024	
<b>SRC Chair Notification to PIC and OC</b>		<b>07/29/2024</b>	07/30/2024	
<b>PIC Review</b>	<b>COI indicated by PIC member</b>	<b>None</b>	08/07/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	08/07/2024	
	<b>PIC Review Meeting</b>	<b>08/07/2024</b>	08/07/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	08/07/2024	
<b>Oversight Committee Approval</b>	<b>CEO Notification to Oversight Committee</b>	<b>N/A</b>		
	<b>COI Indicated by Oversight Committee member</b>	<b>N/A</b>		
	<b>COI Recused from participation</b>	<b>N/A</b>		
	<b>Donation(s) made to CPRIT / foundation</b>	<b>N/A</b>		
	<b>Presented to CPRIT Oversight Committee</b>	<b>N/A</b>		
	<b>Award approved by Oversight Committee</b>	<b>N/A</b>		
	<b>Authority to advance funds requested</b>	<b>N/A</b>		
	<b>Advance authority approved by Oversight Committee</b>	<b>N/A</b>		



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240557**  
**Clinical Investigator Award**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Clinical Investigator Award Request for Applications* (RFA). CPRIT received six applications in response to this RFA. This application was assigned to the Clinical and Translational Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."

  
\_\_\_\_\_  
Kristen P. Doyle,  
CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
the 8<sup>th</sup> day of August, 2024,  
by KRISTEN P. DOYLE.

  
\_\_\_\_\_  
Sandra Reyes  
Notary Public, State of Texas



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/07/2024 01:29 PM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** Clinical Investigator Award  
**APPLICATION ID:** RP240557  
**APPLICATION TITLE:** Dietary intervention to modulate the microbiome and immune response  
**APPLICANT NAME:** McQuade, Jennifer  
**ORGANIZATION:** The University of Texas M. D. Anderson Cancer Center  
**PANEL NAME:** 24.2 Clinical and Translational Cancer Research-1

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	RFA Approved by CSO	09/13/2023	07/09/2024	
	RFA Approved by CSO (revised)	10/17/2023	07/09/2024	
	RFA Approved by CSO (2nd revision)	01/16/2024	07/09/2024	
	RFA published in Texas.gov eGrants	09/14/2023	07/09/2024	
	CPRIT Application Receipt System (CARS) opened	10/17/2023	07/09/2024	
	CPRIT Application Receipt System (CARS) closed	01/18/2024	07/09/2024	
	Date application submitted	01/12/2024	07/10/2024	
	Method of submission	CARS	07/10/2024	
	Within receipt period	YES	07/10/2024	
	Request for extension to submit application after CARS closed	N/A	07/10/2024	
<b>Receipt, Referral, and Assignment</b>	Request for extension for late application submission accepted	N/A	07/10/2024	
	Administrative review notification	N/A	07/10/2024	
	Donation(s) made to CPRIT / foundation	NO	07/10/2024	
	Assigned to primary reviewers	03/11/2024	07/10/2024	
	Applicant notified of review panel assignment	02/28/2024	07/09/2024	
	Primary Reviewer 1 COI signed	03/04/2024	07/10/2024	
	Primary Reviewer 2 COI signed	03/04/2024	07/10/2024	
	Primary Reviewer 3 COI signed	02/28/2024	07/10/2024	
	Primary (Advocate) Reviewer 4 COI signed	02/27/2024	07/10/2024	
	<b>Preliminary Evaluation</b>	Primary Reviewer 1 critique submitted	N/A	07/10/2024
Primary Reviewer 2 critique submitted		N/A	07/10/2024	
Primary Reviewer 3 critique submitted		N/A	07/10/2024	
Primary (Advocate) Reviewer 4 critique submitted		N/A	07/10/2024	
COI indicated by non-primary reviewer		N/A	07/10/2024	
Preliminary Evaluation score summary sent to Chair		N/A	07/10/2024	
Recommended for full review		N/A	07/10/2024	
Applicant notified of outcome		N/A	07/10/2024	
<b>Peer Review Meeting</b>		Assigned to primary reviewers	03/11/2024	07/10/2024
		Primary Reviewer 1 COI signed	03/04/2024	07/10/2024
	Primary Reviewer 2 COI signed	03/04/2024	07/10/2024	
	Primary Reviewer 3 COI signed	02/28/2024	07/10/2024	
	Primary (Advocate) Reviewer 4 COI signed	02/27/2024	07/10/2024	
	Primary Reviewer 1 critique submitted	04/07/2024	07/10/2024	
	Primary Reviewer 2 critique submitted	03/21/2024	07/10/2024	
	Primary Reviewer 3 critique submitted	04/08/2024	07/10/2024	
	Primary (Advocate) Reviewer 4 critique submitted	03/16/2024	07/10/2024	
	COI indicated by non-primary reviewer	NONE	07/10/2024	
	COI recused from participation	N/A	07/10/2024	
	Discussed at Peer Review Meeting	YES	07/10/2024	
	Peer Review Meeting	04/18/2024	07/10/2024	
	Post review statements signed	04/18/2024	07/09/2024	
	Third Party Observer Report	04/23/2024	07/09/2024	
	Score report delivered to CSO	05/09/2024	07/09/2024	
	Recommended for SRC review	YES	07/10/2024	
	<b>Final SRC Recommendation</b>	COI indicated by SRC member	NONE	07/12/2024
COI recused from participation		N/A	07/12/2024	
SRC Meeting		07/11/2024	07/16/2024	
Third Party Observer Report		07/17/2024	07/30/2024	
Recommended for grant award		YES	07/12/2024	
SRC Chair Notification to PIC and OC		07/29/2024	07/30/2024	
<b>PIC Review</b>	COI indicated by PIC member	none	08/07/2024	
	COI recused from participation	N/A	08/07/2024	
	PIC Review Meeting	08/07/2024	08/07/2024	
	Recommended for grant award	YES	08/07/2024	
<b>Oversight Committee Approval</b>	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240518**  
**Clinical Investigator Award**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Clinical Investigator Award* Request for Applications (RFA). CPRIT received six applications in response to this RFA. This application was assigned to the Clinical and Translational Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."

  
 \_\_\_\_\_  
 Kristen P. Doyle,  
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
 the 8<sup>th</sup> day of August, 2024,  
 by KRISTEN P. DOYLE.

  
 \_\_\_\_\_  
 Sandra Reyes  
 Notary Public, State of Texas



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/07/2024 01:28 PM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** Clinical Investigator Award  
**APPLICATION ID:** RP240518  
**APPLICATION TITLE:** Adapting radiotherapy clinical trials to treatment response and artificial intelligence innovations  
**APPLICANT NAME:** Desai, Neil  
**ORGANIZATION:** The University of Texas Southwestern Medical Center  
**PANEL NAME:** 24.2 Clinical and Translational Cancer Research-1

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	RFA Approved by CSO	09/13/2023	07/09/2024	
	RFA Approved by CSO (revised)	10/17/2023	07/09/2024	
	RFA Approved by CSO (2nd revision)	01/16/2024	07/09/2024	
	RFA published in Texas.gov eGrants	09/14/2023	07/09/2024	
	CPRIT Application Receipt System (CARS) opened	10/17/2023	07/09/2024	
	CPRIT Application Receipt System (CARS) closed	01/18/2024	07/09/2024	
	Date application submitted	01/15/2024	07/10/2024	
	Method of submission	CARS	07/10/2024	
	Within receipt period	YES	07/10/2024	
	Request for extension to submit application after CARS closed	N/A	07/10/2024	
<b>Receipt, Referral, and Assignment</b>	Request for extension for late application submission accepted	N/A	07/10/2024	
	Administrative review notification	N/A	07/10/2024	
	Donation(s) made to CPRIT / foundation	NO	07/10/2024	
	Assigned to primary reviewers	03/11/2024	07/10/2024	
	Applicant notified of review panel assignment	02/28/2024	07/09/2024	
	Primary Reviewer 1 COI signed	03/06/2024	07/10/2024	
	Primary Reviewer 2 COI signed	03/03/2024	07/10/2024	
	Primary Reviewer 3 COI signed	02/28/2024	07/10/2024	
	Primary (Advocate) Reviewer 4 COI signed	02/27/2024	07/10/2024	
	<b>Preliminary Evaluation</b>	Primary Reviewer 1 critique submitted	N/A	07/10/2024
Primary Reviewer 2 critique submitted		N/A	07/10/2024	
Primary Reviewer 3 critique submitted		N/A	07/10/2024	
Primary (Advocate) Reviewer 4 critique submitted		N/A	07/10/2024	
COI indicated by non-primary reviewer		N/A	07/10/2024	
Preliminary Evaluation score summary sent to Chair		N/A	07/10/2024	
Recommended for full review		N/A	07/10/2024	
Applicant notified of outcome		N/A	07/10/2024	
<b>Peer Review Meeting</b>		Assigned to primary reviewers	03/11/2024	07/10/2024
		Primary Reviewer 1 COI signed	03/06/2024	07/10/2024
	Primary Reviewer 2 COI signed	03/03/2024	07/10/2024	
	Primary Reviewer 3 COI signed	02/28/2024	07/10/2024	
	Primary (Advocate) Reviewer 4 COI signed	02/27/2024	07/10/2024	
	Primary Reviewer 1 critique submitted	03/30/2024	07/10/2024	
	Primary Reviewer 2 critique submitted	04/07/2024	07/10/2024	
	Primary Reviewer 3 critique submitted	03/31/2024	07/10/2024	
	Primary (Advocate) Reviewer 4 critique submitted	03/16/2024	07/10/2024	
	COI indicated by non-primary reviewer	NONE	07/10/2024	
	COI recused from participation	N/A	07/10/2024	
	Discussed at Peer Review Meeting	YES	07/10/2024	
	Peer Review Meeting	04/18/2024	07/10/2024	
	Post review statements signed	04/18/2024	07/09/2024	
	Third Party Observer Report	04/23/2024	07/09/2024	
	Score report delivered to CSO	05/09/2024	07/09/2024	
	Recommended for SRC review	YES	07/10/2024	
	<b>Final SRC Recommendation</b>	COI indicated by SRC member	NONE	07/12/2024
COI recused from participation		N/A	07/12/2024	
SRC Meeting		07/11/2024	07/16/2024	
Third Party Observer Report		07/17/2024	07/30/2024	
Recommended for grant award		YES	07/12/2024	
SRC Chair Notification to PIC and OC		07/29/2024	07/30/2024	
<b>PIC Review</b>	COI indicated by PIC member	none	08/07/2024	
	COI recused from participation	N/A	08/07/2024	
	PIC Review Meeting	08/07/2024	08/07/2024	
	Recommended for grant award	YES	08/07/2024	
<b>Oversight Committee Approval</b>	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		





---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240478**  
**Clinical Investigator Award**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Clinical Investigator Award Request for Applications* (RFA). CPRIT received six applications in response to this RFA. This application was assigned to the Clinical and Translational Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."

  
\_\_\_\_\_  
Kristen P. Doyle,  
CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
the 8<sup>th</sup> day of August, 2024,  
by KRISTEN P. DOYLE.

  
\_\_\_\_\_  
Sandra Reyes  
Notary Public, State of Texas



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/07/2024 03:35 PM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** Clinical Investigator Award  
**APPLICATION ID:** RP240478  
**APPLICATION TITLE:** Advancing immunotherapy for high-risk cancers in children and adolescents  
**APPLICANT NAME:** Hegde, Meenakshi  
**ORGANIZATION:** Baylor College of Medicine  
**PANEL NAME:** 24.2 Clinical and Translational Cancer Research-2

Category	Compliance Requirement	Information	Attestation Date
<b>Pre-Receipt</b>	RFA Approved by CSO	09/13/2023	07/09/2024
	RFA Approved by CSO (revised)	10/17/2023	07/09/2024
	RFA Approved by CSO (2nd revision)	01/16/2024	07/09/2024
	RFA published in Texas.gov eGrants	09/14/2023	07/09/2024
	CPRIT Application Receipt System (CARS) opened	10/17/2023	07/09/2024
	CPRIT Application Receipt System (CARS) closed	01/18/2024	07/09/2024
	Date application submitted	01/17/2024	07/10/2024
	Method of submission	CARS	07/10/2024
	Within receipt period	YES	07/10/2024
	Request for extension to submit application after CARS closed	N/A	07/10/2024
Request for extension for late application submission accepted	N/A	07/10/2024	
<b>Receipt, Referral, and Assignment</b>	Administrative review notification	N/A	07/10/2024
	Donation(s) made to CPRIT / foundation	NO	07/10/2024
	Assigned to primary reviewers	03/11/2024	07/10/2024
	Applicant notified of review panel assignment	02/28/2024	07/09/2024
	Primary Reviewer 1 COI signed	03/04/2024	07/10/2024
	Primary Reviewer 2 COI signed	03/07/2024	07/10/2024
	Primary Reviewer 3 COI signed	03/18/2024	07/10/2024
	Primary (Advocate) Reviewer 4 COI signed	03/01/2024	07/10/2024
<b>Preliminary Evaluation</b>	Primary Reviewer 1 critique submitted	N/A	07/10/2024
	Primary Reviewer 2 critique submitted	N/A	07/10/2024
	Primary Reviewer 3 critique submitted	N/A	07/10/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024
	COI indicated by non-primary reviewer	N/A	07/10/2024
	Preliminary Evaluation score summary sent to Chair	N/A	07/10/2024
	Recommended for full review	N/A	07/10/2024
	Applicant notified of outcome	N/A	07/10/2024
<b>Peer Review Meeting</b>	Assigned to primary reviewers	03/11/2024	07/10/2024
	Primary Reviewer 1 COI signed	03/04/2024	07/10/2024
	Primary Reviewer 2 COI signed	03/07/2024	07/10/2024
	Primary Reviewer 3 COI signed	03/18/2024	07/10/2024
	Primary (Advocate) Reviewer 4 COI signed	03/01/2024	07/10/2024
	Primary Reviewer 1 critique submitted	04/07/2024	07/10/2024
	Primary Reviewer 2 critique submitted	04/11/2024	07/10/2024
	Primary Reviewer 3 critique submitted	04/11/2024	07/10/2024
	Primary (Advocate) Reviewer 4 critique submitted	03/22/2024	07/10/2024
	COI indicated by non-primary reviewer	NONE	07/10/2024
	COI recused from participation	N/A	07/10/2024
	Discussed at Peer Review Meeting	YES	07/10/2024
	Peer Review Meeting	04/25/2024	07/10/2024
	Post review statements signed	04/26/2024	07/09/2024
	Third Party Observer Report	04/29/2024	07/09/2024
Score report delivered to CSO	05/09/2024	07/09/2024	
Recommended for SRC review	YES	07/10/2024	
<b>Final SRC Recommendation</b>	COI indicated by SRC member	NONE	07/12/2024
	COI recused from participation	N/A	07/12/2024
	SRC Meeting	07/11/2024	07/16/2024
	Third Party Observer Report	07/17/2024	07/30/2024
	Recommended for grant award	YES	07/12/2024
	SRC Chair Notification to PIC and OC	07/29/2024	07/30/2024
<b>PIC Review</b>	COI indicated by PIC member	none	08/07/2024
	COI recused from participation	N/A	08/07/2024
	PIC Review Meeting	08/07/2024	08/07/2024
	Recommended for grant award	YES	08/07/2024
<b>Oversight Committee Approval</b>	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
	Advance authority approved by Oversight Committee	N/A	



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240473**  
**Clinical Investigator Award**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Clinical Investigator Award Request for Applications* (RFA). CPRIT received six applications in response to this RFA. This application was assigned to the Clinical and Translational Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."

  
\_\_\_\_\_  
Kristen P. Doyle,  
CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
the 8<sup>th</sup> day of August, 2024,  
by KRISTEN P. DOYLE.

  
\_\_\_\_\_  
Sandra Reyes  
Notary Public, State of Texas



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/07/2024 01:28 PM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** Clinical Investigator Award  
**APPLICATION ID:** RP240473  
**APPLICATION TITLE:** Signal-Augmented Cancer Cell Therapies: Integrating Advanced Correlatory Studies and Mentorship  
**APPLICANT NAME:** Omer, Bilal  
**ORGANIZATION:** Baylor College of Medicine  
**PANEL NAME:** 24.2 Clinical and Translational Cancer Research-2

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	09/13/2023	07/09/2024	
	RFA Approved by CSO (revised)	10/17/2023	07/09/2024	
	RFA Approved by CSO (2nd revision)	01/16/2024	07/09/2024	
	RFA published in Texas.gov eGrants	09/14/2023	07/09/2024	
	CPRIT Application Receipt System (CARS) opened	10/17/2023	07/09/2024	
	CPRIT Application Receipt System (CARS) closed	01/18/2024	07/09/2024	
	Date application submitted	01/16/2024	07/10/2024	
	Method of submission	CARS	07/10/2024	
	Within receipt period	YES	07/10/2024	
	Request for extension to submit application after CARS closed	N/A	07/10/2024	
	Request for extension for late application submission accepted	N/A	07/10/2024	
	Receipt, Referral, and Assignment	Administrative review notification	02/19/2024	07/10/2024
		Donation(s) made to CPRIT / foundation	NO	07/10/2024
Assigned to primary reviewers		03/11/2024	07/10/2024	
Applicant notified of review panel assignment		02/28/2024	07/09/2024	
Primary Reviewer 1 COI signed		02/28/2024	07/10/2024	
Primary Reviewer 2 COI signed		03/04/2024	07/10/2024	
Primary Reviewer 3 COI signed		03/02/2024	07/10/2024	
Primary (Advocate) Reviewer 4 COI signed		02/27/2024	07/10/2024	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/10/2024	
	Primary Reviewer 2 critique submitted	N/A	07/10/2024	
	Primary Reviewer 3 critique submitted	N/A	07/10/2024	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024	
	COI indicated by non-primary reviewer	N/A	07/10/2024	
	Preliminary Evaluation score summary sent to Chair	N/A	07/10/2024	
	Recommended for full review	N/A	07/10/2024	
	Applicant notified of outcome	N/A	07/10/2024	
Peer Review Meeting	Assigned to primary reviewers	03/11/2024	07/10/2024	
	Primary Reviewer 1 COI signed	02/28/2024	07/10/2024	
	Primary Reviewer 2 COI signed	03/04/2024	07/10/2024	
	Primary Reviewer 3 COI signed	03/02/2024	07/10/2024	
	Primary (Advocate) Reviewer 4 COI signed	02/27/2024	07/10/2024	
	Primary Reviewer 1 critique submitted	04/09/2024	07/10/2024	
	Primary Reviewer 2 critique submitted	04/12/2024	07/10/2024	
	Primary Reviewer 3 critique submitted	03/25/2024	07/10/2024	
	Primary (Advocate) Reviewer 4 critique submitted	03/14/2024	07/10/2024	
	COI indicated by non-primary reviewer	NONE	07/10/2024	
	COI recused from participation	N/A	07/10/2024	
	Discussed at Peer Review Meeting	YES	07/10/2024	
	Peer Review Meeting	04/25/2024	07/10/2024	
	Post review statements signed	04/26/2024	07/09/2024	
	Third Party Observer Report	04/29/2024	07/09/2024	
Score report delivered to CSO	05/09/2024	07/09/2024		
Recommended for SRC review	YES	07/10/2024		
Final SRC Recommendation	COI indicated by SRC member	NONE	07/12/2024	
	COI recused from participation	N/A	07/12/2024	
	SRC Meeting	07/11/2024	07/16/2024	
	Third Party Observer Report	07/17/2024	07/30/2024	
	Recommended for grant award	YES	07/12/2024	
	SRC Chair Notification to PIC and OC	07/29/2024	07/30/2024	
PIC Review	COI indicated by PIC member	none	08/07/2024	
	COI recused from participation	N/A	08/07/2024	
	PIC Review Meeting	08/07/2024	08/07/2024	
	Recommended for grant award	YES	08/07/2024	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240442**  
**Clinical Investigator Award**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Clinical Investigator Award Request for Applications* (RFA). CPRIT received six applications in response to this RFA. This application was assigned to the Clinical and Translational Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."

  
\_\_\_\_\_  
Kristen P. Doyle,  
CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
the 8<sup>th</sup> day of August, 2024,  
by KRISTEN P. DOYLE.

  
\_\_\_\_\_  
Sandra Reyes  
Notary Public, State of Texas





# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/07/2024 03:35 PM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** Clinical Investigator Award  
**APPLICATION ID:** RP240442  
**APPLICATION TITLE:** Identifying and exploiting novel metabolic vulnerabilities in the treatment of kidney cancer  
**APPLICANT NAME:** Courtney, Kevin  
**ORGANIZATION:** The University of Texas Southwestern Medical Center  
**PANEL NAME:** 24.2 Clinical and Translational Cancer Research-1

Category	Compliance Requirement	Information	Attestation Date
<b>Pre-Receipt</b>	RFA Approved by CSO	09/13/2023	07/09/2024
	RFA Approved by CSO (revised)	10/17/2023	07/09/2024
	RFA Approved by CSO (2nd revision)	01/16/2024	07/09/2024
	RFA published in Texas.gov eGrants	09/14/2023	07/09/2024
	CPRIT Application Receipt System (CARS) opened	10/17/2023	07/09/2024
	CPRIT Application Receipt System (CARS) closed	01/18/2024	07/09/2024
	Date application submitted	01/16/2024	07/10/2024
	Method of submission	CARS	07/10/2024
	Within receipt period	YES	07/10/2024
	Request for extension to submit application after CARS closed	N/A	07/10/2024
Request for extension for late application submission accepted	N/A	07/10/2024	
<b>Receipt, Referral, and Assignment</b>	Administrative review notification	N/A	07/10/2024
	Donation(s) made to CPRIT / foundation	NO	07/10/2024
	Assigned to primary reviewers	03/11/2024	07/10/2024
	Applicant notified of review panel assignment	02/28/2024	07/09/2024
	Primary Reviewer 1 COI signed	03/02/2024	07/10/2024
	Primary Reviewer 2 COI signed	03/02/2024	07/10/2024
	Primary Reviewer 3 COI signed	02/27/2024	07/10/2024
	Primary (Advocate) Reviewer 4 COI signed	02/27/2024	07/10/2024
<b>Preliminary Evaluation</b>	Primary Reviewer 1 critique submitted	N/A	07/10/2024
	Primary Reviewer 2 critique submitted	N/A	07/10/2024
	Primary Reviewer 3 critique submitted	N/A	07/10/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024
	COI indicated by non-primary reviewer	N/A	07/10/2024
	Preliminary Evaluation score summary sent to Chair	N/A	07/10/2024
	Recommended for full review	N/A	07/10/2024
	Applicant notified of outcome	N/A	07/10/2024
<b>Peer Review Meeting</b>	Assigned to primary reviewers	03/11/2024	07/10/2024
	Primary Reviewer 1 COI signed	03/02/2024	07/10/2024
	Primary Reviewer 2 COI signed	03/02/2024	07/10/2024
	Primary Reviewer 3 COI signed	02/27/2024	07/10/2024
	Primary (Advocate) Reviewer 4 COI signed	02/27/2024	07/10/2024
	Primary Reviewer 1 critique submitted	04/02/2024	07/10/2024
	Primary Reviewer 2 critique submitted	04/06/2024	07/10/2024
	Primary Reviewer 3 critique submitted	03/30/2024	07/10/2024
	Primary (Advocate) Reviewer 4 critique submitted	03/13/2024	07/10/2024
	COI indicated by non-primary reviewer	NONE	07/10/2024
	COI recused from participation	N/A	07/10/2024
	Discussed at Peer Review Meeting	YES	07/10/2024
	Peer Review Meeting	04/18/2024	07/10/2024
	Post review statements signed	04/18/2024	07/09/2024
	Third Party Observer Report	04/23/2024	07/09/2024
Score report delivered to CSO	05/09/2024	07/09/2024	
Recommended for SRC review	YES	07/10/2024	
<b>Final SRC Recommendation</b>	COI indicated by SRC member	NONE	07/12/2024
	COI recused from participation	N/A	07/12/2024
	SRC Meeting	07/11/2024	07/16/2024
	Third Party Observer Report	07/17/2024	07/30/2024
	Recommended for grant award	YES	07/12/2024
SRC Chair Notification to PIC and OC	07/29/2024	07/30/2024	
<b>PIC Review</b>	COI indicated by PIC member	none	08/07/2024
	COI recused from participation	N/A	08/07/2024
	PIC Review Meeting	08/07/2024	08/07/2024
	Recommended for grant award	YES	08/07/2024
<b>Oversight Committee Approval</b>	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240441**  
**Clinical Investigator Award**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Clinical Investigator Award Request for Applications* (RFA). CPRIT received six applications in response to this RFA. This application was assigned to the Clinical and Translational Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."

  
\_\_\_\_\_  
Kristen P. Doyle,  
CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
the 8<sup>th</sup> day of August, 2024,  
by KRISTEN P. DOYLE.

  
\_\_\_\_\_  
Sandra Reyes  
Notary Public, State of Texas



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/07/2024 03:34 PM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** Clinical Investigator Award  
**APPLICATION ID:** RP240441  
**APPLICATION TITLE:** Precision Lung Cancer Interception by Targeting High-Risk Lung Nodules  
**APPLICANT NAME:** Zhang, Jianjun  
**ORGANIZATION:** The University of Texas M. D. Anderson Cancer Center  
**PANEL NAME:** 24.2 Clinical and Translational Cancer Research-1

Category	Compliance Requirement	Information	Attestation Date
<b>Pre-Receipt</b>	RFA Approved by CSO	09/13/2023	07/09/2024
	RFA Approved by CSO (revised)	10/17/2023	07/09/2024
	RFA Approved by CSO (2nd revision)	01/16/2024	07/09/2024
	RFA published in Texas.gov eGrants	09/14/2023	07/09/2024
	CPRIT Application Receipt System (CARS) opened	10/17/2023	07/09/2024
	CPRIT Application Receipt System (CARS) closed	01/18/2024	07/09/2024
	Date application submitted	01/12/2024	07/10/2024
	Method of submission	CARS	07/10/2024
	Within receipt period	YES	07/10/2024
	Request for extension to submit application after CARS closed	N/A	07/10/2024
Request for extension for late application submission accepted	N/A	07/10/2024	
<b>Receipt, Referral, and Assignment</b>	Administrative review notification	N/A	07/10/2024
	Donation(s) made to CPRIT / foundation	NO	07/10/2024
	Assigned to primary reviewers	03/11/2024	07/10/2024
	Applicant notified of review panel assignment	02/28/2024	07/09/2024
	Primary Reviewer 1 COI signed	02/28/2024	07/10/2024
	Primary Reviewer 2 COI signed	02/28/2024	07/10/2024
	Primary Reviewer 3 COI signed	03/04/2024	07/10/2024
	Primary (Advocate) Reviewer 4 COI signed	02/27/2024	07/10/2024
<b>Preliminary Evaluation</b>	Primary Reviewer 1 critique submitted	N/A	07/10/2024
	Primary Reviewer 2 critique submitted	N/A	07/10/2024
	Primary Reviewer 3 critique submitted	N/A	07/10/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024
	COI indicated by non-primary reviewer	N/A	07/10/2024
	Preliminary Evaluation score summary sent to Chair	N/A	07/10/2024
	Recommended for full review	N/A	07/10/2024
	Applicant notified of outcome	N/A	07/10/2024
<b>Peer Review Meeting</b>	Assigned to primary reviewers	03/11/2024	07/10/2024
	Primary Reviewer 1 COI signed	02/28/2024	07/10/2024
	Primary Reviewer 2 COI signed	02/28/2024	07/10/2024
	Primary Reviewer 3 COI signed	03/04/2024	07/10/2024
	Primary (Advocate) Reviewer 4 COI signed	02/27/2024	07/10/2024
	Primary Reviewer 1 critique submitted	04/08/2024	07/10/2024
	Primary Reviewer 2 critique submitted	04/07/2024	07/10/2024
	Primary Reviewer 3 critique submitted	04/07/2024	07/10/2024
	Primary (Advocate) Reviewer 4 critique submitted	03/16/2024	07/10/2024
	COI indicated by non-primary reviewer	NONE	07/10/2024
	COI recused from participation	N/A	07/10/2024
	Discussed at Peer Review Meeting	YES	07/10/2024
	Peer Review Meeting	04/18/2024	07/10/2024
	Post review statements signed	04/18/2024	07/09/2024
	Third Party Observer Report	04/23/2024	07/09/2024
Score report delivered to CSO	05/09/2024	07/09/2024	
Recommended for SRC review	YES	07/10/2024	
<b>Final SRC Recommendation</b>	COI indicated by SRC member	NONE	07/12/2024
	COI recused from participation	N/A	07/12/2024
	SRC Meeting	07/11/2024	07/16/2024
	Third Party Observer Report	07/17/2024	07/30/2024
	Recommended for grant award	YES	07/12/2024
	SRC Chair Notification to PIC and OC	07/29/2024	07/30/2024
<b>PIC Review</b>	COI indicated by PIC member	none	08/07/2024
	COI recused from participation	N/A	08/07/2024
	PIC Review Meeting	08/07/2024	08/07/2024
	Recommended for grant award	YES	08/07/2024
<b>Oversight Committee Approval</b>	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
	Advance authority approved by Oversight Committee	N/A	



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240446**  
**High-Impact/High-Risk Research Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 101 applications in response to this RFA, including eight withdrawn applications. This application was assigned to the Basic Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that one application submitted in response to this RFA was not recommended for a grant award and it has a score that is the same as an application that was recommended for a grant award. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.


An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules.


This statement is true.”

  
 \_\_\_\_\_  
 Kristen P. Doyle,  
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
 the 8<sup>th</sup> day of August, 2024,  
 by KRISTEN P. DOYLE.

  
 \_\_\_\_\_  
 Sandra Reyes  
 Notary Public, State of Texas



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/07/2024 03:35 PM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** High-Impact/High-Risk Research Awards  
**APPLICATION ID:** RP240446  
**APPLICATION TITLE:** Regulation of Transcription Factor Function by Local Chromatin Context  
**APPLICANT NAME:** Soshnev, Alexey A  
**ORGANIZATION:** The University of Texas at San Antonio  
**PANEL NAME:** 24.2 Basic Cancer Research 2

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	<b>RFA Approved by CSO</b>	<b>09/13/2023</b>	07/09/2024	
	<b>RFA Approved by CSO (revised)</b>	<b>01/16/2024</b>	07/09/2024	
	<b>RFA published in Texas.gov eGrants</b>	<b>09/14/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) opened</b>	<b>10/17/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) closed</b>	<b>01/18/2024</b>	07/09/2024	
	<b>Date application submitted</b>	<b>01/16/2024</b>	07/09/2024	
	<b>Method of submission</b>	<b>CARS</b>	07/09/2024	
	<b>Within receipt period</b>	<b>YES</b>	07/09/2024	
	<b>Request for extension to submit application after CARS closed</b>	<b>N/A</b>	07/09/2024	
	<b>Request for extension for late application submission accepted</b>	<b>N/A</b>	07/09/2024	
	<b>Receipt, Referral, and Assignment</b>	<b>Administrative review notification</b>	<b>N/A</b>	07/09/2024
		<b>Donation(s) made to CPRIT / foundation</b>	<b>NO</b>	07/09/2024
		<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/09/2024
<b>Applicant notified of review panel assignment</b>		<b>02/28/2024</b>	07/09/2024	
<b>Primary Reviewer 1 COI signed</b>		<b>03/01/2024</b>	07/09/2024	
<b>Primary Reviewer 2 COI signed</b>		<b>03/05/2024</b>	07/09/2024	
<b>Primary Reviewer 3 COI signed</b>		<b>02/28/2024</b>	07/09/2024	
<b>Primary (Advocate) Reviewer 4 COI signed</b>		<b>03/04/2024</b>	07/09/2024	
<b>Preliminary Evaluation</b>	<b>Primary Reviewer 1 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>N/A</b>	07/09/2024	
	<b>Preliminary Evaluation score summary sent to Chair</b>	<b>N/A</b>	07/09/2024	
	<b>Recommended for full review</b>	<b>N/A</b>	07/09/2024	
<b>Peer Review Meeting</b>	<b>Applicant notified of outcome</b>	<b>N/A</b>	07/09/2024	
	<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/09/2024	
	<b>Primary Reviewer 1 COI signed</b>	<b>03/01/2024</b>	07/09/2024	
	<b>Primary Reviewer 2 COI signed</b>	<b>03/05/2024</b>	07/09/2024	
	<b>Primary Reviewer 3 COI signed</b>	<b>02/28/2024</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 COI signed</b>	<b>03/04/2024</b>	07/09/2024	
	<b>Primary Reviewer 1 critique submitted</b>	<b>04/04/2024</b>	07/09/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>04/09/2024</b>	07/09/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>03/28/2024</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>03/26/2024</b>	07/09/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>NONE</b>	07/09/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/09/2024	
	<b>Discussed at Peer Review Meeting</b>	<b>YES</b>	07/09/2024	
	<b>Peer Review Meeting</b>	<b>04/17/2024</b>	07/09/2024	
	<b>Post review statements signed</b>	<b>04/26/2024</b>	07/09/2024	
	<b>Third Party Observer Report</b>	<b>04/23/2024</b>	07/09/2024	
	<b>Score report delivered to CSO</b>	<b>05/09/2024</b>	07/09/2024	
	<b>Recommended for SRC review</b>	<b>YES</b>	07/09/2024	
	<b>Final SRC Recommendation</b>	<b>COI indicated by SRC member</b>	<b>NONE</b>	07/12/2024
		<b>COI recused from participation</b>	<b>N/A</b>	07/12/2024
		<b>SRC Meeting</b>	<b>07/11/2024</b>	07/16/2024
<b>Third Party Observer Report</b>		<b>07/17/2024</b>	07/30/2024	
<b>Recommended for grant award</b>		<b>YES</b>	07/12/2024	
<b>SRC Chair Notification to PIC and OC</b>		<b>07/29/2024</b>	07/30/2024	
<b>PIC Review</b>	<b>COI indicated by PIC member</b>	<b>none</b>	08/07/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	08/07/2024	
	<b>PIC Review Meeting</b>	<b>08/07/2024</b>	08/07/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	08/07/2024	
<b>Oversight Committee Approval</b>	<b>CEO Notification to Oversight Committee</b>	<b>N/A</b>		
	<b>COI Indicated by Oversight Committee member</b>	<b>N/A</b>		
	<b>COI Recused from participation</b>	<b>N/A</b>		
	<b>Donation(s) made to CPRIT / foundation</b>	<b>N/A</b>		
	<b>Presented to CPRIT Oversight Committee</b>	<b>N/A</b>		
	<b>Award approved by Oversight Committee</b>	<b>N/A</b>		
	<b>Authority to advance funds requested</b>	<b>N/A</b>		
	<b>Advance authority approved by Oversight Committee</b>	<b>N/A</b>		



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240454**  
**High-Impact/High-Risk Research Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 101 applications in response to this RFA, including eight withdrawn applications. This application was assigned to the Clinical and Translational Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle



- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that one application submitted in response to this RFA was not recommended for a grant award and it has a score that is the same as an application that was recommended for a grant award. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules.


This statement is true.”

  
 Kristen P. Doyle,  
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
 the 8<sup>th</sup> day of August, 2024,  
 by KRISTEN P. DOYLE.

  
 Sandra Reyes  
 Notary Public, State of Texas



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/07/2024 03:35 PM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** High-Impact/High-Risk Research Awards  
**APPLICATION ID:** RP240454  
**APPLICATION TITLE:** Reversing Tumor Immune Exclusion with Sphingosine-1-Phosphate Depleting Therapeutics  
**APPLICANT NAME:** Stone, Everett M  
**ORGANIZATION:** The University of Texas at Austin  
**PANEL NAME:** 24.2 Clinical and Translational Cancer Research-2

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	<b>RFA Approved by CSO</b>	<b>09/13/2023</b>	07/09/2024	
	<b>RFA Approved by CSO (revised)</b>	<b>01/16/2024</b>	07/09/2024	
	<b>RFA published in Texas.gov eGrants</b>	<b>09/14/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) opened</b>	<b>10/17/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) closed</b>	<b>01/18/2024</b>	07/09/2024	
	<b>Date application submitted</b>	<b>01/18/2024</b>	07/10/2024	
	<b>Method of submission</b>	<b>CARS</b>	07/10/2024	
	<b>Within receipt period</b>	<b>YES</b>	07/10/2024	
	<b>Request for extension to submit application after CARS closed</b>	<b>N/A</b>	07/10/2024	
	<b>Request for extension for late application submission accepted</b>	<b>N/A</b>	07/10/2024	
	<b>Receipt, Referral, and Assignment</b>	<b>Administrative review notification</b>	<b>N/A</b>	07/10/2024
		<b>Donation(s) made to CPRIT / foundation</b>	<b>NO</b>	07/10/2024
		<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/10/2024
<b>Applicant notified of review panel assignment</b>		<b>02/28/2024</b>	07/09/2024	
<b>Primary Reviewer 1 COI signed</b>		<b>02/28/2024</b>	07/10/2024	
<b>Primary Reviewer 2 COI signed</b>		<b>02/28/2024</b>	07/10/2024	
<b>Primary Reviewer 3 COI signed</b>		<b>03/01/2024</b>	07/10/2024	
<b>Primary (Advocate) Reviewer 4 COI signed</b>		<b>02/27/2024</b>	07/10/2024	
<b>Preliminary Evaluation</b>	<b>Primary Reviewer 1 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>N/A</b>	07/10/2024	
	<b>Preliminary Evaluation score summary sent to Chair</b>	<b>N/A</b>	07/10/2024	
	<b>Recommended for full review</b>	<b>N/A</b>	07/10/2024	
	<b>Applicant notified of outcome</b>	<b>N/A</b>	07/10/2024	
<b>Peer Review Meeting</b>	<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/10/2024	
	<b>Primary Reviewer 1 COI signed</b>	<b>02/28/2024</b>	07/10/2024	
	<b>Primary Reviewer 2 COI signed</b>	<b>02/28/2024</b>	07/10/2024	
	<b>Primary Reviewer 3 COI signed</b>	<b>03/01/2024</b>	07/10/2024	
	<b>Primary (Advocate) Reviewer 4 COI signed</b>	<b>02/27/2024</b>	07/10/2024	
	<b>Primary Reviewer 1 critique submitted</b>	<b>04/03/2024</b>	07/10/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>04/07/2024</b>	07/10/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>04/02/2024</b>	07/10/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>03/14/2024</b>	07/10/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>Weiping Zou</b>	07/10/2024	
	<b>COI recused from participation</b>	<b>YES</b>	07/10/2024	
	<b>Discussed at Peer Review Meeting</b>	<b>YES</b>	07/10/2024	
	<b>Peer Review Meeting</b>	<b>04/25/2024</b>	07/10/2024	
	<b>Post review statements signed</b>	<b>04/26/2024</b>	07/09/2024	
	<b>Third Party Observer Report</b>	<b>04/29/2024</b>	07/09/2024	
	<b>Score report delivered to CSO</b>	<b>05/09/2024</b>	07/09/2024	
	<b>Recommended for SRC review</b>	<b>YES</b>	07/10/2024	
<b>Final SRC Recommendation</b>	<b>COI indicated by SRC member</b>	<b>NONE</b>	07/12/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/12/2024	
	<b>SRC Meeting</b>	<b>07/11/2024</b>	07/16/2024	
	<b>Third Party Observer Report</b>	<b>07/17/2024</b>	07/30/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	07/12/2024	
	<b>SRC Chair Notification to PIC and OC</b>	<b>07/29/2024</b>	07/30/2024	
<b>PIC Review</b>	<b>COI indicated by PIC member</b>	<b>none</b>	08/07/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	08/07/2024	
	<b>PIC Review Meeting</b>	<b>08/07/2024</b>	08/07/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	08/07/2024	
<b>Oversight Committee Approval</b>	<b>CEO Notification to Oversight Committee</b>	<b>N/A</b>		
	<b>COI Indicated by Oversight Committee member</b>	<b>N/A</b>		
	<b>COI Recused from participation</b>	<b>N/A</b>		
	<b>Donation(s) made to CPRIT / foundation</b>	<b>N/A</b>		
	<b>Presented to CPRIT Oversight Committee</b>	<b>N/A</b>		
	<b>Award approved by Oversight Committee</b>	<b>N/A</b>		
	<b>Authority to advance funds requested</b>	<b>N/A</b>		
	<b>Advance authority approved by Oversight Committee</b>	<b>N/A</b>		



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240462**  
**High-Impact/High-Risk Research Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 101 applications in response to this RFA, including eight withdrawn applications. This application was assigned to the Imaging Technology and Informatics panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that one application submitted in response to this RFA was not recommended for a grant award and it has a score that is the same as an application that was recommended for a grant award. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.


An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules.


This statement is true.”

  
 \_\_\_\_\_  
 Kristen P. Doyle,  
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
 the 8<sup>th</sup> day of August, 2024,  
 by KRISTEN P. DOYLE.

  
 \_\_\_\_\_  
 Sandra Reyes  
 Notary Public, State of Texas



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/07/2024 03:35 PM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** High-Impact/High-Risk Research Awards  
**APPLICATION ID:** RP240462  
**APPLICATION TITLE:** Development of an Endoscopic Nuclear Imaging Capsule for Radio-Guided Cancer Surgery  
**APPLICANT NAME:** Zannoni, Elena Maria  
**ORGANIZATION:** The University of Texas at Austin  
**PANEL NAME:** 24.2 Imaging Technology and Informatics

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	<b>RFA Approved by CSO</b>	<b>09/13/2023</b>	07/09/2024	
	<b>RFA Approved by CSO (revised)</b>	<b>01/16/2024</b>	07/09/2024	
	<b>RFA published in Texas.gov eGrants</b>	<b>09/14/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) opened</b>	<b>10/17/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) closed</b>	<b>01/18/2024</b>	07/09/2024	
	<b>Date application submitted</b>	<b>01/18/2024</b>	07/11/2024	
	<b>Method of submission</b>	<b>CARS</b>	07/11/2024	
	<b>Within receipt period</b>	<b>YES</b>	07/11/2024	
	<b>Request for extension to submit application after CARS closed</b>	<b>N/A</b>	07/11/2024	
	<b>Request for extension for late application submission accepted</b>	<b>N/A</b>	07/11/2024	
	<b>Receipt, Referral, and Assignment</b>	<b>Administrative review notification</b>	<b>N/A</b>	07/11/2024
		<b>Donation(s) made to CPRIT / foundation</b>	<b>NO</b>	07/11/2024
		<b>Assigned to primary reviewers</b>	<b>03/12/2024</b>	07/11/2024
<b>Applicant notified of review panel assignment</b>		<b>02/28/2024</b>	07/09/2024	
<b>Primary Reviewer 1 COI signed</b>		<b>02/27/2024</b>	07/11/2024	
<b>Primary Reviewer 2 COI signed</b>		<b>02/27/2024</b>	07/11/2024	
<b>Primary Reviewer 3 COI signed</b>		<b>03/01/2024</b>	07/11/2024	
<b>Primary (Advocate) Reviewer 4 COI signed</b>		<b>02/27/2024</b>	07/11/2024	
<b>Preliminary Evaluation</b>	<b>Primary Reviewer 1 critique submitted</b>	<b>N/A</b>	07/11/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>N/A</b>	07/11/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>N/A</b>	07/11/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>N/A</b>	07/11/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>N/A</b>	07/11/2024	
	<b>Preliminary Evaluation score summary sent to Chair</b>	<b>N/A</b>	07/11/2024	
	<b>Recommended for full review</b>	<b>N/A</b>	07/11/2024	
	<b>Applicant notified of outcome</b>	<b>N/A</b>	07/11/2024	
<b>Peer Review Meeting</b>	<b>Assigned to primary reviewers</b>	<b>03/12/2024</b>	07/11/2024	
	<b>Primary Reviewer 1 COI signed</b>	<b>02/27/2024</b>	07/11/2024	
	<b>Primary Reviewer 2 COI signed</b>	<b>02/27/2024</b>	07/11/2024	
	<b>Primary Reviewer 3 COI signed</b>	<b>03/01/2024</b>	07/11/2024	
	<b>Primary (Advocate) Reviewer 4 COI signed</b>	<b>02/27/2024</b>	07/11/2024	
	<b>Primary Reviewer 1 critique submitted</b>	<b>04/11/2024</b>	07/11/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>04/06/2024</b>	07/11/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>04/20/2024</b>	07/11/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>04/04/2024</b>	07/11/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>NONE</b>	07/11/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/11/2024	
	<b>Discussed at Peer Review Meeting</b>	<b>YES</b>	07/11/2024	
	<b>Peer Review Meeting</b>	<b>04/23/2024</b>	07/11/2024	
	<b>Post review statements signed</b>	<b>04/23/2024</b>	07/09/2024	
	<b>Third Party Observer Report</b>	<b>04/29/2024</b>	07/09/2024	
	<b>Score report delivered to CSO</b>	<b>05/09/2024</b>	07/09/2024	
	<b>Recommended for SRC review</b>	<b>YES</b>	07/11/2024	
<b>Final SRC Recommendation</b>	<b>COI indicated by SRC member</b>	<b>NONE</b>	07/11/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/11/2024	
	<b>SRC Meeting</b>	<b>07/11/2024</b>	07/16/2024	
	<b>Third Party Observer Report</b>	<b>07/17/2024</b>	07/30/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	07/11/2024	
	<b>SRC Chair Notification to PIC and OC</b>	<b>07/29/2024</b>	07/30/2024	
<b>PIC Review</b>	<b>COI indicated by PIC member</b>	<b>none</b>	08/07/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	08/07/2024	
	<b>PIC Review Meeting</b>	<b>08/07/2024</b>	08/07/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	08/07/2024	
<b>Oversight Committee Approval</b>	<b>CEO Notification to Oversight Committee</b>	<b>N/A</b>		
	<b>COI Indicated by Oversight Committee member</b>	<b>N/A</b>		
	<b>COI Recused from participation</b>	<b>N/A</b>		
	<b>Donation(s) made to CPRIT / foundation</b>	<b>N/A</b>		
	<b>Presented to CPRIT Oversight Committee</b>	<b>N/A</b>		
	<b>Award approved by Oversight Committee</b>	<b>N/A</b>		
	<b>Authority to advance funds requested</b>	<b>N/A</b>		
	<b>Advance authority approved by Oversight Committee</b>	<b>N/A</b>		



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240493**  
**High-Impact/High-Risk Research Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 101 applications in response to this RFA, including eight withdrawn applications. This application was assigned to the Clinical and Translational Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that one application submitted in response to this RFA was not recommended for a grant award and it has a score that is the same as an application that was recommended for a grant award. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.


An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules.


This statement is true.”

  
 \_\_\_\_\_  
 Kristen P. Doyle,  
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
 the 8<sup>th</sup> day of August, 2024,  
 by KRISTEN P. DOYLE.

  
 \_\_\_\_\_  
 Sandra Reyes  
 Notary Public, State of Texas



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/07/2024 03:35 PM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** High-Impact/High-Risk Research Awards  
**APPLICATION ID:** RP240493  
**APPLICATION TITLE:** Engineering in vivo chimeric antigen receptor (CAR) macrophages for diffuse midline glioma  
**APPLICANT NAME:** Jiang, Wen  
**ORGANIZATION:** The University of Texas M. D. Anderson Cancer Center  
**PANEL NAME:** 24.2 Clinical and Translational Cancer Research-2

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	<b>RFA Approved by CSO</b>	<b>09/13/2023</b>	07/09/2024	
	<b>RFA Approved by CSO (revised)</b>	<b>01/16/2024</b>	07/09/2024	
	<b>RFA published in Texas.gov eGrants</b>	<b>09/14/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) opened</b>	<b>10/17/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) closed</b>	<b>01/18/2024</b>	07/09/2024	
	<b>Date application submitted</b>	<b>01/02/2024</b>	07/10/2024	
	<b>Method of submission</b>	<b>CARS</b>	07/10/2024	
	<b>Within receipt period</b>	<b>YES</b>	07/10/2024	
	<b>Request for extension to submit application after CARS closed</b>	<b>N/A</b>	07/10/2024	
	<b>Request for extension for late application submission accepted</b>	<b>N/A</b>	07/10/2024	
	<b>Receipt, Referral, and Assignment</b>	<b>Administrative review notification</b>	<b>02/19/2024</b>	07/10/2024
		<b>Donation(s) made to CPRIT / foundation</b>	<b>NO</b>	07/10/2024
		<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/10/2024
<b>Applicant notified of review panel assignment</b>		<b>02/28/2024</b>	07/09/2024	
<b>Primary Reviewer 1 COI signed</b>		<b>03/07/2024</b>	07/10/2024	
<b>Primary Reviewer 2 COI signed</b>		<b>03/18/2024</b>	07/10/2024	
<b>Primary Reviewer 3 COI signed</b>		<b>03/04/2024</b>	07/10/2024	
<b>Primary (Advocate) Reviewer 4 COI signed</b>		<b>03/01/2024</b>	07/10/2024	
<b>Preliminary Evaluation</b>	<b>Primary Reviewer 1 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>N/A</b>	07/10/2024	
	<b>Preliminary Evaluation score summary sent to Chair</b>	<b>N/A</b>	07/10/2024	
	<b>Recommended for full review</b>	<b>N/A</b>	07/10/2024	
	<b>Applicant notified of outcome</b>	<b>N/A</b>	07/10/2024	
<b>Peer Review Meeting</b>	<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/10/2024	
	<b>Primary Reviewer 1 COI signed</b>	<b>03/07/2024</b>	07/10/2024	
	<b>Primary Reviewer 2 COI signed</b>	<b>03/18/2024</b>	07/10/2024	
	<b>Primary Reviewer 3 COI signed</b>	<b>03/04/2024</b>	07/10/2024	
	<b>Primary (Advocate) Reviewer 4 COI signed</b>	<b>03/01/2024</b>	07/10/2024	
	<b>Primary Reviewer 1 critique submitted</b>	<b>04/11/2024</b>	07/10/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>04/11/2024</b>	07/10/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>04/09/2024</b>	07/10/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>04/10/2024</b>	07/10/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>NONE</b>	07/10/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/10/2024	
	<b>Discussed at Peer Review Meeting</b>	<b>YES</b>	07/10/2024	
	<b>Peer Review Meeting</b>	<b>04/25/2024</b>	07/10/2024	
	<b>Post review statements signed</b>	<b>04/26/2024</b>	07/09/2024	
	<b>Third Party Observer Report</b>	<b>04/29/2024</b>	07/09/2024	
	<b>Score report delivered to CSO</b>	<b>05/09/2024</b>	07/09/2024	
	<b>Recommended for SRC review</b>	<b>YES</b>	07/10/2024	
<b>Final SRC Recommendation</b>	<b>COI indicated by SRC member</b>	<b>NONE</b>	07/12/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/12/2024	
	<b>SRC Meeting</b>	<b>07/11/2024</b>	07/16/2024	
	<b>Third Party Observer Report</b>	<b>07/17/2024</b>	07/30/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	07/12/2024	
	<b>SRC Chair Notification to PIC and OC</b>	<b>07/29/2024</b>	07/30/2024	
<b>PIC Review</b>	<b>COI indicated by PIC member</b>	<b>none</b>	08/07/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	08/07/2024	
	<b>PIC Review Meeting</b>	<b>08/07/2024</b>	08/07/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	08/07/2024	
<b>Oversight Committee Approval</b>	<b>CEO Notification to Oversight Committee</b>	<b>N/A</b>		
	<b>COI Indicated by Oversight Committee member</b>	<b>N/A</b>		
	<b>COI Recused from participation</b>	<b>N/A</b>		
	<b>Donation(s) made to CPRIT / foundation</b>	<b>N/A</b>		
	<b>Presented to CPRIT Oversight Committee</b>	<b>N/A</b>		
	<b>Award approved by Oversight Committee</b>	<b>N/A</b>		
	<b>Authority to advance funds requested</b>	<b>N/A</b>		
	<b>Advance authority approved by Oversight Committee</b>	<b>N/A</b>		





CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240498**  
**High-Impact/High-Risk Research Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 101 applications in response to this RFA, including eight withdrawn applications. This application was assigned to the Imaging Technology and Informatics panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that one application submitted in response to this RFA was not recommended for a grant award and it has a score that is the same as an application that was recommended for a grant award. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council for grant award consideration. The panel's decision is based upon a number of factors, including the final score.


An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."

  
 Kristen P. Doyle,  
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
 the 8<sup>th</sup> day of August, 2024,  
 by KRISTEN P. DOYLE.

  
 Sandra Reyes  
 Notary Public, State of Texas



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/07/2024 03:35 PM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** High-Impact/High-Risk Research Awards  
**APPLICATION ID:** RP240498  
**APPLICATION TITLE:** Improving the management of gastric peritoneal carcinomatosis with Photo-Betabody Immunotherapy  
**APPLICANT NAME:** Obaid, Girgis  
**ORGANIZATION:** The University of Texas at Dallas  
**PANEL NAME:** 24.2 Imaging Technology and Informatics

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	<b>RFA Approved by CSO</b>	<b>09/13/2023</b>	07/09/2024	
	<b>RFA Approved by CSO (revised)</b>	<b>01/16/2024</b>	07/09/2024	
	<b>RFA published in Texas.gov eGrants</b>	<b>09/14/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) opened</b>	<b>10/17/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) closed</b>	<b>01/18/2024</b>	07/09/2024	
	<b>Date application submitted</b>	<b>01/16/2024</b>	07/11/2024	
	<b>Method of submission</b>	<b>CARS</b>	07/11/2024	
	<b>Within receipt period</b>	<b>YES</b>	07/11/2024	
	<b>Request for extension to submit application after CARS closed</b>	<b>N/A</b>	07/11/2024	
	<b>Request for extension for late application submission accepted</b>	<b>N/A</b>	07/11/2024	
	<b>Receipt, Referral, and Assignment</b>	<b>Administrative review notification</b>	<b>N/A</b>	07/11/2024
		<b>Donation(s) made to CPRIT / foundation</b>	<b>NO</b>	07/11/2024
		<b>Assigned to primary reviewers</b>	<b>03/12/2024</b>	07/11/2024
<b>Applicant notified of review panel assignment</b>		<b>02/28/2024</b>	07/09/2024	
<b>Primary Reviewer 1 COI signed</b>		<b>03/01/2024</b>	07/11/2024	
<b>Primary Reviewer 2 COI signed</b>		<b>02/27/2024</b>	07/11/2024	
<b>Primary Reviewer 3 COI signed</b>		<b>03/04/2024</b>	07/11/2024	
<b>Primary (Advocate) Reviewer 4 COI signed</b>		<b>02/27/2024</b>	07/11/2024	
<b>Preliminary Evaluation</b>	<b>Primary Reviewer 1 critique submitted</b>	<b>N/A</b>	07/11/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>N/A</b>	07/11/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>N/A</b>	07/11/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>N/A</b>	07/11/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>N/A</b>	07/11/2024	
	<b>Preliminary Evaluation score summary sent to Chair</b>	<b>N/A</b>	07/11/2024	
	<b>Recommended for full review</b>	<b>N/A</b>	07/11/2024	
	<b>Applicant notified of outcome</b>	<b>N/A</b>	07/11/2024	
<b>Peer Review Meeting</b>	<b>Assigned to primary reviewers</b>	<b>03/12/2024</b>	07/11/2024	
	<b>Primary Reviewer 1 COI signed</b>	<b>03/01/2024</b>	07/11/2024	
	<b>Primary Reviewer 2 COI signed</b>	<b>02/27/2024</b>	07/11/2024	
	<b>Primary Reviewer 3 COI signed</b>	<b>03/04/2024</b>	07/11/2024	
	<b>Primary (Advocate) Reviewer 4 COI signed</b>	<b>02/27/2024</b>	07/11/2024	
	<b>Primary Reviewer 1 critique submitted</b>	<b>04/20/2024</b>	07/11/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>04/09/2024</b>	07/11/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>04/14/2024</b>	07/11/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>04/08/2024</b>	07/11/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>NONE</b>	07/11/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/11/2024	
	<b>Discussed at Peer Review Meeting</b>	<b>YES</b>	07/11/2024	
	<b>Peer Review Meeting</b>	<b>04/23/2024</b>	07/11/2024	
	<b>Post review statements signed</b>	<b>04/23/2024</b>	07/09/2024	
	<b>Third Party Observer Report</b>	<b>04/29/2024</b>	07/09/2024	
	<b>Score report delivered to CSO</b>	<b>05/09/2024</b>	07/09/2024	
	<b>Recommended for SRC review</b>	<b>YES</b>	07/11/2024	
<b>Final SRC Recommendation</b>	<b>COI indicated by SRC member</b>	<b>NONE</b>	07/11/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/11/2024	
	<b>SRC Meeting</b>	<b>07/11/2024</b>	07/16/2024	
	<b>Third Party Observer Report</b>	<b>07/17/2024</b>	07/30/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	07/11/2024	
	<b>SRC Chair Notification to PIC and OC</b>	<b>07/29/2024</b>	07/30/2024	
<b>PIC Review</b>	<b>COI indicated by PIC member</b>	<b>none</b>	08/07/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	08/07/2024	
	<b>PIC Review Meeting</b>	<b>08/07/2024</b>	08/07/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	08/07/2024	
<b>Oversight Committee Approval</b>	<b>CEO Notification to Oversight Committee</b>	<b>N/A</b>		
	<b>COI Indicated by Oversight Committee member</b>	<b>N/A</b>		
	<b>COI Recused from participation</b>	<b>N/A</b>		
	<b>Donation(s) made to CPRIT / foundation</b>	<b>N/A</b>		
	<b>Presented to CPRIT Oversight Committee</b>	<b>N/A</b>		
	<b>Award approved by Oversight Committee</b>	<b>N/A</b>		
	<b>Authority to advance funds requested</b>	<b>N/A</b>		
	<b>Advance authority approved by Oversight Committee</b>	<b>N/A</b>		



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240501**  
**High-Impact/High-Risk Research Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 101 applications in response to this RFA, including eight withdrawn applications. This application was assigned to the Basic Cancer Research Panel I for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that one application submitted in response to this RFA was not recommended for a grant award and it has a score that is the same as an application that was recommended for a grant award. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.


An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules.


This statement is true.”

  
 \_\_\_\_\_  
 Kristen R. Doyle,  
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
 the 8<sup>th</sup> day of August, 2024,  
 by KRISTEN P. DOYLE.

  
 \_\_\_\_\_  
 Sandra Reyes  
 Notary Public, State of Texas



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/07/2024 03:35 PM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** High-Impact/High-Risk Research Awards  
**APPLICATION ID:** RP240501  
**APPLICATION TITLE:** Delivering Immunotherapy more effectively to glioblastoma with a “magnetic switch”  
**APPLICANT NAME:** Qin, Zhenpeng  
**ORGANIZATION:** The University of Texas at Dallas  
**PANEL NAME:** 24.2 Basic Cancer Research I

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	<b>RFA Approved by CSO</b>	<b>09/13/2023</b>	07/09/2024	
	<b>RFA Approved by CSO (revised)</b>	<b>01/16/2024</b>	07/09/2024	
	<b>RFA published in Texas.gov eGrants</b>	<b>09/14/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) opened</b>	<b>10/17/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) closed</b>	<b>01/18/2024</b>	07/09/2024	
	<b>Date application submitted</b>	<b>01/16/2024</b>	07/09/2024	
	<b>Method of submission</b>	<b>CARS</b>	07/09/2024	
	<b>Within receipt period</b>	<b>YES</b>	07/09/2024	
	<b>Request for extension to submit application after CARS closed</b>	<b>N/A</b>	07/09/2024	
	<b>Request for extension for late application submission accepted</b>	<b>N/A</b>	07/09/2024	
	<b>Receipt, Referral, and Assignment</b>	<b>Administrative review notification</b>	<b>02/19/2024</b>	07/09/2024
		<b>Donation(s) made to CPRIT / foundation</b>	<b>NO</b>	07/09/2024
		<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/09/2024
<b>Applicant notified of review panel assignment</b>		<b>02/28/2024</b>	07/09/2024	
<b>Primary Reviewer 1 COI signed</b>		<b>02/27/2024</b>	07/09/2024	
<b>Primary Reviewer 2 COI signed</b>		<b>02/27/2024</b>	07/09/2024	
<b>Primary Reviewer 3 COI signed</b>		<b>03/04/2024</b>	07/09/2024	
<b>Primary (Advocate) Reviewer 4 COI signed</b>		<b>02/27/2024</b>	07/09/2024	
<b>Preliminary Evaluation</b>	<b>Primary Reviewer 1 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>N/A</b>	07/09/2024	
	<b>Preliminary Evaluation score summary sent to Chair</b>	<b>N/A</b>	07/09/2024	
	<b>Recommended for full review</b>	<b>N/A</b>	07/09/2024	
	<b>Applicant notified of outcome</b>	<b>N/A</b>	07/09/2024	
<b>Peer Review Meeting</b>	<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/09/2024	
	<b>Primary Reviewer 1 COI signed</b>	<b>02/27/2024</b>	07/09/2024	
	<b>Primary Reviewer 2 COI signed</b>	<b>02/27/2024</b>	07/09/2024	
	<b>Primary Reviewer 3 COI signed</b>	<b>03/04/2024</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 COI signed</b>	<b>02/27/2024</b>	07/09/2024	
	<b>Primary Reviewer 1 critique submitted</b>	<b>03/31/2024</b>	07/09/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>04/04/2024</b>	07/09/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>04/06/2024</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>03/20/2024</b>	07/09/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>NONE</b>	07/09/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/09/2024	
	<b>Discussed at Peer Review Meeting</b>	<b>YES</b>	07/09/2024	
	<b>Peer Review Meeting</b>	<b>04/16/2024</b>	07/09/2024	
	<b>Post review statements signed</b>	<b>04/16/2024</b>	07/09/2024	
	<b>Third Party Observer Report</b>	<b>04/23/2024</b>	07/09/2024	
	<b>Score report delivered to CSO</b>	<b>05/09/2024</b>	07/09/2024	
	<b>Recommended for SRC review</b>	<b>YES</b>	07/09/2024	
	<b>Final SRC Recommendation</b>	<b>COI indicated by SRC member</b>	<b>NONE</b>	07/30/2024
<b>COI recused from participation</b>		<b>N/A</b>	07/30/2024	
<b>SRC Meeting</b>		<b>07/11/2024</b>	07/16/2024	
<b>Third Party Observer Report</b>		<b>07/17/2024</b>	07/30/2024	
<b>Recommended for grant award</b>		<b>YES</b>	07/30/2024	
<b>SRC Chair Notification to PIC and OC</b>		<b>07/29/2024</b>	07/30/2024	
<b>PIC Review</b>	<b>COI indicated by PIC member</b>	<b>none</b>	08/07/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	08/07/2024	
	<b>PIC Review Meeting</b>	<b>08/07/2024</b>	08/07/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	08/07/2024	
<b>Oversight Committee Approval</b>	<b>CEO Notification to Oversight Committee</b>	<b>N/A</b>		
	<b>COI Indicated by Oversight Committee member</b>	<b>N/A</b>		
	<b>COI Recused from participation</b>	<b>N/A</b>		
	<b>Donation(s) made to CPRIT / foundation</b>	<b>N/A</b>		
	<b>Presented to CPRIT Oversight Committee</b>	<b>N/A</b>		
	<b>Award approved by Oversight Committee</b>	<b>N/A</b>		
	<b>Authority to advance funds requested</b>	<b>N/A</b>		
	<b>Advance authority approved by Oversight Committee</b>	<b>N/A</b>		



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240516**  
**High-Impact/High-Risk Research Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 101 applications in response to this RFA, including eight withdrawn applications. This application was assigned to the Basic Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that one application submitted in response to this RFA was not recommended for a grant award and it has a score that is the same as an application that was recommended for a grant award. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.


An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules.


This statement is true.”

  
 \_\_\_\_\_  
 Kristen P. Doyle,  
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
 the 8<sup>th</sup> day of August, 2024,  
 by KRISTEN P. DOYLE.

  
 \_\_\_\_\_  
 Sandra Reyes  
 Notary Public, State of Texas





# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/07/2024 03:35 PM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** High-Impact/High-Risk Research Awards  
**APPLICATION ID:** RP240516  
**APPLICATION TITLE:** Mapping multivalent chromatin interactions to define the 3D genome of Clear cell renal cell carcinoma  
**APPLICANT NAME:** Mani, Ram S  
**ORGANIZATION:** The University of Texas Southwestern Medical Center  
**PANEL NAME:** 24.2 Basic Cancer Research 2

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	<b>RFA Approved by CSO</b>	<b>09/13/2023</b>	07/09/2024	
	<b>RFA Approved by CSO (revised)</b>	<b>01/16/2024</b>	07/09/2024	
	<b>RFA published in Texas.gov eGrants</b>	<b>09/14/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) opened</b>	<b>10/17/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) closed</b>	<b>01/18/2024</b>	07/09/2024	
	<b>Date application submitted</b>	<b>01/17/2024</b>	07/09/2024	
	<b>Method of submission</b>	<b>CARS</b>	07/09/2024	
	<b>Within receipt period</b>	<b>YES</b>	07/09/2024	
	<b>Request for extension to submit application after CARS closed</b>	<b>N/A</b>	07/09/2024	
	<b>Request for extension for late application submission accepted</b>	<b>N/A</b>	07/09/2024	
	<b>Receipt, Referral, and Assignment</b>	<b>Administrative review notification</b>	<b>N/A</b>	07/09/2024
		<b>Donation(s) made to CPRIT / foundation</b>	<b>NO</b>	07/09/2024
		<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/09/2024
<b>Applicant notified of review panel assignment</b>		<b>02/28/2024</b>	07/09/2024	
<b>Primary Reviewer 1 COI signed</b>		<b>03/05/2024</b>	07/09/2024	
<b>Primary Reviewer 2 COI signed</b>		<b>02/27/2024</b>	07/09/2024	
<b>Primary Reviewer 3 COI signed</b>		<b>03/05/2024</b>	07/09/2024	
<b>Primary (Advocate) Reviewer 4 COI signed</b>		<b>03/04/2024</b>	07/09/2024	
<b>Preliminary Evaluation</b>	<b>Primary Reviewer 1 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>N/A</b>	07/09/2024	
	<b>Preliminary Evaluation score summary sent to Chair</b>	<b>N/A</b>	07/09/2024	
	<b>Recommended for full review</b>	<b>N/A</b>	07/09/2024	
	<b>Applicant notified of outcome</b>	<b>N/A</b>	07/09/2024	
<b>Peer Review Meeting</b>	<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/09/2024	
	<b>Primary Reviewer 1 COI signed</b>	<b>03/05/2024</b>	07/09/2024	
	<b>Primary Reviewer 2 COI signed</b>	<b>02/27/2024</b>	07/09/2024	
	<b>Primary Reviewer 3 COI signed</b>	<b>03/05/2024</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 COI signed</b>	<b>03/04/2024</b>	07/09/2024	
	<b>Primary Reviewer 1 critique submitted</b>	<b>04/07/2024</b>	07/09/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>04/04/2024</b>	07/09/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>04/06/2024</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>04/02/2024</b>	07/09/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>NONE</b>	07/09/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/09/2024	
	<b>Discussed at Peer Review Meeting</b>	<b>YES</b>	07/09/2024	
	<b>Peer Review Meeting</b>	<b>04/17/2024</b>	07/09/2024	
	<b>Post review statements signed</b>	<b>04/26/2024</b>	07/09/2024	
	<b>Third Party Observer Report</b>	<b>04/23/2024</b>	07/09/2024	
	<b>Score report delivered to CSO</b>	<b>05/09/2024</b>	07/09/2024	
	<b>Recommended for SRC review</b>	<b>YES</b>	07/09/2024	
<b>Final SRC Recommendation</b>	<b>COI indicated by SRC member</b>	<b>NONE</b>	07/12/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/12/2024	
	<b>SRC Meeting</b>	<b>07/11/2024</b>	07/16/2024	
	<b>Third Party Observer Report</b>	<b>07/17/2024</b>	07/30/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	07/12/2024	
	<b>SRC Chair Notification to PIC and OC</b>	<b>07/29/2024</b>	07/30/2024	
<b>PIC Review</b>	<b>COI indicated by PIC member</b>	<b>none</b>	08/07/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	08/07/2024	
	<b>PIC Review Meeting</b>	<b>08/07/2024</b>	08/07/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	08/07/2024	
<b>Oversight Committee Approval</b>	<b>CEO Notification to Oversight Committee</b>	<b>N/A</b>		
	<b>COI Indicated by Oversight Committee member</b>	<b>N/A</b>		
	<b>COI Recused from participation</b>	<b>N/A</b>		
	<b>Donation(s) made to CPRIT / foundation</b>	<b>N/A</b>		
	<b>Presented to CPRIT Oversight Committee</b>	<b>N/A</b>		
	<b>Award approved by Oversight Committee</b>	<b>N/A</b>		
	<b>Authority to advance funds requested</b>	<b>N/A</b>		
	<b>Advance authority approved by Oversight Committee</b>	<b>N/A</b>		



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240539**  
**High-Impact/High-Risk Research Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 101 applications in response to this RFA, including eight withdrawn applications. This application was assigned to the Clinical and Translational Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that one application submitted in response to this RFA was not recommended for a grant award and it has a score that is the same as an application that was recommended for a grant award. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council for grant award consideration. The panel's decision is based upon a number of factors, including the final score.


An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."

  
 \_\_\_\_\_  
 Kristen P. Doyle,  
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
 the 8<sup>th</sup> day of August, 2024,  
 by KRISTEN P. DOYLE.

  
 \_\_\_\_\_  
 Sandra Reyes  
 Notary Public, State of Texas



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/07/2024 03:36 PM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** High-Impact/High-Risk Research Awards  
**APPLICATION ID:** RP240539  
**APPLICATION TITLE:** Spectroscopy for quantitative real-time imaging of radical formation in ultra-high dose rate radiation therapy  
**APPLICANT NAME:** Gustavsson, Anna-Karin  
**ORGANIZATION:** Rice University  
**PANEL NAME:** 24.2 Clinical and Translational Cancer Research-1

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	<b>RFA Approved by CSO</b>	<b>09/13/2023</b>	07/09/2024	
	<b>RFA Approved by CSO (revised)</b>	<b>01/16/2024</b>	07/09/2024	
	<b>RFA published in Texas.gov eGrants</b>	<b>09/14/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) opened</b>	<b>10/17/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) closed</b>	<b>01/18/2024</b>	07/09/2024	
	<b>Date application submitted</b>	<b>01/09/2024</b>	07/10/2024	
	<b>Method of submission</b>	<b>CARS</b>	07/10/2024	
	<b>Within receipt period</b>	<b>YES</b>	07/10/2024	
	<b>Request for extension to submit application after CARS closed</b>	<b>N/A</b>	07/10/2024	
	<b>Request for extension for late application submission accepted</b>	<b>N/A</b>	07/10/2024	
	<b>Receipt, Referral, and Assignment</b>	<b>Administrative review notification</b>	<b>N/A</b>	07/10/2024
		<b>Donation(s) made to CPRIT / foundation</b>	<b>NO</b>	07/10/2024
		<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/10/2024
<b>Applicant notified of review panel assignment</b>		<b>02/28/2024</b>	07/09/2024	
<b>Primary Reviewer 1 COI signed</b>		<b>03/06/2024</b>	07/10/2024	
<b>Primary Reviewer 2 COI signed</b>		<b>02/28/2024</b>	07/10/2024	
<b>Primary Reviewer 3 COI signed</b>		<b>03/01/2024</b>	07/10/2024	
<b>Primary (Advocate) Reviewer 4 COI signed</b>		<b>02/27/2024</b>	07/10/2024	
<b>Preliminary Evaluation</b>	<b>Primary Reviewer 1 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>N/A</b>	07/10/2024	
	<b>Preliminary Evaluation score summary sent to Chair</b>	<b>N/A</b>	07/10/2024	
	<b>Recommended for full review</b>	<b>N/A</b>	07/10/2024	
	<b>Applicant notified of outcome</b>	<b>N/A</b>	07/10/2024	
<b>Peer Review Meeting</b>	<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/10/2024	
	<b>Primary Reviewer 1 COI signed</b>	<b>03/06/2024</b>	07/10/2024	
	<b>Primary Reviewer 2 COI signed</b>	<b>02/28/2024</b>	07/10/2024	
	<b>Primary Reviewer 3 COI signed</b>	<b>03/01/2024</b>	07/10/2024	
	<b>Primary (Advocate) Reviewer 4 COI signed</b>	<b>02/27/2024</b>	07/10/2024	
	<b>Primary Reviewer 1 critique submitted</b>	<b>03/31/2024</b>	07/10/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>04/05/2024</b>	07/10/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>04/07/2024</b>	07/10/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>03/18/2024</b>	07/10/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>NONE</b>	07/10/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/10/2024	
	<b>Discussed at Peer Review Meeting</b>	<b>YES</b>	07/10/2024	
	<b>Peer Review Meeting</b>	<b>04/18/2024</b>	07/10/2024	
	<b>Post review statements signed</b>	<b>04/18/2024</b>	07/09/2024	
	<b>Third Party Observer Report</b>	<b>04/23/2024</b>	07/09/2024	
	<b>Score report delivered to CSO</b>	<b>05/09/2024</b>	07/09/2024	
	<b>Recommended for SRC review</b>	<b>YES</b>	07/10/2024	
<b>Final SRC Recommendation</b>	<b>COI indicated by SRC member</b>	<b>NONE</b>	07/12/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/12/2024	
	<b>SRC Meeting</b>	<b>07/11/2024</b>	07/16/2024	
	<b>Third Party Observer Report</b>	<b>07/17/2024</b>	07/30/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	07/12/2024	
	<b>SRC Chair Notification to PIC and OC</b>	<b>07/29/2024</b>	07/30/2024	
<b>PIC Review</b>	<b>COI indicated by PIC member</b>	<b>none</b>	08/07/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	08/07/2024	
	<b>PIC Review Meeting</b>	<b>08/07/2024</b>	08/07/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	08/07/2024	
<b>Oversight Committee Approval</b>	<b>CEO Notification to Oversight Committee</b>	<b>N/A</b>		
	<b>COI Indicated by Oversight Committee member</b>	<b>N/A</b>		
	<b>COI Recused from participation</b>	<b>N/A</b>		
	<b>Donation(s) made to CPRIT / foundation</b>	<b>N/A</b>		
	<b>Presented to CPRIT Oversight Committee</b>	<b>N/A</b>		
	<b>Award approved by Oversight Committee</b>	<b>N/A</b>		
	<b>Authority to advance funds requested</b>	<b>N/A</b>		
	<b>Advance authority approved by Oversight Committee</b>	<b>N/A</b>		



CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240542**  
**High-Impact/High-Risk Research Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 101 applications in response to this RFA, including eight withdrawn applications. This application was assigned to the Clinical and Translational Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that one application submitted in response to this RFA was not recommended for a grant award and it has a score that is the same as an application that was recommended for a grant award. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules.

This statement is true.”


  
 \_\_\_\_\_  
 Kristen P. Doyle,

CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
 the 8<sup>th</sup> day of August, 2024,  
 by KRISTEN P. DOYLE.

  
 \_\_\_\_\_  
 Sandra Reyes  
 Notary Public, State of Texas



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/07/2024 03:36 PM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** High-Impact/High-Risk Research Awards  
**APPLICATION ID:** RP240542  
**APPLICATION TITLE:** Digital Twin Augmented Reality for Prostate Laparoscopic Surgery  
**APPLICANT NAME:** Fei, Baowei  
**ORGANIZATION:** The University of Texas at Dallas  
**PANEL NAME:** 24.2 Clinical and Translational Cancer Research-1

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	<b>RFA Approved by CSO</b>	<b>09/13/2023</b>	07/09/2024	
	<b>RFA Approved by CSO (revised)</b>	<b>01/16/2024</b>	07/09/2024	
	<b>RFA published in Texas.gov eGrants</b>	<b>09/14/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) opened</b>	<b>10/17/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) closed</b>	<b>01/18/2024</b>	07/09/2024	
	<b>Date application submitted</b>	<b>01/16/2024</b>	07/10/2024	
	<b>Method of submission</b>	<b>CARS</b>	07/10/2024	
	<b>Within receipt period</b>	<b>YES</b>	07/10/2024	
	<b>Request for extension to submit application after CARS closed</b>	<b>N/A</b>	07/10/2024	
	<b>Request for extension for late application submission accepted</b>	<b>N/A</b>	07/10/2024	
	<b>Receipt, Referral, and Assignment</b>	<b>Administrative review notification</b>	<b>N/A</b>	07/10/2024
		<b>Donation(s) made to CPRIT / foundation</b>	<b>NO</b>	07/10/2024
		<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/10/2024
<b>Applicant notified of review panel assignment</b>		<b>02/28/2024</b>	07/09/2024	
<b>Primary Reviewer 1 COI signed</b>		<b>03/03/2024</b>	07/10/2024	
<b>Primary Reviewer 2 COI signed</b>		<b>03/01/2024</b>	07/10/2024	
<b>Primary Reviewer 3 COI signed</b>		<b>03/06/2024</b>	07/10/2024	
<b>Primary (Advocate) Reviewer 4 COI signed</b>		<b>02/27/2024</b>	07/10/2024	
<b>Preliminary Evaluation</b>	<b>Primary Reviewer 1 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>N/A</b>	07/10/2024	
	<b>Preliminary Evaluation score summary sent to Chair</b>	<b>N/A</b>	07/10/2024	
	<b>Recommended for full review</b>	<b>N/A</b>	07/10/2024	
	<b>Applicant notified of outcome</b>	<b>N/A</b>	07/10/2024	
<b>Peer Review Meeting</b>	<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/10/2024	
	<b>Primary Reviewer 1 COI signed</b>	<b>03/03/2024</b>	07/10/2024	
	<b>Primary Reviewer 2 COI signed</b>	<b>03/01/2024</b>	07/10/2024	
	<b>Primary Reviewer 3 COI signed</b>	<b>03/06/2024</b>	07/10/2024	
	<b>Primary (Advocate) Reviewer 4 COI signed</b>	<b>02/27/2024</b>	07/10/2024	
	<b>Primary Reviewer 1 critique submitted</b>	<b>04/02/2024</b>	07/10/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>04/07/2024</b>	07/10/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>03/31/2024</b>	07/10/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>03/16/2024</b>	07/10/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>NONE</b>	07/10/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/10/2024	
	<b>Discussed at Peer Review Meeting</b>	<b>YES</b>	07/10/2024	
	<b>Peer Review Meeting</b>	<b>04/18/2024</b>	07/10/2024	
	<b>Post review statements signed</b>	<b>04/18/2024</b>	07/09/2024	
	<b>Third Party Observer Report</b>	<b>04/23/2024</b>	07/09/2024	
	<b>Score report delivered to CSO</b>	<b>05/09/2024</b>	07/09/2024	
	<b>Recommended for SRC review</b>	<b>YES</b>	07/10/2024	
	<b>Final SRC Recommendation</b>	<b>COI indicated by SRC member</b>	<b>NONE</b>	07/12/2024
<b>COI recused from participation</b>		<b>N/A</b>	07/12/2024	
<b>SRC Meeting</b>		<b>07/11/2024</b>	07/16/2024	
<b>Third Party Observer Report</b>		<b>07/17/2024</b>	07/30/2024	
<b>Recommended for grant award</b>		<b>YES</b>	07/12/2024	
<b>SRC Chair Notification to PIC and OC</b>		<b>07/29/2024</b>	07/30/2024	
<b>PIC Review</b>	<b>COI indicated by PIC member</b>	<b>none</b>	08/07/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	08/07/2024	
	<b>PIC Review Meeting</b>	<b>08/07/2024</b>	08/07/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	08/07/2024	
<b>Oversight Committee Approval</b>	<b>CEO Notification to Oversight Committee</b>	<b>N/A</b>		
	<b>COI Indicated by Oversight Committee member</b>	<b>N/A</b>		
	<b>COI Recused from participation</b>	<b>N/A</b>		
	<b>Donation(s) made to CPRIT / foundation</b>	<b>N/A</b>		
	<b>Presented to CPRIT Oversight Committee</b>	<b>N/A</b>		
	<b>Award approved by Oversight Committee</b>	<b>N/A</b>		
	<b>Authority to advance funds requested</b>	<b>N/A</b>		
	<b>Advance authority approved by Oversight Committee</b>	<b>N/A</b>		



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240579**  
**High-Impact/High-Risk Research Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 101 applications in response to this RFA, including eight withdrawn applications. This application was assigned to the Clinical and Translational Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle



- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that one application submitted in response to this RFA was not recommended for a grant award and it has a score that is the same as an application that was recommended for a grant award. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council for grant award consideration. The panel's decision is based upon a number of factors, including the final score.


An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.

This statement is true."




Kristen P. Doyle,  
CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
the 8<sup>th</sup> day of August, 2024,  
by KRISTEN P. DOYLE.



Sandra Reyes  
Notary Public, State of Texas



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/08/2024 09:18 AM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** High-Impact/High-Risk Research Awards  
**APPLICATION ID:** RP240579  
**APPLICATION TITLE:** Renal Clearable Nano Delivery Systems for Maximizing Anti-tumor Immunity in Breast Cancer Brain Metastasis Treatment  
**APPLICANT NAME:** Zheng, Jie  
**ORGANIZATION:** The University of Texas at Dallas  
**PANEL NAME:** 24.2 Clinical and Translational Cancer Research-1

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	<b>RFA Approved by CSO</b>	<b>09/13/2023</b>	07/09/2024	
	<b>RFA Approved by CSO (revised)</b>	<b>01/16/2024</b>	07/09/2024	
	<b>RFA published in Texas.gov eGrants</b>	<b>09/14/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) opened</b>	<b>10/17/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) closed</b>	<b>01/18/2024</b>	07/09/2024	
	<b>Date application submitted</b>	<b>01/12/2024</b>	07/10/2024	
	<b>Method of submission</b>	<b>CARS</b>	07/10/2024	
	<b>Within receipt period</b>	<b>YES</b>	07/10/2024	
	<b>Request for extension to submit application after CARS closed</b>	<b>N/A</b>	07/10/2024	
	<b>Request for extension for late application submission accepted</b>	<b>N/A</b>	07/10/2024	
	<b>Receipt, Referral, and Assignment</b>	<b>Administrative review notification</b>	<b>N/A</b>	07/10/2024
		<b>Donation(s) made to CPRIT / foundation</b>	<b>NO</b>	07/10/2024
		<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/10/2024
<b>Applicant notified of review panel assignment</b>		<b>02/28/2024</b>	07/09/2024	
<b>Primary Reviewer 1 COI signed</b>		<b>03/04/2024</b>	07/10/2024	
<b>Primary Reviewer 2 COI signed</b>		<b>02/27/2024</b>	07/10/2024	
<b>Primary Reviewer 3 COI signed</b>		<b>03/12/2024</b>	07/10/2024	
<b>Primary (Advocate) Reviewer 4 COI signed</b>		<b>02/27/2024</b>	07/10/2024	
<b>Preliminary Evaluation</b>	<b>Primary Reviewer 1 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>N/A</b>	07/10/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>N/A</b>	07/10/2024	
	<b>Preliminary Evaluation score summary sent to Chair</b>	<b>N/A</b>	07/10/2024	
	<b>Recommended for full review</b>	<b>N/A</b>	07/10/2024	
	<b>Applicant notified of outcome</b>	<b>N/A</b>	07/10/2024	
<b>Peer Review Meeting</b>	<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/10/2024	
	<b>Primary Reviewer 1 COI signed</b>	<b>03/04/2024</b>	07/10/2024	
	<b>Primary Reviewer 2 COI signed</b>	<b>02/27/2024</b>	07/10/2024	
	<b>Primary Reviewer 3 COI signed</b>	<b>03/12/2024</b>	07/10/2024	
	<b>Primary (Advocate) Reviewer 4 COI signed</b>	<b>02/27/2024</b>	07/10/2024	
	<b>Primary Reviewer 1 critique submitted</b>	<b>04/01/2024</b>	07/10/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>04/01/2024</b>	07/10/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>04/08/2024</b>	07/10/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>03/19/2024</b>	07/10/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>NONE</b>	07/10/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/10/2024	
	<b>Discussed at Peer Review Meeting</b>	<b>YES</b>	07/10/2024	
	<b>Peer Review Meeting</b>	<b>04/18/2024</b>	07/10/2024	
	<b>Post review statements signed</b>	<b>04/18/2024</b>	07/09/2024	
	<b>Third Party Observer Report</b>	<b>04/23/2024</b>	07/09/2024	
	<b>Score report delivered to CSO</b>	<b>05/09/2024</b>	07/09/2024	
	<b>Recommended for SRC review</b>	<b>YES</b>	07/10/2024	
	<b>Final SRC Recommendation</b>	<b>COI indicated by SRC member</b>	<b>NONE</b>	07/12/2024
<b>COI recused from participation</b>		<b>N/A</b>	07/12/2024	
<b>SRC Meeting</b>		<b>07/11/2024</b>	07/16/2024	
<b>Third Party Observer Report</b>		<b>07/17/2024</b>	07/30/2024	
<b>Recommended for grant award</b>		<b>YES</b>	07/12/2024	
<b>SRC Chair Notification to PIC and OC</b>		<b>07/29/2024</b>	07/30/2024	
<b>PIC Review</b>	<b>COI indicated by PIC member</b>	<b>none</b>	08/07/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	08/07/2024	
	<b>PIC Review Meeting</b>	<b>08/07/2024</b>	08/07/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	08/07/2024	
<b>Oversight Committee Approval</b>	<b>CEO Notification to Oversight Committee</b>	<b>N/A</b>		
	<b>COI Indicated by Oversight Committee member</b>	<b>N/A</b>		
	<b>COI Recused from participation</b>	<b>N/A</b>		
	<b>Donation(s) made to CPRIT / foundation</b>	<b>N/A</b>		
	<b>Presented to CPRIT Oversight Committee</b>	<b>N/A</b>		
	<b>Award approved by Oversight Committee</b>	<b>N/A</b>		
	<b>Authority to advance funds requested</b>	<b>N/A</b>		
	<b>Advance authority approved by Oversight Committee</b>	<b>N/A</b>		



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240590**  
**High-Impact/High-Risk Research Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 101 applications in response to this RFA, including eight withdrawn applications. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that one application submitted in response to this RFA was not recommended for a grant award and it has a score that is the same as an application that was recommended for a grant award. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council for grant award consideration. The panel's decision is based upon a number of factors, including the final score.


An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."

  
 \_\_\_\_\_  
 Kristen P. Doyle,  
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 8<sup>th</sup> day of August, 2024, by KRISTEN P. DOYLE.

  
 \_\_\_\_\_  
 Sandra Reyes  
 Notary Public, State of Texas



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/08/2024 09:18 AM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** High-Impact/High-Risk Research Awards  
**APPLICATION ID:** RP240590  
**APPLICATION TITLE:** Bidentate ERK Traps: Revolutionizing Combination Cancer Therapy Strategies  
**APPLICANT NAME:** Dalby, Kevin N  
**ORGANIZATION:** The University of Texas at Austin  
**PANEL NAME:** 24.2 Cancer Biology

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	<b>RFA Approved by CSO</b>	<b>09/13/2023</b>	07/09/2024	
	<b>RFA Approved by CSO (revised)</b>	<b>01/16/2024</b>	07/09/2024	
	<b>RFA published in Texas.gov eGrants</b>	<b>09/14/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) opened</b>	<b>10/17/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) closed</b>	<b>01/18/2024</b>	07/09/2024	
	<b>Date application submitted</b>	<b>01/18/2024</b>	07/09/2024	
	<b>Method of submission</b>	<b>CARS</b>	07/09/2024	
	<b>Within receipt period</b>	<b>YES</b>	07/09/2024	
	<b>Request for extension to submit application after CARS closed</b>	<b>N/A</b>	07/09/2024	
	<b>Request for extension for late application submission accepted</b>	<b>N/A</b>	07/09/2024	
	<b>Receipt, Referral, and Assignment</b>	<b>Administrative review notification</b>	<b>N/A</b>	07/09/2024
		<b>Donation(s) made to CPRIT / foundation</b>	<b>NO</b>	07/09/2024
		<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/09/2024
<b>Applicant notified of review panel assignment</b>		<b>02/28/2024</b>	07/09/2024	
<b>Primary Reviewer 1 COI signed</b>		<b>03/04/2024</b>	07/09/2024	
<b>Primary Reviewer 2 COI signed</b>		<b>03/07/2024</b>	07/09/2024	
<b>Primary Reviewer 3 COI signed</b>		<b>02/27/2024</b>	07/09/2024	
<b>Primary (Advocate) Reviewer 4 COI signed</b>		<b>03/06/2024</b>	07/09/2024	
<b>Preliminary Evaluation</b>	<b>Primary Reviewer 1 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>N/A</b>	07/09/2024	
	<b>Preliminary Evaluation score summary sent to Chair</b>	<b>N/A</b>	07/09/2024	
	<b>Recommended for full review</b>	<b>N/A</b>	07/09/2024	
	<b>Applicant notified of outcome</b>	<b>N/A</b>	07/09/2024	
<b>Peer Review Meeting</b>	<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/09/2024	
	<b>Primary Reviewer 1 COI signed</b>	<b>03/04/2024</b>	07/09/2024	
	<b>Primary Reviewer 2 COI signed</b>	<b>03/07/2024</b>	07/09/2024	
	<b>Primary Reviewer 3 COI signed</b>	<b>02/27/2024</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 COI signed</b>	<b>03/06/2024</b>	07/09/2024	
	<b>Primary Reviewer 1 critique submitted</b>	<b>04/14/2024</b>	07/09/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>04/09/2024</b>	07/09/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>04/09/2024</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>04/03/2024</b>	07/09/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>NONE</b>	07/09/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/09/2024	
	<b>Discussed at Peer Review Meeting</b>	<b>YES</b>	07/09/2024	
	<b>Peer Review Meeting</b>	<b>04/24/2024</b>	07/09/2024	
	<b>Post review statements signed</b>	<b>04/29/2024</b>	07/09/2024	
	<b>Third Party Observer Report</b>	<b>04/29/2024</b>	07/09/2024	
	<b>Score report delivered to CSO</b>	<b>05/09/2024</b>	07/09/2024	
	<b>Recommended for SRC review</b>	<b>YES</b>	07/09/2024	
	<b>Final SRC Recommendation</b>	<b>COI indicated by SRC member</b>	<b>NONE</b>	07/12/2024
<b>COI recused from participation</b>		<b>N/A</b>	07/12/2024	
<b>SRC Meeting</b>		<b>07/11/2024</b>	07/16/2024	
<b>Third Party Observer Report</b>		<b>07/17/2024</b>	07/30/2024	
<b>Recommended for grant award</b>		<b>YES</b>	07/12/2024	
<b>SRC Chair Notification to PIC and OC</b>		<b>07/29/2024</b>	07/30/2024	
<b>PIC Review</b>	<b>COI indicated by PIC member</b>	<b>none</b>	08/07/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	08/07/2024	
	<b>PIC Review Meeting</b>	<b>08/07/2024</b>	08/07/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	08/07/2024	
<b>Oversight Committee Approval</b>	<b>CEO Notification to Oversight Committee</b>	<b>N/A</b>		
	<b>COI Indicated by Oversight Committee member</b>	<b>N/A</b>		
	<b>COI Recused from participation</b>	<b>N/A</b>		
	<b>Donation(s) made to CPRIT / foundation</b>	<b>N/A</b>		
	<b>Presented to CPRIT Oversight Committee</b>	<b>N/A</b>		
	<b>Award approved by Oversight Committee</b>	<b>N/A</b>		
	<b>Authority to advance funds requested</b>	<b>N/A</b>		
	<b>Advance authority approved by Oversight Committee</b>	<b>N/A</b>		



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240605**  
**High-Impact/High-Risk Research Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 101 applications in response to this RFA, including eight withdrawn applications. This application was assigned to the Basic Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that one application submitted in response to this RFA was not recommended for a grant award and it has a score that is the same as an application that was recommended for a grant award. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.


An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules.


This statement is true.”

  
 Kristen P. Doyle,  
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
 the 8<sup>th</sup> day of August, 2024,  
 by KRISTEN P. DOYLE.

  
 Sandra Reyes  
 Notary Public, State of Texas



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 08/08/2024 09:18 AM CT

**FY:** 2024  
**CYCLE:** 2  
**PROGRAM:** Research  
**MECHANISM:** High-Impact/High-Risk Research Awards  
**APPLICATION ID:** RP240605  
**APPLICATION TITLE:** Stimulate Mucosal-associated Invariant T cells to Kill Cancer Cells  
**APPLICANT NAME:** Huang, Shouxiong  
**ORGANIZATION:** Texas Biomedical Research Institute  
**PANEL NAME:** 24.2 Basic Cancer Research 2

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	<b>RFA Approved by CSO</b>	<b>09/13/2023</b>	07/09/2024	
	<b>RFA Approved by CSO (revised)</b>	<b>01/16/2024</b>	07/09/2024	
	<b>RFA published in Texas.gov eGrants</b>	<b>09/14/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) opened</b>	<b>10/17/2023</b>	07/09/2024	
	<b>CPRIT Application Receipt System (CARS) closed</b>	<b>01/18/2024</b>	07/09/2024	
	<b>Date application submitted</b>	<b>01/16/2024</b>	07/09/2024	
	<b>Method of submission</b>	<b>CARS</b>	07/09/2024	
	<b>Within receipt period</b>	<b>YES</b>	07/09/2024	
	<b>Request for extension to submit application after CARS closed</b>	<b>N/A</b>	07/09/2024	
	<b>Request for extension for late application submission accepted</b>	<b>N/A</b>	07/09/2024	
	<b>Receipt, Referral, and Assignment</b>	<b>Administrative review notification</b>	<b>N/A</b>	07/09/2024
		<b>Donation(s) made to CPRIT / foundation</b>	<b>NO</b>	07/09/2024
		<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/09/2024
<b>Applicant notified of review panel assignment</b>		<b>02/28/2024</b>	07/09/2024	
<b>Primary Reviewer 1 COI signed</b>		<b>03/05/2024</b>	07/09/2024	
<b>Primary Reviewer 2 COI signed</b>		<b>02/29/2024</b>	07/09/2024	
<b>Primary Reviewer 3 COI signed</b>		<b>02/28/2024</b>	07/09/2024	
<b>Primary (Advocate) Reviewer 4 COI signed</b>		<b>03/01/2024</b>	07/09/2024	
<b>Preliminary Evaluation</b>	<b>Primary Reviewer 1 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>N/A</b>	07/09/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>N/A</b>	07/09/2024	
	<b>Preliminary Evaluation score summary sent to Chair</b>	<b>N/A</b>	07/09/2024	
	<b>Recommended for full review</b>	<b>N/A</b>	07/09/2024	
	<b>Applicant notified of outcome</b>	<b>N/A</b>	07/09/2024	
<b>Peer Review Meeting</b>	<b>Assigned to primary reviewers</b>	<b>03/11/2024</b>	07/09/2024	
	<b>Primary Reviewer 1 COI signed</b>	<b>03/05/2024</b>	07/09/2024	
	<b>Primary Reviewer 2 COI signed</b>	<b>02/29/2024</b>	07/09/2024	
	<b>Primary Reviewer 3 COI signed</b>	<b>02/28/2024</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 COI signed</b>	<b>03/01/2024</b>	07/09/2024	
	<b>Primary Reviewer 1 critique submitted</b>	<b>04/15/2024</b>	07/09/2024	
	<b>Primary Reviewer 2 critique submitted</b>	<b>04/02/2024</b>	07/09/2024	
	<b>Primary Reviewer 3 critique submitted</b>	<b>03/28/2024</b>	07/09/2024	
	<b>Primary (Advocate) Reviewer 4 critique submitted</b>	<b>03/23/2024</b>	07/09/2024	
	<b>COI indicated by non-primary reviewer</b>	<b>NONE</b>	07/09/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/09/2024	
	<b>Discussed at Peer Review Meeting</b>	<b>YES</b>	07/09/2024	
	<b>Peer Review Meeting</b>	<b>04/17/2024</b>	07/09/2024	
	<b>Post review statements signed</b>	<b>04/26/2024</b>	07/09/2024	
	<b>Third Party Observer Report</b>	<b>04/23/2024</b>	07/09/2024	
	<b>Score report delivered to CSO</b>	<b>05/09/2024</b>	07/09/2024	
	<b>Recommended for SRC review</b>	<b>YES</b>	07/09/2024	
<b>Final SRC Recommendation</b>	<b>COI indicated by SRC member</b>	<b>NONE</b>	07/12/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	07/12/2024	
	<b>SRC Meeting</b>	<b>07/11/2024</b>	07/16/2024	
	<b>Third Party Observer Report</b>	<b>07/17/2024</b>	07/30/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	07/12/2024	
	<b>SRC Chair Notification to PIC and OC</b>	<b>07/29/2024</b>	07/30/2024	
<b>PIC Review</b>	<b>COI indicated by PIC member</b>	<b>none</b>	08/07/2024	
	<b>COI recused from participation</b>	<b>N/A</b>	08/07/2024	
	<b>PIC Review Meeting</b>	<b>08/07/2024</b>	08/07/2024	
	<b>Recommended for grant award</b>	<b>YES</b>	08/07/2024	
<b>Oversight Committee Approval</b>	<b>CEO Notification to Oversight Committee</b>	<b>N/A</b>		
	<b>COI Indicated by Oversight Committee member</b>	<b>N/A</b>		
	<b>COI Recused from participation</b>	<b>N/A</b>		
	<b>Donation(s) made to CPRIT / foundation</b>	<b>N/A</b>		
	<b>Presented to CPRIT Oversight Committee</b>	<b>N/A</b>		
	<b>Award approved by Oversight Committee</b>	<b>N/A</b>		
	<b>Authority to advance funds requested</b>	<b>N/A</b>		
	<b>Advance authority approved by Oversight Committee</b>	<b>N/A</b>		





---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240438**  
**Multi-Investigator Research Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Multi-Investigator Research Awards* Request for Applications (RFA). CPRIT received 18 applications in response to this RFA. This application was assigned to Clinical and Translational Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that one application submitted in response to this RFA has a final overall evaluation score that is more favorable than three applications that were recommended for grant awards. An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be discussed or recommended for funding by a peer review panel.

CPRIT's administrative rules allow for the chairperson of each peer review panel to determine what applications are discussed during the peer review meeting if there is not enough time to discuss all applications that are assigned to the panel. The chairperson's decision is largely based on the initial overall evaluation score, which is the average of the scores from the primary reviewers of an application. If an application is not discussed at the peer review meeting, then the initial score becomes the final overall evaluation score. If an application is discussed by the full panel, then the primary reviewers may revise their initial scores based on the discussion at the panel. This means that the final overall evaluation score of a discussed application could be higher or lower than the initial evaluation score of that application. It is possible that this could result in a discussed application having a less favorable score than an application that was not discussed.


The four applications noted above were each assigned to a different peer review panel. The three recommended applications were discussed by each of their panels and the not-recommended application was not discussed. Since the application was not discussed, the initial overall evaluation score became the final overall evaluation score of the not-recommended application. The three applications that were discussed by the other panels had the chance for the primary reviewers to adjust their scores based on panel discussion. All of the panels conducted their review within CPRIT's administrative rules.

The Scientific Review Council (SRC) met twice to consider and recommend applications from this review cycle to the PIC. After its first meeting on July 11, 2024, the SRC met on July 29 to recommend an additional application from this grant mechanism after it became clear to the SRC that grant funds were available to fund the additional application.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true.”




Kristen P. Doyle,  
CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
the 8<sup>th</sup> day of August, 2024,  
by KRISTEN P. DOYLE.



Sandra Reyes  
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/08/2024 09:17 AM CT

FY: 2024  
 CYCLE: 2  
 PROGRAM: Research  
 MECHANISM: Multi-Investigator Research Awards (Version 2)  
 APPLICATION ID: RP240438  
 APPLICATION TITLE: Overcoming major barriers to the delivery of successful T-cell immunotherapies  
 APPLICANT NAME: Rooney, Cliona M  
 ORGANIZATION: Baylor College of Medicine  
 PANEL NAME: 24.2 Clinical and Translational Cancer Research-2

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	09/13/2023	07/09/2024	
	RFA Approved by CSO (revised)	10/17/2023	07/09/2024	
	RFA Approved by CSO (2nd revision)	01/16/2024	07/09/2024	
	RFA published in Texas.gov eGrants	09/14/2023	07/09/2024	
	CPRIT Application Receipt System (CARS) opened	10/17/2023	07/09/2024	
	CPRIT Application Receipt System (CARS) closed	01/18/2024	07/09/2024	
	Date application submitted	01/12/2024	07/10/2024	
	Method of submission	CARS	07/10/2024	
	Within receipt period	YES	07/10/2024	
	Request for extension to submit application after CARS closed	N/A	07/10/2024	
Request for extension for late application submission accepted	N/A	07/10/2024		
Receipt, Referral, and Assignment	Administrative review notification	N/A	07/10/2024	
	Donation(s) made to CPRIT / foundation	NO	07/10/2024	
	Assigned to primary reviewers	03/11/2024	07/10/2024	
	Applicant notified of review panel assignment	02/28/2024	07/09/2024	
	Primary Reviewer 1 COI signed	02/28/2024	07/10/2024	
	Primary Reviewer 2 COI signed	03/01/2024	07/10/2024	
	Primary Reviewer 3 COI signed	N/A	07/10/2024	
	Primary (Advocate) Reviewer 3 COI signed	03/01/2024	07/10/2024	
	Primary (Advocate) Reviewer 4 COI signed	N/A	07/10/2024	
	Project 1 Primary Reviewer 1 COI signed	03/03/2024	07/10/2024	
	Project 1 Primary Reviewer 2 COI signed	03/01/2024	07/10/2024	
	Project 1 Primary Reviewer 3 COI signed	02/28/2024	07/10/2024	
	Project 1 Primary (Advocate) Reviewer 4 COI signed	N/A	07/10/2024	
	Project 2 Primary Reviewer 1 COI signed	03/07/2024	07/10/2024	
	Project 2 Primary Reviewer 2 COI signed	03/03/2024	07/10/2024	
	Project 2 Primary Reviewer 3 COI signed	02/27/2024	07/10/2024	
	Project 2 Primary (Advocate) Reviewer 4 COI signed	N/A	07/10/2024	
	Project 3 Primary Reviewer 1 COI signed	03/02/2024	07/10/2024	
	Project 3 Primary Reviewer 2 COI signed	03/03/2024	07/10/2024	
	Project 3 Primary Reviewer 3 COI signed	02/28/2024	07/10/2024	
	Project 3 Primary (Advocate) Reviewer 4 COI signed	N/A	07/10/2024	
	Project 4 Primary Reviewer 1 COI signed	03/18/2024	07/10/2024	
	Project 4 Primary Reviewer 2 COI signed	02/28/2024	07/10/2024	
	Project 4 Primary Reviewer 3 COI signed	03/03/2024	07/10/2024	
	Project 4 Primary (Advocate) Reviewer 4 COI signed	N/A	07/10/2024	
	Admin Core Primary Reviewer 1 COI signed	03/01/2024	07/10/2024	
	Admin Core Primary Reviewer 2 COI signed	02/28/2024	07/10/2024	
	Admin Core Primary Reviewer 3 COI signed	N/A	07/10/2024	
	Admin Core Primary (Advocate) Reviewer 4 COI signed	N/A	07/10/2024	
	Core 1 Primary Reviewer 1 COI signed	03/02/2024	07/10/2024	
	Core 1 Primary Reviewer 2 COI signed	03/01/2024	07/10/2024	
	Core 1 Primary Reviewer 3 COI signed	N/A	07/10/2024	
	Core 1 Primary (Advocate) Reviewer 4 COI signed	N/A	07/10/2024	
	Core 2 Primary Reviewer 1 COI signed	03/02/2024	07/10/2024	
	Core 2 Primary Reviewer 2 COI signed	03/07/2024	07/10/2024	
	Core 2 Primary Reviewer 3 COI signed	N/A	07/10/2024	
	Core 2 Primary (Advocate) Reviewer 4 COI signed	N/A	07/10/2024	
	Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/10/2024
		Primary Reviewer 2 critique submitted	N/A	07/10/2024
		Primary Reviewer 3 critique submitted	N/A	07/10/2024
		Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024
		COI indicated by non-primary reviewer	N/A	07/10/2024
Preliminary Evaluation score summary sent to Chair		N/A	07/10/2024	
Recommended for full review		N/A	07/10/2024	
Applicant notified of outcome		N/A	07/10/2024	
Peer Review Meeting		Primary Reviewer 1 critique submitted	04/12/2024	07/10/2024
		Primary Reviewer 2 critique submitted	04/01/2024	07/10/2024
	Primary Reviewer 3 critique submitted	N/A	07/10/2024	
	Primary (Advocate) Reviewer 3 critique submitted	04/10/2024	07/10/2024	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024	
	Project 1 Primary Reviewer 1 critique submitted	03/31/2024	07/10/2024	
	Project 1 Primary Reviewer 2 critique submitted	04/01/2024	07/10/2024	
	Project 1 Primary Reviewer 3 critique submitted	04/12/2024	07/10/2024	
	Project 1 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024	
	Project 2 Primary Reviewer 1 critique submitted	04/18/2024	07/10/2024	
	Project 2 Primary Reviewer 2 critique submitted	03/31/2024	07/10/2024	
	Project 2 Primary Reviewer 3 critique submitted	04/11/2024	07/10/2024	
	Project 2 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024	
	Project 3 Primary Reviewer 1 critique submitted	04/04/2024	07/10/2024	
	Project 3 Primary Reviewer 2 critique submitted	03/31/2024	07/10/2024	
	Project 3 Primary Reviewer 3 critique submitted	04/12/2024	07/10/2024	
	Project 3 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024	
	Project 4 Primary Reviewer 1 critique submitted	04/11/2024	07/10/2024	
	Project 4 Primary Reviewer 2 critique submitted	04/12/2024	07/10/2024	
	Project 4 Primary Reviewer 3 critique submitted	03/31/2024	07/10/2024	
	Project 4 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024	
	Admin Core Primary Reviewer 1 critique submitted	04/01/2024	07/10/2024	
	Admin Core Primary Reviewer 2 critique submitted	04/12/2024	07/10/2024	
	Admin Core Primary Reviewer 3 critique submitted	N/A	07/10/2024	
	Admin Core Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024	
	Core 1 Primary Reviewer 1 critique submitted	03/21/2024	07/10/2024	
	Core 1 Primary Reviewer 2 critique submitted	04/01/2024	07/10/2024	
	Core 1 Primary Reviewer 3 critique submitted	N/A	07/10/2024	
	Core 1 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024	
	Core 2 Primary Reviewer 1 critique submitted	03/21/2024	07/10/2024	
	Core 2 Primary Reviewer 2 critique submitted	04/17/2024	07/10/2024	
	Core 2 Primary Reviewer 3 critique submitted	N/A	07/10/2024	
	Core 2 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024	
	COI indicated by non-primary reviewer	NONE	07/10/2024	
	COI recused from participation	N/A	07/10/2024	
	Discussed at Peer Review Meeting	YES	07/10/2024	
	Peer Review Meeting	04/25/2024	07/10/2024	
	Post review statements signed	04/26/2024	07/09/2024	
	Third Party Observer Report	04/29/2024	07/09/2024	
	Score report delivered to CSO	05/09/2024	07/09/2024	
Recommended for SRC review	YES	07/10/2024		
Final SRC Recommendation	COI indicated by SRC member	NONE	07/12/2024	
	COI recused from participation	N/A	07/12/2024	
	SRC Meeting	07/11/2024	07/16/2024	
	Third Party Observer Report	07/17/2024	07/30/2024	
	Recommended for grant award	YES	07/12/2024	
PIC Review	SRC Chair Notification to PIC and OC	07/29/2024	07/30/2024	
	COI indicated by PIC member	none	08/07/2024	
	COI recused from participation	N/A	08/07/2024	
Oversight Committee Approval	PIC Review Meeting	08/07/2024	08/07/2024	
	Recommended for grant award	YES	08/07/2024	
	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
Authority to advance funds requested	N/A			
Advance authority approved by Oversight Committee	N/A			



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240439**  
**Multi-Investigator Research Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Multi-Investigator Research Awards* Request for Applications (RFA). CPRIT received 18 applications in response to this RFA. This application was assigned to Clinical and Translational Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that one application submitted in response to this RFA has a final overall evaluation score that is more favorable than three applications that were recommended for grant awards. An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be discussed or recommended for funding by a peer review panel.

CPRIT's administrative rules allow for the chairperson of each peer review panel to determine what applications are discussed during the peer review meeting if there is not enough time to discuss all applications that are assigned to the panel. The chairperson's decision is largely based on the initial overall evaluation score, which is the average of the scores from the primary reviewers of an application. If an application is not discussed at the peer review meeting, then the initial score becomes the final overall evaluation score. If an application is discussed by the full panel, then the primary reviewers may revise their initial scores based on the discussion at the panel. This means that the final overall evaluation score of a discussed application could be higher or lower than the initial evaluation score of that application. It is possible that this could result in a discussed application having a less favorable score than an application that was not discussed.


The four applications noted above were each assigned to a different peer review panel. The three recommended applications were discussed by each of their panels and the not-recommended application was not discussed. Since the application was not discussed, the initial overall evaluation score became the final overall evaluation score of the not-recommended application. The three applications that were discussed by the other panels had the chance for the primary reviewers to adjust their scores based on panel discussion. All of the panels conducted their review within CPRIT's administrative rules.

The Scientific Review Council (SRC) met twice to consider and recommend applications from this review cycle to the PIC. After its first meeting on July 11, 2024, the SRC met on July 29 to recommend an additional application from this grant mechanism after it became clear to the SRC that grant funds were available to fund the additional application.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.

This statement is true.”




Kristen P. Doyle,  
CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
the 8<sup>th</sup> day of August, 2024,  
by KRISTEN P. DOYLE.



Sandra Reyes  
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/08/2024 09:17 AM CT

FY: 2024  
 CYCLE: 2  
 PROGRAM: Research  
 MECHANISM: Multi-Investigator Research Awards (Version 2)  
 APPLICATION ID: RP240439  
 APPLICATION TITLE: Innovative cell therapy approaches for hematological and solid malignancies  
 APPLICANT NAME: Neelapu, Sattva S  
 ORGANIZATION: The University of Texas M. D. Anderson Cancer Center  
 PANEL NAME: 24.2 Clinical and Translational Cancer Research-2

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	09/13/2023	07/09/2024	
	RFA Approved by CSO (revised)	10/17/2023	07/09/2024	
	RFA Approved by CSO (2nd revision)	01/16/2024	07/09/2024	
	RFA published in Texas.gov eGrants	09/14/2023	07/09/2024	
	CPRIT Application Receipt System (CARS) opened	10/17/2023	07/09/2024	
	CPRIT Application Receipt System (CARS) closed	01/18/2024	07/09/2024	
	Date application submitted	01/12/2024	07/10/2024	
	Method of submission	CARS	07/10/2024	
	Within receipt period	YES	07/10/2024	
	Request for extension to submit application after CARS closed	N/A	07/10/2024	
Request for extension for late application submission accepted	N/A	07/10/2024		
Receipt, Referral, and Assignment	Administrative review notification	N/A	07/10/2024	
	Donation(s) made to CPRIT / foundation	NO	07/10/2024	
	Assigned to primary reviewers	03/11/2024	07/10/2024	
	Applicant notified of review panel assignment	02/28/2024	07/09/2024	
	Primary Reviewer 1 COI signed	03/02/2024	07/10/2024	
	Primary Reviewer 2 COI signed	02/27/2024	07/10/2024	
	Primary Reviewer 3 COI signed	N/A	07/10/2024	
	Primary (Advocate) Reviewer 3 COI signed	02/27/2024	07/10/2024	
	Primary (Advocate) Reviewer 4 COI signed	N/A	07/10/2024	
	Project 1 Primary Reviewer 1 COI signed	02/28/2024	07/10/2024	
	Project 1 Primary Reviewer 2 COI signed	02/27/2024	07/10/2024	
	Project 1 Primary Reviewer 3 COI signed	02/27/2024	07/10/2024	
	Project 1 Primary (Advocate) Reviewer 4 COI signed	N/A	07/10/2024	
	Project 2 Primary Reviewer 1 COI signed	03/18/2024	07/10/2024	
	Project 2 Primary Reviewer 2 COI signed	03/31/2024	07/10/2024	
	Project 2 Primary Reviewer 3 COI signed	02/28/2024	07/10/2024	
	Project 2 Primary (Advocate) Reviewer 4 COI signed	N/A	07/10/2024	
	Project 3 Primary Reviewer 1 COI signed	03/03/2024	07/10/2024	
	Project 3 Primary Reviewer 2 COI signed	03/07/2024	07/10/2024	
	Project 3 Primary Reviewer 3 COI signed	02/27/2024	07/10/2024	
	Project 3 Primary (Advocate) Reviewer 4 COI signed	N/A	07/10/2024	
	Project 4 Primary Reviewer 1 COI signed	N/A	07/10/2024	
	Project 4 Primary Reviewer 2 COI signed	N/A	07/10/2024	
	Project 4 Primary Reviewer 3 COI signed	N/A	07/10/2024	
	Project 4 Primary (Advocate) Reviewer 4 COI signed	N/A	07/10/2024	
	Admin Core Primary Reviewer 1 COI signed	02/27/2024	07/10/2024	
	Admin Core Primary Reviewer 2 COI signed	03/02/2024	07/10/2024	
	Admin Core Primary Reviewer 3 COI signed	N/A	07/10/2024	
	Admin Core Primary (Advocate) Reviewer 4 COI signed	N/A	07/10/2024	
	Core 1 Primary Reviewer 1 COI signed	02/27/2024	07/10/2024	
	Core 1 Primary Reviewer 2 COI signed	03/02/2024	07/10/2024	
	Core 1 Primary Reviewer 3 COI signed	N/A	07/10/2024	
	Core 1 Primary (Advocate) Reviewer 4 COI signed	N/A	07/10/2024	
	Core 2 Primary Reviewer 1 COI signed	N/A	07/10/2024	
	Core 2 Primary Reviewer 2 COI signed	N/A	07/10/2024	
	Core 2 Primary Reviewer 3 COI signed	N/A	07/10/2024	
	Core 2 Primary (Advocate) Reviewer 4 COI signed	N/A	07/10/2024	
	Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/10/2024
		Primary Reviewer 2 critique submitted	N/A	07/10/2024
		Primary Reviewer 3 critique submitted	N/A	07/10/2024
Primary (Advocate) Reviewer 4 critique submitted		N/A	07/10/2024	
COI indicated by non-primary reviewer		N/A	07/10/2024	
Preliminary Evaluation score summary sent to Chair		N/A	07/10/2024	
Recommended for full review		N/A	07/10/2024	
Applicant notified of outcome		N/A	07/10/2024	
Peer Review Meeting		Primary Reviewer 1 critique submitted	04/01/2024	07/10/2024
		Primary Reviewer 2 critique submitted	04/15/2024	07/10/2024
	Primary Reviewer 3 critique submitted	N/A	07/10/2024	
	Primary (Advocate) Reviewer 3 critique submitted	03/13/2024	07/10/2024	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024	
	Project 1 Primary Reviewer 1 critique submitted	04/10/2024	07/10/2024	
	Project 1 Primary Reviewer 2 critique submitted	04/10/2024	07/10/2024	
	Project 1 Primary Reviewer 3 critique submitted	04/11/2024	07/10/2024	
	Project 1 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024	
	Project 2 Primary Reviewer 1 critique submitted	04/10/2024	07/10/2024	
	Project 2 Primary Reviewer 2 critique submitted	04/12/2024	07/10/2024	
	Project 2 Primary Reviewer 3 critique submitted	04/10/2024	07/10/2024	
	Project 2 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024	
	Project 3 Primary Reviewer 1 critique submitted	03/31/2024	07/10/2024	
	Project 3 Primary Reviewer 2 critique submitted	04/19/2024	07/10/2024	
	Project 3 Primary Reviewer 3 critique submitted	04/10/2024	07/10/2024	
	Project 3 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024	
	Project 4 Primary Reviewer 1 critique submitted	N/A	07/10/2024	
	Project 4 Primary Reviewer 2 critique submitted	N/A	07/10/2024	
	Project 4 Primary Reviewer 3 critique submitted	N/A	07/10/2024	
	Project 4 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024	
	Admin Core Primary Reviewer 1 critique submitted	04/10/2024	07/10/2024	
	Admin Core Primary Reviewer 2 critique submitted	04/01/2024	07/10/2024	
	Admin Core Primary Reviewer 3 critique submitted	N/A	07/10/2024	
	Admin Core Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024	
	Core 1 Primary Reviewer 1 critique submitted	04/10/2024	07/10/2024	
	Core 1 Primary Reviewer 2 critique submitted	04/02/2024	07/10/2024	
	Core 1 Primary Reviewer 3 critique submitted	N/A	07/10/2024	
	Core 1 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024	
	Core 2 Primary Reviewer 1 critique submitted	N/A	07/10/2024	
	Core 2 Primary Reviewer 2 critique submitted	N/A	07/10/2024	
	Core 2 Primary Reviewer 3 critique submitted	N/A	07/10/2024	
	Core 2 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024	
	COI indicated by non-primary reviewer	Joshua Campbell	07/10/2024	
	COI recused from participation	YES	07/10/2024	
	Discussed at Peer Review Meeting	YES	07/10/2024	
	Peer Review Meeting	04/25/2024	07/10/2024	
	Post review statements signed	04/26/2024	07/09/2024	
	Third Party Observer Report	04/29/2024	07/09/2024	
	Score report delivered to CSO	05/09/2024	07/09/2024	
Recommended for SRC review	YES	07/10/2024		
Final SRC Recommendation	COI indicated by SRC member	NONE	07/12/2024	
	COI recused from participation	N/A	07/12/2024	
	SRC Meeting	07/11/2024	07/16/2024	
	Third Party Observer Report	07/17/2024	07/30/2024	
	Recommended for grant award	YES	07/12/2024	
PIC Review	SRC Chair Notification to PIC and OC	07/29/2024	07/30/2024	
	COI indicated by PIC member	none	08/07/2024	
	COI recused from participation	N/A	08/07/2024	
	PIC Review Meeting	08/07/2024	08/07/2024	
Oversight Committee Approval	Recommended for grant award	YES	08/07/2024	
	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
Advance authority approved by Oversight Committee	N/A			





---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240440**  
**Multi-Investigator Research Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Multi-Investigator Research Awards* Request for Applications (RFA). CPRIT received 18 applications in response to this RFA. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that one application submitted in response to this RFA has a final overall evaluation score that is more favorable than three applications that were recommended for grant awards. An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be discussed or recommended for funding by a peer review panel.

CPRIT's administrative rules allow for the chairperson of each peer review panel to determine what applications are discussed during the peer review meeting if there is not enough time to discuss all applications that are assigned to the panel. The chairperson's decision is largely based on the initial overall evaluation score, which is the average of the scores from the primary reviewers of an application. If an application is not discussed at the peer review meeting, then the initial score becomes the final overall evaluation score. If an application is discussed by the full panel, then the primary reviewers may revise their initial scores based on the discussion at the panel. This means that the final overall evaluation score of a discussed application could be higher or lower than the initial evaluation score of that application. It is possible that this could result in a discussed application having a less favorable score than an application that was not discussed.

The four applications noted above were each assigned to a different peer review panel. The three recommended applications were discussed by each of their panels and the not-recommended application was not discussed. Since the application was not discussed, the initial overall evaluation score became the final overall evaluation score of the not-recommended application. The three applications that were discussed by the other panels had the chance for the primary reviewers to adjust their scores based on panel discussion. All of the panels conducted their review within CPRIT's administrative rules.

The Scientific Review Council (SRC) met twice to consider and recommend applications from this review cycle to the PIC. After its first meeting on July 11, 2024, the SRC met on July 29 to recommend an additional application from this grant mechanism after it became clear to the SRC that grant funds were available to fund the additional application.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true.”

  
\_\_\_\_\_  
Kristen P. Doyle,  
CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
the 8<sup>th</sup> day of August, 2024,  
by KRISTEN P. DOYLE.

  
\_\_\_\_\_  
Sandra Reyes  
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/08/2024 09:17 AM CT

FY: 2024  
 CYCLE: 2  
 PROGRAM: Research  
 MECHANISM: Multi-Investigator Research Awards (Version 2)  
 APPLICATION ID: RP240440  
 APPLICATION TITLE: Novel Therapies for Osteosarcoma  
 APPLICANT NAME: Gorlick, Richard  
 ORGANIZATION: The University of Texas M. D. Anderson Cancer Center  
 PANEL NAME: 24.2 Cancer Biology

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	09/13/2023	07/09/2024	
	RFA Approved by CSO (revised)	10/17/2023	07/09/2024	
	RFA Approved by CSO (2nd revision)	01/16/2024	07/09/2024	
	RFA published in Texas.gov eGrants	09/14/2023	07/09/2024	
	CPRIT Application Receipt System (CARS) opened	10/17/2023	07/09/2024	
	CPRIT Application Receipt System (CARS) closed	01/18/2024	07/09/2024	
	Date application submitted	01/12/2024	07/09/2024	
	Method of submission	CARS	07/09/2024	
	Within receipt period	YES	07/09/2024	
	Request for extension to submit application after CARS closed	N/A	07/09/2024	
Request for extension for late application submission accepted	N/A	07/09/2024		
Receipt, Referral, and Assignment	Administrative review notification	N/A	07/09/2024	
	Donation(s) made to CPRIT / foundation	NO	07/09/2024	
	Assigned to primary reviewers	03/11/2024	07/09/2024	
	Applicant notified of review panel assignment	02/28/2024	07/09/2024	
	Primary Reviewer 1 COI signed	03/02/2024	07/09/2024	
	Primary Reviewer 2 COI signed	03/07/2024	07/09/2024	
	Primary Reviewer 3 COI signed	N/A	07/09/2024	
	Primary (Advocate) Reviewer 3 COI signed	02/28/2024	07/09/2024	
	Primary (Advocate) Reviewer 4 COI signed	N/A	07/09/2024	
	Project 1 Primary Reviewer 1 COI signed	03/08/2024	07/09/2024	
	Project 1 Primary Reviewer 2 COI signed	03/02/2024	07/09/2024	
	Project 1 Primary Reviewer 3 COI signed	03/07/2024	07/09/2024	
	Project 1 Primary (Advocate) Reviewer 4 COI signed	N/A	07/09/2024	
	Project 2 Primary Reviewer 1 COI signed	03/07/2024	07/09/2024	
	Project 2 Primary Reviewer 2 COI signed	03/02/2024	07/09/2024	
	Project 2 Primary Reviewer 3 COI signed	02/27/2024	07/09/2024	
	Project 2 Primary (Advocate) Reviewer 4 COI signed	N/A	07/09/2024	
	Project 3 Primary Reviewer 1 COI signed	02/27/2024	07/09/2024	
	Project 3 Primary Reviewer 2 COI signed	02/28/2024	07/09/2024	
	Project 3 Primary Reviewer 3 COI signed	02/27/2024	07/09/2024	
	Project 3 Primary (Advocate) Reviewer 4 COI signed	N/A	07/09/2024	
	Project 4 Primary Reviewer 1 COI signed	N/A	07/09/2024	
	Project 4 Primary Reviewer 2 COI signed	N/A	07/09/2024	
	Project 4 Primary Reviewer 3 COI signed	N/A	07/09/2024	
	Project 4 Primary (Advocate) Reviewer 4 COI signed	N/A	07/09/2024	
	Admin Core Primary Reviewer 1 COI signed	03/07/2024	07/09/2024	
	Admin Core Primary Reviewer 2 COI signed	03/02/2024	07/09/2024	
	Admin Core Primary Reviewer 3 COI signed	N/A	07/09/2024	
	Admin Core Primary (Advocate) Reviewer 4 COI signed	N/A	07/09/2024	
	Core 1 Primary Reviewer 1 COI signed	03/08/2024	07/09/2024	
	Core 1 Primary Reviewer 2 COI signed	02/27/2024	07/09/2024	
	Core 1 Primary Reviewer 3 COI signed	N/A	07/09/2024	
	Core 1 Primary (Advocate) Reviewer 4 COI signed	N/A	07/09/2024	
	Core 2 Primary Reviewer 1 COI signed	02/27/2024	07/09/2024	
	Core 2 Primary Reviewer 2 COI signed	02/28/2024	07/09/2024	
	Core 2 Primary Reviewer 3 COI signed	N/A	07/09/2024	
	Core 2 Primary (Advocate) Reviewer 4 COI signed	N/A	07/09/2024	
	Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/09/2024
		Primary Reviewer 2 critique submitted	N/A	07/09/2024
		Primary Reviewer 3 critique submitted	N/A	07/09/2024
Primary (Advocate) Reviewer 4 critique submitted		N/A	07/09/2024	
COI indicated by non-primary reviewer		N/A	07/09/2024	
Preliminary Evaluation score summary sent to Chair		N/A	07/09/2024	
Recommended for full review		N/A	07/09/2024	
Applicant notified of outcome		N/A	07/09/2024	
Peer Review Meeting		Primary Reviewer 1 critique submitted	04/14/2024	07/09/2024
		Primary Reviewer 2 critique submitted	04/10/2024	07/09/2024
	Primary Reviewer 3 critique submitted	N/A	07/09/2024	
	Primary (Advocate) Reviewer 3 critique submitted	03/14/2024	07/09/2024	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/09/2024	
	Project 1 Primary Reviewer 1 critique submitted	04/11/2024	07/09/2024	
	Project 1 Primary Reviewer 2 critique submitted	04/04/2024	07/09/2024	
	Project 1 Primary Reviewer 3 critique submitted	04/10/2024	07/09/2024	
	Project 1 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/09/2024	
	Project 2 Primary Reviewer 1 critique submitted	04/10/2024	07/09/2024	
	Project 2 Primary Reviewer 2 critique submitted	04/05/2024	07/09/2024	
	Project 2 Primary Reviewer 3 critique submitted	04/09/2024	07/09/2024	
	Project 2 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/09/2024	
	Project 3 Primary Reviewer 1 critique submitted	04/12/2024	07/09/2024	
	Project 3 Primary Reviewer 2 critique submitted	04/11/2024	07/09/2024	
	Project 3 Primary Reviewer 3 critique submitted	03/12/2024	07/09/2024	
	Project 3 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/09/2024	
	Project 4 Primary Reviewer 1 critique submitted	N/A	07/09/2024	
	Project 4 Primary Reviewer 2 critique submitted	N/A	07/09/2024	
	Project 4 Primary Reviewer 3 critique submitted	N/A	07/09/2024	
	Project 4 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/09/2024	
	Admin Core Primary Reviewer 1 critique submitted	04/10/2024	07/09/2024	
	Admin Core Primary Reviewer 2 critique submitted	04/05/2024	07/09/2024	
	Admin Core Primary Reviewer 3 critique submitted	N/A	07/09/2024	
	Admin Core Primary (Advocate) Reviewer 4 critique submitted	N/A	07/09/2024	
	Core 1 Primary Reviewer 1 critique submitted	04/11/2024	07/09/2024	
	Core 1 Primary Reviewer 2 critique submitted	04/12/2024	07/09/2024	
	Core 1 Primary Reviewer 3 critique submitted	N/A	07/09/2024	
	Core 1 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/09/2024	
	Core 2 Primary Reviewer 1 critique submitted	04/10/2024	07/09/2024	
	Core 2 Primary Reviewer 2 critique submitted	04/11/2024	07/09/2024	
	Core 2 Primary Reviewer 3 critique submitted	N/A	07/09/2024	
	Core 2 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/09/2024	
	COI indicated by non-primary reviewer	Patrick Grohar	07/09/2024	
	COI recused from participation	YES	07/09/2024	
	Discussed at Peer Review Meeting	YES	07/09/2024	
	Peer Review Meeting	04/24/2024	07/09/2024	
	Post review statements signed	04/29/2024	07/09/2024	
	Third Party Observer Report	04/29/2024	07/09/2024	
	Score report delivered to CSO	05/09/2024	07/09/2024	
Recommended for SRC review	YES	07/09/2024		
Final SRC Recommendation	COI indicated by SRC member	NONE	07/12/2024	
	COI recused from participation	N/A	07/12/2024	
	SRC Meeting	07/11/2024	07/16/2024	
	Third Party Observer Report	07/17/2024	07/30/2024	
	Recommended for grant award	YES	07/12/2024	
SRC Chair Notification to PIC and OC	SRC Chair Notification to PIC and OC	07/29/2024	07/30/2024	
	PIC Review	COI indicated by PIC member	none	08/07/2024
		COI recused from participation	N/A	08/07/2024
PIC Review Meeting		08/07/2024	08/07/2024	
Oversight Committee Approval	Recommended for grant award	YES	08/07/2024	
	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
Advance authority approved by Oversight Committee	N/A			



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240474**  
**Multi-Investigator Research Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Multi-Investigator Research Awards* Request for Applications (RFA). CPRIT received 18 applications in response to this RFA. This application was assigned to Clinical and Translational Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that one application submitted in response to this RFA has a final overall evaluation score that is more favorable than three applications that were recommended for grant awards. An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be discussed or recommended for funding by a peer review panel.

CPRIT's administrative rules allow for the chairperson of each peer review panel to determine what applications are discussed during the peer review meeting if there is not enough time to discuss all applications that are assigned to the panel. The chairperson's decision is largely based on the initial overall evaluation score, which is the average of the scores from the primary reviewers of an application. If an application is not discussed at the peer review meeting, then the initial score becomes the final overall evaluation score. If an application is discussed by the full panel, then the primary reviewers may revise their initial scores based on the discussion at the panel. This means that the final overall evaluation score of a discussed application could be higher or lower than the initial evaluation score of that application. It is possible that this could result in a discussed application having a less favorable score than an application that was not discussed.

The four applications noted above were each assigned to a different peer review panel. The three recommended applications were discussed by each of their panels and the not-recommended application was not discussed. Since the application was not discussed, the initial overall evaluation score became the final overall evaluation score of the not-recommended application. The three applications that were discussed by the other panels had the chance for the primary reviewers to adjust their scores based on panel discussion. All of the panels conducted their review within CPRIT's administrative rules.

The Scientific Review Council (SRC) met twice to consider and recommend applications from this review cycle to the PIC. After its first meeting on July 11, 2024, the SRC met on July 29 to recommend an additional application from this grant mechanism after it became clear to the SRC that grant funds were available to fund the additional application.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true.”




Kristen P. Doyle,  
CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
the 8<sup>th</sup> day of August, 2024,  
by KRISTEN P. DOYLE.



Sandra Reyes  
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/08/2024 09:18 AM CT

FY: 2024  
 CYCLE: 2  
 PROGRAM: Research  
 MECHANISM: Multi-Investigator Research Awards (Version 2)  
 APPLICATION ID: RP240474  
 APPLICATION TITLE: Cellular Immunotherapies for Pediatric Solid Tumors  
 APPLICANT NAME: Metelitsa, Leonid S  
 ORGANIZATION: Baylor College of Medicine  
 PANEL NAME: 24.2 Clinical and Translational Cancer Research-2

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	09/13/2023	07/09/2024	
	RFA Approved by CSO (revised)	10/17/2023	07/09/2024	
	RFA Approved by CSO (2nd revision)	01/16/2024	07/09/2024	
	RFA published in Texas.gov eGrants	09/14/2023	07/09/2024	
	CPRIT Application Receipt System (CARS) opened	10/17/2023	07/09/2024	
	CPRIT Application Receipt System (CARS) closed	01/18/2024	07/09/2024	
	Date application submitted	01/16/2024	07/10/2024	
	Method of submission	CARS	07/10/2024	
	Within receipt period	YES	07/10/2024	
	Request for extension to submit application after CARS closed	N/A	07/10/2024	
Request for extension for late application submission accepted	N/A	07/10/2024		
Receipt, Referral, and Assignment	Administrative review notification	02/29/2024	07/10/2024	
	Donation(s) made to CPRIT / foundation	NO	07/10/2024	
	Assigned to primary reviewers	03/11/2024	07/10/2024	
	Applicant notified of review panel assignment	02/28/2024	07/09/2024	
	Primary Reviewer 1 COI signed	02/28/2024	07/10/2024	
	Primary Reviewer 2 COI signed	03/02/2024	07/10/2024	
	Primary Reviewer 3 COI signed	N/A	07/10/2024	
	Primary (Advocate) Reviewer 3 COI signed	03/01/2024	07/10/2024	
	Primary (Advocate) Reviewer 4 COI signed	N/A	07/10/2024	
	Project 1 Primary Reviewer 1 COI signed	03/02/2024	07/10/2024	
	Project 1 Primary Reviewer 2 COI signed	03/04/2024	07/10/2024	
	Project 1 Primary Reviewer 3 COI signed	02/28/2024	07/10/2024	
	Project 1 Primary (Advocate) Reviewer 4 COI signed	N/A	07/10/2024	
	Project 2 Primary Reviewer 1 COI signed	03/04/2024	07/10/2024	
	Project 2 Primary Reviewer 2 COI signed	02/28/2024	07/10/2024	
	Project 2 Primary Reviewer 3 COI signed	03/07/2024	07/10/2024	
	Project 2 Primary (Advocate) Reviewer 4 COI signed	N/A	07/10/2024	
	Project 3 Primary Reviewer 1 COI signed	02/28/2024	07/10/2024	
	Project 3 Primary Reviewer 2 COI signed	02/27/2024	07/10/2024	
	Project 3 Primary Reviewer 3 COI signed	03/07/2024	07/10/2024	
	Project 3 Primary (Advocate) Reviewer 4 COI signed	N/A	07/10/2024	
	Project 4 Primary Reviewer 1 COI signed	N/A	07/10/2024	
	Project 4 Primary Reviewer 2 COI signed	N/A	07/10/2024	
	Project 4 Primary Reviewer 3 COI signed	N/A	07/10/2024	
	Project 4 Primary (Advocate) Reviewer 4 COI signed	N/A	07/10/2024	
	Admin Core Primary Reviewer 1 COI signed	03/02/2024	07/10/2024	
	Admin Core Primary Reviewer 2 COI signed	02/28/2024	07/10/2024	
	Admin Core Primary Reviewer 3 COI signed	N/A	07/10/2024	
	Admin Core Primary (Advocate) Reviewer 4 COI signed	N/A	07/10/2024	
	Core 1 Primary Reviewer 1 COI signed	02/28/2024	07/10/2024	
	Core 1 Primary Reviewer 2 COI signed	03/04/2024	07/10/2024	
	Core 1 Primary Reviewer 3 COI signed	N/A	07/10/2024	
	Core 1 Primary (Advocate) Reviewer 4 COI signed	N/A	07/10/2024	
	Core 2 Primary Reviewer 1 COI signed	03/31/2024	07/10/2024	
	Core 2 Primary Reviewer 2 COI signed	03/07/2024	07/10/2024	
	Core 2 Primary Reviewer 3 COI signed	N/A	07/10/2024	
	Core 2 Primary (Advocate) Reviewer 4 COI signed	N/A	07/10/2024	
	Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/10/2024
		Primary Reviewer 2 critique submitted	N/A	07/10/2024
		Primary Reviewer 3 critique submitted	N/A	07/10/2024
Primary (Advocate) Reviewer 4 critique submitted		N/A	07/10/2024	
COI indicated by non-primary reviewer		N/A	07/10/2024	
Preliminary Evaluation score summary sent to Chair		N/A	07/10/2024	
Recommended for full review		N/A	07/10/2024	
Applicant notified of outcome		N/A	07/10/2024	
Peer Review Meeting		Primary Reviewer 1 critique submitted	04/11/2024	07/10/2024
		Primary Reviewer 2 critique submitted	03/22/2024	07/10/2024
	Primary Reviewer 3 critique submitted	N/A	07/10/2024	
	Primary (Advocate) Reviewer 3 critique submitted	04/10/2024	07/10/2024	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024	
	Project 1 Primary Reviewer 1 critique submitted	04/07/2024	07/10/2024	
	Project 1 Primary Reviewer 2 critique submitted	04/08/2024	07/10/2024	
	Project 1 Primary Reviewer 3 critique submitted	04/11/2024	07/10/2024	
	Project 1 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024	
	Project 2 Primary Reviewer 1 critique submitted	04/07/2024	07/10/2024	
	Project 2 Primary Reviewer 2 critique submitted	04/12/2024	07/10/2024	
	Project 2 Primary Reviewer 3 critique submitted	04/21/2024	07/10/2024	
	Project 2 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024	
	Project 3 Primary Reviewer 1 critique submitted	04/12/2024	07/10/2024	
	Project 3 Primary Reviewer 2 critique submitted	04/11/2024	07/10/2024	
	Project 3 Primary Reviewer 3 critique submitted	04/16/2024	07/10/2024	
	Project 3 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024	
	Project 4 Primary Reviewer 1 critique submitted	N/A	07/10/2024	
	Project 4 Primary Reviewer 2 critique submitted	N/A	07/10/2024	
	Project 4 Primary Reviewer 3 critique submitted	N/A	07/10/2024	
	Project 4 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024	
	Admin Core Primary Reviewer 1 critique submitted	03/25/2024	07/10/2024	
	Admin Core Primary Reviewer 2 critique submitted	04/11/2024	07/10/2024	
	Admin Core Primary Reviewer 3 critique submitted	N/A	07/10/2024	
	Admin Core Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024	
	Core 1 Primary Reviewer 1 critique submitted	04/11/2024	07/10/2024	
	Core 1 Primary Reviewer 2 critique submitted	04/12/2024	07/10/2024	
	Core 1 Primary Reviewer 3 critique submitted	N/A	07/10/2024	
	Core 1 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024	
	Core 2 Primary Reviewer 1 critique submitted	04/12/2024	07/10/2024	
	Core 2 Primary Reviewer 2 critique submitted	04/16/2024	07/10/2024	
	Core 2 Primary Reviewer 3 critique submitted	N/A	07/10/2024	
	Core 2 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2024	
	COI indicated by non-primary reviewer	W. Martin Kast	07/10/2024	
	COI recused from participation	YES	07/10/2024	
	Discussed at Peer Review Meeting	YES	07/10/2024	
	Peer Review Meeting	04/25/2024	07/10/2024	
	Post review statements signed	04/26/2024	07/09/2024	
	Third Party Observer Report	04/29/2024	07/09/2024	
	Score report delivered to CSO	05/09/2024	07/09/2024	
Recommended for SRC review	NO	07/10/2024		
Final SRC Recommendation	COI indicated by SRC member	N/A	07/10/2024	
	COI recused from participation	N/A	07/10/2024	
	SRC Meeting	N/A	07/10/2024	
	Third Party Observer Report	N/A	07/10/2024	
	Recommended for grant award	N/A	07/10/2024	
	SRC Chair Notification to PIC and OC	N/A	07/10/2024	
	COI indicated by SRC member (2nd Meeting)	NONE	07/30/2024	
	COI recused from participation (2nd Meeting)	N/A	07/30/2024	
	2nd SRC Meeting	07/29/2024	07/30/2024	
	Third Party Observer Report (2nd Meeting)	08/02/2024	08/02/2024	
Recommended for grant award	YES	07/30/2024		
SRC Chair Notification to PIC and OC (2nd Meeting)	07/29/2024	07/30/2024		
PIC Review	COI indicated by PIC member	none	08/07/2024	
	COI recused from participation	N/A	08/07/2024	
	PIC Review Meeting	08/07/2024	08/07/2024	
Oversight Committee Approval	Recommended for grant award	YES	08/07/2024	
	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
Advance authority approved by Oversight Committee	N/A			





---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RP240489**  
**Multi-Investigator Research Awards**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Multi-Investigator Research Awards* Request for Applications (RFA). CPRIT received 18 applications in response to this RFA. This application was assigned to the Basic Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that one application submitted in response to this RFA has a final overall evaluation score that is more favorable than three applications that were recommended for grant awards. An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be discussed or recommended for funding by a peer review panel.

CPRIT's administrative rules allow for the chairperson of each peer review panel to determine what applications are discussed during the peer review meeting if there is not enough time to discuss all applications that are assigned to the panel. The chairperson's decision is largely based on the initial overall evaluation score, which is the average of the scores from the primary reviewers of an application. If an application is not discussed at the peer review meeting, then the initial score becomes the final overall evaluation score. If an application is discussed by the full panel, then the primary reviewers may revise their initial scores based on the discussion at the panel. This means that the final overall evaluation score of a discussed application could be higher or lower than the initial evaluation score of that application. It is possible that this could result in a discussed application having a less favorable score than an application that was not discussed.


The four applications noted above were each assigned to a different peer review panel. The three recommended applications were discussed by each of their panels and the not-recommended application was not discussed. Since the application was not discussed, the initial overall evaluation score became the final overall evaluation score of the not-recommended application. The three applications that were discussed by the other panels had the chance for the primary reviewers to adjust their scores based on panel discussion. All of the panels conducted their review within CPRIT's administrative rules.

The Scientific Review Council (SRC) met twice to consider and recommend applications from this review cycle to the PIC. After its first meeting on July 11, 2024, the SRC met on July 29 to recommend an additional application from this grant mechanism after it became clear to the SRC that grant funds were available to fund the additional application.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true.”

  
\_\_\_\_\_  
Kristen P. Doyle,  
CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
the 8<sup>th</sup> day of August, 2024,  
by KRISTEN P. DOYLE.

  
\_\_\_\_\_  
Sandra Reyes  
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/08/2024 09:18 AM CT

FY: 2024  
 CYCLE: 2  
 PROGRAM: Research  
 MECHANISM: Multi-Investigator Research Awards (Version 2)  
 APPLICATION ID: RP240489  
 APPLICATION TITLE: Neural Regulation of Childhood Cancers  
 APPLICANT NAME: Morrison, Sean J  
 ORGANIZATION: The University of Texas Southwestern Medical Center  
 PANEL NAME: 24.2 Basic Cancer Research I

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	09/13/2023	07/09/2024	
	RFA Approved by CSO (revised)	10/17/2023	07/09/2024	
	RFA Approved by CSO (2nd revision)	01/16/2024	07/09/2024	
	RFA published in Texas.gov eGrants	09/14/2023	07/09/2024	
	CPRIT Application Receipt System (CARS) opened	10/17/2023	07/09/2024	
	CPRIT Application Receipt System (CARS) closed	01/18/2024	07/09/2024	
	Date application submitted	01/15/2024	07/09/2024	
	Method of submission	CARS	07/09/2024	
	Within receipt period	YES	07/09/2024	
	Request for extension to submit application after CARS closed	N/A	07/09/2024	
Request for extension for late application submission accepted	N/A	07/09/2024		
Receipt, Referral, and Assignment	Administrative review notification	N/A	07/09/2024	
	Donation(s) made to CPRIT / foundation	NO	07/09/2024	
	Assigned to primary reviewers	03/11/2024	07/09/2024	
	Applicant notified of review panel assignment	02/28/2024	07/09/2024	
	Primary Reviewer 1 COI signed	03/01/2024	07/09/2024	
	Primary Reviewer 2 COI signed	02/27/2024	07/09/2024	
	Primary Reviewer 3 COI signed	N/A	07/09/2024	
	Primary (Advocate) Reviewer 3 COI signed	03/06/2024	07/09/2024	
	Primary (Advocate) Reviewer 4 COI signed	N/A	07/09/2024	
	Project 1 Primary Reviewer 1 COI signed	02/27/2024	07/09/2024	
	Project 1 Primary Reviewer 2 COI signed	02/27/2024	07/09/2024	
	Project 1 Primary Reviewer 3 COI signed	02/27/2024	07/09/2024	
	Project 1 Primary (Advocate) Reviewer 4 COI signed	N/A	07/09/2024	
	Project 2 Primary Reviewer 1 COI signed	02/28/2024	07/09/2024	
	Project 2 Primary Reviewer 2 COI signed	02/27/2024	07/09/2024	
	Project 2 Primary Reviewer 3 COI signed	02/27/2024	07/09/2024	
	Project 2 Primary (Advocate) Reviewer 4 COI signed	N/A	07/09/2024	
	Project 3 Primary Reviewer 1 COI signed	02/27/2024	07/09/2024	
	Project 3 Primary Reviewer 2 COI signed	03/01/2024	07/09/2024	
	Project 3 Primary Reviewer 3 COI signed	02/28/2024	07/09/2024	
	Project 3 Primary (Advocate) Reviewer 4 COI signed	N/A	07/09/2024	
	Project 4 Primary Reviewer 1 COI signed	N/A	07/09/2024	
	Project 4 Primary Reviewer 2 COI signed	N/A	07/09/2024	
	Project 4 Primary Reviewer 3 COI signed	N/A	07/09/2024	
	Project 4 Primary (Advocate) Reviewer 4 COI signed	N/A	07/09/2024	
	Admin Core Primary Reviewer 1 COI signed	02/27/2024	07/09/2024	
	Admin Core Primary Reviewer 2 COI signed	03/01/2024	07/09/2024	
	Admin Core Primary Reviewer 3 COI signed	N/A	07/09/2024	
	Admin Core Primary (Advocate) Reviewer 4 COI signed	N/A	07/09/2024	
	Core 1 Primary Reviewer 1 COI signed	N/A	07/09/2024	
	Core 1 Primary Reviewer 2 COI signed	N/A	07/09/2024	
	Core 1 Primary Reviewer 3 COI signed	N/A	07/09/2024	
	Core 1 Primary (Advocate) Reviewer 4 COI signed	N/A	07/09/2024	
	Core 2 Primary Reviewer 1 COI signed	N/A	07/09/2024	
	Core 2 Primary Reviewer 2 COI signed	N/A	07/09/2024	
	Core 2 Primary Reviewer 3 COI signed	N/A	07/09/2024	
	Core 2 Primary (Advocate) Reviewer 4 COI signed	N/A	07/09/2024	
	Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/09/2024
		Primary Reviewer 2 critique submitted	N/A	07/09/2024
		Primary Reviewer 3 critique submitted	N/A	07/09/2024
Primary (Advocate) Reviewer 4 critique submitted		N/A	07/09/2024	
COI indicated by non-primary reviewer		N/A	07/09/2024	
Preliminary Evaluation score summary sent to Chair		N/A	07/09/2024	
Recommended for full review		N/A	07/09/2024	
Applicant notified of outcome		N/A	07/09/2024	
Peer Review Meeting		Primary Reviewer 1 critique submitted	04/02/2024	07/09/2024
		Primary Reviewer 2 critique submitted	04/04/2024	07/09/2024
	Primary Reviewer 3 critique submitted	N/A	07/09/2024	
	Primary (Advocate) Reviewer 3 critique submitted	04/05/2024	07/09/2024	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/09/2024	
	Project 1 Primary Reviewer 1 critique submitted	04/03/2024	07/09/2024	
	Project 1 Primary Reviewer 2 critique submitted	04/04/2024	07/09/2024	
	Project 1 Primary Reviewer 3 critique submitted	03/25/2024	07/09/2024	
	Project 1 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/09/2024	
	Project 2 Primary Reviewer 1 critique submitted	04/04/2024	07/09/2024	
	Project 2 Primary Reviewer 2 critique submitted	04/03/2024	07/09/2024	
	Project 2 Primary Reviewer 3 critique submitted	03/30/2024	07/09/2024	
	Project 2 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/09/2024	
	Project 3 Primary Reviewer 1 critique submitted	04/04/2024	07/09/2024	
	Project 3 Primary Reviewer 2 critique submitted	04/02/2024	07/09/2024	
	Project 3 Primary Reviewer 3 critique submitted	04/04/2024	07/09/2024	
	Project 3 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/09/2024	
	Project 4 Primary Reviewer 1 critique submitted	N/A	07/09/2024	
	Project 4 Primary Reviewer 2 critique submitted	N/A	07/09/2024	
	Project 4 Primary Reviewer 3 critique submitted	N/A	07/09/2024	
	Project 4 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/09/2024	
	Admin Core Primary Reviewer 1 critique submitted	04/04/2024	07/09/2024	
	Admin Core Primary Reviewer 2 critique submitted	04/02/2024	07/09/2024	
	Admin Core Primary Reviewer 3 critique submitted	N/A	07/09/2024	
	Admin Core Primary (Advocate) Reviewer 4 critique submitted	N/A	07/09/2024	
	Core 1 Primary Reviewer 1 critique submitted	N/A	07/09/2024	
	Core 1 Primary Reviewer 2 critique submitted	N/A	07/09/2024	
	Core 1 Primary Reviewer 3 critique submitted	N/A	07/09/2024	
	Core 1 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/09/2024	
	Core 2 Primary Reviewer 1 critique submitted	N/A	07/09/2024	
	Core 2 Primary Reviewer 2 critique submitted	N/A	07/09/2024	
	Core 2 Primary Reviewer 3 critique submitted	N/A	07/09/2024	
	Core 2 Primary (Advocate) Reviewer 4 critique submitted	N/A	07/09/2024	
	COI indicated by non-primary reviewer	NONE	07/09/2024	
	COI recused from participation	N/A	07/09/2024	
	Discussed at Peer Review Meeting	YES	07/09/2024	
	Peer Review Meeting	04/16/2024	07/09/2024	
	Post review statements signed	04/16/2024	07/09/2024	
	Third Party Observer Report	04/23/2024	07/09/2024	
	Score report delivered to CSO	05/09/2024	07/09/2024	
Recommended for SRC review	YES	07/09/2024		
Final SRC Recommendation	COI indicated by SRC member	NONE	07/12/2024	
	COI recused from participation	N/A	07/12/2024	
	SRC Meeting	07/11/2024	07/16/2024	
	Third Party Observer Report	07/17/2024	07/30/2024	
	Recommended for grant award	YES	07/12/2024	
SRC Chair Notification to PIC and OC	07/29/2024	07/30/2024		
PIC Review	COI indicated by PIC member	none	08/07/2024	
	COI recused from participation	N/A	08/07/2024	
	PIC Review Meeting	08/07/2024	08/07/2024	
	Recommended for grant award	YES	08/07/2024	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
Advance authority approved by Oversight Committee	N/A			



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RR240070**  
**Recruitment of First-Time, Tenure-Track Faculty Members**  
**Nomination of Louai Labanieh, Ph.D.**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received nine applications in response to this RFA during cycle 24.12, including one application that was withdrawn. This application was assigned to the Scientific Review Council (SRC) for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."

  
\_\_\_\_\_  
Kristen P. Doyle,  
CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
the 8<sup>th</sup> day of August, 2024,  
by KRISTEN P. DOYLE.

  
\_\_\_\_\_  
Sandra Reyes  
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE Date and time exported: 08/08/2024 09:18 AM CT

FY:	2024			
CYCLE:	1			
PROGRAM:	Recruitment			
MECHANISM:	Recruitment of First-Time, Tenure-Track Faculty Members			
APPLICATION ID:	RR240070			
APPLICATION TITLE:	Expanding the Accessibility and Efficacy of CAR-T Cells Through In Vivo Engineering			
APPLICANT NAME:	Labanieh, Louai			
ORGANIZATION:	Baylor College of Medicine			
PANEL NAME:	Recruitment FY24_Cycle 12			
Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	06/20/2023	09/29/2023	
	RFA Approved by CSO (revised)	03/20/2024	03/29/2024	
	RFA Approved by CSO (24.12)	05/14/2024	07/12/2024	
	RFA published in Texas.gov eGrants	06/22/2023	09/29/2023	
	CPRIT Application Receipt Cycle opened	05/15/2024	07/12/2024	
	CPRIT Application Receipt Cycle closed	06/20/2024	07/12/2024	
	Date application submitted	06/19/2024	07/12/2024	
	Method of submission	CARS	07/12/2024	
	Within receipt period	YES	07/12/2024	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	07/12/2024
Donation(s) made to CPRIT / foundation		NO	07/12/2024	
Assigned to primary reviewers		06/28/2024	07/12/2024	
Applicant notified of review panel assignment		N/A	07/12/2024	
Primary Reviewer 1 COI signed		06/24/2024	07/12/2024	
Primary Reviewer 2 COI signed		06/21/2024	07/12/2024	
Peer Review Meeting		Primary Reviewer 1 critique submitted	07/09/2024	07/12/2024
		Primary Reviewer 2 critique submitted	07/06/2024	07/12/2024
	COI indicated by non-primary reviewer	NONE	07/12/2024	
	COI recused from participation	N/A	07/12/2024	
	Discussed at Peer Review Meeting	YES	07/12/2024	
	Peer Review Meeting	07/11/2024	07/12/2024	
	Post review statements signed	07/11/2024	07/12/2024	
	Third Party Observer Report	07/17/2024	07/22/2024	
	Score report delivered to CSO	07/15/2024	07/23/2024	
	Recommended for SRC review	YES	07/12/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/12/2024	
	COI recused from participation	N/A	07/12/2024	
	SRC Meeting	07/11/2024	07/12/2024	
	Third Party Observer Report	07/17/2024	07/24/2024	
	Recommended for grant award	YES	07/12/2024	
PIC Review	SRC Chair Notification to PIC and OC	07/29/2024	07/29/2024	
	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	08/07/2024	
	COI indicated by PIC member	none	08/07/2024	
	COI recused from participation	N/A	08/07/2024	
	PIC Review Meeting	08/07/2024	08/07/2024	
Oversight Committee Approval	Recommended for grant award	YES	08/07/2024	
	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	NO		
Authority to advance funds requested	N/A			
Advance authority approved by Oversight Committee	N/A			

CPRIT retains the identity of the attesting party.



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RR240076**  
**Recruitment of First-Time, Tenure-Track Faculty Members**  
**Nomination of Hojong Yoon, Ph.D.**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received nine applications in response to this RFA during cycle 24.12, including one application that was withdrawn. This application was assigned to the Scientific Review Council (SRC) for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle




- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."

  
 \_\_\_\_\_  
 Kristen P. Doyle,  
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
 the 8<sup>th</sup> day of August, 2024,  
 by KRISTEN P. DOYLE.

  
 \_\_\_\_\_  
 Sandra Reyes  
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE Date and time exported: 08/08/2024 09:18 AM CT

<b>FY:</b>	2024			
<b>CYCLE:</b>	1			
<b>PROGRAM:</b>	Recruitment			
<b>MECHANISM:</b>	Recruitment of First-Time, Tenure-Track Faculty Members			
<b>APPLICATION ID:</b>	RR240076			
<b>APPLICATION TITLE</b>	Discovery of Molecular Glue Degraders Targeting the Undruggable Cancer Proteome			
<b>APPLICANT NAME:</b>	Yoon, Hojong			
<b>ORGANIZATION:</b>	The University of Texas M. D. Anderson Cancer Center			
<b>PANEL NAME:</b>	Recruitment FY24 Cycle 12			
<b>Category</b>	<b>Compliance Requirement</b>	<b>Information</b>	<b>Attestation Date</b>	
<b>Pre-Receipt</b>	RFA Approved by CSO	06/20/2023	09/29/2023	
	RFA Approved by CSO (revised)	03/20/2024	03/29/2024	
	RFA Approved by CSO (24.12)	05/14/2024	07/12/2024	
	RFA published in Texas.gov eGrants	06/22/2023	09/29/2023	
	CPRIT Application Receipt Cycle opened	05/15/2024	07/12/2024	
	CPRIT Application Receipt Cycle closed	06/20/2024	07/12/2024	
	Date application submitted	06/17/2024	07/12/2024	
	Method of submission	CARS	07/12/2024	
	Within receipt period	YES	07/12/2024	
	<b>Receipt, Referral, and Assignment</b>	Administrative review notification	N/A	07/12/2024
Donation(s) made to CPRIT / foundation		NO	07/12/2024	
Assigned to primary reviewers		06/28/2024	07/12/2024	
Applicant notified of review panel assignment		N/A	07/12/2024	
Primary Reviewer 1 COI signed		06/24/2024	07/12/2024	
Primary Reviewer 2 COI signed		06/21/2024	07/12/2024	
<b>Peer Review Meeting</b>		Primary Reviewer 1 critique submitted	07/08/2024	07/12/2024
		Primary Reviewer 2 critique submitted	07/06/2024	07/12/2024
		COI indicated by non-primary reviewer	Nathanael Gray	07/12/2024
		COI recused from participation	YES	07/12/2024
	Discussed at Peer Review Meeting	YES	07/12/2024	
	Peer Review Meeting	07/11/2024	07/12/2024	
	Post review statements signed	07/11/2024	07/12/2024	
	Third Party Observer Report	07/17/2024	07/22/2024	
	Score report delivered to CSO	07/15/2024	07/23/2024	
	Recommended for SRC review	YES	07/12/2024	
<b>Final SRC Recommendation</b>	COI indicated by SRC member	Nathanael Gray	07/12/2024	
	COI recused from participation	YES	07/12/2024	
	SRC Meeting	07/11/2024	07/12/2024	
	Third Party Observer Report	07/17/2024	07/24/2024	
	Recommended for grant award	YES	07/12/2024	
<b>PIC Review</b>	SRC Chair Notification to PIC and OC	07/29/2024	07/29/2024	
	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	08/07/2024	
	COI indicated by PIC member	none	08/07/2024	
	COI recused from participation	N/A	08/07/2024	
	PIC Review Meeting	08/07/2024	08/07/2024	
<b>Oversight Committee Approval</b>	Recommended for grant award	YES	08/07/2024	
	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	NO		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		

CPRIT retains the identity of the attesting party.



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RR240079**  
**Recruitment of First-Time, Tenure-Track Faculty Members**  
**Nomination of Marianna Trakala, Ph.D.**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received nine applications in response to this RFA during cycle 24.12, including one application that was withdrawn. This application was assigned to the Scientific Review Council (SRC) for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."

  
\_\_\_\_\_  
Kristen P. Doyle,  
CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
the 8<sup>th</sup> day of August, 2024,  
by KRISTEN P. DOYLE.

  
\_\_\_\_\_  
Sandra Reyes  
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE Date and time exported: 08/08/2024 09:18 AM CT

FY:	2024		
CYCLE:	1		
PROGRAM:	Recruitment		
MECHANISM:	Recruitment of First-Time, Tenure-Track Faculty Members		
APPLICATION ID:	RR240079		
APPLICATION TITLE:	Immune surveillance and elimination of aneuploid cells in vivo.		
APPLICANT NAME:	Trakala, Marianna		
ORGANIZATION:	The University of Texas M. D. Anderson Cancer Center		
PANEL NAME:	Recruitment FY24_Cycle 12		
Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/20/2023	09/29/2023
	RFA Approved by CSO (revised)	03/20/2024	03/29/2024
	RFA Approved by CSO (24.12)	05/14/2024	07/12/2024
	RFA published in Texas.gov eGrants	06/22/2023	09/29/2023
	CPRIT Application Receipt Cycle opened	05/15/2024	07/12/2024
	CPRIT Application Receipt Cycle closed	06/20/2024	07/12/2024
	Date application submitted	06/17/2024	07/12/2024
	Method of submission	CARS	07/12/2024
	Within receipt period	YES	07/12/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2024
Assigned to primary reviewers		06/28/2024	07/12/2024
Applicant notified of review panel assignment		N/A	07/12/2024
Primary Reviewer 1 COI signed		06/24/2024	07/12/2024
Primary Reviewer 2 COI signed		06/21/2024	07/12/2024
Peer Review Meeting		Primary Reviewer 1 critique submitted	07/10/2024
	Primary Reviewer 2 critique submitted	07/06/2024	07/12/2024
	COI indicated by non-primary reviewer	NONE	07/12/2024
	COI recused from participation	N/A	07/12/2024
	Discussed at Peer Review Meeting	YES	07/12/2024
	Peer Review Meeting	07/11/2024	07/12/2024
	Post review statements signed	07/11/2024	07/12/2024
	Third Party Observer Report	07/17/2024	07/22/2024
	Score report delivered to CSO	07/15/2024	07/23/2024
	Recommended for SRC review	YES	07/12/2024
Final SRC Recommendation	COI indicated by SRC member	NONE	07/12/2024
	COI recused from participation	N/A	07/12/2024
	SRC Meeting	07/11/2024	07/12/2024
	Third Party Observer Report	07/17/2024	07/24/2024
	Recommended for grant award	YES	07/12/2024
	SRC Chair Notification to PIC and OC	07/29/2024	07/29/2024
PIC Review	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	08/07/2024
	COI indicated by PIC member	none	08/07/2024
	COI recused from participation	N/A	08/07/2024
	PIC Review Meeting	08/07/2024	08/07/2024
Oversight Committee Approval	Recommended for grant award	YES	08/07/2024
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		

CPRIT retains the identity of the attesting party.



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**CEO AFFIDAVIT**  
**Application RR240082**  
**Recruitment of First-Time, Tenure-Track Faculty Members**  
**Nomination of Yanjun Sun, Ph.D.**

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received nine applications in response to this RFA during cycle 24.12, including one application that was withdrawn. This application was assigned to the Scientific Review Council (SRC) for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."

  
\_\_\_\_\_  
Kristen P. Doyle,  
CEO, Cancer Prevention and Research Institute of Texas

State of Texas  
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on  
the 8<sup>th</sup> day of August, 2024,  
by KRISTEN P. DOYLE.

  
\_\_\_\_\_  
Sandra Reyes  
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE Date and time exported: 08/08/2024 09:18 AM CT

FY:	2024		
CYCLE:	1		
PROGRAM:	Recruitment		
MECHANISM:	Recruitment of First-Time, Tenure-Track Faculty Members		
APPLICATION ID:	RR240082		
APPLICATION TITLE:	Identification of Neural Mechanisms Contributing to Chemotherapy-Associated Cognitive Impairments		
APPLICANT NAME:	Sun, Yanjun		
ORGANIZATION:	The University of Texas Health Science Center at Houston		
PANEL NAME:	Recruitment FY24_Cycle 12		
Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/20/2023	09/29/2023
	RFA Approved by CSO (revised)	03/20/2024	03/29/2024
	RFA Approved by CSO (24.12)	05/14/2024	07/12/2024
	RFA published in Texas.gov eGrants	06/22/2023	09/29/2023
	CPRIT Application Receipt Cycle opened	05/15/2024	07/12/2024
	CPRIT Application Receipt Cycle closed	06/20/2024	07/12/2024
	Date application submitted	06/20/2024	07/12/2024
	Method of submission	CARS	07/12/2024
	Within receipt period	YES	07/12/2024
	Receipt, Referral, and Assignment	Administrative review notification	06/27/2024
Donation(s) made to CPRIT / foundation		NO	07/12/2024
Assigned to primary reviewers		06/28/2024	07/12/2024
Applicant notified of review panel assignment		N/A	07/12/2024
Primary Reviewer 1 COI signed		06/26/2024	07/12/2024
Primary Reviewer 2 COI signed		06/21/2024	07/12/2024
Peer Review Meeting		Primary Reviewer 1 critique submitted	07/10/2024
	Primary Reviewer 2 critique submitted	07/02/2024	07/12/2024
	COI indicated by non-primary reviewer	NONE	07/12/2024
	COI recused from participation	N/A	07/12/2024
	Discussed at Peer Review Meeting	YES	07/12/2024
	Peer Review Meeting	07/11/2024	07/12/2024
	Post review statements signed	07/11/2024	07/12/2024
	Third Party Observer Report	07/17/2024	07/22/2024
	Score report delivered to CSO	07/15/2024	07/23/2024
	Recommended for SRC review	YES	07/12/2024
Final SRC Recommendation	COI indicated by SRC member	NONE	07/12/2024
	COI recused from participation	N/A	07/12/2024
	SRC Meeting	07/11/2024	07/12/2024
	Third Party Observer Report	07/17/2024	07/24/2024
	Recommended for grant award	YES	07/12/2024
	SRC Chair Notification to PIC and OC	07/29/2024	07/29/2024
PIC Review	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	08/07/2024
	COI indicated by PIC member	none	08/07/2024
	COI recused from participation	N/A	08/07/2024
	PIC Review Meeting	08/07/2024	08/07/2024
	Recommended for grant award	YES	08/07/2024
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	N/A	
	Advance authority approved by Oversight Committee	N/A	

CPRIT retains the identity of the attesting party.